

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/83729 A2

- (51) International Patent Classification⁷: C12N 15/00
- (21) International Application Number: PCT/EP01/04863
- (22) International Filing Date: 30 April 2001 (30.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/562,934 1 May 2000 (01.05.2000) US
- (71) Applicants: NOVARTIS AG [CH/CH]; Schwarzwal-
dallee 215, CH-4058 Basel (CH). THE SCRIPPS
RESEARCH INSTITUTE [US/US]; 10550 North Torrey
Pines Road, La Jolla, CA 92037 (US).
- (71) Applicants and
(72) Inventors: NEMEROW, Glen, R. [US/US]; 462 Cerro
Street, Encinitas, CA 92024 (US). VON SEGGERN,
Daniel, J. [US/US]; Apartment 30, 5175 Luigi Terrace,
San Diego, CA 92122 (US). FRIEDLANDER, Marty
[US/US]; 1720 Zapo Street, Del Mar, CA 92014 (US).
- (54) Agent: BECKER, Konrad; Novartis AG, Corporate In-
tellectual Property, Patent & Trademark Dept., CH-4002
Basel (CH).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished
upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 01/83729 A2

(54) Title: VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY

(57) Abstract: Adenovirus vector-based gene therapy methods for treating ocular disorders are provided. Adenovirus vectors for therapy of ocular diseases and methods of treatment using the vectors are provided. Compositions, kits, and methods of preparation and use of the vectors for gene therapy are provided.

VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY

Work described herein was supported by NIH grants EY11431 and HL54352. The government has certain rights in such subject matter.

5 RELATED APPLICATIONS

This application claims the benefit of priority to U.S. application Serial No. 09/562,934, filed May 1, 2000, to Glen R. Nemerow, Daniel Von Seggern,; Martin Friedlander, entitled "VECTORS FOR OCULAR TRANSDUCTION AND USE THEREFOR FOR GENETIC THERAPY".

- 10 This application is related to copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265, filed January 14, 2000)), to Daniel Von Seggern, Glen R. Nemerow, Paul Hallenbeck, Susan Stevenson, Yelena Skripchenko, filed January 14, 2000, entitled "Adenovirus Vectors, Packaging Cell Lines, Compositions, and
- 15 Methods for Preparation and Use," which is a continuation-in-part of U.S. Application 09/423,783 filed November 12, 1999 and claims the benefit of the filing date of U.S. Provisional Application 60/115,920 filed January 14, 1999. Where permitted, the contents and subject matter of each application and of the provisional application are incorporated in their entirety herein by reference.

20 FIELD OF INVENTION

- The present invention relates to gene therapy, especially to adenovirus vector-based gene therapy. In particular, adenovirus vectors for therapy of ocular diseases and methods of treatment using the vectors are provided. Compositions, kits, and methods of preparation and use of the vectors for gene
- 25 therapy are provided.

BACKGROUND OF THE INVENTION

Retinal dystrophies

- The eye is susceptible to a number of hereditary and/or age related degenerative disorders. In the United States, common causes of irreversible
- 30 blindness or severe loss of vision are retinal dystrophies (see, *e.g.*, Cotlier *et al.* (1995) *Surv. Ophthalmology* 40:51-61; Bird (1995) *Am. J. Ophthalm.* 119: 543-562; and Adler (1996) *Arch Ophthalm* 114:79-83). The retina is the sensory

-2-

tunic of the eye, containing light sensitive receptors, a complex of neurons, and pigmented epithelium, arranged in discrete layers. In humans, the macula is the portion of the retina that lies directly behind the lens. Cones, the photoreceptor cells responsible for central vision, are heavily concentrated in the macula.

5 Central dystrophies, which affect the macula, include Best's disease, age-related macular degeneration, and Stargardt's macular dystrophy. The peripheral retina is composed mainly of rods, which are responsible for side and night vision. Peripheral degenerative retinal diseases include retinitis pigmentosa, choroidemia and Bietti's crystalline dystrophy.

10 Macular degenerations are a heterogenous group of diseases, characterized by progressive central vision loss and degeneration of the macula and underlying retinal pigmented epithelium. Age-related macular degeneration (ARMD) is the most common form of the disease, affecting an estimated 20% of persons over 75 years of age. ARMD is poorly understood in terms of etiology
15 and pathogenesis. The very late onset of the disease has made genetic mapping particularly difficult. Certain macular degenerative conditions with a clear genetic basis, such as Stargardt's and Best's diseases, share many features with ARMD, but have been more amenable to molecular and genetic analysis.

Hereditary peripheral retinopathies are also relatively common. Retinitis
20 pigmentosa (RP), for example, affects approximately 1.5 million people worldwide. Substantial genetic heterogeneity has been observed in this condition, with over 20 chromosomal loci identified. A predisposition to retinitis pigmentosa can be inherited by autosomal dominant, autosomal recessive, X-linked or digenic mode. Mutations have been identified in seven genes, four of
25 which encode proteins in the rod phototransduction cascade: rhodopsin, alpha and beta subunits of rod cGMP phosphodiesterase, and rod cGMP cation-gated channel protein .alpha. subunit. Mutations in the peripherin/RDS gene have been linked to retinitis pigmentosa and macular degeneration. A single peripherin/RDS mutation apparently caused retinitis pigmentosa, pattern dystrophy and fundus
30 flavimaculatus, in different family members.

-3-

In spite of causal heterogeneity, there is significant clinical similarity among RP subtypes. Common signs and symptoms include early electroretinographic abnormalities, ophthalmoscopic findings, and protracted, contiguous expansion of the ring-like scotoma toward the macula, leading to progressively worsening tunnel vision. A recent hypothesis is that active photoreceptor cell death, which is characteristic of these genetically distinct disorders, is mediated by a common induction of apoptosis. It may be possible to treat these conditions by the administration of agents that block induction of apoptosis in photoreceptors, such as neurotrophic factors.

10 Adenovirus delivery vectors

Adenovirus, which is a DNA virus with a 36 kilobase (kb) genome, is very well-characterized and its genetics and genetic organization are understood. The genetic organization of adenoviruses permits substitution of large fragments of viral DNA with foreign DNA. In addition, recombinant adenoviruses are structurally stable and no rearranged viruses are observed after extensive amplification.

Adenoviruses have been employed as delivery vehicles for introducing desired genes into eukaryotic cells. The adenovirus delivers such genes to eukaryotic cells by binding to cellular receptors followed by internalization. The adenovirus fiber protein is responsible for binding to cells. The fiber protein has two domains, a rod-like shaft portion and a globular head portion that contains the receptor binding region. The fiber spike is a homotrimer, and there are 12 spikes per virion. Human adenoviruses bind to and infect a broad range of cultured cell lines and primary tissues from different species.

The 35,000+ base pair (bp) genome of adenovirus type 2 has been sequenced and the predicted amino acid sequences of the major coat proteins (hexon, fiber and penton base) have been described (see, e.g., Neumann *et al.*, *Gene* 69: 153-157 (1988); Herisse *et al.*, *Nuc. Acids Res.* 9: 4023-4041 (1981); Roberts *et al.*, *J. Biol. Chem.* 259: 13968-13975 (1984); Kinloch *et al.*, *J. Biol. Chem.* 259: 6431-6436 (1984); and Chroboczek *et al.*, *Viol.* 161: 549-554, 1987).

-4-

The 35,935 bp sequence of Ad5 DNA is also known and portions of many other adenovirus genomes have been sequenced. The upper packaging limit for adenovirus virions is about 105% of the wild-type genome length (see, *e.g.*, Bett, *et al.*, *J. Virol.* 67(10): 5911-21, 1993). Thus, for Ad2 and Ad5, this would be an upper packaging limit of about 38kb of DNA.

Adenovirus DNA also includes inverted terminal repeat sequences (ITRs) ranging in size from about 100 to 150 bp, depending on the serotype. The inverted repeats permit single strands of viral DNA to circularize by base-pairing of their terminal sequences to form base-paired "panhandle" structures that are required for replication of the viral DNA.

For efficient packaging, the ITRs and the packaging signal (a few hundred bp in length) comprise the "minimum requirement" for replication and packaging of a genomic nucleic acid into an adenovirus particle. Helper-dependent vectors lacking all viral ORFs but including these essential *cis* elements (the ITRs and contiguous packaging sequence) have been constructed.

Ad vectors have several distinct advantages as gene delivery vehicles. For example, recombination of such vectors is rare; there are no known associations of human malignancies with adenoviral infections despite common human infection with adenoviruses; the genome may be manipulated to accommodate foreign genes of a fairly substantial size; and host proliferation is not required for expression of adenoviral proteins. Adenovirus (Ad)-based gene delivery vectors efficiently infect many different cells and tissues. This broad tropism, however, means that gene delivery cannot be directed to a specific target cell. A large fraction of intravenously administered adenovirus is retained by the liver, which could lead to undesirable side-effects. Adenovirus may potentiate immune responses. For example, Adenovirus type 5 (Ad5) also transduces dendritic cells, which present antigens very efficiently, thereby possibly exacerbating the immune response against the vector. It has been proposed that vectors with different targeting efficiencies might eliminate these problems, permitting a lower total particle dose and more specific targeting (see, *e.g.*, U.S. application Serial No. 09/482,682).

-5-

The wealth of information on adenovirus structure and mechanism of infection, its efficient infection of nondividing cells, and its large genetic capacity make adenovirus a popular gene therapy vector. The wide expression of receptors to which adenovirus binds makes targeting adenovirus vectors
5 difficult.

Hence there is a need to improve delivery and targeting of adenoviral vectors and also to provide treatments for ocular disorders. Therefore, it is an object herein to provide adenoviral vectors that specifically or selectively target cells in the eye. It is also an object herein to provide these vectors for treatment
10 of ocular disorders.

SUMMARY OF THE INVENTION

Degenerative ocular diseases, such as, but not limited to, retinitis pigmentosa, Stargardt's disease, diabetic retinopathies, retinal vascularization, and others (see, *e.g.*, Table below), have a genetic basis. Genes expressed in
15 the photoreceptor cells at the back of the retina are implicated in these diseases. Provided herein are recombinant viral vectors for targeting therapeutic products to these cells.

Recombinant adenoviral vectors that include nucleic acid that permits specific binding to these photoreceptors are provided. In particular, the vector
20 particles contain a fiber protein of Ad37 or a modified form thereof. As shown herein, fiber protein from Ad37 permits efficient infection of photoreceptor cells. Fiber proteins from other adenovirus D serotypes may also be used. In addition, the portions of the fiber protein, particularly those that interact with other viral structural proteins, such as penton, may be modified to resemble the viral source
25 of the other structural proteins. As exemplified herein, the recombinant virus provided herein include Ad5 structural components. The N-terminus of the Ad37 fiber protein, which interacts with the penton protein, is modified to resemble the Ad5 fiber protein N-terminus to ensure production of viral particles.

The recombinant adenoviral vectors are intended for gene therapy of
30 diseases in which genes expressed in the photoreceptors are implicated. Such diseases include, but are not limited to, degenerative ocular diseases, such as retinitis pigmentosa and Stargardt's disease. These vectors are also useful for

-6-

targeting to other ocular cells, such as conjunctival cells, which also bear receptors to which fiber from Ad37 and related serotypes bind.

The vectors will deliver therapeutic agents to the targeted cells for treatment of a variety of disorders (see *e.g.*, Tables 3 and 4, below)). The
5 therapeutic agents are intended for expression in the photoreceptors and for secretion from the photoreceptor cells, which are surrounded on one side by choroidal vasculature, and on the other side by retinal vasculature, thereby providing a means for delivery of products. In addition, expression of growth factors, such as VEGF and others, can be used to enhance blood flow to the
10 retina and prevent or slow the degeneration.

Therapeutic agents encoded by the recombinant adenoviral vectors include, but are not limited to, nucleic acid molecules encoding genes that are defective in certain hereditary disorders, nucleic acid molecules that encode antiangiogenics and antitumor agents for treatment of retinal
15 disorders, such as retinoblastomas; nucleic acid molecules encoding trophic factors, such as glial cell line-derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF), growth factors and growth factor inhibitors, antiapoptotic factors, such as Bcl-2 (CNTF), antitumor agents, anti-angiogenics, and genes or portions thereof for gene replacement or repair of defective genes.
20 Hence, methods for treatment of inherited and acquired retinal diseases, including diseases involving neovascular and vascular degeneration are provided.

Methods for treating diseases involving genes expressed in photoreceptor cells are provided herein. The methods provided herein are practiced by
25 administration of the recombinant viral vectors by any means suitable for delivery to the photoreceptors. A preferred mode of administration is intraocular injection including intravitreal and subretinal injection. Other modes of administration include, but are not limited to, intrascleral, periorbital and intravenous administration. The vectors also can include photoreceptor-specific
30 promoters thereby providing a means, not only for specific targeting of expression in these cells, but also for photoreceptor-restricted transgene expression.

-7-

DETAILED DESCRIPTION OF THE INVENTION**A. DEFINITIONS**

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents, applications, published applications and other publications and sequences from GenBank and other data bases referred to anywhere in the disclosure herein are incorporated by reference in their entirety.

As used herein, the amino acids, which occur in the various amino acid sequences appearing herein, are identified according to their three-letter or one-letter abbreviations. The nucleotides, which occur in the various DNA fragments, are designated with the standard single-letter designations used routinely in the art (see Table 1).

As used herein, amino acid residue refers to an amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are preferably in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. NH₂ refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxyl terminus of a polypeptide. In keeping with standard polypeptide nomenclature described in *J. Biol. Chem.*, 243:3552-59 (1969) and adopted at 37 C.F.R. § 1.821 - 1.822, abbreviations for amino acid residues are shown in the following Table:

25

Table 1
Table of Correspondence

SYMBOL		AMINO ACID
1-Letter	3-Letter	
Y	Tyr	tyrosine
G	Gly	glycine
F	Phe	phenylalanine
M	Met	methionine

30

-8-

5

10

15

20

SYMBOL		
A	Ala	alanine
S	Ser	serine
I	Ile	isoleucine
L	Leu	leucine
T	Thr	threonine
V	Val	valine
P	Pro	proline
K	Lys	lysine
H	His	histidine
Q	Gln	glutamine
E	Glu	glutamic acid
Z	Glx	Glu and/or Gln
W	Trp	tryptophan
R	Arg	arginine
D	Asp	aspartic acid
N	Asn	asparagine
B	Asx	Asn and/or Asp
C	Cys	cysteine
X	Xaa	Unknown or other

It should be noted that all amino acid residue sequences represented herein by formulae have a left to right orientation in the conventional direction of amino-terminus to carboxyl-terminus. In addition, the phrase "amino acid residue" is broadly defined to include the amino acids listed in the Table of Correspondence and modified and unusual amino acids, such as those referred to in 37 C.F.R. § § 1.821-1.822, and incorporated herein by reference. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or

-9-

more amino acid residues or to an amino-terminal group such as NH₂ or to a carboxyl-terminal group such as COOH.

In a peptide or protein, suitable conservative substitutions of amino acids are known to those of skill in this art and may be made generally without altering the biological activity of the resulting molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson et al. *Molecular Biology of the Gene*, 4th Edition, 1987, The Bejacmin/Cummings Pub. co., p.224).

Such substitutions are preferably made in accordance with those set forth in TABLE 2 as follows:

TABLE 2	
Original residue	Conservative substitution
Ala (A)	Gly; Ser
Arg (R)	Lys
Asn (N)	Gln; His
Cys (C)	Ser
Gln (Q)	Asn
Glu (E)	Asp
Gly (G)	Ala; Pro
His (H)	Asn; Gln
Ile (I)	Leu; Val
Leu (L)	Ile; Val
Lys (K)	Arg; Gln; Glu
Met (M)	Leu; Tyr; Ile
Phe (F)	Met; Leu; Tyr
Ser (S)	Thr
Thr (T)	Ser
Trp (W)	Tyr
Tyr (Y)	Trp; Phe
Val (V)	Ile; Leu

Other substitutions are also permissible and may be determined empirically or in accord with known conservative substitutions.

As used herein, a complementing plasmid describes plasmid vectors that deliver nucleic acids into a packaging cell line for stable integration into a chromosome in the cellular genome.

As used herein, a delivery plasmid is a plasmid vector that carries or delivers nucleic acids encoding a therapeutic gene or gene that encodes a

-10-

therapeutic product or a precursor thereof or a regulatory gene or other factor that results in a therapeutic effect when delivered *in vivo* in or into a cell line, such as, but not limited to a packaging cell line, to propagate therapeutic viral vectors.

5 As used herein, a variety of vectors with different requirements are described. For example, one vector is used to deliver particular nucleic acid molecules into a packaging cell line for stable integration into a chromosome. These types of vectors are generally identified herein as complementing plasmids. A further type of vector described herein carries or delivers nucleic
10 acid molecules in or into a cell line (*e.g.*, a packaging cell line) for the purpose of propagating therapeutic viral vectors; hence, these vectors are generally referred to herein as delivery plasmids. A third "type" of vector described herein is used to carry nucleic acid molecules encoding therapeutic proteins or polypeptides or regulatory proteins or are regulatory sequences to specific cells or cell types in a
15 subject in need of treatment; these vectors are generally identified herein as therapeutic viral vectors or recombinant adenoviral vectors or viral Ad-derived . vectors and are in the form of a virus particle encapsulating a viral nucleic acid containing an expression cassette for expressing the therapeutic gene.

As used herein, a DNA or nucleic acid homolog refers to a nucleic acid
20 that includes a preselected conserved nucleotide sequence, such as a sequence encoding a therapeutic polypeptide. By the term "substantially homologous" is meant having at least 80%, preferably at least 90%, most preferably at least 95% homology therewith or a lesser percentage of homology or identity and conserved biological activity or function.

25 The terms "homology" and "identity" are often used interchangeably. In this regard, percent homology or identity may be determined, for example, by comparing sequence information using a GAP computer program. The GAP program utilizes the alignment method of Needleman and Wunsch (*J. Mol. Biol.* 48:443 (1970), as revised by Smith and Waterman (*Adv. Appl. Math.* 2:482
30 (1981)). Briefly, the GAP program defines similarity as the number of aligned symbols (*i. .*, nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default

-11-

parameters for the GAP program may include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov and Burgess, *Nucl. Acids Res.* 14:6745 (1986), as described by Schwartz and Dayhoff, eds., *ATLAS OF PROTEIN SEQUENCE*
 5 *AND STRUCTURE*, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

Whether any two nucleic acid molecules have nucleotide sequences that
 10 are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical" can be determined using known computer algorithms such as the "FAST A" program, using for example, the default parameters as in Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 (1988). Alternatively the BLAST function of the
 National Center for Biotechnology Information database may be used to
 15 determine identity.

In general, sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. (See, e.g.: *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics*
 20 *and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).
 25 While there exist a number of methods to measure identity between two polynucleotides or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge
 30 Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988). Methods to determine identity and similarity are codified in computer programs. Preferred

-12-

computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., *et al.*, *Nucleic Acids Research* 12(II):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., *et al.*, *J Molec Biol* 215:403 (1990)).

5 Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide. For example, a test polypeptide may be defined as any polypeptide that is 90% or more identical to a reference polypeptide. As used herein, the term at least "90% identical to" refers to percent identities from 90 to 99.99 relative to the
10 reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared. No more than 10% (i.e., 10 out of 100) amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons may be made between a test and
15 reference polynucleotides. Such differences may be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they may be clustered in one or more locations of varying length up to the maximum allowable, e.g. 10/100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, or
20 deletions.

As used herein, genetic therapy involves the transfer of heterologous DNA to the certain cells, target cells, of a mammal, particularly a human, with a disorder or conditions for which such therapy is sought. The DNA is introduced into the selected target cells in a manner such that the heterologous DNA is
25 expressed and a therapeutic product encoded thereby is produced. Alternatively, the heterologous DNA may in some manner mediate expression of DNA that encodes the therapeutic product, it may encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product. Genetic therapy may also be used to deliver nucleic
30 acid encoding a gene product to replace a defective gene or supplement a gene product produced by the mammal or the cell in which it is introduced. The introduced nucleic acid may encode a therapeutic compound, such as a growth

-13-

factor inhibitor thereof, or a tumor necrosis factor or inhibitor thereof, such as a receptor therefor, that is not normally produced in the mammalian host or that is not produced in therapeutically effective amounts or at a therapeutically useful time. The heterologous DNA encoding the therapeutic product may be modified
5 prior to introduction into the cells of the afflicted host in order to enhance or otherwise alter the product or expression thereof.

As used herein, heterologous DNA is DNA that encodes RNA and proteins that are not normally produced *in vivo* by the cell in which it is expressed or that mediates or encodes mediators that alter expression of endogenous DNA by
10 affecting transcription, translation, or other regulatable biochemical processes. Heterologous DNA may also be referred to as foreign DNA. Any DNA that one of skill in the art would recognize or consider as heterologous or foreign to the cell in which it is expressed is herein encompassed by heterologous DNA.

Examples of heterologous DNA include, but are not limited to, DNA that encodes
15 traceable marker proteins, such as a protein that confers drug resistance, DNA that encodes therapeutically effective substances, such as anti-cancer agents, enzymes and hormones, and DNA that encodes other types of proteins, such as antibodies. Antibodies that are encoded by heterologous DNA may be secreted or expressed on the surface of the cell in which the heterologous DNA has been
20 introduced.

Hence, herein heterologous DNA or foreign DNA, refers to a DNA molecule not present in the exact orientation and position as the counterpart DNA molecule found in the corresponding wild-type adenovirus. It may also refer to a DNA molecule from another organism or species (*i.e.*, exogenous) or
25 from another Ad serotype.

As used herein, a therapeutically effective product is a product that is encoded by heterologous DNA that, upon introduction of the DNA into a host, a product is expressed that effectively ameliorates or eliminates the symptoms, manifestations of an inherited or acquired disease or that cures said disease.

30 Typically, DNA encoding the desired heterologous DNA is cloned into a plasmid vector and introduced by routine methods, such as calcium-phosphate mediated DNA uptake (see, (1981) Somat. Cell. Mol. Genet. 7:603-616) or

-14-

microinjection, into producer cells, such as packaging cells. After amplification in producer cells, the vectors that contain the heterologous DNA are introduced into selected target cells.

As used herein, an expression or delivery vector refers to any plasmid or
5 virus into which a foreign or heterologous DNA may be inserted for expression in a suitable host cell — *i.e.*, the protein or polypeptide encoded by the DNA is synthesized in the host cell's system. Vectors capable of directing the expression of DNA segments (genes) encoding one or more proteins are referred to herein as "expression vectors." Also included are vectors that allow cloning
10 of cDNA (complementary DNA) from mRNAs produced using reverse transcriptase.

As used herein, a gene is a nucleic acid molecule whose nucleotide sequence encodes RNA or polypeptide. A gene can be either RNA or DNA. Genes may include regions preceding and following the coding region (leader and
15 trailer) as well as intervening sequences (introns) between individual coding segments (exons).

As used herein, tropism with reference to an adenovirus refers to the selective infectivity or binding that is conferred on the particle by the fiber protein, such as by the C-terminus portion that comprises the knob.

20 As used herein, isolated with reference to a nucleic acid molecule or polypeptide or other biomolecule means that the nucleic acid or polypeptide has separated from the genetic environment from which the polypeptide or nucleic acid were obtained. It may also mean altered from the natural state. For example, a polynucleotide or a polypeptide naturally present in a living animal is
25 not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Thus, a polypeptide or polynucleotide produced and/or contained within a recombinant host cell is considered isolated. Also intended as an "isolated polypeptide" or an "isolated polynucleotide" are polypeptides or polynucleotides
30 that have been purified, partially or substantially, from a recombinant host cell or from a native source. For example, a recombinantly produced version of a compound can be substantially purified by the one-step method described in

-15-

Smith and Johnson, *Gene* 67:31-40 (1988). The terms isolated and purified are sometimes used interchangeably.

Thus, by "isolated" is meant that the nucleic acid is free of the coding sequences of those genes that, in the naturally-occurring genome of the
5 organism (if any) immediately flank the gene encoding the nucleic acid of interest. Isolated DNA may be single-stranded or double-stranded, and may be genomic DNA, cDNA, recombinant hybrid DNA, or synthetic DNA. It may be identical to a native DNA sequence, or may differ from such sequence by the deletion, addition, or substitution of one or more nucleotides.

10 Isolated or purified as it refers to preparations made from biological cells or hosts means any cell extract containing the indicated DNA or protein including a crude extract of the DNA or protein of interest. For example, in the case of a protein, a purified preparation can be obtained following an individual technique or a series of preparative or biochemical techniques and the DNA or protein of
15 interest can be present at various degrees of purity in these preparations. The procedures may include for example, but are not limited to, ammonium sulfate fractionation, gel filtration, ion exchange chromatography, affinity chromatography, density gradient centrifugation and electrophoresis.

A preparation of DNA or protein that is "substantially pure" or "isolated"
20 should be understood to mean a preparation free from naturally occurring materials with which such DNA or protein is normally associated in nature. "Essentially pure" should be understood to mean a "highly" purified preparation that contains at least 95% of the DNA or protein of interest.

A cell extract that contains the DNA or protein of interest should be
25 understood to mean a homogenate preparation or cell-free preparation obtained from cells that express the protein or contain the DNA of interest. The term "cell extract" is intended to include culture media, especially spent culture media from which the cells have been removed.

As used herein, a packaging cell line is a cell line that provides a missing
30 gene product or its equivalent.

As used her in, an adenovirus viral particle is the minimal structural or functional unit of a virus. A virus can refer to a single particle, a stock of

-16-

particles or a viral genome. The adenovirus (Ad) particle is relatively complex and may be resolved into various substructures.

As used herein, "penton" or "penton complex" are preferentially used herein to designate a complex of penton base and fiber. The term "penton" may
5 also be used to indicate penton base, as well as penton complex. The meaning of the term "penton" alone should be clear from the context within which it is used.

As used herein, a plasmid refers to an autonomous self-replicating extrachromosomal circular nucleic acid molecule, typically DNA.

10 As used herein, a post-transcription regulatory element (PRE) is a regulatory element found in viral or cellular messenger RNA that is not spliced, i.e. intronless messages. Examples include, but are not limited to, human hepatitis virus, woodchuck hepatitis virus, the TK gene and mouse histone gene. The PRE may be placed before a polyA sequence and after a heterologous DNA
15 sequence.

As used herein, pseudotyping describes the production of adenoviral vectors having modified capsid protein or capsid proteins from a different serotype than the serotype of the vector itself. One example, is the production of an adenovirus 5 vector particle containing an Ad37 fiber protein. This may be
20 accomplished by producing the adenoviral vector in packaging cell lines expressing different fiber proteins.

As used herein, promoters of interest herein may be inducible or constitutive. Inducible promoters will initiate transcription only in the presence of an additional molecule; constitutive promoters do not require the presence of
25 any additional molecule to regulate gene expression. a regulatable or inducible promoter may also be described as a promoter where the rate or extent of RNA polymerase binding and initiation is modulated by external stimuli. Such stimuli include, but are not limited to various compounds or compositions, light, heat, stress and chemical energy sources. Inducible, suppressible and repressible
30 promoters are considered regulatable promoters. Preferred promoters herein, are promoters that are selectively expressed in ocular cells, particularly photoreceptor cells.

-17-

As used herein, receptor refers to a biologically active molecule that specifically or selectively binds to (or with) other molecules. The term "receptor protein" may be used to more specifically indicate the proteinaceous nature of a specific receptor.

5 As used herein, recombinant refers to any progeny formed as the result of genetic engineering. This may also be used to describe a virus formed by recombination of plasmids in a packaging cell.

As used herein, a transgene or therapeutic nucleic acid molecule includes DNA and RNA molecules encoding an RNA or polypeptide. Such molecules may
10 be "native" or naturally-derived sequences; they may also be "non-native" or "foreign" that are naturally- or recombinantly-derived. The term "transgene," which may be used interchangeably herein with the term "therapeutic nucleic acid molecule," is often used to describe a heterologous or foreign (exogenous) gene that is carried by a viral vector and transduced into a host cell.

15 Therefore, therapeutic nucleotide nucleic acid molecules include antisense sequences or nucleotide sequences which may be transcribed into antisense sequences. Therapeutic nucleotide sequences (or transgenes) all include nucleic acid molecules that function to produce a desired effect in the cell or cell nucleus into which said therapeutic sequences are delivered. For example, a therapeutic
20 nucleic acid molecule can include a sequence of nucleotides that encodes a functional protein intended for delivery into a cell which is unable to produce that functional protein.

As used herein, the vitreous of the eye refers to material that fills the chamber behind the lens of the eye (i.e., vitreous humor or vitreous body).

25 As used herein, a promoter region refers to the portion of DNA of a gene that controls transcription of the DNA to which it is operatively linked. The promoter region includes specific sequences of DNA that are sufficient for RNA polymerase recognition, binding and transcription initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region
30 includes sequences that modulate this recognition, binding and transcription initiation activity of the RNA polymerase. These sequences may be *cis* acting or

-18-

may be responsive to *trans* acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated.

Thus, promoters are nucleic acid fragments that contain a DNA sequence that controls the expression of a gene located 3' or downstream of the promoter. The promoter is the DNA sequence to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene, typically located 3' of the promoter. A promoter also includes DNA sequences that direct the initiation of transcription, including those to which RNA polymerase specifically binds. If more than one nucleic acid sequence encoding a particular polypeptide or protein is included in a therapeutic viral vector or nucleotide sequence, more than one promoter or enhancer element may be included, particularly if that would enhance efficiency of expression.

A regulatable or inducible promoter may be described as a promoter wherein the rate of RNA polymerase binding and initiation is modulated by external stimuli. (see, *e.g.*, U.S. Patent Nos. 5,750,396 and 5,998,205). Such stimuli include various compounds or compositions, light, heat, stress, chemical energy sources, and the like. Inducible, suppressible and repressible promoters are considered regulatable promoters.

Regulatable promoters may also include tissue-specific promoters. Tissue-specific promoters direct the expression of the gene to which they are operably linked to a specific cell type. Tissue-specific promoters cause the gene located 3' of it to be expressed predominantly, if not exclusively, in the specific cells where the promoter expressed its endogenous gene. Typically, it appears that if a tissue-specific promoter expresses the gene located 3' of it at all, then it is expressed appropriately in the correct cell types (see, *e.g.*, Palmiter et al. (1986) Ann. Rev. Genet. 20: 465-499).

As used herein, the phrase "operatively linked" generally means the sequences or segments have been covalently joined into one piece of DNA, whether in single or double stranded form, whereby control sequences on one segment control expression or replication or other such control of other segments. The two segments are not necessarily contiguous.

As used herein, exogenous encompasses any therapeutic composition that is administered by the therapeutic methods provided herein. Thus, exogenous may also be referred to herein as foreign, or non-native or other equivalent expression.

5 B. Ad37 fiber tropism

The adenovirus fiber protein is a major determinant of adenovirus tropism (Gall *et al.* (1996) *J. Virol.* 70:2116-2123; Stevenson *et al.* (1995) *J. Virol.* 69:2850-2857). The fiber protein extends from the capsid and mediates viral binding to the cell surface by binding to specific cell receptors (Philipson *et al.* (1968) *J. Virol.* 2:1064-1075). The fiber is a trimeric protein that includes an N-terminal tail domain that interacts with the adenovirus penton base, a central shaft domain of varying length, and a C-terminal knob domain that contains the cell receptor binding site (Chroboczek *et al.* (1995) *Curr. Top. Microbiol. Immunol.* 199:163-200; Riurok *et al.* (1990) *J. Mol. Biol.* 215:589-596; Stevenson *et al.* (1995) *J. Virol.* 69:2850-2857). Fiber proteins of most adenovirus subgroups have been shown to bind specifically or selectively to the 46 kDa coxsackievirus-adenovirus receptor (CAR), (Bergelson *et al.* (1997) *Science* 275:1320-1323; Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915). CAR appears to be expressed in a variety of human tissues, including the lung, at various levels (Bergelson *et al.* (1997) *Science* 275:1320-1323), but Ad37 binds poorly to lung epithelial cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). This suggests that the tropism of this serotype may be influenced by factors independent of CAR expression.

Structural and biochemical data also suggest that distinct receptor binding sites are located on different regions of the Ad5 and Ad37 fiber knobs.

Adopting the nomenclature of Xia *et al.* (Xia *et al.* (1994) *Structure* 2:1259-1270), the receptor binding site for Ad5 is located at the AB-loop on the side of the fiber knob (Bewley *et al.* (1999) *Science* 286:1579-1583; Roelvink *et al.* (1999) *Science* 286:1568-1571). It is known that a lysine residue at position 240 of the Ad37 fiber, located in the CD-loop, is important for receptor binding (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). The co-crystal structure of the Ad12 knob and the N-terminal domain of CAR (Bewley *et al.* (1999) *Science* 286:1579-1583) show that the CD-loop does not contact CAR. It thus appears

-20-

that different regions of the Ad5 and Ad37 fiber knobs recognize distinct cell receptors.

A 46 kDa receptor for coxsackieviruses and adenoviruses (CAR) mediates attachment for many adenovirus serotypes. The wide distribution of CAR fails to explain why certain adenovirus serotypes (i.e. Ad37) are highly associated with severe ocular infections such as epidemic keratoconjunctivitis (EKC). Ad37 does not use CAR, but instead uses a glycoprotein that contains sialic acid as its primary receptor (Arnberg *et al.* (2000) *J. Virol.* 74:42-48). The modest number of Ad37 binding sites per cell (Huang *et al.* (1999) *J. Virol.* 73:2798-2802) also suggests that Ad37 recognizes a specific glycoprotein as its primary receptor for binding to conjunctival cells.

Adenovirus type 37 (subgroup D) has been associated with infections of the eye and genital tract. The tropism of Ad37 derives from the binding preference of its fiber protein, which binds to a receptor located on the surface of cells including Chang C, conjunctival epithelial cell line (Huang *et al.* (1999) *J. Virology* 73:2798-2802).

A protein receptor that is preferentially expressed on conjunctival cells to which Ad37 fiber binds is shown herein. The preferential expression of the Ad37 receptor protein on conjunctival cells suggests that this receptor likely influences Ad37 tropism and should play a key role in ocular pathogenesis. It is shown herein that Ad37 uses a distinct protein receptor that is selectively expressed on conjunctival cells. It is shown that Ad37 binds well to conjunctival cells (Chang C), but poorly to lung carcinoma cells (A549). To determine if infection correlated with cell binding, an Ad5 vector containing the Ad37 fiber protein was constructed. The 'pseudotyped' vector delivered transgenes to Chang C cells better than to A549 cells. Ad37 binding was abolished by protease treatment of Chang C cells, indicating the receptor is a membrane protein. Ad37 binding to conjunctival cells is shown herein to be calcium-dependent. It is also shown that Ad37 infection was not inhibited by a function-blocking anti-CAR monoclonal antibody, which is a feature distinct from Ad5 fiber interaction with CAR. Using a virus overlay protein blot assay (VOPBA), calcium-dependent Ad37 binding to a 50 KDa membrane protein on Chang C

-21-

cells, but not A549 cells was detected. Ad19p a closely related serotype that fails to bind to conjunctival cells, does not recognize the 50 kDa protein. Together, these data indicate that the 50 kDa protein is a candidate receptor for Ad37 on conjunctival cells.

5 Significantly, it is also shown herein that, upon administration of the vector to the vitreous humor, the recombinant adenovirus with the Ad37 fiber preferentially and selectively binds to photoreceptor cells. Hence, a recombinant adenoviral delivery vehicle that has an Ad37 fiber protein can serve as a vector for delivery of therapeutic agents to the eye for treatment of ocular disorders,
10 including genetic and acquired disorders. The identification of the receptor for Ad37 and the resulting recognition of Ad37 tropism allows targeting of adenovirus vectors to specific human ocular cells.

 As noted, fiber plays a crucial role in adenovirus infection by attaching the virus to a specific receptor on a cell surface. Hexon, penton and fiber
15 capsomeres are the major components on the surface of the virion. The fiber is an elongated protein which exists as a trimer of three identical polypeptides (polypeptide IV) of 582 amino acids in length. An adenovirus fiber includes three domains: an N-terminal tail domain that interacts with penton base; a shaft composed of variable numbers of repeats of a 15-amino-acid segment that
20 forms beta-sheet and beta-bends; and a knob at the C-terminus ("head domain") that contains the type-specific antigen and is responsible for binding to the cell surface receptor. The gene encoding the fiber protein from Ad2 has been expressed in human cells and has been shown to be correctly assembled into trimers, glycosylated and transported to the nucleus (see, *e.g.*, Hong and Engler,
25 *Virology* 185: 758-761, 1991). Thus, alteration of the fiber in recombinant Ad vectors can lead to alteration in gene delivery.

 As shown herein, alteration of fiber in recombinant Ad vectors such that the fiber is derived from Ad37 or another adenovirus serotype D, provides a means for selective delivery of a recombinant virus to particular cells in the eye,
30 including conjunctival cells, and most significantly photoreceptors, thereby providing a means for targeted delivery to photoreceptor cells.

-22-

Photoreceptor cells are implicated in a number of hereditary and acquired retinal degenerative disorders. In addition, photoreceptor cells are located such that products produced therein can be delivered to other areas of the eye by virtue of the blood flow in the vicinity of the photoreceptor cells and also by
5 virtue of the proximity of the photoreceptors to the retinal pigmented epithelium (RPE) and other retinal cells.

Hence it is contemplated herein that the recombinant viral vector will include a packaged recombinant adenovirus genome containing at least the minimal elements for replication and packaging; heterologous DNA encoding a
10 desired gene product, typically a therapeutic product or plurality of products, such as several trophic factors, whose combined activity is effective for treating a disorder, such as a retinal degenerative disorder; and the resulting virion particles will include a fiber that has a sufficient portion to confer specific
targeting to photoreceptor cells when the recombinant viral particles are
15 introduced into the aqueous humor of a mammalian, preferably a human, eye, or otherwise contacted with the photoreceptor cells. The fiber may be a chimeric protein that has been modified for effective interaction with other coat structural proteins, such as penton. In addition, the fiber may be modified to include other elements that alter its tropism to permit binding to other cells as well (see, *e.g.*,
20 U.S. Patent Nos. 5,756,086 and 5,543,328, International PCT application No. WO 95/26412 and WO 98/44121 and Krasnykh, *et al.* (*J. Virol.* 70: 6839-46, 1996).

C. Construction of the viral particles

1. Selection of viral genome and fiber protein

25 Methods for preparing recombinant adenoviral vectors for gene product delivery are well known. Preferred among those are the methods exemplified herein (see EXAMPLES) and also described in copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265, filed January 14, 2000, which claims priority to U.S.
30 provisional application Serial No. 60/115,920, as does U.S. application Serial No. 09/482,682)).

-23-

As noted, any desired recombinant adenovirus is contemplated for use in the methods herein as long as the viral genome is packaged in a capsid that includes at least the portion of a fiber protein that provides selective binding to photoreceptor cells. This fiber protein is preferably from an adenovirus type D serotype and is preferably an Ad37 fiber. The fiber protein should retain the knob region at the C-terminus ("head domain") from the Ad virus of subgroup D that contains the type-specific antigen and is responsible for binding to the cell surface receptor. Hence the fiber protein can be a chimeric fiber protein as long as it retains a sufficient portion of the type D serotype to specifically or selectively bind to photoreceptor cells. Generally the portion retained will be all or a portion of the knob region. The precise amount of knob region required can be determined empirically by including portions thereof and identifying the minimum residues from an Ad type D serotype, preferably Ad37, to effect selective targeting of a virion packaged with such fiber to photoreceptors in the eye upon introduction of the packaged virion into the aqueous humor.

Recombinant adenovirus containing heterologous nucleic acids that encode a desired product, such a gene to correct a genetic defect, may be made by any methods known to those of skill in the art. The viruses must be packaged in a cell line that results in expression of fiber on the particles that specifically, electively or preferentially targets (binds and results in internalization) the viral particle to cells in the eye. The fiber protein from Ad37 and other Adenoviruses of serotype D that infect the eye effects such targeting. The resulting adenovirus particles that express such fiber is administered by intraocular injection, subretinal injection, particularly intravitreal injection, or any means that results in preferential accumulation in photoreceptor cells.

The family of Adenoviridae includes many members with at least 47 known serotypes of human adenovirus (Ad1-Ad47) (Shenk, *Virology*, Chapter 67, in Fields *et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) as well as members of the genus Mastadenovirus including human, simian, bovine, equine, porcine, ovine, canine and opossum viruses and members of the Aviadenovirus genus, including bird viruses, such as CELO.

-24-

Thus it is contemplated that the methods herein can be applied to any recombinant viral vectors derived from any adenovirus species. One of skill in the art would have knowledge of the different adenoviruses (see, *e.g.*, Shenk, *Virology*, Chapter 67, in Fields *et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) and can construct recombinant viruses containing portions of the genome of any such virus.

In the exemplified embodiment, viral particles with Ad37 fiber were prepared. Site-directed mutations were made to the Ad37 fiber gene to make the tail sequence more closely match that of Ad5 to facilitate Ad37 fiber binding to the Ad5 penton base. The plasmid for the expression of the Ad37 fiber protein, pDV80, contains the CMV promoter, the adenovirus type 5 tripartite leader (TPL), and the modified Ad37 fiber gene sequence. Genes of interest, such as nucleic acid encoding the β subunit of cGMP phosphodiesterase (β PDE), β -glucuronidase, rhodopsin, growth factors, anti-cancer agents, growth factor receptors and other anti-angiogenic agents, and anti-apoptotic agents, can be incorporated into these vectors using the methods known to those of skill in the art and exemplified herein.

Known adenovirus vectors, previously constructed for intraocular therapy (see, *e.g.*, Bennett *et al.* (1996) *Nature Medicine* 2:649-654, which provides an Ad virus encoding β PDE for treatment of retinitis pigmentosa; Cayouette *et al.* (1998) *Human Gene Therapy* 8:423-430, which provides an Ad vector that expresses CNTF for treatment of retinitis pigmentosa and other retinal degenerative diseases; and Li *et al.* (1995) *Proc. Natl. Acad. Sci. U.S.A.* 92:7700-7704, which provides an Ad virus vector that encodes a human β -glucuronidase for treatment of lysosomal storage disease caused by β -glucuronidase deficiency) can be modified by repackaging the recombinant genome using a packaging line that expresses an Ad37 fiber or other D serotype fiber.

For exemplification, nucleic acid encoding GFP was incorporated into these vectors as a means to visualize their localization. Other genes, such as genes that encode therapeutic products, may be included in place of or in addition to GFP.

-25-

Plasmid pDV80 was electroporated into E1-2a S8 cells and stable lines were selected. The fiber-deleted vectors Ad5. β gal. Δ F and Ad5.GFP. Δ F were grown in cells in a resulting cell line, designated 705, to produce virions, which express the Ad37 fiber (Ad5. β gal. Δ F/37F and Ad5.GFP. Δ F/37F) and CsCl-
5 purified. These virions selectively transduce photoreceptor cells when injected intraocularly into the vitreous humor.

2. Packaging

Recombinant adenoviral vectors generally have at least a deletion in the first viral early gene region, referred to as E1, which includes the E1a and E1b
10 regions. Deletion of the viral E1 region renders the recombinant adenovirus defective for replication and incapable of producing infectious viral particles in, subsequently-infected target cells. Thus, to generate E1-deleted adenovirus genome replication and to produce virus particles requires a system of
15 complementation which provides the missing E1 gene product. E1 complementation is typically provided by a cell line expressing E1, such as the human embryonic kidney packaging cell line, i.e. an epithelial cell line, called 293. Cell line 293 contains the E1 region of adenovirus, which provides E1 gene region products to "support" the growth of E1-deleted virus in the cell line (see, e.g., Graham *et al.*, *J. Gen. Virol.* 36: 59-71, 1977). Additionally, cell lines
20 that may be usable for production of defective adenovirus having a portion of the adenovirus E4 region have been reported (WO 96/22378).

Multiply deficient adenoviral vectors and complementing cell lines have also been described (WO 95/34671, U.S. Patent No. 5,994,106).

Copending U.S. application Serial No. 09/482,682 (also filed as
25 International PCT application No. PCT/US00/00265, filed January 14, 2000)) provides packaging cell lines that support viral vectors with deletions of major portions of the viral genome, without the need for helper viruses and also provides cell lines and helper viruses for use with helper-dependent vectors. The packaging cell line has heterologous DNA stably integrated into the
30 chromosomes of the cellular genome. The heterologous DNA sequence encodes one or more adenovirus regulatory and/or structural polypeptides that complement the genes deleted or mutated in the adenovirus vector genome to

-26-

be replicated and packaged. The packaging cell line express, for example, one or more adenovirus structural proteins, polypeptides, or fragments thereof, such as penton base, hexon, fiber, polypeptide IIIa, polypeptide V, polypeptide VI, polypeptide VII, polypeptide VIII, and biologically active fragments thereof. The
5 expression can be constitutive or under the control of a regulatable promoter. These cell lines are designed for expression of recombinant adenoviruses intended for delivery of therapeutic products.

Particular packaging cell lines complement viral vectors having a deletion or mutation of a DNA sequence encoding an adenovirus structural protein,
10 regulatory polypeptides E1A and E1B, and/or one or more of the following regulatory proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof.

The packaging cell lines are produced by introducing each DNA molecule into the cells and then into the genome via a separate complementing plasmid or plurality of DNA molecules encoding the complementing proteins can be
15 introduced via a single complementing plasmid. Of interest herein, is a variation in which the complementing plasmid includes DNA encoding adenovirus fiber protein (or a chimeric or modified variant thereof), from Ad virus of subgroup D, such as Ad 37, polypeptide or fragment thereof.

For therapeutic applications, the delivery plasmid further includes a
20 nucleotide sequence encoding a foreign polypeptide. Exemplary delivery plasmids include, but are not limited to, pDV44, pΔE1Bβ-gal and pΔE1sp1B. In a similar or analogous manner, therapeutic genes may be introduced.

The cell further includes a complementing plasmid encoding a fiber as contemplated herein; the plasmid or portion thereof is integrated into a
25 chromosome(s) of the cellular genome of the cell.

In one embodiment, a composition comprises a cell containing first and second delivery plasmids wherein a first delivery plasmid comprises an adenovirus genome lacking a nucleotide sequence encoding fiber and incapable of directing the packaging of new viral particles in the absence of a second
30 delivery plasmid, and a second delivery plasmid comprises an adenoviral genome capable of directing the packaging of new viral particles in the presence of the first delivery plasmid.

-27-

In a variation, the packaging cell line expresses fiber protein or chimeric variant thereof from an Ad virus of subgroup D, preferably Ad37, serotype or it can be any fiber protein but one that has been modified to include the portion of the Ad virus of subgroup D, such as Ad37, responsible for selective targeting to photoreceptors upon introduction into the vitreous humor of the eye of a mammal, preferably a human. The fiber protein can be further modified to include a non-native amino acid residue sequence that targets additional specific receptors. In all instances, the modification should not disrupt trimer formation or transport of fiber into the nucleus. In another variation, the non-native amino acid residue sequence alters the binding specificity of the fiber for a targeted cell type. The structural protein is fiber can include amino acid residue sequences from more than one adenovirus serotype. The nucleotide sequences encoding fiber protein or polypeptide need not be modified solely at one or both termini; fiber protein, may be modified "internally" as well as at the termini.

Additional nucleic acid fragments can encode polypeptides that are added to the fiber protein. In one variation, the non-native amino acid residue sequence is coupled to the carboxyl terminus of the fiber. In another, the non-native amino acid residue sequence further includes a linker sequence. Alternatively, the fiber protein further comprises a ligand coupled to the linker. Suitable ligands include, but are not limited to, ligands that specifically or selectively bind to a cell surface receptor and ligands that can be used to couple other proteins or nucleic acid molecules. Typically, the packaging cell lines will contain nucleic acid encoding the fiber protein or modified protein stably integrated into a chromosome or chromosomes in the cellular genome.

The packaging cell line can be derived from a procaryotic cell line or from a eukaryotic cell line. While various embodiments suggest the use of mammalian cells, and more particularly, epithelial cell lines, a variety of other, non-epithelial cell lines are used in various embodiments. Thus, while various embodiments disclose the use of a cell line selected from among the 293, A549, W162, HeLa, Vero, 211, and 211A cell lines, and any other cell lines suitable for such use are likewise contemplated herein.

3. Components of the nucleic acid molecule included in the particle

-28-

A recombinant viral vector or therapeutic viral vector for use in the methods herein, typically includes a nucleic acid fragment that encodes a protein or polypeptide molecule, or a biologically active fragment thereof, or other regulatory sequence, that is intended for use in therapeutic applications.

- 5 The nucleic acid molecule to be packaged in the viral particle also may include an enhancer element and/or a promoter located 3' or 5' to and controlling the expression of the therapeutic product-encoding nucleic acid molecule if the product is a protein. Further, for purposes herein, the promoter and/or other transcriptional and translational regulatory sequences controlling
10 expression of the product is preferably one that is expressed specifically in the targeted cells, such as the a photoreceptor-specific promoter, such as a rhodopsin gene promoter.

- The nucleic acid molecule to be packaged in viral capsid includes at least 2 different operatively linked DNA segments. The DNA can be manipulated and
15 amplified by PCR as described herein and by using standard techniques, such as those described in *Molecular Cloning: A Laboratory Manual, 2nd Ed.*, Sambrook *et al.*, eds., Cold Spring Harbor, New York (1989). Typically, to produce such molecule, the sequence encoding the selected polypeptide and the promoter or enhancer are operatively linked to a DNA molecule capable of autonomous
20 replication in a cell either *in vivo* or *in vitro*. By operatively linking the enhancer element or promoter and nucleic acid molecule to the vector, the attached segments are replicated along with the vector sequences.

- Thus, the recombinant DNA molecule (rDNA) is a hybrid DNA molecule comprising at least 2 nucleotide sequences not normally found together in
25 nature. In various preferred embodiments, one of the sequences is a sequence encoding an Ad-derived polypeptide, protein, or fragment thereof. The nucleic acid molecule intended to be packaged is from about 20 base pairs to about 40,000 base pairs in length, preferably about 50 bp to about 38,000 bp in length. In various embodiments, the nucleic acid molecule is of sufficient length
30 to encode on or more adenovirus proteins or functional polypeptide portions thereof. Since individual Ad polypeptides vary in length from about 19 amino acid residues to about 967 amino acid residues, encoding nucleic acid molecules

-29-

from about 50 bp up to about 3000 bp, depending on the number and size of individual polypeptide-encoding sequences that are "replaced" in the viral vectors by therapeutic product-encoding nucleic acid molecules.

Preferably the molecule includes an adenovirus tripartite leader (TPL)

- 5 nucleic acid sequence operatively linked to an intron containing RNA processing signals (such as for example, splice donor or splice acceptor sites) suitable for expression in the packaging cell line. Most preferably the intron contains a splice donor site and a splice acceptor site. Alternatively, the TPL nucleotide sequence may not comprise an intron. The intron includes any sequence of
- 10 nucleotides that function in the packaging cell line to provide RNA processing signals, including splicing signals. Introns have been well characterized from a large number of structural genes, and include but are not limited to a native intron 1 from adenovirus, such as Ad5's TPL intron 1; others include the SV40 VP intron; the rabbit beta-globin intron, and synthetic intron constructs (see,
- 15 *e.g.*, Petitcherc *et al.* (1995) *J. Biothechnol.*, 40:169; and Choi *et al.* (1991) *Mol. Cell. Biol.*, 11:3070).

- The nucleic acid molecule encoding the TPL includes either (a) first and second TPL exons or (b) first, second and third TPL exons, where each TPL exon in the sequence is selected from among the complete TPL exon 1, partial TPL
- 20 exon 1, complete TPL exon 2 and complete TPL exon 3. A complete exon is one which contains the complete nucleic acid sequence based on the sequence found in the wild type viral genome. Preferably the TPL exons are from Ad2, Ad3, Ad5, Ad7 and the like, however, they may come from any Ad serotype, as described herein. A preferred partial TPL exon 1 is described in the Examples.
- 25 The use of a TPL with a partial exon 1 has been reported (International PCT application No. WO 98/13499).

- The intron and the TPL exons can be operatively linked in a variety of configurations to provide a functional TPL nucleotide sequence. An intron may not be a part of the construct. For example, the intron can be positioned
- 30 between any of TPL exons 1, 2 or 3, and the exons can be in any order of first and second, or first/second/third. The intron can also be placed preceding the first TPL exon or following the last TPL exon. In a preferred embodiment,

-30-

complete TPL exon 1 is operatively linked to complete TPL exon 2 operatively linked to complete TPL exon 3. In a preferred variation, adenovirus TPL intron 1 is positioned between complete TPL exon 1 and complete TPL exon 2. It may also be possible to use analogous translational regulators from other viral systems such as rabiesvirus.

A preferred "complete" TPL nucleic acid molecule containing complete TPL exons 1, 2 and 3 with adenovirus intron 1 inserted between exons 1 and 2 has a nucleotide sequence shown in SEQ ID NO: 32. A preferred "partial" TPL nucleic acid molecule containing partial TPL exon 1 and complete TPL exons 2 and 3 in that order has a nucleotide sequence shown in SEQ ID NO: 26. The construction of these preferred TPL nucleotide sequences is described in the Examples.

Thus, preferred expression cassettes and complementing plasmids for expressing adenovirus structural genes, particularly fiber protein, contain an adenovirus TPL nucleotide sequence as described herein.

4. Complementing Plasmids

Also contemplated are the use of nucleic acid molecules, typically in the form of DNA plasmid vectors, which are capable of expression of an adenovirus structural protein or regulatory protein. Because these expression plasmids are used to complement the defective genes of a recombinant adenovirus vector genome, the plasmids are referred to as complementing or complementation plasmids.

The complementing plasmid contains an expression cassette, a nucleotide sequence capable of expressing a protein product encoded by the nucleic acid molecule. Expression cassettes typically contain a promoter and a structural gene operatively linked to the promoter. The complementing plasmid can further include a sequence of nucleotides encoding TPL nucleotide to enhance expression of the structural gene product when used in the context of adenovirus genome replication and packaging.

A complementing plasmid can include a promoter operatively linked to a sequence of nucleotides encoding an adenovirus structural polypeptide, such as, but are not limited to, penton base; hexon; fiber; polypeptide IIIa; polypeptide V;

-31-

polypeptide VI; polypeptide VII; polypeptide VIII; and biologically active fragments thereof. In another variation, a complementing plasmid may also include a sequence of nucleotides encoding a first adenovirus regulatory polypeptide, a second regulatory polypeptide, and/or a third regulatory polypeptide, and any combination of the foregoing.

Plasmid pDV80 is a preferred plasmid herein. Other plasmids constructed in an analogous manner to encode modified fiber proteins and chimeric fiber proteins are also contemplated herein.

5. Nucleic Acid Molecule Synthesis

A nucleic acid molecule comprising synthetic oligonucleotides can be prepared using any suitable method, such as the phosphotriester or phosphodiester methods (see, *e.g.*, Narang (1979) *et al.*, *Meth. Enzymol.*, 68:90; U.S. Patent No. 4,356,270; and Brown *et al.*, (1979) *Meth. Enzymol.*, 68:109). For oligonucleotides, the synthesis of the family members can be conducted simultaneously in a single reaction vessel, or can be synthesized independently and later admixed in preselected molar ratios. For simultaneous synthesis, the nucleotide residues that are conserved at preselected positions of the sequence of the family member can be introduced in a chemical synthesis protocol simultaneously to the variants by the addition of a single preselected nucleotide precursor to the solid phase oligonucleotide reaction admixture when that position number of the oligonucleotide is being chemically added to the growing oligonucleotide polymer. The addition of nucleotide residues to those positions in the sequence that vary can be introduced simultaneously by the addition of amounts, preferably equimolar amounts, of multiple preselected nucleotide precursors to the solid phase oligonucleotide reaction admixture during chemical synthesis. For example, where all four possible natural nucleotides (A,T,G and C) are to be added at a preselected position, their precursors are added to the oligonucleotide synthesis reaction at that step to simultaneously form four variants (see, *e.g.*, Ausubel *et al.* (*Current Protocols in Molecular Biology*, Suppl. 8. p.2.11.7, John Wiley & Sons, Inc., N w York ,1991).

-32-

Nucleotide bases other than the common four nucleotides (A,T,G or C), or the RNA equivalent nucleotide uracil (U), can also be used. For example, it is well known that inosine (I) is capable of hybridizing with A, T and G, but not C. Examples of other useful nucleotide analogs are known in the art and may be
5 found referred to in 37 C.F.R. §1.822.

Thus, where all four common nucleotides are to occupy a single position of a family of oligonucleotides, that is, where the preselected nucleotide sequence is designed to contain oligonucleotides that can hybridize to four sequences that vary at one position, several different oligonucleotide structures
10 are contemplated. The composition can contain four members, where a preselected position contains A,T,G or C. Alternatively, a composition can contain two nucleotide sequence members, where a preselected position contains I or C, and has the capacity to hybridize at that position to all four possible common nucleotides. Finally, other nucleotides may be included at the
15 preselected position that have the capacity to hybridize in a non-destabilizing manner with more than one of the common nucleotides in a manner similar to inosine.

Similarly, larger nucleic acid molecules can be constructed in synthetic oligonucleotide pieces, and assembled by complementary hybridization and
20 ligation, as is well known.

D. Adenovirus Expression Vector Systems

The adenovirus vector genome that is encapsulated in the virus particle and that expresses exogenous genes in a gene therapy setting is a key component of the system. Thus, the components of a recombinant adenovirus
25 vector genome include the ability to express selected adenovirus structural genes, to express a desired exogenous protein, and to contain sufficient replication and packaging signals that the genome is packaged into a gene delivery vector particle. The preferred replication signal is an adenovirus inverted terminal repeat
30 containing an adenovirus origin of replication, as is well known and described her in.

-33-

Although adenovirus include many proteins, not all adenovirus proteins are required for assembly of a recombinant adenovirus particle (vector). Thus, deletion of the appropriate genes from a recombinant Ad vector permits accommodation of even larger "foreign" DNA segments.

5 A preferred recombinant adenovirus vector genome is "helper independent" so that genome can replicate and be packaged without the help of a second, complementing helper virus. Complementation is provided by a packaging cell.

10 In a preferred embodiment, the adenovirus vector genome does not encode a functional adenovirus fiber protein. A non-functional fiber gene refers to a deletion, mutation or other modification to the adenovirus fiber gene such that the gene does not express any or insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of the fiber gene by a complementing plasmid or packaging cell line. Such a genome is
15 referred to as a "fiberless" genome, not to be confused with a fiberless particle. Alternatively, a fiber protein may be encoded but is insufficiently expressed to result in a fiber containing particle.

 Thus, contemplated for use are helper-independent fiberless recombinant adenovirus vector genomes that include genes that (a) express all adenovirus
20 structural gene products but express insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene, (b) express an exogenous protein, and (c) contain an adenovirus packaging signal and inverted terminal repeats containing adenovirus origin of replication.

25 The adenovirus vector genome is propagated in the laboratory in the form of rDNA plasmids containing the genome, and upon introduction into an appropriate host, the viral genetic elements provide for viral genome replication and packaging rather than plasmid-based propagation. Exemplary methods for preparing an Ad-vector genome are described in the Examples.

30 A vector her in includes a nucleic acid (preferably DNA) molecule capable of autonomous replication in a cell and to which a DNA segment, *e.g.*, a gene or polynucleotide, can be operatively linked to bring about replication of the

-34-

attached segment. For purposes herein, one of the nucleotide segments to be operatively linked to vector sequences encodes at least a portion of a therapeutic nucleic acid molecule. As noted above, therapeutic nucleic acid molecules include those encoding proteins and also those that encode regulatory factors
5 that can lead to expression or inhibition or alteration of expression of a gene product in a targeted cell.

1. Nucleic Acid Gene Expression Cassettes

In various embodiments, a peptide-coding sequence of the therapeutic gene is inserted into an expression vector and expressed; however, it is also
10 feasible to construct an expression vector which also includes some non-coding sequences as well. Preferably, however, non-coding sequences are excluded. Alternatively, a nucleotide sequence for a soluble form of a polypeptide may be utilized. Another preferred therapeutic viral vector includes a nucleotide
15 sequence encoding at least a portion of a therapeutic nucleotide sequence operatively linked to the expression vector for expression of the coding sequence in the therapeutic nucleotide sequence.

The choice of viral vector into which a therapeutic nucleic acid molecule is operatively linked depends directly, as is well known in the art, on the functional properties desired, *e.g.*, vector replication and protein expression, and
20 the host cell to be transformed -- these being limitations inherent in the art of constructing recombinant DNA molecules. Although certain adenovirus serotypes are recited herein in the form of specific examples, it should be understood that the use of *any* adenovirus serotype, including hybrids and derivatives thereof are contemplated.

25 A translatable nucleotide sequence is a linear series of nucleotides that provide an uninterrupted series of at least 8 codons that encode a polypeptide in one reading frame. Preferably, the nucleotide sequence is a DNA sequence. The vector itself may be of any suitable type, such as a viral vector (RNA or DNA), naked straight-chain or circular DNA, or a vesicle or envelope containing the
30 nucleic acid material and any polypeptides that are to be inserted into the cell.

-35-

2. Promoters

As noted elsewhere herein, an expression nucleic acid in an Ad-derived vector may also include a promoter, particularly a tissue or cell specific promoter, preferably one expressed in ocular cells, particularly photoreceptors.

- 5 Promoters contemplated for use herein include regulatable (inducible) as well as constitutive promoters, which may be used, either on separate vectors or on the same vector. Some useful regulatable promoters are those of the CREB-regulated gene family and include inhibin, gonadotropin, cytochrome c, glucagon, and the like. (See, *e.g.*, International PCT application No. WO 10 96/14061). Preferably the promoter selected is from a photoreceptor-specific gene, such as a rhodopsin gene or gene that encodes a protein that regulates rhodopsin expression.

E. Formulation and administration

- Compositions containing therapeutically effective concentrations of 15 recombinant adenovirus delivery vectors are provided. These are for delivery of therapeutic gene products to cells, particularly cells express a particular 50 kDa receptor or other receptor with which the vectors interact. These cells include cells of the eye and genital tract. Of particular interest are photoreceptor cells of the eye. Administration is effected by any means through which contacting with 20 the photoreceptors is effected. Preferable modes of administration include, but are not limited to, subretinal injection, particularly intravitreal injection, to provide access to photoreceptor cells.

- The recombinant viral compositions may also be formulated for 25 implantation into the anterior or posterior chamber of the eye, preferably the vitreous cavity, in sustained released formulations, such as those adsorbed to biodegradable supports, including collagen sponges, or in liposomes. Sustained release formulations may be formulated for multiple dosage administration, so that during a selected period of time, such as a month or up to about a year, several dosages are administered. Thus, for example, liposomes may be 30 prepared such that a total of about two to up to about five or more times the single dosage is administered in one injection.

-36-

The vectors are formulated in an ophthalmologically acceptable carrier for intraocular, preferably intravitreal, administration in a volume of between about 0.05 ml and 0.150 ml, preferably about 0.05 and 0.100 ml.

The composition can be provided in a sealed sterile vial containing an
5 amount of a compound of formula I, that upon intraocular administration will deliver a sufficient amount of viral particles to the photoreceptors in a volume of about 50 to 150 μ l, containing at least about 10^7 , more preferably at least about 10^8 plaque forming units in such volume. Typically, the vials will, thus, contain about 0.150 ml of the composition.

10 To prepare compositions the viral particles are dialyzed into a suitable ophthalmologically acceptable carrier or viral particles, for example, may be concentrated and/or mixed therewith. The resulting mixture may be a solution, suspension or emulsion. In addition, the viral particles may be formulated as the sole pharmaceutically active ingredient in the composition or may be
15 combined with other active agents for the particular disorder treated.

For administration by intraocular injection or via eyedrops, suitable carriers include, but are not limited to, physiological saline, phosphate buffered saline (PBS), balanced salt solution (BSS), lactate Ringers solution, and solutions containing thickening and solubilizing agents, such as glucose, polyethylene
20 glycol, and polypropylene glycol and mixtures thereof. Liposomal suspensions may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. Suitable ophthalmologically acceptable carriers are known. Solutions or mixtures intended for ophthalmic use may be formulated as 0.01% - 10% isotonic
25 solutions, pH about 5-7, with appropriate salts [see, e.g., U.S. Patent No. 5,116,868, which describes typical compositions of ophthalmic irrigation solutions and solutions for local application]. Such solutions, which have a pH adjusted to about 7.4, contain, for example, 90-100 mM sodium chloride, 4-6 mM dibasic potassium phosphate, 4-6 mM dibasic sodium phosphate, 8-12 mM
30 sodium citrate, 0.5-1.5 mM magnesium chloride, 1.5-2.5 mM calcium chloride, 15-25 mM sodium acetate, 10-20 mM D.L.-sodium β -hydroxybutyrate and 5-5.5 mM glucose.

-37-

The compositions may be prepared with carriers that protect them from rapid elimination from the body, such as time release formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to, microencapsulated delivery systems, and biodegradable, biocompatible polymers, 5 such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and other types of implants that may be placed directly into the anterior or posterior chamber or vitreous cavity of the eye. The compositions may also be administered in pellets, such as Elvax pellets (ethylene-vinyl acetate copolymer resin).

10 Liposomal suspensions, including tissue-targeted liposomes, may also be suitable as pharmaceutically acceptable carriers. For example, liposome formulations may be prepared by methods known to those of skill in the art [see, e.g., Kimm et al. (1983) Bioch. Bioph. Acta 728:339-398; Assil et al. (1987) Arch Ophthalmol. 105:400; and U.S. Patent No. 4,522,811]. The viral particles 15 may be encapsulated into the aqueous phase of liposome systems.

The active materials can also be mixed with other active materials, that do not impair the desired action, or with materials that supplement the desired action or have other action, including viscoelastic materials, such as hyaluronic acid, which is sold under the trademark HEALON, which is a solution of a high 20 molecular weight (MW) of about 3 millions fraction of sodium hyaluronate [manufactured by Pharmacia, Inc; see, e.g., U.S. Patent Nos. 5,292,362, 5,282,851, 5,273,056, 5,229,127, 4,517,295 and 4,328,803], VISCOAT [fluorine-containing (meth)acrylates, such as, 1H,1H,2H,2H-hepta-decafluorodecylmethacrylate; see, e.g., U.S. Patent Nos. 5,278,126, 5,273,751 25 and 5,214,080; commercially available from Alcon Surgical, Inc.], ORCOLON [see, e.g., U.S. Patent No. 5,273,056; commercially available from Optical Radiation Corporation], methylcellulose, methyl hyaluronate, polyacrylamide and polymethacrylamide [see, e.g., U.S. Patent No. 5,273,751]. The viscoelastic materials are present generally in amounts ranging from about 0.5 to 5.0%, 30 preferably 1 to 3% by weight of the conjugate material and serve to coat and protect the treated tissues. The compositions may also include a dye, such as

-38-

methylene blue or other inert dye, so that the composition can be seen when injected into the eye. Additional active agents may be included.

The compositions can be enclosed in ampules, disposable syringes or multiple or single dose vials made of glass, plastic or other suitable material.

5 Such enclosed compositions can be provided in kits. In particular, kits containing vials, ampules or other containers, preferably disposable vials with sufficient amount of the composition to deliver about 0.100 ml thereof, and disposable needles, preferably self sealing 25-30 gauge needles, are provided herein.

10 Finally, the compounds may be packaged as articles of manufacture containing packaging material, typically a vial, an ophthalmologically acceptable composition containing the viral particles and a label that indicates the therapeutic use of the composition.

Also provided are kits for practice of the methods herein. The kits
15 contain one or more containers, such as sealed vials, with sufficient composition for single dosage administration, and one or more needles, such as self sealing 25-33 gauge needles, preferably 33 gauge or smaller needles, precisely calibrated syringes or other precisely calibrated delivery device, suitable for intravitreal injection.

20 Administration of the composition is preferably by intraocular injection, although other modes of administration may be effective, if the sufficient amount of the compound achieves contact with the vitreous cavity. Intraocular injection may be effected by intravitreal injection, aqueous humor injection or injection into the external layers of the eye, such as subconjunctival injection or
25 subtenon injection, or by topical application to the cornea, if a penetrating formulation is used.

Administration

The compositions containing the compounds are administered intraocularly or by other means, such as topically in the form of penetrating
30 eyedrops, whereby contact of the recombinant vectors with the aqueous humor is effected. Intraocular administration may be effected by intravitreal injection, aqueous humor injection, injection into the external layers of the eye, such as

-39-

subconjunctival injection or subtenon injection, preferably in free form, but, alternatively, in liposomes or other sustained drug delivery device.

Administration is preferably by intravitreal injection, preferably through self sealing 25-30 gauge needles or other suitably calibrated delivery device.

- 5 Injection into the eye may be through the pars plana via the self-sealing needle.

It is further understood that, for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the recombinant viruses, and that the concentration ranges set

- 10 forth herein are exemplary only and are not intended to limit the scope or practice of the claimed methods

E. Diseases, Disorders and therapeutic products

1. Disease and disorders

Retinitis pigmentosa

- 15 Methods for specifically or selectively targeting recombinant adenovirus vectors for delivery of gene products, particularly therapeutic products are provided herein. These methods are particularly suitable for targeting cells that express receptors that are selectively recognized by Ad virus of subgroup D viruses, particularly Ad37. It is shown herein that these viruses selectively
- 20 recognize receptors on cells, such as conjunctival cells and photoreceptors, that are not recognized by other adenoviruses. Hence, methods for targeting to these cell types by providing vectors that are packaged in viral particles that contain a sufficient portion of a fiber protein from one of these Ad serotypes to bind to these receptors. These methods are useful for targeting to
- 25 photoreceptors and for treating ocular disorders, including, but are not limited to, inherited and acquired retinal, neovascular degenerative diseases (see table below).

- It is estimated that 1 in 3,500 individuals in the United States suffer from one of the pigmented retinopathies. This group of retinal diseases, commonly
- 30 call d retinitis pigmentosa, is characterized by progressive loss of peripheral and night vision. Patients may be affected at almost any age and it is not uncommon to experience symptoms in early childhood in certain inherited forms.

-40-

It has been shown that there are a variety of mutations in genes expressed in the photoreceptors, including genes in the rhodopsin gene and pathway that appear to be responsible for these diseases. In addition to mutations in rhodopsin, changes in the retinal pigmented epithelial (RPE) cells, also undergo
5 degenerative changes and can form clumps of pigment that give rise to the characteristic pigmentary changes seen in patients with RP.

Angiogenesis and ocular diseases and disorders

The vast majority of diseases that cause catastrophic loss of vision do so as a result of ocular neovascularization; age related macular degeneration
10 (ARMD) affects 12-15 million American over the age of 65 and causes visual loss in 10-15% of them as a direct effect of choroidal (sub-retinal) neovascularization. The leading cause of visual loss for Americans under the age of 65 is diabetes; 16 million individuals in the United States are diabetic and 40,000 per year suffer from ocular complications of the disease, which often are
15 a result of retinal neovascularization. Laser photocoagulation has been effective in preventing severe visual loss in subgroups of high risk diabetic patients, but the overall 10 year incidence of retinopathy remains essentially unchanged. For patients with choroidal neovascularization due to ARMD or inflammatory eye disease, such as ocular histoplasmosis, photocoagulation, with few exceptions,
20 is ineffective in preventing visual loss. While recently developed, non-destructive photodynamic therapies hold promise for temporarily reducing individual loss in patients with previously untreatable choroidal neovascularization, only 61.4% of patients treated every 3-4 months had improved or stabilized vision compared to 45.9% of the placebo-treated group.

25 In the normal adult, angiogenesis is tightly regulated and limited to wound healing, pregnancy and uterine cycling. Angiogenesis is turned on by specific angiogenic molecules such as basic and acidic fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiogenin, transforming growth factor (TGF), tumor necrosis factor- α (TNF- α) and platelet derived growth factor
30 (PDGF). Angiogenesis can be suppressed by inhibitory molecules such as interferon- α , thrombospondin-1, angiostatin and endostatin. It is the balance of these naturally occurring stimulators and inhibitors that controls the normally

-41-

quiescent capillary vasculature. When this balance is upset, as in certain disease states, capillary endothelial cells are induced to proliferate, migrate and ultimately differentiate.

Angiogenesis plays a central role in a variety of diseases, including, but
 5 are not limited to, cancer and ocular neovascularization. Sustained growth and metastasis of a variety of tumors has also been shown to be dependent on the growth of new host blood vessels into the tumor in response to tumor derived angiogenic factors. Proliferation of new blood vessels in response to a variety of stimuli occurs as the dominant finding in the majority of eye diseases that blind,
 10 such as, but are not limited to, proliferative diabetic retinopathy (PDR), ARMD, rubeotic glaucoma, interstitial keratitis and retinopathy of prematurity. In these diseases, tissue damage can stimulate release of angiogenic factors resulting in capillary proliferation. VEGF plays a dominant role in iris neovascularization and neovascular retinopathies. While reports clearly show a correlation between
 15 intraocular VEGF levels and ischemic retinopathic ocular neovascularization, FGF likely plays a role. Basic and acidic FGF are known to be present in the normal adult retina, even though detectable levels are not consistently correlated with neovascularization. This may be largely due to the fact that FGF binds very tightly to charged components of the extracellular matrix and may not be readily
 20 available in a freely diffusible form that would be detected by standard assays of intraocular fluids.

A final common pathway in the angiogenic response involves integrin-mediated information exchange between a proliferating vascular endothelial cell and the extracellular matrix. This class of adhesion receptors, called integrins,
 25 are expressed as heterodimers having an α and β subunit on all cells. One such integrin, $\alpha_v\beta_3$, is the most promiscuous member of this family and allows endothelial cells to interact with a wide variety of extracellular matrix components. Peptide and antibody antagonists of this integrin inhibit angiogenesis by selectively inducing apoptosis of the proliferating vascular
 30 endothelial cells. Two cytokine-dependent pathways of angiogenesis exist and may be defined by their dependency on distinct vascular cell integrins, $\alpha_v\beta_3$ and $\alpha_v\beta_5$. Specifically, basic FGF- and VEGF-induced angiogenesis depend on integrin

-42-

$\alpha_v\beta_3$ and $\alpha_v\beta_5$, respectively, since antibody antagonists of each integrin selectively block one of these angiogenic pathways in the rabbit corneal and chick chorioallantoic membrane (CAM) models. Peptide antagonists that block all α_v integrins inhibit FGF- and VEGF-stimulated angiogenesis. While normal human ocular blood vessels do not display either integrin, $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrins are selectively displayed on blood vessels in tissues from patients with active neovascular eye disease. While only $\alpha_v\beta_3$ was consistently observed in tissue from patients with ARMD, $\alpha_v\beta_3$ and $\alpha_v\beta_5$ were present in tissues from patients with PDR. Systemically administered peptide antagonists of integrins blocked new blood vessel formation in a mouse model of retinal vasculogenesis.

In addition to adhesion events described above, cell migration through the extracellular matrix also depends on proteolysis. Matrix metalloproteinases are a family of zinc-requiring matrix-degrading enzymes that include the collagenases, gelatinases and stromelysins, all of which have been implicated in invasive cell behavior. Invasive cell processes such as tumor metastasis and angiogenesis have been found to be associated with the expression of integrins and MMP-2, MMP-2 are all found throughout the eye where they may interact to maintain a quiescent vasculature until the balance is upset, resulting in pathological angiogenesis. A non-catalytic C-terminal hemopexin-like domain of MMP-2 (PEX) can block cell surface collagenolytic activity and inhibit angiogenesis in the CAM model by preventing localization of MMP-2 to the surface of invasive cells through interaction with the integrin $\alpha_v\beta_3$.

Hence, anti-angiogenic agents have a role in treating retinal degeneration to prevent the damaging effects of these trophic and growth factors. Angiogenic agents, also have a role in promoting desirable vascularization to retard retinal degeneration by enhancing blood flow to cells.

Members of adenovirus subgroup D, Ad8, 19A, and 37, are infectious agents that cause particularly severe cases of epidemic keratoconjunctivitis (EKC) (Arnberg *et al.* (1998) *Virology* 227:239-244; Curtis *et al.* (1998) *J. Med. Microbiol.* 47:91-94; Ritterband *et al.* (1998) *Rev. Med. Virol.* 8:187-201; and Takeuchi *et al.* (1999) *J. Clin. Microbiol.* 37:3392-3394). There is no effective treatment for this debilitating and contagious disease and EKC

-43-

continues to be a problem in ophthalmology clinics worldwide (Curtis *et al.* (1998) *J.Med.Microbiol.* 47:91-94, Lukashok *et al.* (1998) *Curr.Clin.Top.Infec.Dis.* 18:286-304). Hence the vectors herein may be used for treating the disease.

5

Table 3
Candidate targets for ocular disease therapy

CANDIDATE TARGETS FOR OCULAR DISEASE THERAPY	
Disease	Candidate target(s)
Retinitis pigmentosa	Rhodopsin gene, and genes that regulate expression thereof <i>rds/peripherin</i>
10 Stargardt's disease	rim protein (ARC protein)
Choroideremia	rab geranylgeranyl transferase CHM, TCD, CHML*
Gyrate Atrophy	ornithine aminotransferase
15 Macular dystrophy	<i>rds/peripherin</i>

* see, "MSR6-yeast homologue of the choroideraemia gene," Nature Genetics 3: 193-4 (1993)

TABLE 4

Other Diseases	
20	Exudative Choroidal Diseases
	ICSC, fluorescein angiogram
	ICSC with large serous detachment of RPE (retinal pigmented epithelium)
	ICSC with bullous retinal detachment
	Macular drusen, exudative, confluent
25	Drusen, sub-RPE choroidal neovascularization
	Drusen, notched serous detachment of RPE

Other Diseases	
	Drusen, notched serous and hemorrhagic detachment of RPE
	Drusen, serous and hemorrhagic detachment of RPE and retina
	Drusen, organized RPE detachment causing bullous retinal detachment
	Drusen, geographic atrophy of RPE
5	Drusen, exudative and cuticular, vitelliform macular detachment
	Drusen, cuticular, large vitelliform macular detachment
	North Carolina dystrophy with macular staphyloma
	North Carolina dystrophy with macular staphyloma
	Angioid streaks, pseudoxanthoma elasticum (PXE), CNVM
10	Angioid streaks, PXE, large notched retinal detachment
	Myopic degeneration, Foerster-Fuchs spot
	Presumed ocular histoplasmosis syndrome (POHS)
	Submacular bacterial abscess
	<i>Toxocara canis</i> , subretinal granuloma
15	Serpiginous (geographic) choroiditis
	Posterior scleritis
	Harada's disease
	Posterior sympathetic uveitis
	Benign reactive lymphoid hyperplasia of uveal tract
20	Choroidal ruptures and CNVM
	Cavernous hemangioma of choroid
	Choroidal osteoma
	Choroidal nevus, serous macular detachment
	Choroidal nevus with CNVM
25	Diffuse sclerochoroidal melanocytic nevus
	Choroidal melanoma with serous detachment of RPE
	Metastatic lung carcinoma to choroid
	Sub-RPE reticulum cell sarcoma

Other Diseases	
	RPE tear, idiopathic choroidal neovascularization
Heredodystrophic Disorders Affecting RPE & Retina	
	Best's vitelliform macular dystrophy
	Best's vitelliform macular dystrophy with CNVM
5	Best's vitelliform macular dystrophy, multiple lesions
	Adult-onset vitelliform foveomacular dystrophy
	Pattern dystrophy simulating fundus flavimaculatus
	Stargardt's disease (fundus flavimaculatus)
	Asteroid macular dystrophy
10	Sjögren-Larssen syndrome
	Oguchi's disease, light-adapted state
	Oguchi's disease, dark-adapted state
	Fundus albipunctatus
	Retinitis pigmentosa, cystoid macular edema
15	Crystalline tapetoretinal dystrophy
	Choroideremia
	Goldmann-Favre syndrome
	Sex-linked juvenile retinoschisis
	Perivenous retinitis pigmentosa
20	Retinal Vascular Disorders
	Retinal arteriovenous aneurysm
	Central retinal artery occlusion
	Cilioretinal artery obstruction
	Ischemic retinopathy in systemic lupus erythematosus
25	Ischemic retinopathy in scleroderma
	Hemorrhagic detachment of internal limiting membrane, hypertensive retinopathy
	Acquired retinal arterial macroaneurysm

Other Diseases	
	Cystoid macular edema, aphakic
	Cystoid macular edema, nicotinic acid maculopathy
	Congenital retinal telangiectasis
	Acquired bilateral juxtafoveal telangiectasis
5	Acquired bilateral juxtafoveal obliterative telangiectasis
	Diabetic optic neuropathy
	X-ray radiation exudative retinopathy
	Sickle cell SC disease, macular hemorrhage
	Retinal arterial aneurysms, arteritis, neuroretinitis
10	Branch retinal vein obstruction (BRVO)
	BRVO, exudative maculopathy
	BRVO, optic disc new vessels, photocoagulation
	Waldenström's macroglobulinemia
Inflammatory Diseases of the Retina and Choroid	
15	Luetic retinal vasculitis
	Focal <i>Candida</i> retinal abscess
	Toxoplasmosis, atrophic chorioretinal scar
	Toxoplasmosis retinitis and macular detachment
	Toxoplasmosis scar, CNVM, macular detachment
20	Diffuse unilateral subacute neuroretinitis, small worm
	Diffuse unilateral subacute neuroretinitis, large worm
	Cytomegalic inclusion disease, papillitis
	Acute posterior multifocal placoid pigment epitheliopathy
	Acute macular neuroretinitis
25	Sarcoid retinitis
	Sarcoid papillitis
	Behcet's disease
	Vitiliginous (bird-shot) chorioretinitis

-47-

	Other Diseases
	Multifocal choroiditis and panuveitis (pseudo-POHS)
	Retinal and Pigment Epithelial Hamartomas
	Congenital grouped albinotic RPE spots
	Congenital hyperplasia of RPE
5	Combined RPE and retinal hamartoma, juxtapapillary
	Combined RPE and retinal hamartoma, peripheral
	Cystic astrocytoma, juxtapapillary
	Astrocytoma, macula
	Astrocytoma, juxtapapillary
10	Cavernous hemangioma of retina
	Juxtapapillary sessile retinal capillary hemangioma
	Juxtapapillary endophytic retinal capillary hemangioma
	Other Tumors of the Choroid
	Choroidal metastasis
15	Choroidal osteoma
	Choroidal hemangioma
	Miscellaneous uveal tumors
	Intraocular Lymphoid Tumors
	The leukemias and lymphomas
20	Tumors of the Vitreous
	Non-Hodgkins ("reticulum cell") lymphoma
	Tumor involvement of the vitreous cavity
	Macular Disease
	Age-related macular degeneration -- atrophic form
25	Exudative age-related macular degeneration
	Choroidal neovascular membrane in degenerative myopia
	Central serous retinopathy
	Macular hole

-48-

		Other Diseases
		Macular dystrophies
		Retinal Vascular Disease
		Etiologic mechanisms in diabetic retinopathy
		Background diabetic retinopathy
5		Proliferative diabetic retinopathy
		Retinal arterial obstructive disease
		Central retinal vein occlusion
		Retinal branch vein occlusion
		Pregnancy and retinal disease
10		Pregnancy-induced hypertension
		Hypertension
		The rheumatic disease
		Parafoveal telangiectasis
		Coats disease
15		Disseminated intravascular systemic coagulopathy and related vasculopathies
		Hemoglobinopathies
		Retinopathy of prematurity
		Acquired retinal macroaneurysms
		Eales disease
20		Radiation retinopathy
		The ocular ischemic syndrome
		Inflammatory Disease
		Ocular toxoplasmosis
		Ocular toxocariasis
25		Ocular cysticercosis
		Cytomegalovirus infections of the retina
		Retinal and ophthalmologic manifestations of AIDS
		Acute retinal necrosis syndrome

-49-

	Other Diseases
	Endogenous fungal infections of the retina and choroid
	Pars planitis
	Syphilis and tuberculosis
	Diffuse unilateral subacute neuroretinitis
5	Scleritis
	Birdshot retinochoroidopathy
	Punctate inner choroidopathy
	Sarcoidosis
	Acute multifocal placoid pigment epitheliopathy
10	Geographic helicoid peripapillary choroidopathy (GHPC); serpiginous choroiditis
	Sympathetic ophthalmia
	Vogt-Koyanagi-Harada syndrome (uveomeningitic syndrome)
	Ciliochoroidal (uveal) effusion

15 Reproduced from: Stereoscopic Atlas of Ocular Diseases Diagnosis and Treatment, 2nd Edition, J. Donald O. Gass, Vol. 1 & 2, C.V. Mosley Co. (1987); and Retina Vol. II, Editor, Stephen J. Ryan, Medical Retina, C.V. Mosley Co. (1989).

20 2. Therapeutic products

Therapeutic products include but are not limited to, wild-type genes that are defective in ocular disorders, such as rhodopsin, or fragments thereof sufficient to correct the genetic defect, trophic factors, including growth factors, inhibitors and agonists of trophic factors, anti-apoptosis factors and other

25 products described herein or known to those of skill in the art to be useful for treatment of disorders of the eye or that can be treated by a product expressed by a photoreceptor.

OCULAR GENE THERAPY STRATEGIES		
GENERAL DISEASE	EXAMPLES	STRATEGY

-50-

OCULAR GENE THERAPY STRATEGIES		
Hereditary retinal and macular degeneration	<ul style="list-style-type: none"> • Retinitis pigmentosa • Stargardt's disease • Other macular dystrophies 	Growth factors (e.g., GDNF) anti-apoptotic factors (e.g., bcl2 gene) Stargardt Disease Gene (ABCR) [†]
Neovascular	<ul style="list-style-type: none"> • Diabetes • Choroidal neovascularization 	Anti-angiogenesis factors
Anti-tumor	Retinoblastoma	Antiproliferant
5 Glaucoma	Nerve fiber layer atrophy	Neuroprotective agent

[†] See Allikmets *et al.* (1997) *Science* 277:1805-1807.

For example, for treatment of retinitis pigmentosa the adenovirus vector can deliver a wild-type rhodopsin gene or a growth factor or trophic factor, such as ciliary neurotrophic factor CNTF; for treatment of Stargardt's disease, the
 10 vector can deliver a wild type ABCR (also called STGD1) or a growth factor or anti-angiogenic agent; for diabetic retinopathies, retinal vascularization the vector can deliver growth factors, such as a TGF (TGF β), to prevent degeneration.

15 The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

EXAMPLE 1

Preparation of Adenovirus Packaging Cell Lines

Cell lines that are commonly used for growing adenovirus are useful as
 20 host cells for the preparation of adenovirus packaging cell lines. Preferred cells include 293 cells, an adenovirus-transformed human embryonic kidney cell line obtained from the ATCC, having Accession Number CRL 1573; HeLa, a human epithelial carcinoma cell line (ATCC Accession Number CCL-2); A549, a human lung carcinoma cell line (ATCC Accession Number CCL 1889); and other
 25 epithelial-derived cell lines. As a result of the adenovirus transformation, the

-51-

293 cells contain the E1 early region regulatory gene. All cells were maintained in complete DMEM + 10% fetal calf serum unless otherwise noted.

These cell lines allow the production and propagation of adenovirus-based gene delivery vectors that have deletions in preselected gene regions and that are obtained by cellular complementation of adenoviral genes. To provide the desired complementation of such deleted adenoviral genomes in order to generate a viral vector, plasmid vectors that contain preselected functional units have been designed. Such units include but are not limited to E1 early region, E4 and the viral fiber gene. The preparation of plasmids providing such complementation, thereby being "complementary plasmids or constructs," that are stably inserted into host cell chromosomes are described below.

A. Preparation of an E4-Expressing Plasmid for Complementation of E4-Gene-Deleted Adenoviruses

The viral E4 regulatory region contains a single transcription unit that is alternately spliced to produce several different mRNA products. The E4-expressing plasmid prepared as described herein and used to transfect the 293 cell line contains the entire E4 transcription unit. A DNA fragment extending from 175 nucleotides upstream of the E4 transcription start site including the natural E4 promoter to 153 nucleotides downstream of the E4 polyadenylation signal including the natural E4 terminator signal, corresponding to nucleotides 32667-35780 of the adenovirus type 5 (hereinafter referred to as Ad5) genome as described in Chroboczek *et al.* (*Viol.*, 186:280-285 (1992), GenBank Accession Number M73260), was amplified from Ad5 genomic DNA, obtained from the ATCC, via the polymerase chain reaction (PCR). Sequences of the primers used were 5'CGGTACACAGAATTCAGGAGACACAACTCC3' (forward or 5' primer referred to as E4L) (SEQ ID NO: 1) and 5'GCCTGGATCCGGGAAGTTACGTAACGTGGGAAAAC3' (SEQ ID NO: 2) (backward or 3' primer referred to as E4R). To facilitate cloning of the PCR fragment, these oligonucleotides were designed to create new sites for the restriction enzymes EcoRI and BamHI, respectively, as indicated with underlined nucleotides. DNA was amplified via PCR using 30 cycles of 92 C for 1 minut ,

-52-

50 C for 1 minute, and 72 C for 3 minutes resulting in amplified full-length E4 gene products.

The amplified DNA E4 products were then digested with EcoRI and BamHI for cloning into the compatible sites of pBluescript/SK+ by standard techniques to create the plasmid pBS/E4. A 2603 base pair (bp) cassette including the herpes simplex virus thymidine kinase promoter, the hygromycin resistance gene, and the thymidine kinase polyadenylation signal was excised from the plasmid pMEP4 (Invitrogen, San Diego, CA) by digestion with FspI followed by addition of BamHI linkers (5'CGCGGATCCGCG3') (SEQ ID NO: 3) for subsequent digestion with BamHI to isolate the hygromycin-containing fragment.

The isolated BamHI-modified fragment was then cloned into the BamHI site of pBS/E4 containing the E4 region to create the plasmid pE4/Hygro containing 8710 bp. The pE4/Hygro plasmid has been deposited with the ATCC under accession number 97739. The complete nucleotide sequence of pE4/Hygro is set forth in SEQ ID NO: 4. Position number 1 of the linearized vector corresponds to approximately the middle portion of the pBS/SK+ backbone. The 5' and 3' ends of the E4 gene are located at respective nucleotide positions 3820 and 707 of SEQ ID NO: 4 while the 5' and 3' ends of the hygromycin insert are located at respective nucleotide positions 3830 and 6470. In the clone that was selected for use, the E4 and hygromycin resistance genes were divergently transcribed.

B. Preparation of a Fiber-Expressing Plasmid for Complementation of Fiber-Gene-Deleted Adenoviruses

To prepare a fiber-encoding construct, primers were designed to amplify the fiber coding region from Ad5 genomic DNA with the addition of unique BamHI and NotI sites at the 5' and 3' ends of the fragment, respectively. The Ad5 nucleotide sequence is available with the GenBank Accession Number M18369. The 5' and 3' primers had the respective nucleotide sequences of 5'ATGGGATCCAAGATGAAGCGCGCAAGACCG3' (SEQ ID NO: 5) and 5'CATAACGCGGCCGCTTCTTTATTCTTGGGC3' (SEQ ID NO: 6), where the inserted BamHI and NotI sites are indicated by underlining. The 5' primer also

-53-

contained a nucleotide substitution 3 nucleotides 5' of the second ATG codon (C to A) that is the initiation site. The nucleotide substitution was included so as to improve the consensus for initiation of fiber protein translation.

The amplified DNA fragment was inserted into the BamHI and NotI sites
5 of pcDNA3 (Invitrogen) to create the plasmid designated pCDNA3/Fiber having 7148 bp. The parent plasmid contained the CMV promoter, the bovine growth hormone (BHG) terminator and the gene for conferring neomycin resistance. The viral sequence included in this construct corresponds to nucleotides 31040-32791 of the Ad5 genome.

10 The complete nucleotide sequence of pCDNA3/Fiber is listed in SEQ ID NO: 7 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 vector sequence. The 5' and 3' ends of the fiber gene are located at respective nucleotide positions 916 with ATG and 2661 with TAA.

To enhance expression of fiber protein by the constitutive CMV promoter
15 provided by the pcDNA vector, a BglII fragment containing the tripartite leader (TPL) of adenovirus type 5 was excised from pRD112a (Sheay *et al.*, *BioTechniques*, 15:856-862 (1993) and inserted into the BamHI site of pCDNA3/Fiber to create the plasmid pCLF having 7469 bp. The adenovirus tripartite leader sequence, present at the 5' end of all major late adenoviral
20 mRNAs as described by Logan *et al.*, *Proc. Natl. Acad. Sci., USA*, 81:3655-3659 (1984) and Berkner, *BioTechniques*, 6:616-629 (1988), also referred to as a "partial TPL" since it contains a partial exon 1, shows correspondence with the Ad5 leader sequence having three spatially separated exons corresponding to nucleotide positions 6081-6089 (the 3' end of the first leader segment), 7111-
25 7182 (the entire second leader segment), and 9644-9845 (the third leader segment and sequence downstream of that segment). The corresponding cDNA sequence of the partial tripartite leader sequence present in pCLF is included in SEQ ID NO: 8 bordered by BamHI/BglII 5' and 3' sites at respective nucleotide positions 907-912 to 1228-1233. The nucleotide sequence of an isolated partial
30 TPL is also listed separately as SEQ ID No. 22 with the noted 5' and 3' restriction sites and with the following nucleotide regions identified: 1-6 nt BglII site; 1-18 nt polylinker; 19-27 nt last 9 nt of the first leader segment (exon 1);

-54-

28-99 nt second leader segment (exon 2); 100-187 nt third leader segment (exon 3); 188-301 nt contains the nt sequence immediately following the third leader in the genome with an unknown function; and 322-327 nt BglII site.

The pCLF plasmid has been deposited with the ATCC as described in

- 5 Example 4. The complete nucleotide sequence of pCLF is listed in SEQ ID NO: 8 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 parent vector sequence. The 5' and 3' ends of the Ad5 fiber gene are located at respective nucleotide positions 1237-1239 with ATG and 2980-2982 with TAA.

10 C. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E4 and Fiber Proteins

The 293 cell line was selected for preparing the first adenovirus packaging line as it already contains the E1 gene as prepared by Graham *et al.*, *J. Gen. Virol.*, 36:59-74 (1977) and as further characterized by Spector, *Virol.*,

- 15 130:533-538 (1983). Before electroporation, 293 cells were grown in RPMI medium + 10% fetal calf serum. Four x 10⁶ cells were electroporated with 20 µg each of pE4/Hygro DNA and pCLF DNA using a BioRad GenePulser and settings of 300 V, 25 µF. DNA for electroporation was prepared using the Qiagen system according to the manufacturer's instructions (Bio-Rad, Richmond, CA).

Following electroporation, cells were split into fresh complete DMEM + 10% fetal calf serum containing 200 µg/ml Hygromycin B (Sigma, St. Louis, MO).

- From expanded colonies, genomic DNA was isolated using the
25 "MICROTURBOGEN" system (Invitrogen) according to manufacturer's instructions. The presence of integrated E4 DNA was assessed by PCR using the primer pair E4R and ORF6L (5'TGCTTAAGCGGCCGCGAAGGAGA AGTCC3') (SEQ ID NO: 9), the latter of which is a 5' forward primer near adenovirus 5 open reading frame 6.

- 30 One clone, designated 211, was selected exhibiting altered growth properties relative to that seen in parent cell line 293. The 211 clone contained the product, indicating the presence of inserted DNA corresponding to most, if

-55-

not all, of the E4 fragment contained in the pE4/Hygro plasmid. The 211 cell line has been deposited with the ATCC as described in Example 4. This line was further evaluated by amplification using the primer pair E4L/E4R described above, and a product corresponding to the full-length E4 insert was detected.

- 5 Genomic Southern blotting was performed on DNA restricted with EcoRI and BamHI. The E4 fragment was then detected at approximately one copy/genome compared to standards with the EcoRI/BamHI E4 fragment as cloned into pBS/E4 for use as a labeled probe with the Genius system according to manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN). In DNA from the 211 cell
- 10 line, the labeled internal fragment pE4/Hygro hybridized with the isolated E4 sequences. In addition, the probe hybridized to a larger fragment which may be the result of a second insertion event.

- Although the 211 cell line was not selected by neomycin resistance, thus indicating the absence of fiber gene, to confirm the lack of fiber gene, the 211
- 15 cell line was analyzed for expression of fiber protein by indirect immunofluorescence with an anti-fiber polyclonal antibody and a FITC-labeled anti-rabbit IgG (KPL) as secondary. No immunoreactivity was detected. Therefore, to generate 211 clones containing recombinant fiber genes, the 211 clone was expanded by growing in RPMI medium and subjected to additional
- 20 electroporation with the fiber-encoding pCLF plasmid as described above.

- Following electroporation, cells were plated in DMEM + 10% fetal calf serum and colonies were selected with 200 μ g/ml G418 (Gibco, Gaithersburg, MD). Positive cell lines remained hygromycin resistant. These candidate sublines of 211 were then screened for fiber protein expression by indirect
- 25 immunofluorescence as described above. The three sublines screened, 211A, 211B and 211R, along with a number of other sublines, all exhibited nuclear staining qualitatively comparable to the positive control of 293 cells infected with AdRSV β gal (1 pfu/cell) and stained 24 hours post-infection.

- Lines positive for nuclear staining in this assay were then subjected to
- 30 Western blot analysis under denaturing conditions using the same antibody. Several lines in which the antibody detected a protein of the predicted molecular weight (62 kd for the Ad5 fiber protein) were selected for further study including

-56-

211A, 211B and 211R. The 211A cell line has been deposited with ATCC as described in Example 4.

Immunoprecipitation analysis using soluble nuclear extracts from these three cell lines and a semipreparative electrophoresis system demonstrated that the fiber protein expressed is in the functional trimeric form characteristic of the native fiber protein. The predicted molecular weight of a trimerized fiber is 186 kd. Under denaturing conditions, the trimeric form was destroyed resulting in detectable fiber monomers. Those clones containing endogenous E1, newly expressed recombinant E4 and fiber proteins were selected for use in complementing adenovirus gene delivery vectors having the corresponding adenoviral genes deleted as described in Example 2.

D. Preparation of an E1-Expressing Plasmid for Complementation of E1-Gene-Deleted Adenoviruses

In order to prepare adenoviral packaging cell lines other than those based on the E1-gene containing 293 cell line as described in Example 1C above, plasmid vectors containing E1 alone or in various combinations with E4 and fiber genes are constructed as described below.

The region of the adenovirus genome containing the E1a and E1b gene is amplified from viral genomic DNA by PCR as previously described. The primers used are E1L, the 5' or forward primer, and E1R, the 3' or backward primer, having the respective nucleotide sequences 5'CCG AGCTAGC GACTGAAAATGAG3' (SEQ ID NO: 10) and 5'CCTCTCGAG AGACAGC AAGACAC3' (SEQ ID NO: 11). The E1L and E1R primers include the respective restriction sites NheI and XhoI as indicated by the underlines. The sites are used to clone the amplified E1 gene fragment into the NheI/XhoI sites in pMAM commercially available from Clontech (Palo Alto, CA) to form the plasmid pDEX/E1 having 11152 bp.

The complete nucleotide sequence of pDEX/E1 is listed in SEQ ID NO: 12 where the nucleotide position 1 corresponds to approximately 1454 nucleotides from the 3' end of the pMAM backbone vector sequence. The pDEX/E1 plasmid includes nucleotides 552 to 4090 of the adenovirus genome positioned downstream (beginning at nucleotide position 1460 and ending at 4998 in the

-57-

pDEX/E1 plasmid) of the glucocorticoid-inducible mouse mammary tumor virus (MMTV) promoter of pMAM. The pMAM vector contains the *E. coli gpt* gene that allows stable transfectants to be isolated using hypoxanthine/aminopterin/thymidine (HAT) selection. The pMAM backbone occupies nucleotide
5 positions 1-1454 and 5005-11152 of SEQ ID NO: 12.

E. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E1, and Fiber Proteins

To create separate adenovirus packaging cell lines equivalent to that of the 211 sublines, 211A, 211B and 211R, as described in Example 1C,
10 alternative cell lines lacking adenoviral genomes are selected for transfection with the plasmid constructs as described below. Acceptable host cells include A549, Hela, Vero and the like cell lines as described in Example 1. The selected cell line is transfected with the separate plasmids, pDEX/E1 and pCLF, respectively for expressing E1, and fiber complementary proteins. Following
15 transfection procedures as previously described, clones containing stable insertions of the two plasmids are isolated by selection with neomycin and HAT. Integration of full-length copy of the E1 gene is assessed by PCR amplification from genomic DNA using the primer set E1L/E1R, as described above. Functional insertion of the fiber gene is assayed by staining with the anti-fiber
20 antibody as previously described.

The resultant stably integrated cell line is then used as a packaging cell system to complement adenoviral gene delivery vectors having the corresponding adenoviral gene deletions as described in Example 2.

**F. Preparation of a Plasmid Containing Two or More Adenoviral Genes for
25 Complementing Gene-Deleted Adenoviruses**

The methods described in the preceding Examples rely on the use of two plasmids, pE4/Hygro and pCLF, or, pCLF and pDEX/E1 for generating adenoviral cell packaging systems. In alternative embodiments, complementing plasmids containing two or more adenoviral genes for expressing of encoded proteins in
30 various combinations are also prepared as described below. The resultant plasmids are then used in various cell systems with delivery plasmids having the corresponding adenoviral gene deletions. The selection of packaging cell, content of the delivery plasmids and content of the complementing plasmids for

-58-

use in generating recombinant adenovirus viral vectors thus depends on whether other adenoviral genes are deleted along with the adenoviral fiber gene, and, if so, which ones.

5 1. Preparation of a Complementing Plasmid Containing Fiber and E1 Adenoviral Genes

A DNA fragment containing sequences for the CMV promoter, adenovirus tripartite leader, fiber gene and bovine growth hormone terminator is amplified from pCLF prepared in Example 1B using the forward primer 5'GACGGATCGGGAGATCTCC3' (SEQ ID NO: 13), that anneals to the
10 nucleotides 1-19 of the pCDNA3 vector backbone in pCLF, and the backward primer 5'CCGCCTCAGAAGCCATAGAGCC3' (SEQ ID NO: 14) that anneals to nucleotides 1278-1257 of the pCDNA3 vector backbone. The fragment is amplified as previously described and then cloned into the pDEX/E1 plasmid prepared in Example 1D. For cloning in the DNA fragment, the pDEX/E1 vector
15 is first digested with NdeI, that cuts at a unique site in the pMAM vector backbone in pDEX/E1, then the ends are repaired by treatment with bacteriophage T4 polymerase and dNTPs.

The resulting plasmid containing E1 and fiber genes, designated pE1/Fiber, provides dexamethasone-inducible E1 function as described for
20 DEX/E1 and expression of Ad5 fiber protein as described above.

The complete nucleotide sequence of pE1/Fiber is listed in SEQ ID NO: 15 where the nucleotide position 1 corresponds to approximately 1459 nucleotides from the 3' end of the parent vector pMAM sequence. The 5' and 3' ends of the Ad5 E1 gene are located at respective nucleotide positions 1460 and 4998
25 followed by pMAM backbone and then separated from the Ad5 fiber from pCLF by the filled-in blunt ended NdeI site. The 5' and 3' ends of the pCLF fiber gene fragment are located at respective nucleotide positions 10922-14223 containing elements as previously described for pCLF.

The resultant pE1/Fiber plasmid is then used to complement one or more
30 delivery plasmids expressing E1 and fiber.

The pE1/Fiber construct is then used to transfect a selected host cell as described in Example 1E to generate stable chromosomal insertions performed as

-59-

previously described followed by selection on HAT medium. The stable cells are then used as packaging cells as described in Example 2.

2. Preparation of a Complementing Plasmid Containing E4 and Fiber Adenoviral Genes

5 Plasmid pCLF prepared as described in Example 1B is partially digested with BglII to cut only at the site in the pCDNA3 backbone. The pE4/Hygro plasmid prepared in Example 1A is digested with BamHI to produce a fragment containing E4. The E4 fragment is then inserted into the BamHI site of pCLF to form plasmid pE4/Fiber. The resultant plasmid provides expression of the fiber
10 gene as described for pCLF and E4 function as described for pE4/Hygro.

A schematic plasmid map of pE4/Fiber, having 10610 bp. The complete nucleotide sequence of pE4/Fiber is listed in SEQ ID NO: 16 where the nucleotide position 1 corresponds to approximately 14 bp from the 3' end of the parent vector pCDNA3 backbone sequence. The 5' and 3' ends of the Ad5 E4
15 gene are located at respective nucleotide positions 21 and 3149 followed by fused BglII/BamHI sites and pCDNA3 backbone including the CMV promoter again followed by BglII/BamHI sites. The adenovirus leader sequence begins at nucleotide position 4051 and extends to 4366 followed by fused BamHI/BglII sites and the 5' and 3' ends of the fiber gene located at respective nucleotide
20 positions 4372 and 6124.

Stable chromosomal insertions of pE4/Fiber in host cells are obtained as described above.

EXAMPLE 2

Preparation of Adenoviral Gene Delivery Vectors Using Adenoviral Packaging Cell Lines

25 Adenoviral delivery vectors are prepared to separately lack the combinations of E1/fiber and E4/fiber. Such vectors are more replication-defective than those previously in use due to the absence of multiple viral genes. A preferred adenoviral delivery vector is replication competent but only via a
30 non-fiber means is one that only lacks the fiber gene but contains the remaining functional adenoviral regulatory and structural genes. Furthermore, these adenovirus delivery vectors have a higher capacity for insertion of foreign DNA.

-60-

A. Preparation of Adenoviral Gene Delivery Vectors Having Specific Gene Deletions and Methods of Use

- To construct the E1/ fiber deleted viral vector containing the LacZ reporter gene construct, two new plasmids were constructed. The plasmid pΔ
- 5 E1Bβgal was constructed as follows. A DNA fragment containing the SV40 regulatory sequences and *E. coli* β-galactosidase gene was isolated from pSVβgal (Promega) by digesting with *VspI*, filling the overhanging ends by treatment with Klenow fragment of DNA polymerase I in the presence of dNTP's and digesting with *Bam* HI. The resulting fragment was cloned into the *EcoRV* and *Bam* HI
- 10 sites in the polylinker of pΔ E1sp1B (Microbix Biosystems, Hamilton, Ontario) to form pΔ E1B βgal that therefore contained the left end of the adenovirus genome with the *Ela* region replaced by the LacZ cassette (nucleotides 6690 to 4151) of pSVβgal. Plasmid DNA may be prepared by the alkaline lysis method as described by Birnboim and Doly, *Nuc. Acids Res.*, 7:1513-1523 (1978) or by the
- 15 Quiagen method according to the manufacturer's instruction, from transformed cells used to expand the plasmid DNA was then purified by CsCl-ethidium bromide density gradient centrifugation. Alternatively, plasmid DNAs may be purified from *E. coli* by standard methods known in the art (e.g. see Sambrook *et al.*)
- 20 The second plasmid (pDV44), prepared as described herein, is derived from pBHG10, a vector prepared as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994) (see, also International PCT application No. WO 95/00655) using methods well known to one of skill in the art. This vector is also commercially available from Microbix and and contains an Ad5 genome
- 25 with the packaging signals at the left end deleted and the E3 region (nucleotides 28133:30818) replaced by a linker with a unique site for the restriction enzyme *PacI*. An 11.9 kb *Bam* HI fragment, which contains the right end of the adenovirus genome, is isolated from pBHG10 and cloned into the *Bam* HI site of pBS/SK(+) to create plasmid p11.3 having approximately 14,658 bp. The p11.3
- 30 plasmid was then digested with *PacI* and *Sall* to remove the fiber, E4, and inverted terminal repeat (ITR) sequences.

-61-

This fragment was replaced with a 3,4 kb fragment containing the ITR segments and the E4 gene which was generated by PCR amplification from pBHG10 using the following oligonucleotide sequences:

5' TGTACACCG GATCCGGCGCACACC3' SEQ ID NO: 17; and

5 5' CACAACGAGCTC AATTAATTAATTGCCACATCCTC3' SEQ ID NO: 18.

These primers incorporated sites for *PacI* and *BamHI*. Cloning this fragment into the *PacI* and blunt ended *Sall* sites of the p11.3 backbone resulted in a substitution of the fused ITRs, E4 region and fiber gene present in pBHG10, by the ITRs and E4 region alone. The resulting p11.3 plasmid containing the ITR and E4 regions, designated plasmid pDV43a, was then digested with *BamHI*. This *BamHI* fragment was then used to replace a *BamHI* fragment in pBHG10 thereby creating pDV44 in a pBHG10 backbone.

In an alternative approach to preparing pDV44 with an additional subcloning step to facilitate the incorporation of restriction cloning sites, the following cloning procedure was performed. pDV44 as above was constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10 (Microbix Biosystems). As above, to simplify manipulations, the 11.9 kb *BamHI* fragment including the rightmost part of the Ad5 genome was removed from pBHG10 and inserted into pBS/SK. The resulting plasmid was termed p11.3.

20 The 3.4 kb DNA fragment corresponding to the E4 region and both ITRs of adenovirus type 5 was amplified as described above from pBHG10 using the oligonucleotides listed above and subcloned into the vector pCR2.1 (Invitrogen) to create pDV42. This step is the additional cloning step to facilitate the incorporation of a *Sall* restriction site. pDV42 was then digested with *PacI*,

25 which cuts at a unique site (bold type) in one of the PCR primers, and with *Sall*, which cuts at a unique site in the pCR2.1 polylinker. This fragment was used to replace the corresponding *PacI*/*XhoI* fragment of p11.3 (the pBS polylinker adjacent to the Ad DNA fragment contains a unique *XhoI* site), creating pDV43.

30 A plasmid designated pDV44 was constructed by replacing the 11.9 kb *BamHI* fragment of pBHG10 by the analogous *BamHI* fragment of pDV43. As generated in the first procedure, pDV44 therefore differs from pBHG10 by the

-62-

deletion of Ad5 nucleotides 30819:32743 (residual E3 sequences and all but the 3'-most 41 nucleotides of the fiber open reading frame).

Thus, to summarize, the cloning procedures described above result in the production of a fiber-deleted Ad5 genomic plasmid (pDV44) that was

5 constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10. pDV44 contains a wild-type E4 region, but only the last 41 nucleotides of the fiber ORF (this sequence was retained to avoid affecting expression of the adjacent E4 transcription unit). Plasmids pBHG10 and pDV44 contain unpackageable Ad5 genomes, and must be rescued by cotransfection

10 and subsequent homologous recombination with DNA carrying functional packaging signals. In order to generate vectors marked with a reporter gene, either pDV44 or pBHG10 was cotransfected with p Δ E1B β gal, which contains the left end of the Ad5 genome with an SV40-driven β -galactosidase reporter gene inserted in place of the E1 region.

15 In general, and as described below, the method for virus production by recombination of plasmids followed by complementation in cell culture involves the isolation of recombinant viruses by cotransfection of any one of the adenovirus packaging cell systems prepared in Example 1, namely 211A, 211B, 211R, A549, Vero cells, and the like, with plasmids carrying sequences

20 corresponding to viral gene delivery vectors.

A selected cell line is plated in dishes and cotransfected with pDV44 and p Δ E1B β gal using the calcium phosphate method as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994). Recombination between the overlapping adenovirus sequences in the two plasmids leads to the creation of a

25 full-length viral chromosome where pDV44 and p Δ E1B β gal recombine to form a recombinant adenovirus vector having multiple deletions. The deletion of E1 and of the fiber gene from the viral chromosome is compensated for by the sequences integrated into the packaging cell genome, and infectious virus particles are produced. The plaques thus generated are isolated and stocks of

30 the recombinant virus are produced by standard methods.

Because of the fiber deletion, a pDV44-derived virus is replication-defective, cells in which it is grown must complement this defect.

-63-

The 211B cell line (a derivative of 293 cells which expresses the wild-type (wt) AD5 fiber and is equivalent to 211A on deposit with ATCC as described in Example 4) was used for rescue and propagation of the virus described here. pDV44 and pΔE1βgal were cotransfected into 211B cells, and the monolayers
5 were observed for evidence of cytopathic effect (CPE). Briefly, for virus construction, cells were transfected with the indicated plasmids using the Gibco Calcium Phosphate Transfection system according to the manufacturer's instructions and observed daily for evidence of CPE.

One of a total of 58 transfected dishes showed evidence of spreading cell
10 death at day 15. A crude freeze-thaw lysate was prepared from these cells and the resulting virus (termed Ad5.βgal.ΔF) was plaque purified twice and then expanded. To prepare purified viral preparations, cells were infected with the indicated Ad and observed for completion of CPE. Briefly, at day zero, 211B
15 cells were plated in DMEM plus 10% fetal calf serum at approximately 1×10^7 cells/150 cm² flask or equivalent density. At day one, the medium was replaced with one half the original volume of fresh DMEM containing the indicated Ad, in this case Ad5.βgal.ΔF, at approximately 100 particles/cell. At day two, an equal volume of medium was added to each flask and the cells were observed for CPE. Two to five days after infection, cells were collected and virus isolated by lysis
20 via four rapid freeze-thaw cycles. Virus was then purified by centrifugation on preformed 15-40% CsCl gradients ($111,000 \times g$ for three hours at 4°C). The bands were harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCl, and 10% glycerol), aliquoted and stored at -70°C. Purified Ad5.βgal.ΔF virus particles containing human adenovirus Ad5.βgal.ΔF genome (described
25 further below) have been deposited with the ATCC on January 15, 1999 as further described in Example 4.

For viral titering, as necessary in the below Examples, Ad preparations were titered by plaque assay on 211B cells. Cells were plated on polylysine-coated 6 well plates at 1.5×10^6 cells/well. Duplicate dilutions of
30 virus stock were added to the plates in 1 ml/well of complete DMEM. After a five hour incubation at 37°C, virus was removed and the wells overlaid with 2

-64-

ml of 0.6% low-melting agarose in Medium 199 (Gibco). An additional 1 ml of overlay was added at five day intervals.

As a control, the first-generation virus Ad5. β gal.wt, which is identical to Ad5. β gal. Δ F except for the fiber deletion, was constructed by cotransfection of pBHG10 and p Δ E1B β gal. In contrast to the low efficiency of recovery of the fiberless genome (1/58 dishes), all of 9 dishes cotransfected with p Δ E1B β gal and pBHG10 produced virus.

In another embodiment, a delivery plasmid is prepared that does not require the above-described recombination events to prepare a viral vector having a fiber gene deletion. In one embodiment, a single delivery plasmid containing all the adenoviral genome necessary for packaging but lacking the fiber gene is prepared from plasmid pFG140 containing full-length Ad5 that is commercially available from Microbix. The resultant delivery plasmid referred to as pFG140-f is then used with pCLF stably integrated cells as described above to prepare a viral vector lacking fiber. For genetic therapy, the fiber gene can be replaced with a therapeutic gene of interest for preparing a therapeutic delivery adenoviral vector. Methods for producing a fiberless vector with a complete TPL are described in Example 3.

Vectors for the delivery of any desired gene and preferably a therapeutic gene are prepared by cloning the gene of interest into the multiple cloning sites in the polylinker of commercially available p Δ E1sp1B (Microbix Biosystems), in an analogous manner as performed for preparing pE1B β gal as described above. The same cotransfection and recombination procedure is then followed as described herein to obtain viral gene delivery vectors as further discussed in later Examples.

1. Characterization of the Ad5. β gal. Δ F Genome

To confirm that the vector genomes had the proper structures and that the fiber gene was absent from the Ad5. β gal. Δ F chromosome, the DNA isolated from viral particles was analyzed. Briefly, purified viral DNA was obtained by adding 10 μ l of 10 mg/ml proteinase K, 40 μ l of 0.5 M EDTA and 50 μ l of 10% SDS to 800 μ l of adenovirus-containing culture supernatant. The suspension

-65-

was then incubated at 55°C for 60 minutes. The solution was then extracted once with 400 μ l of a 24:1 mixture of chloroform:isoamyl alcohol. The aqueous phase was then removed and precipitated with sodium acetate/ethanol. The pellet was washed once with 70% ethanol and lightly dried. The pellet was then suspended in 40 μ l of 10 mM Tris-HCl, pH 8.0, 1 mM EDTA. Genomic DNA from Ad5. β gal.wt and Ad5. β gal. Δ F produced the expected restriction patterns following digestion with either EcoRI or with NdeI. Southern blotting, performed with standard methods, with labeled fiber DNA as a probe demonstrated the presence of fiber sequence in Ad5. β gal.wt but not in Ad5. β gal. Δ F DNA. As a positive control, the blot was stripped and reprobed with labeled E4 sequence. Fiber and E4 sequences were detected by using labeled inserts from pCLF and pE4/Hygro, respectively. E4 signal was readily detectable in both genomes at equal intensities. The complete nucleotide sequence of Ad5. β gal. Δ F is presented in SEQ ID NO: 23 and is contained in the virus particle on deposit with ATCC.

2. Characterization of the Fiberless Adenovirus Ad5. β gal. Δ F

To verify that Ad5. β gal. Δ F was fiber-defective, 293 cells (which are permissive for growth of E1-deleted Ad vectors but do not express fiber) were infected with Ad5. β gal. Δ F or with Ad5. β gal.wt. Twenty-four hours post infection, the cells were stained with polyclonal antibodies directed either against fiber or against the penton base protein. Cells infected with either virus were stained by the anti-penton base antibody, while only cells infected with the Ad5. β gal.wt control virus reacted with the anti-fiber antibody. This confirms that the fiber-deleted Ad mutant does not direct the synthesis of fiber protein.

3. Growth of the Fiber-Deleted Ad5. β gal. Δ F Vector in Complementing Cells

Ad5. β gal. Δ F was found to readily be propagated in 211B cells. As assayed by protein concentration, CsCl-purified stocks of either Ad5. β gal. Δ F or Ad5. β gal.wt contained similar numbers of viral particles. The particles appeared to band normally on CsCl gradients. Infectivity of the Ad5. β gal. Δ F particles was lower than the Ad5. β gal.wt control, as indicated by an increased particle/PFU ratio. Ad5. β gal. Δ F was also found to plaque more slowly than the control

-66-

virus. When plated on 211B cells, Ad5.βgal.wt plaques appeared within 5-7 days, while plaques of Ad5.βgal.ΔF continued to appear until as much as 15-18 days post infection. Despite their slower formation, the morphology of Ad5.βgal.ΔF plaques was essentially normal.

5 4. Production of Fiberless Ad5.βgal.ΔF Particles

As Ad5.βgal.ΔF represents a true fiber null mutation and its stocks are free of helper virus, the fiber mutant phenotype was readily investigated. A single round of growth in cells (such as 293) which do not produce fiber generating a homogeneous preparation of fiberless Ad allowed for the determination of whether such particles would be stable and/or infectious. Either Ad5.βgal.wt or Ad5.βgal.ΔF was grown in 293 or 211B cells, and the resulting particles purified on CsCl gradients as previously described. Ad5.βgal.ΔF particles were readily produced in 293 cells at approximately the same level as the control virus and behaved similarly on the gradients, indicating that there was not a gross defect in morphogenesis of fiberless capsids.

Particles of either virus contained similar amounts of penton base regardless of the cell type in which they were grown. This demonstrated that fiber is not required for assembly of the penton base complex into virions. The Ad5.βgal.ΔF particles produced in 293 cells did not contain fiber protein.

20 211B-grown Ad5.βgal.ΔF also contained less fiber than the Ad5.βgal.wt control virus. The infectivities of the different viral preparations on epithelial cells correlated with the amount of fiber protein present. The fiberless Ad particles were several thousand-fold less infectious than the first-generation vector control on a per-particle basis, while infectivity of 211B-grown Ad5.βgal.ΔF was only

25 50-100 fold less than that of Ad5.βgal.wt. These studies confirmed fiber's crucial role in infection of epithelial cells via CAR binding.

5. Composition and Structure of the Fiberless Ad5.βgal.ΔF Particles

30 The proteins contained in particles of 293-grown Ad5.βgal.ΔF were compared to those in Ad5.βgal.wt, to determine whether proteolysis or particle assembly was defective in this fiber null mutant. The overall pattern of proteins in the fiberless particles was observed to be quite similar to that of a

-67-

first-generation vector, with the exception of reduced intensity of the composite band resulting from proteins IIIa and IV (fiber). The fiberless particles also had a reduced level of protein VII. Although substantial amounts of uncleaved precursors to proteins VI, VII, and VIII were not seen, it is possible that the

5 low-molecular weight bands migrating ahead of protein VII represent either aberrantly cleaved viral proteins or their breakdown products.

Cryo-electron microscopy was used to more closely examine the structure of the 293 grown Ad5.βgal.ΔF and of Ad5βgal.wt. The fiber, having an extended stalk with a knob at the end, was faintly visible in favorable

10 orientations of wild-type Ad5 particles, but not in images of the fiberless particles. Filamentous material likely corresponding to free viral DNA was seen in micrographs of fiberless particles. This material was also present in micrographs of the first-generation control virus, albeit at much lower levels.

Three-dimensional image reconstructions of fiberless and wild-type

15 particles at ~20 Å resolution showed similar sizes and overall features, with the exception that fiberless particles lacked density corresponding to the fiber protein. The densities corresponding to other capsid proteins, including penton base and proteins IIIa, VI, and IX, were comparable in the two structures. This confirms that absence of fiber does not prevent assembly of these components

20 into virions. The fiber was truncated in the wild-type structure as only the lower portion of its flexible shaft follows icosahedral symmetry. The RGD protrusions on the fiberless penton base were angled slightly inward relative to those of the wild-type structure. Another difference between the two penton base proteins was that there is a ~30 Å diameter depression in the fiberless penton base

25 around the five-fold axis where the fiber would normally sit. The Ad5 reconstructions confirm that capsid assembly, including addition of penton base to the vertices, is able to proceed in the complete absence of fiber.

6. Integrin-Dependent Infectivity of Fiberless Ad5.βgal.ΔF Particles

30 While attachment via the viral fiber protein is a critical step in the infection of epithelial cells, an alternative pathway for infection of certain hematopoietic cells has been described. In this case, penton base mediates

-68-

binding to the cells (via $\beta 2$ integrins) and internalization (through interaction with αv integrins). Particles lacking fiber might therefore be expected to be competent for infection of these cells, even though on a per-particle basis they are several thousand-fold less infectious than normal Ad vectors on epithelial
5 cells.

To investigate this, THP-1 monocytic cells were infected with Ad5. β gal.wt or with Ad5. β gal. Δ F grown in the absence of fiber. Infection of THP-1 cells was assayed by infecting 2×10^5 cells at the indicated m.o.i. in 0.5 ml of complete RPMI. Forty-eight hours post-infection, the cells were fixed with
10 glutaraldehyde and stained with X-gal, and the percentage of stained cells was determined by light microscopy. The results of the infection assay showed that the fiberless particles were only a few-fold less infectious than first-generation Ad on THP-1 cells. Large differences were seen in plaquing efficiency on epithelial (211B) cells. Infection of THP-1 cells by either Ad5. β gal. Δ F or
15 Ad5. β gal.wt was not blocked by an excess of soluble recombinant fiber protein, but could be inhibited by the addition of recombinant penton base). These results indicate that the fiberless Ad particles use a fiber-independent pathway to infect these cells. Furthermore, the lack of fiber protein did not prevent Ad5. β gal. Δ F from internalizing into the cells and delivering its genome to the
20 nucleus, demonstrating that fiberless particles are properly assembled and are capable of uncoating.

The foregoing results with the recombinant viruses thus produced indicates that they can be used as gene delivery tools in cultured cells and *in vivo* as described more fully in the Examples. For example, for studies of the
25 effectiveness and relative immunogenicity of multiply-deleted vectors, virus particles are produced by growth in the packaging lines described in Example 1 and are purified by CsCl gradient centrifugation. Following titering, virus particles are administered to mice via systemic or local injection or by aerosol delivery to lung. The LacZ reporter gene allows the number and type of cells
30 which are successfully transduced to be evaluated. The duration of transgene expression is evaluated in order to determine the long-term effectiveness of treatment with multiply-deleted recombinant adenoviruses relative to the

-69-

standard technologies which have been used in clinical trials to date. The immune response to the improved vectors described here is determined by assessing parameters such as inflammation, production of cytotoxic T lymphocytes directed against the vector, and the nature and magnitude of the antibody response directed against viral proteins.

Versions of the vectors which contain therapeutic genes such as CFTR for treatment of cystic fibrosis or tumor suppressor genes for cancer treatment are evaluated in the animal system for safety and efficiency of gene transfer and expression. Following this evaluation, they are used as experimental therapeutic agents in human clinical trials.

B. Retargeting of Adenoviral Gene Delivery Vectors by Producing Viral Particles Containing Different or Altered Fiber Proteins

As the specificity of adenovirus binding to target cells is largely determined by the fiber protein, viral particles that incorporate modified fiber proteins or fiber proteins from different adenoviral serotypes (pseudotyped vectors) have different specificities. Thus, the methods of expression of the native Ad5 fiber protein in adenovirus packaging cells as described above is also applicable to production of different fiber proteins.

Chimeric fiber proteins can be produced according to known methods (see, *e.g.*, Stevenson *et al.* (1995) *J. Virol.*, 69:2850-2857). Determinants for fiber receptor binding activity are located in the head domain of the fiber and an isolated head domain is capable of trimerization and binding to cellular receptors. The head domains of adenovirus type 3 (Ad3) and Ad5 were exchanged in order to produce chimeric fiber proteins. Similar constructs for encoding chimeric fiber proteins for use in the methods herein are contemplated. Thus, instead of the using the intact Ad5 fiber-encoding construct prepared in above and in U.S. application Serial No. 09/482,682) as a complementing viral vector in adenoviral packaging cells, the constructs described herein are used to transfect cells along with E4 and/or E1-encoding constructs.

Briefly, full-length Ad5 and Ad3 fiber genes were amplified from purified adenovirus genomic DNA as a template. The Ad5 and Ad3 nucleotide sequences are available with the respective GenBank Accession Numbers

-70-

M18369 and M12411. Oligonucleotide primers are designed to amplify the entire coding sequence of the full-length fiber genes, starting from the start codon, ATG, and ending with the termination codon TAA. For cloning purposes, the 5' and 3' primers contain the respective restriction sites BamHI and NotI for cloning into pcDNA plasmid as described in Example 1A. PCR is performed as described above.

The resulting products are then used to construct chimeric fiber constructs by PCR gene overlap extension (Horton *et al.* (1990) *BioTechniques*, 8:525-535). The Ad5 fiber tail and shaft regions (5TS; the nucleotide region encoding amino acid residue positions 1 to 403) are connected to the Ad3 fiber head region (3H; the nucleotide region encoding amino acid residue positions 136 to 319) to form the 5TS3H fiber chimera. Conversely, the Ad3 fiber tail and shaft regions (3TS; the nucleotide region encoding amino acid residues positions 1 to 135) are connected to the Ad5 fiber head region (5H; the nucleotide region encoding the amino acid residue positions 404 to 581) to form the 3TS5H fiber chimera. The fusions are made at the conserved TLWT (SEQ ID NO: 19) sequence at the fiber shaft-head junction.

The resultant chimeric fiber PCR products are then digested with BamHI and NotI for separate directional ligation into a similarly digested pcDNA 3.1. The TPL sequence is then subcloned into the BamHI as described in Example 1A for preparing an expression vector for subsequent transfection into 211 cells as described above or into the alternative packaging cell systems as previously described. The resultant chimeric fiber construct-containing adenoviral packaging cell lines are then used to complement adenoviral delivery vectors as previously described. Other fiber chimeric constructs are obtained with the various adenovirus serotypes using a similar approach.

In an alternative embodiment, the use of modified proteins including with modified epitopes (see, *e.g.*, Michael *et al.* (1995) *Gene Therapy*, 2:660-668 and International PCT application Publication No. WO 95/26412, which describe the construction of a cell-type specific therapeutic viral vector having a new binding specificity incorporated into the virus concurrent with the destruction of the endogenous viral binding specificity). In particular, the authors described the

-71-

production of an adenoviral vector encoding a gastrin releasing peptide (GRP) at the 3' end of the coding sequence of the Ad5 fiber gene. The resulting fiber-GRP fusion protein was expressed and shown to assemble functional fiber trimers that were correctly transported to the nucleus of HeLa cells following synthesis.

Similar constructs are contemplated for use in the complementing adenoviral packaging cell systems for generating new adenoviral gene delivery vectors that are targetable, replication-deficient and less immunogenic. Heterologous ligands contemplated for use herein to redirect fiber specificity range from as few as 10 amino acids in size to large globular structures, some of which necessitate the addition of a spacer region so as to reduce or preclude steric hindrance of the heterologous ligand with the fiber or prevent trimerization of the fiber protein. The ligands are inserted at the end or within the linker region. Preferred ligands include those that target specific cell receptors or those that are used for coupling to other moieties such as biotin and avidin.

A preferred spacer includes a short 12 amino acid peptide linker composed of a series of serines and alanine flanked by a proline residue at each end using routine procedures known to those of skill in the art. The skilled artisan will be with the preparation of linkers to accomplish sufficient protein presentation and to alter the binding specificity of the fiber protein without compromising the cellular events that follow viral internalization. Moreover, within the context of this disclosure, preparation of modified fibers having ligands positioned internally within the fiber protein and at the carboxy terminus as described below are contemplated for use with the methods described herein.

25

The preparation of a fiber having a heterologous binding ligand is prepared essentially as described in the above-cited paper. Briefly, for the ligand of choice, site-directed mutagenesis is used to insert the coding sequence for a linker into the 3' end of the Ad5 fiber construct in pCLF as prepared in Example 1.

30

The 3' or antisense or mutagenic oligonucleotide encodes a preferred linker sequence of ProSerAlaSerAlaSerAlaSerAlaProGlySer (SEQ ID NO: 20)

-72-

followed by a unique restriction site and two stop codons, respectively, to allow the insertion of a coding sequence for a selected heterologous ligand and to ensure proper translation termination. Flanking this linker sequence, the mutagenic oligonucleotide contains sequences that overlap with the vector
5 sequence and allow its incorporation into the construct. Following mutagenesis of the pCLF sequence adding the linker and stop codon sequences, a nucleotide sequence encoding a preselected ligand is obtained, linkers corresponding to the unique restriction site in the modified construct are attached and then the sequence is cloned into linearized corresponding restriction site. The
10 resultant fiber-ligand construct is then used to transfect 211 or the alternative cell packaging systems previously described to produce complementing viral vector packaging systems.

In a further embodiment, intact fiber genes from different Ad serotypes are expressed by 211 cells or an alternative packaging system as previously
15 described. A gene encoding the fiber protein of interest is first cloned to create a plasmid analogous to pCLF, and stable cell lines producing the fiber protein are generated as described above for Ad5 fiber. The adenovirus vector described which lacks the fiber gene is then propagated in the cell line producing the fiber protein relevant for the purpose at hand. As the only fiber gene present is the
20 one in the packaging cells, the adenoviruses produced contain only the fiber protein of interest and therefore have the binding specificity conferred by the complementing protein. Such viral particles are used in studies such as those described above to determine their properties in experimental animal systems.

EXAMPLE 3

25 Tripartite leader sequences (TPLs) that are useful in enhancing the expression of complementing adenoviral proteins, particularly fiber protein, for use in preparing an adenoviral gene delivery vector are provided. The complete Ad5 TPL was constructed by assembling PCR fragments. First, the third TPL exon (exon 3) (nt 9644-9731 of the Ad5 genome) was amplified from Ad5
30 genomic DNA using the synthetic oligonucleotide primers
5'CTCAACAATTGTGGATCCGTACTCC3' (SEQ ID No. 24) and
5'GTGCTCAGCAGATCTTGCGACTGTG3' (SEQ ID No. 25). The resulting

-73-

product was cloned to the BamHI and BglII sites of pΔE1Sp1a (Microbix Biosystems) using sites in the primers (shown in bold) to create plasmid pDV52. A fragment corresponding to the first TPL exon (exon 1), the natural first intron (intron 1), and the second TPL exon (exon 2) (Ad5 nt 6049-7182) was then
5 amplified using primers 5'GGCGCGTTCGGATCCACTCTCTTCC3' (SEQ ID No. 26) and 5'CTACATGCTAGGCAGATCTCGTTCCGAG3' (SEQ ID No. 27), and cloned into the BamHI site of pDV52 (again using sites in the primers) to create pDV55.

This plasmid contains a 1.2 kb BamHI/BglII fragment containing the first
10 TPL exon, the natural first intron, and the fused second and third TPL exons. The nucleotide sequence of the complete TPL containing the noted 5' and 3' restriction sites is shown in SEQ ID No 28 with the following nucleotide regions identified: 1-6 nt BamHI site; 7-47 nt first leader segment (exon 1); 48-1068 nt natural first intron (intron 1); 1069-1140 nt second leader segment (exon 2);
15 1141-1146 nt fused BamHI and BglII sites; 1147-1234 nt third leader segment (exon 3); and 1235-1240 nt BglII site.

EXAMPLE 4

Deposit of Materials

The following cell lines and plasmids were deposited on September 25,
20 1996, with the American Type Culture Collection, 10801 University Blvd, Manassas, Virginia, USA (ATCC) under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty): Plasmid pE4/Hygro (accession number 97739), Plasmid pCLF (accession number 97737),
25 211 Cell Line (accession number CRL-12193) and 211A Cell Line (accession number CRL-12194)

The following virus, Ad5.βgal.ΔF, was deposited on January 15, 1999, with the ATCC as listed above and provided with accession number VR2636.

Additionally, plasmids pDV60, pDV67, pDV69, pDV80 and pDV90 were
30 deposited at the ATCC on January 5, 2000 and provided with accession numbers PTA-1144, PTA-1145, PTA-1146, PTA-1147 and PTA-1148 respectively.

-74-

EXAMPLE 5**Preparation and Use of Adenoviral Packaging Cell Lines
Containing Plasmids Containing Alternative TPLs**

Plasmids containing tripartite leaders (TPLs) have been constructed. The
5 resulting plasmids that contain different selectable markers, such as neomycin
and zeocin, were then used to prepare fiber-complementing stable cell lines for
use as for preparing adenoviral vectors.

A. pDV60

Plasmid pDV60 was constructed by inserting this TPL cassette of SEQ ID
10 No. 28 into the BamHI site upstream of the Ad5 fiber gene in pcDNA3/Fiber, a
neomycin selectable plasmid (see, *e.g.*, U.S. application Serial No. 09/482,682
(also filed as International PCT application No. PCT/US00/00265 on January 14,
2000); see also Von Seggern *et al.* (1998) *J. Gen Virol.*, 79: 1461-1468). The nucleotide sequence of pDV60 is
15 listed in SEQ ID NO: 29. Plasmid pDV60 has been deposited in the ATCC under
accession number PTA-1144.

B. pDV61

To construct pDV61, an Asp718/NotI fragment containing the CMV
promoter, partial Ad5 TPL, wildtype Ad5 fiber gene, and bovine growth hormone
20 terminator was transferred from pCLF (ATCC accession number 97737; and
described in copending U.S. application Serial No. 09/482,682 (also filed as
International PCT application No. PCT/US00/00265 on January 14, 2000));, to a
zeocin selectable cloning vector referred to as pCDNA3.1/Zeo (+) (commercially
available from Invitrogen and for which the sequence is known).

25 C. pDV67

In an analogous process, pDV67 containing complete TPL was
constructed by transferring an Asp 718/XbaI fragment from pDV60 into
pcDNA3.1/Zeo(+) backbone. The nucleotide sequence of pDV67 is set forth in

-75-

SEQ ID No. 30. Plasmid pDV67 is available from the ATCC under accession number PTA-1145.

D. pDV69

To prepare pDV69 containing a modified fiber protein, the chimeric
5 Ad3/Ad5 fiber gene was amplified from pGEM5TS3H (Stevenson *et al.* (1995) *J. Virol.*, 69: 2850-2857) using the primers 5'ATGGGAT
CAAGATGAAGCGCGCAAGACCG3' (SEQ ID No. 31) and
5'CACTATAGCGGCCGCATTCTCAGTCATCTT3' (SEQ ID No. 32), and cloned to
the BamHI and NotI sites of pcDNA3.1/Zeo(+) via new BamHI and NotI sites
10 engineered into the primers to create pDV68. Finally, the complete TPL
fragment described above was then added to the unique BamHI site of pDV68
to create pDV69. The nucleotide sequence of pDV69 is listed in SEQ ID No. 33
and has been deposited in the ATCC under accession number PTA-1146.

E. Preparation of Stable Adenovirus Packaging Cell Lines

15 E1-2a S8 cells are derivatives of the A549 lung carcinoma line (ATCC #
CCL 185) with chromosomal insertions of the plasmids pGRE5-2.E1 (also
referred to as GRE5-E1-SV40-Hygro construct and listed in SEQ ID No. 34) and
pMNeoE2a-3.1 (also referred to as MMTV-E2a-SV40-Neo construct and listed in
SEQ ID No. 35), which provide complementation of the adenoviral E1 and E2a
20 functions, respectively. This line and its derivatives were grown in Richter's
modified medium (BioWhitaker) + 10% FCS. E1-2a S8 cells were
electroporated as previously described (Von Seggern *et al.* (1998) *J. Gen Virol.*,
79: 1461-1468) with pDV61, pDV67, or with pDV69, and stable lines were
selected with zeocin (600 µg/ml).

25 The cell line generated with pDV61 is designated 601. The cell line
generated with pDV67 is designated 633 while that generated with pDV69 is
designated 644. Candidate clones were evaluated by immunofluorescent
staining with a polyclonal antibody raised against the Ad2 fiber. Lines
expressing the highest level of fiber protein were further characterized.

30 For the S8 cell complementing cell lines, to induce E1 expression, 0.3 µM
of dexamethasone was added to cell cultures 16-24 hours prior to challenge
with virus for optimal growth kinetics. For preparing viral plaques, 5×10^5

-76-

cells/well in 6 well plates are prepared and pre-induced with the same concentration of dexamethasone the day prior to infection with 0.5 μ M included at a final concentration in the agar overlay after infection.

F. Development of Cell Lines for Complementation of E1/E2a Vectors

5 The Adenovirus 5 genome was digested with Scal enzyme, separated on an agarose gel, and the 6,095 bp fragment containing the left end of the virus genome was isolated. The complete Adenovirus 5 genome is registered as Genbank accession #M73260, incorporated herein by reference, and the virus is available from the American Type Culture Collection, Manassas, Virginia, U.S.A.,
10 under accession number VR-5. The Scal 6,095 bp fragment was digested further with Clal at bp 917 and BglII at bp 3,328. The resulting 2,411 bp Clal to BglII fragment was purified from an agarose gel and ligated into the superlinker shuttle plasmid pSE280 (Invitrogen, San Diego, CA), which was digested with Clal and BglII, to form pSE280-E.

15 Polymerase chain reaction (PCR) was performed to synthesize DNA encoding an XhoI and SalI restriction site contiguous with Adenovirus 5 DNA bp 552 through 924. The primers which were employed were as follows:

5' end, Ad5 bp 552-585:

5'-GTCACTCGAGGACTCGGTC-GACTGAAAATGAGACATATTATCTGCCACGGA

20 CC-3' (SEQ ID No 36)

3' end, Ad5 bp 922-891:

5'-CGAGATCGATCACCTCCGGTACAAGGTTTGGCATAG-3' (SEQ ID No. 37)

 This amplified DNA fragment (sometimes hereinafter referred to as
Fragment A) then was digested with XhoI and Clal, which cleaves at the native
25 Clal site (bp 917), and ligated to the XhoI and Clal sites of pSE280-E, thus reconstituting the 5' end of the E1 region beginning 8 bp upstream of the ATG codon.

 PCR then was performed to amplify Adenovirus 5 DNA from bp 3,323 through 4,090 contiguous with an EcoRI restriction site. The primers which
30 were employed were as follows:

5' end, Ad5 bp 3323-3360:

-77-

5'-CATGAAGATCTGGAAGGTGCTGAGGTACGATGAGACC-3' (SEQ ID No. 38);

and

3' end, Ad5 bp 4090-4060:

5'-GCGACTTAAGCAGTCAGCTG-AGACAGCAAGACACTTGCTTGATCCAAATCC

5 -3' (SEQ ID No. 39).

This amplified DNA fragment (sometimes hereinafter referred to as Fragment B) was digested with BglII, thereby cutting at the Adenovirus 5 BglII site (bp 3,382) and EcoRI, and ligated to the BglII and EcoRI sites of pSE280-AE to reconstruct the complete E1a and E1b region from Adenovirus 5 bp 552 through 4,090. The resulting plasmid is designated pSE280-E1.

A construct containing the intact E1a/b region under the control of the synthetic promoter GRE5 was prepared as follows. The intact E1a/b region was excised from pSE280-E1, which was modified previously to contain a BamHI site 3' to the E1 gene, by digesting with XhoI and BamHI. The XhoI to BamHI fragment containing the E1a/b fragment was cloned into the unique XhoI and BamHI sites of pGRE5-2/EBV (U.S. Biochemicals, Cleveland, Ohio) to form pGRE5-E1).

Bacterial transformants containing the final construct were identified. Plasmid DNA was prepared and purified by banding in CsTFA prior to use for transfection of cells.

Construction of plasmid including Adenovirus 5 E2A sequence.

The Adenovirus 5 genome was digested with BamHI and SpeI, which cut at bp 21,562 and 27,080, respectively. Fragments were separated on an agarose gel and the 5,518 bp BamHI to SpeI fragment was isolated. The 5,518 bp BamHI to SpeI fragment was digested further with SmaI, which cuts at bp 23,912. The resulting 2,350 bp BamHI to SmaI fragment was purified from an agarose gel, and ligated into the superlinker shuttle plasmid pSE280, and digested with BamHI and SmaI to form pSE280-E2 BamHI-SmaI.

PCR then was performed to amplify Adenovirus 5 DNA from the SmaI site at bp 23,912 through 24,730 contiguous with NheI and EcoRI restriction sites.

The primers which were employed were as follows:

5' end, Ad5 bp 24,732-24,708:

-78-

5'-CACGAATTCGTCAGCGCTTCTCGTCGCGTCCAAGACCC-3' (SEQ ID No. 40);
3' end, Ad5 bp 23,912-23,934:

5'-CACCCCGGGGAGGCGGCGGCGACGGGGACGGG-3' (SEQ ID No. 41)

This amplified DNA fragment was digested with SmaI and EcoRI, and
5 ligated to the SmaI and EcoRI sites of pSE280-E2 Bam-Sma to reconstruct the
complete E2a region from Ad5 bp 24,730 through 21,562. The resulting
construct is pSE280-E2a.

In order to convert the BamHI site at the 3' end of E2a to a Sall site, the
E2a region was excised from pSE280-E2a by cutting with BamHI and NheI, and
10 recloned into the unique BamHI and NheI sites of pSE280. Subsequently, the
E2a region was excised from this construction with NheI and Sall in order to
clone into the NheI and Sall sites of the pMAMneo (Clontech, Palo Alto, CA)
multiple cloning site in a 5' to 3' orientation, respectively. The resulting
construct is pMAMneo E2a.

15 Bacterial transformants containing the final pMAMneo-E2a were
identified. Plasmid DNA was prepared and purified by banding in CsTFA.
Circular plasmid DNA was linearized at the XmnI site within the ampicillin
resistance gene of pMAMneo-E2a, and further purified by the phenol/chloroform
extraction and ethanol precipitation prior to use for transfection of cells.

20 Transfection and selection of cells.

In general, this process involved the sequential introduction, by calcium
phosphate precipitation, or other means of DNA delivery, of two plasmid
constructions each with a different viral gene, into a single tissue culture cell.
The cells were transfected with a first construct and selected for expression of
25 the associated drug resistance gene to establish stable integrants. Individual cell
clones were established and assayed for function of the introduced viral gene.
Appropriate candidate clones then were transfected with a second construct
including a second viral gene and a second selectable marker. Transfected cells
then were selected to establish stable integrants of the second construct, and
30 cell clones were established. Cell clones were assayed for functional expression
of both viral genes.

-79-

A549 (ATCC Accession No. CCL-185) were used for transfection.

Appropriate selection conditions were established for G418 and hygromycin B by standard kill curve determination.

Transfection of A549 cells with plasmids including E1 and E2a regions.

- 5 pMAMNeo-E2a was linearized with XmnI with the Amp^R gene, introduced into cells by transfection, and cells were selected for stable integration of this plasmid by G418 selection until drug resistant colonies arose. The clones were isolated and screened for E2a expression by staining for E2a protein with a polyclonal antiserum, and visualizing by immunofluorescence. E2a function was
- 10 screened by complementation of the temperature-sensitive mutant Ad5ts125 virus which contains a temperature-sensitive mutation in the E2a gene. (Van Der Vliet, et al., J. Virology, Vol. 15, pgs. 348-354 (1975)). Positive clones expressing the E2a gene were identified and used for transfection with the 7 kb EcoRV to XmnI fragment from pGRE5-E1, which contains the GRE5 promoted
- 15 E1a/b region plus the hygromycin^R gene. Cells were selected for hygromycin resistance and assayed for E1a/b expression by staining with a monoclonal antibody for the E1 protein (Oncogene Sciences, Uniondale, N.Y.). E1 function was assayed by ability to complement an E1-deleted vector. At this point, expression and function of E2a was verified as described above, thus
- 20 establishing the expression of E1a/b and E2a in the positive cell clones.

A transfected A549 (A549 (ATCC Accession No. CCL-185);) cell lines showed good E1a/b and E2a expression and was selected for further characterization. It was designated the S8 cell line.

25 **G. Preparation of Adenoviral Vectors Containing Ad5. β gal. Δ F Genome in S8 Improved Fiber-Complementing Cell Lines**

- To prepare adenoviral vectors containing Ad5. β gal. Δ F (Ad5. β gal. Δ F has been deposited the ATCC under accession number VR2636) in S8 cells containing alternative forms of TPL for enhancing the expression of fiber proteins, the protocol as described in Example 2 for preparing Ad5. β gal. Δ F in
- 30 211B cells was followed with the exception of pretreatment with 0.3 μ M dexamethasone for 24 hours as described above. Thus, viral particles with the wildtype Ad5 fiber protein on their surface and containing the fiberless

-80-

Ad5. β gal. Δ F genome were produced in 633 cells. Particles produced in 644 cells also contained the fiberless Ad5. β gal. Δ F genome, but had the chimeric 5T3H fiber protein, with the Ad3 fiber knob, on their surface.

Thus, these viral preparations, prepared as described herein are useful for
5 targeting delivery of the Ad5. β gal. Δ F, Ad5.GFP. Δ F, or other similarly constructed fiberless genome with either wild-type or modified fibers. Preferably for purposes herein the fibers are from an Ad serotype D virus, more preferably from Ad37.

EXAMPLE 6

10 Pseudotyping and Infectivity of Recombinant Adenoviral Vectors Produced with Improved Fiber-Complementing Cell Lines

A. Pseudotyping of Ad5. β gal. Δ F

To verify that adenoviral vectors were produced had altered tropisms,
viral particles were purified from either 633 or 644 cells and were then Western
15 blotted and probed with a polyclonal rabbit antibody against the Ad2 fiber (which detects the Ad5 and chimeric 5T3H fiber proteins).

B. Infectivity of Cells with 633 or 644 Generated Virus Particles The
cell lines, 633 or 644, prepared as described above, were infected with the
indicated number of particles/cell of Ad5. β gal. Δ F and virus particles produced.
20 Virus was then used to infect selected cell lines, including 211B, MRC-5 human fibroblasts, A-10 rat aortic endothelial cells, and THP-1 human monocytic cells. Unbound virus was removed by washing the cells and the cells were further incubated at 37°C for 48 hours. Cells were then fixed with glutaraldehyde and stained with X-gal. The percentage of stained cells was then determined by light
25 microscopy where all experiments were done in triplicate.

The results indicated that adenoviral vectors could be retargeted by pseudotyping using packaging cell lines expressing different fiber proteins. Particles containing either fiber were equally infectious on 211B cells, while MRC-5 fibroblasts and THP-1 cells were more readily infected by virus containing
30 the chimeric fiber. The A-10 rat endothelial cells were more readily infected by particles containing the wildtype Ad5 fiber protein.

-81-

EXAMPLE 7

Transient Transcomplementation

The ability of adenovirus type 5 (Ad5) to deliver therapeutic genes to cells is mediated by the interaction of the adenoviral fiber protein with the

- 5 coxsackievirus-adenoviral receptor (CAR). Because a wide-range of cells express CAR, it was thought that it would be difficult to use adenoviruses to deliver genes to specific cell types. A system for testing modified fiber genes to identify tropisms of interest is described in copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No.
- 10 PCT/US00/00265 on January 14, 2000). An *in vitro* system has been developed that involves infection of tissue culture cells with a fiber-deleted Ad and transient co-transfection with a plasmid directing fiber expression. This system allows one to produce and evaluate modified fibers expressed on a viral particle. This system can be used to produce therapeutic quantities of
- 15 adenoviral vectors with modified fiber proteins, with such fibers having a new tropism added by insertion of a desired ligand into the fiber gene. These fibers may also have the natural tropism (*i.e.* binding to CAR) ablated.

- Plasmids used were pDV60 and pDV55 were prepared as described herein and in U.S. application Serial No. 09/482,682 (also filed as International
- 20 PCT application No. PCT/US00/00265 on January 14, 2000). pDV60 is an pcDNA3.1-based expression plasmid that contains the CMV promoter, Ad5 tripartite leader, an intron, and the Ad5 fiber gene sequence. pDV55 contains no fiber gene and serves as the negative control. Ad5. β gal. Δ F and 211B are described above. 293T cells are identical to 293 cells except they express an
- 25 integrated SV40 large T antigen gene. HDF cells are human diploid fibroblasts. 293T cells express CAR and α_v integrins; HDF cells express α_v integrins but no CAR. Transfections with fiber expression plasmids were performed with Lipofectamine (GIBCO-BRL) using 20mg DNA and 50ml Lipofectamine per 15cm dish. Cells were maintained in DMEM supplemented with 10% fetal bovine
- 30 serum.

The fiber deletion mutation of Ad5. β gal. Δ F is complemented in *trans* by passaging virions through 211B, a cell line that stably expresses functional Ad5

-82-

fiber. The present system was designed to complement Ad5. β gal. Δ F by modified fibers expressed from transfected episomal plasmids in 293T cells. The result is a simplified and rapid method to incorporate modified fibers on a viral particle containing the Ad5. β gal. Δ F genome that does not require propagation of the virus.

The feasibility of transcomplementation of Ad5. β gal. Δ F with episomal fiber-expressing plasmids was demonstrated in the following experiment. 293T cells were transfected with one of two plasmids: pDV55, which expresses no fiber or pDV60, which expresses wildtype Ad5 fiber. Fiber expression persists for at least six days. Twenty-four hours after transfection, these cells were infected at 2000 particles/cell with Ad5. β gal. Δ F passaged through 211B cells. Seventy-two hours later, a crude viral lysate (CVL) was generated by exposing the cells to five freeze-thaw cycles. Viral particles were purified by cesium chloride gradient centrifugation. The resulting virions incorporated the fiber expressed from the episomal plasmid, as confirmed by Western blots performed with an antibody specific to the Ad5 fiber.

Episomal plasmid transcomplementation system is suitable for quickly expressing and evaluating the properties of modified fibers in the context of a viral particle. Episomal plasmid transcomplementation will also be of great utility for quickly evaluating a bank of modified fibers for other binding properties, including new tropisms and the ablation of the native tropism. In addition to the rapid generation and testing of large numbers of modified fibers, there are other advantages to the Ad5. β gal. Δ F transcomplementation system in terms of production and safety. Episomal plasmid transcomplementation has the inherent advantage over transcomplementation in that it is not necessary to make a stable cell line for every modified fiber for complementation with Ad5. β gal. Δ F. Because the Ad5. β gal. Δ F is deleted in E1, E3 and fiber, there is an additional gene deletion, which should render it very suitable for gene therapy. In addition, the presence of the fiber gene deletion decreases the opportunity to generate replication-competent virus via recombination in the packaging cells. A single Ad vector preparation can be retargeted to any number of different cell types simply by transfecting the cells with the appropriate fiber-expression construct.

-83-

EXAMPLE 8**Preparation of Adenoviral Gene Delivery Vectors Containing the Ad37 fiber protein**

This example describes construction of packaging cell lines expressing the Ad37 fiber protein, and their use in generating particles of a fiber-deleted Ad vector (such as Ad5. β gal. Δ F) containing this fiber protein. The fiber protein is attached to the viral capsid by binding to the penton base protein through its N-terminus, and the Ad37 fiber was modified in order to make its N-terminal sequence more closely match that of the Ad5 protein to ensure that it would efficiently bind the Ad5 penton base in these vectors.

A. Materials and methods

Cell lines and wild-type adenovirus. Human A549 lung carcinoma epithelial cells and human Chang C conjunctival cells (American Type Culture Collection) were maintained in complete Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum. Wild-type Ad19p and Ad37 (ATCC) were propagated in A549 cells and purified by banding on CsCl₂ density gradients as previously described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Viral protein concentration was determined by the Bio-Rad Protein Assay, and was used to calculate the number of viral particles based on the known molecular weight of Ad2 virions (1 μ g = 4 x 10⁹ particles).

B. Construction of the Ad37 fiber expressing cell lines and the recombinant Ad37 knob protein.**1. Construction of an Expression Plasmid for the Ad37 Fiber Protein (pDV80)**

The plasmid designated pDV80 (see, SEQ ID No. 42) prepared for expression of the Ad37 fiber protein in mammalian cells, uses the same regulatory elements as the elements in pDV60, pDV67, and pDV69 to express the Ad37 fiber in packaging lines. It was constructed in two steps.

First, the Ad37 fiber open reading frame was amplified from Ad37 genomic DNA using synthetic oligonucleotide primers, L37: 5' TGT CCT GGA TCC AAG ATG AAG CGC GCC CGC CCC AGC GAA GAT GAC TTC 3' (SEQ ID NO. 43) and 37FR: 5' AAA CAC GGC GGC CGC TCT TTC ATT CTT G 3' (SEQ ID NO. 44). L37 contains nucleotides (underlined) that differ from the Ad37.

-84-

genomic sequence in order to add a unique *Bam*H1 site (bold) before the start codon (italicized) and to create point mutations that make the N-terminal sequence of the fiber more closely match the N-terminal sequence of the Ad5 fiber protein as follows:

5 Ad37 MSKRLRVEDDFNPVYPY (SEQ ID No. 45)

↓ ↓ ↓ ↓ ↓ ↓

KRARPS

(SEQ ID No. 46)

Ad5 MKRARPS EDTFNPVYPY (SEQ ID No. 47)

37FR also incorporates a unique *Not*I site (bold). The PCR product was inserted

10 into the *Bam*H1 and *Not*I sites of pCDNA3.1zeo(+) (Invitrogen) to create pDV78. The correct sequence of the Ad37 fiber protein, including inserted changes, was confirmed by sequencing.

Two point mutations in the fiber gene in the 705 line, S356 to P356 and I362 to T362, were discovered by the sequencing. The mutations are not in the
15 receptor binding domain in Ad37 fiber gene in the 705 cell line. They are buried in the knob trimer interface. To confirm that these mutations do not affect receptor binding, the Ad37 fiber protein with the correct sequence was recloned, and 293T cells transfected with the virus and subsequently infected with Ad5.GFPΔF to produce Ad37 pseudotyped virus. The results were the same as
20 the results of the experiments with Ad37 pseudotyped virus produced from line 705 (see, Wu *et al.* (2001) *Virology* 279:78-89).

Second, a 1.2 kb *Bam* H1/*Bgl* II fragment containing an adenovirus type 5 tripartite leader was excised from pDV55 (see EXAMPLE 3) and inserted into the *Bam* H1 site of pDV78 to create pDV80 (SEQ ID No 42). Plasmid pDV80 has
25 been deposited in the ATCC under accession number PTA-1147.

2. Construction of the recombinant Ad37 knob protein

Recombinant Ad37 knob protein containing an N-terminal T7•Tag was produced in *E. coli* using the PET expression system (Novagen). Ad37 fiber DNA (GenBank accession number U69132) was PCR amplified from wild-type Ad37
30 genomic DNA using the following primers (SEQ ID Nos. 48 and 49):
5' GGATCCATGGGATACTTGGTAGCA 3' (*Bam*HI site underlined and
5' GCAACTCGAGTCATTCTTGGGCAATATAGG 3' (*Xho*I site underlined).

-85-

The PCR reactions were performed at 94 °C (denaturation), 55 °C (annealing), 72 °C (extension, 30 cycles) using *Taq* DNA polymerase (Qiagen). The amplified DNA fragments, which contained residues 172 to 365 of the Ad37 fiber protein with the addition of an N-terminal start codon (*italicized*), were

5 purified and subcloned into the pCR-TOPO vector using the TA-Cloning Kit (Invitrogen). No replication errors were found by DNA sequencing. Plasmids from cultured transformed colonies were purified and digested with *Bam*HI and *Xho*I. The fragment was inserted into the *Bam*HI and *Xho*I sites of the bacterial expression vector, pET21a (Novagen), and transformed into (DE3)pLYS S

10 expression cells (Invitrogen). Colonies were selected for knob expression by induction with 1 mM IPTG for four hours at 37 °C and knob expression was determined by SDS-PAGE. The colony displaying highest knob expression was used for large-scale knob expression and induced with 0.5 mM IPTG at 30 °C for four hours.

15 The recombinant T7•Tagged Ad37 knob protein was purified from sonicated bacteria using the T7•Tag Affinity Purification Kit as recommended by the manufacturer (Novagen). Recovered protein was analyzed for purity by SDS-PAGE followed by Coomassie staining or Western blotting with an HRP-conjugated α -T7•Tag monoclonal antibody as described by the manufacturer

20 (Novagen) or an α -Ad37 fiber rabbit antibody.

3. Preparation of Cell Lines that Express the Ad37 fiber protein

Plasmid pDV80 DNA was purified using the Qiagen method and electroporated into the adenovirus-complementing cell line E1-2a S8 (see Examples herein; see also, Gorziglia *et al.* (1996) *J. Virology* 70:4173-4178;

25 and Von Seggern *et al.* (1998) *J. Gen. Virol.* 79:1461-1468). Stable clones were selected with 600 μ g/ml zeocin (Invitrogen).

Clones were expanded and were screened for fiber expression by indirect immunofluorescence (Von Seggern *et al.* (1998) *J. Gen. Virol.* 79:1461-1468) using a rabbit polyclonal antibody directed against the Ad37 fiber (α -Ad37 fiber

30 rabbit antibody) raised by immunizing rabbits with recombinant Ad37 fiber protein. Two clones (lines 705 and 731) that expressed the protein at a uniformly high level were selected.

-86-

EXAMPLE 9

Production of Pseudotyped Ad Vector Particles

To generate vector particles equipped ('pseudotyped') with the Ad37 fiber protein, the Ad37 fiber-expressing 705 cells were infected (approximately
5 1000 particles/cell) with Ad5. β gal. Δ F or with Ad5.GFP. Δ F.

Materials and methods

Ad5. β gal. Δ F

The construction of Ad5. β gal. Δ F is described in Example 2 (it has been deposited on January 15, 1999, with the ATCC as listed above under accession
10 number VR2636; see also, Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608; copending U.S. application Serial No. 09/482,682 filed January 14, 2000, and also International PCT application No. PCT/US00/00265, filed January 14, 2000).

Ad5.GFP. Δ F

15 Ad5.GFP. Δ F was constructed by recombination in bacteria using a modification of the AdEasy System (see, U.S. Patent No. 5,922,576; see, also He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514; the system is publicly available from the authors and other sources).

First, a fiber-deleted genomic plasmid was constructed by removing the
20 fiber gene from pAdEasy-1 (see, U.S. Patent No. 5,922,576; and He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514; the AdEasy system and vectors are publicly available from He *et al.* at Johns Hopkins University). Plasmid pAdEasy-1 contains the entire Ad5 genome, except for nucleotides 1-3,533, which encompass the E1 genes, and nucleotides 28,130-30,820, which
25 encompass the E3 gene.

Plasmid pDV43 (see Example 2; see, also Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608) was digested with *Pac*1, the ends blunted by treatment with the large fragment of *E. coli* DNA polymerase and dNTPs, and the product re-ligated to produce plasmid pDV76. The resulting plasmid pDV76 is identical to
30 pDV43 except for loss of the *Pac*1 site and contains the right end of the Ad5 genome with E3 and fiber deletions. A 4.23 kb fragment from pDV76 was amplified using the oligonucleotide primers (SEQ ID Nos. 50 and 51:

-87-

5' CGC GCT GAC TCT TAA GGA CTA GTT TC 3', including the unique *Spe*1 site in the Ad5 genome (bold); and 5' GCG CTT AAT TAA CAT CAT CAA TAA TAT ACC TTA TTT T 3', including a new *Pac*1 site (bold) adjacent to the right Ad5 ITR. Hence the resulting PCR amplified fragment contains nucleotides
5 27,082 to 35,935 of the Ad5 genome with deletions of nucleotides 28,133 to 32,743 (the E3 and fiber genes), and was used to replace the corresponding *Spe*1/*Pac*1 fragment of pAdEasy 1 (see, U.S. Patent No. 5,922,576) to create pDV77.

Second, *E. coli* strain BJ5183 was electroporated with a mixture of
10 pDV77 and *Pme*1-linearized pAdTrack as described (U.S. Patent No. 5,922,576; He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514), and DNA was isolated from kanamycin-resistant colonies. The resulting plasmid, pDV83, contains a complete Ad5 genome with E1-, E3-, and fiber-deletions with a CMV-driven GFP reporter gene inserted at the site of the E1 deletion. The full length
15 Ad chromosome was isolated by *Pac*1 digestion, and transfected into the E1- and fiber-complementing 633 cells (Von Seggern *et al.* (2000) *J. Virol.* 74:354-362). The 633 cells were produced by electroporating pDV67 (SEQ ID No. 30, deposited under ATCC accession number PTA-1145) into the E1-2a S8 cells, described above. The recovered virus Ad5.GFP.ΔF was then plaque purified by
20 plating on 633 cells and virus stocks were prepared by freeze-thawing cell pellets.

Ad5-pseudotype particle production

Particles with Ad5 fiber

Ad5-pseudotyped particles were generated by virus growth in 633 cells,
25 which express the wild type Ad5 fiber protein. Viral particles were isolated and purified over CsCl gradients (Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608; purified by centrifugation on preformed 15-40% CsCl gradients (111,000 x g for three hours at 4°C)). For analysis of viral proteins, ten μg of the purified particles were electrophoresed on 8-16% gradient gels and the protein
30 transferred to nylon membranes. The resulting blot was probed with rabbit polyclonal antibodies raised against recombinant Ad37 fiber or Ad5 fiber or penton base proteins expressed in baculovirus-infected cells.

-88-

Particles with Ad37 fiber

Cells from the Ad37 fiber producing cell line 705 were infected at approximately 1000 particles/cell with Ad5. β gal. Δ F or with Ad5.GFP. Δ F. Viral particles were isolated and purified over CsCl gradients. The bands were
5 harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCl, and 10% glycerol), aliquoted and stored at -70°C.

Viral protein analyses

For analysis of viral proteins, 10 μ g of purified Ad5. β gal. Δ F particles with no fiber (grown in 293 cells), the Ad5 fiber (grown in 633 cells), or the Ad37
10 fiber (grown in 705 cells) were electrophoresed by 8-16% polyacrylamide gradient SDS-PAGE and the proteins were transferred to nylon membranes. The blot was then probed with α -Ad37 fiber rabbit antibody. Ad5 fiber and penton base were detected by reprobing the blot with polyclonal antibodies raised against recombinant proteins expressed in baculovirus-infected cells (Wickman *et al.* (1993) *Cell* 2:309-319).
15

Adenovirus infection and cell binding assays

Adherent Chang C and A549 cells were infected with GFP expressing Ad5 vectors containing the Ad5 fiber (Ad5.GFP. Δ F/5F) or the Ad37 fiber (Ad5.GFP. Δ F/37F) at 10,000 particles per cell for 3 hours at 37°C, 5% CO₂ in
20 DMEM, 10% FCS. Cells were washed twice with saline and then cultured overnight at 37°C, 5% CO₂. The next day, the cells were detached with buffer containing 0.05% (w/v) trypsin and 0.5 mM EDTA (Boehringer Mannheim) for 5 minutes at 37°C. Suspended cells were washed once with PBS and then resuspended in phosphate-buffered saline (PBS), pH 7.4. GFP fluorescence was
25 measured with a FACScan flow cytometer. A threshold established by the fluorescence of uninfected cells was used to distinguish cells expressing GFP. To assess the role of CAR in Ad infection, 10,000 attached cells were pre-incubated with 180 μ g/ml RmCB, a function-blocking anti-CAR monoclonal antibody (Hsu *et al.* (1988) *J. Virol.* 62:1647-1652), in complete DMEM for 1
30 hour at 4°C. A small volume containing Ad5.GFP. Δ F/5F or Ad5.GFP. Δ F/37F was then added at 10,000 particles per cell. The cells were infected for 3 hours, cultured overnight, harvested, and analyzed for GFP expression. Percent

-89-

cells expressing GFP was determined by the percent of cells detected above a threshold set by the fluorescence of uninfected Chang C cells.

To measure adenovirus binding to cells, wild type Ad37 was labeled with ^{125}I using Iodogen (Pierce) according to manufacturer instructions and separated
5 from free ^{125}I by gel filtration as described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Binding of radiolabeled wild type Ad37 on Chang C cells was then quantitated as described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Non-specific binding was determined by incubating cells and labeled Ad37 particles in the presence of 100-fold concentration of unlabeled Ad37. Specific
10 binding was calculated by subtracting the non-specific binding from the total cpm bound. To examine if divalent cations are required for binding, 10 mM ethylenediaminetetraacetic acid (EDTA) or various concentrations of CaCl_2 , or MgCl_2 were added to cells before incubation with labeled virus. To examine if
15 the receptor for Ad37 is a protein, cells were pretreated with 10 $\mu\text{g}/\text{ml}$ trypsin (GIBCO), subtilisin (Sigma), proteinase K (Boehringer-Mannheim), and bromelain (Sigman) at 37°C for 1 hour, then washed twice with complete DMEM before adding labeled virus. Cells were >95% viable after protease treatment.

Ad37 binding to conjunctival cells is calcium-dependent. Specific ^{125}I -labeled Ad37 binding to Chang C cells was measured in the presence of 10 mM
20 EDTA and in the presence of varying concentrations of calcium chloride or magnesium chloride. Specific binding was determined by subtracting the nonspecific counts in the presence of 100-fold excess unlabeled virus from the total counts.

Pretreatment of conjunctival cells with proteases inhibits Ad37 binding.
25 Change C cells were pretreated with various proteases for 1 hour before binding ^{125}I -labeled Ad37 to the cells. Nonspecific binding was measured by adding 100-fold unlabeled Ad37 to cells with ^{125}I -labeled Ad37 and subtracting from total counts for specific binding. Percent inhibition represents the difference in specific binding of untreated cells and pretreated cells as a percentage of the
30 specific binding of untreated cells.

-90-

Virus overlay protein blot assay (VOPBA)

For VOPBA of human conjunctival membrane proteins probed with Ad37 in the presence of EDTA or calcium chloride, Chang C membrane fractions were separated by 8% SDS-PAGE and transferred to a PDVF membrane. The
5 membrane was subsequently probed with or without whole Ad37 particles, a polyclonal antibody against Ad37 fiber, and finally a horseradish peroxidase conjugated anti-rabbit antibody, in the presence of EDTA or calcium chloride. Transferred Chang C membrane proteins were probed with recombinant Ad37 knob protein, instead of Ad37 knob, in the presence of calcium chloride.

10 Confluent monolayers of Chang C and A549 cells were detached by scraping, pelleted by centrifugation, and then resuspended in 250 mM sucrose, 20 mM HEPES, pH 7.0, 1 mM EDTA, and 2 μ g/ml aprotinin and leupeptin. Cells were transferred into a dounce homogenizer and disrupted with 30 strokes. Organelles and nuclei were pelleted at 500g for 15 min. Plasma membrane
15 fragments were then pelleted from the supernatant of cell lysates at 200,000g for 1 hour and then resuspended in 10 mM Tris•Cl, pH 8.1, 10 μ g/ml aprotinin and leupeptin.

Cell membranes of Chang C or A549 cells were incubated (1:1) with a 2% SDS, non-reducing buffer and separated on an 8% polyacrylamide gel
20 without boiling. Membrane proteins were then electroblotted onto a PVDF membrane (Immobilon-P) and blocked in 5% (w/v) milk in PBS, pH 7.4, 0.02% Tween-20 (PBS-T). After blocking, the membrane was incubated with 1 μ g/ml wild-type Ad19p or Ad37 in 0.5% (w/v) milk in PBS-T, 1 mM CaCl_2 , for 1 hour at room temperature. The membrane was then washed once with phosphate-
25 buffered saline, pH 7.4 (PBS), 1 mM CaCl_2 , and incubated with 1:500 dilution of α -Ad37 fiber rabbit antibody in 0.5% (w/v) milk in PBS-T, 1 mM CaCl_2 , for 30 minutes at room temperature. The membrane was washed again with PBS, 1 mM CaCl_2 , and incubated with 1:5000 dilution of horseradish peroxidase (HRP) conjugated α -rabbit antibody (Sigma) in 0.5% (w/v) milk in PBS-T, 1 mM CaCl_2 ,
30 for 30 minutes at room temperature. The membrane was washed four times in PBS, 1 mM CaCl_2 , once with PBS-T, 1 mM CaCl_2 , and once in 1 mM CaCl_2 . The blot was developed with enhanced chemiluminescence reagents (Pierce) for 5

-91-

minutes and placed onto a piece of Biomax film (Kodak) for 5 seconds to 1 minute. For divalent metal cation experiments, membranes were incubated in the presence of 2 mM EDTA instead of 1 mM CaCl_2 in all solutions. To assay fiber knob binding to cell membrane proteins, membrane filters were incubated
5 with 1 $\mu\text{g/ml}$ purified T7-tagged Ad37 knob protein in Tris-buffered saline, 0.1% Tween-20, 1 mM CaCl_2 , for 1 hour at room temperature. α -Ad37 fiber rabbit antibody and HRP-conjugated anti-rabbit antibody were applied and the membrane was developed with substrate solution as described above.

Results: Comparison of adenovirus infection of human conjunctival and lung epithelial cells with virus particles retargeted with Ad5 or Ad37 fiber proteins
10

Packaging cell lines producing the Ad37 fiber protein were generated.

Since the N-terminal amino acid sequences of the Ad5 and Ad37 fiber proteins differ significantly, and to ensure that the Ad37 fiber would be efficiently
incorporated into Ad5 vector particles, several residues in the wild-type Ad37
15 fiber were mutated to more closely match the Ad5 sequence. Stable cell lines producing this fiber under control of the CMV promoter and the adenovirus type 5 tripartite leader were then generated and screened for fiber expression by indirect immunofluorescence. One clone (line 705), which expressed the Ad37
fiber at a high level, was selected for further study.

20 Cells from one cell line 633, which expresses the wild-type Ad5 fiber protein, and line 705 were infected with a fiber-deleted Ad5 vector carrying a β galactosidase reporter gene. The resulting vector particles contained the Ad5 fiber protein (Ad5. β gal. Δ F/5F) and the Ad37 fiber protein (Ad5. β gal. Δ F/37F), respectively. Incorporation of the correct fiber protein into viral particles was
25 verified by Western blotting. Adenoviral vectors containing the GFP reporter gene, Ad5.GFP. Δ F/5F and Ad5.GFP. Δ F/37F, were created in the same fashion.

Infection of a variety of cell types using the retargeted adenovirus particles was examined. As assayed by GFP fluorescence, Ad5.GFP. Δ F/5F exhibited good gene delivery to lung epithelial (A549) and conjunctival cells
30 (Chang C). In contrast, Ad5.GFP. Δ F/37F efficiently delivered GFP to Chang C cells, but exhibited very poor gene delivery to A549 cells. Although CAR is expressed on the surface of A549 cells, as indicated by AD5.GFP. Δ F/5F

-92-

infection, Ad5.GFP. Δ F/37F was unable to infect these cells efficiently. This experiment shows that the Ad37 fiber protein can confer preferential infection of human conjunctival cells, but not CAR-expressing human lung epithelial cells.

Hence CAR is not the primary receptor for Ad37. Recent studies reported
5 that expression of CAR on the surface of chinese hamster ovary (CHO) cells did not improve Ad37 binding (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), implying that Ad37 does not use CAR as a primary receptor. In order to verify this on human conjunctival cells, A549 and Chang C cells were pretreated with RmcB (Hsu *et al.* (1988) *J. Virol.* 62:1647-1652), a function-blocking monoclonal
10 antibody against CAR. The RmcB antibody inhibited infection of A549 cells by Ad5.GFP. Δ F/5F, but it had little effect on infection of Chang C cells by Ad5.GFP. Δ F/37F. This indicates that CAR is not the primary receptor for Ad37 on Chang C conjunctival cells.

Ad37 binding to conjunctival cells requires divalent metal cations. It has
15 been proposed (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915) that a combination of fiber binding to CAR and penton base binding to α_v -integrins allows some adenovirus serotypes to attach to cells. Although α_v -integrin binding to the RGD motif of the adenovirus penton base is of relatively low affinity (Wickman *et al.* (1993) *Cell* 2:309-319), it may nonetheless contribute to viral attachment to the
20 cell surface. Ad37 shows a particularly strong affinity for binding to integrin $\alpha_v\beta_5$ (Mathias *et al.* (1998) *J. Virol.* 72:8669-8675), suggesting that integrin $\alpha_v\beta_5$ might be a primary receptor for Ad37. Binding of the RGD motif by α_v -integrins requires the presence of divalent cations, such as calcium or magnesium (Stuiver *et al.* (1996) *J. Cell Physiol.* 168:521-531). In contrast, no divalent cations were
25 required for binding in the CAR-Ad12 knob complex (Bewley *et al.* (1999) *Science* 286:1579-1583).

To investigate the potential role of α_v -integrins and divalent metal cations in Ad37 receptor binding, 125 I-labeled Ad37 binding to Chang C cells was
examined in the absence or presence of EDTA. EDTA inhibited Ad37 binding to
30 conjunctival cells but did not alter Ad5 binding. These findings suggest a requirement for divalent metals for Ad37 binding.

-93-

The presence of either calcium or magnesium ions helps $\alpha_v\beta_5$ organize in focal contacts (Stuiver *et al.* (1996) *J. Cell Physiol.* 168:521-531), suggesting that calcium and magnesium aid in integrin $\alpha_v\beta_5$ function. To further test the potential role of integrin $\alpha_v\beta_5$ in Ad37 cell attachment, ^{125}I -labeled Ad37 binding to Chang C cells was measured in the presence of varying concentrations of calcium or magnesium chloride. Magnesium ions had little effect on Ad37 binding to Chang C cells. In contrast, calcium ions dramatically enhanced Ad37 binding to Chang C cells. The optimal concentration of calcium chloride for Ad37 binding was 1 mM, while higher concentrations of calcium actually decreased virus binding to cells. The fact that calcium, but not magnesium, promoted Ad37 attachment is not consistent with integrin $\alpha_v\beta_5$ as the primary receptor for viral attachment to the cells since either metal will support ligand binding to integrin $\alpha_v\beta_5$. Moreover, A549 cells express abundant α_v -integrins (Mathias *et al.* (1998) *J. Virol.* 72:8669-8675) but were unable to support efficient binding of Ad37.

Wild-type Ad37 particles bind to three conjunctival membrane proteins. Recent studies reported that protease treatment of CHO cells abolished Ad37 binding (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), implying that Ad37 bound to a protein receptor on CHO cells. Scatchard analysis of Ad37 binding to Chang C cells showed that each cell expresses approximately 24,000 fiber binding sites (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). To determine if the Ad37 binding site on human conjunctival cells is also a protein, Chang C cells were treated with different proteases prior to measuring binding of ^{125}I -labeled Ad37. Digestion of surface proteins by all four proteases inhibited Ad37 binding to Chang C cells by greater than 50%. This finding showed that Ad37 also binds to a protein receptor on Chang C cells.

Virus overlay protein blot assays (VOPBAs) were used to identify candidate viral protein receptors. This Western blot technique uses intact viral particles in place of antibodies to probe viral-receptors interactions. VOPBA was used herein to identify Chang C membrane proteins that bind to Ad37. In the absence of Ad37 particles, no protein bands were observed, while addition of virus in the absence of calcium revealed binding to a single 45 kDa protein. In

-94-

the presence of 1 mM calcium chloride, Ad37 reacted with three proteins with approximate molecular weights of 45, 50 and 60 kDa. The same three proteins were detected using a recombinant Ad37 fiber knob alone, indicating that Ad37-receptor interactions are fiber mediated and do not involve interactions of other capsid proteins such as the penton base. The size of the calcium-independent protein (45 kDa) is very similar to the known molecular weight of CAR. A direct comparison of the Ad37 VOPBA and a CAR Western blot showed that the 45 kDa receptor co-migrates with CAR on SDS-PAGE. Moreover, two other members of subgroup D adenoviruses, Ad9 and AD15, have been shown to bind to CAR (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915).

Since CAR does not appear to mediate Ad37 binding on intact Chang C cells, the possibility that the 50 or 60 kDa protein serves this function was tested by examining an adenovirus serotype that does not bind to Chang C cells. Ad19p, a closely related subgroup D adenovirus, binds poorly to Chang C cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802) and Ad19p recognition of the Ad37 receptor is therefore unlikely. Ad19p particles bound to the 45 and 60 kDa receptors in the VOPBA, but did not bind to the 50 kDa receptor. Moreover, the 50 kDa receptor is expressed on Chang C cells, but not A549 cells, which only support low levels of Ad37 binding and infection. Taken together, these data indicate that the 50 kDa protein is a primary candidate receptor for Ad37 on human conjunctival cells.

Discussion

The identification of the CAR protein as a major adenovirus receptor does not explain why certain subgroup D members, such as Ad37, preferentially infect ocular cells. A 50 kDa human conjunctival cell membrane protein is identified herein as a primary candidate for the receptor for Ad37. This 50 kDa protein is not present on A549 lung epithelial cells. Ad37 binding to this receptor is calcium-dependent, which is consistent with Ad37 binding and infection experiments. Ad37 also bound to a 60 kDa protein that is present on human conjunctival and lung epithelial cells. It does not, however, appear to be serotype specific. The molecular weights of MHC class I heavy chain, which has been proposed as a receptor for Ad5, and $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrins, receptors for

-95-

the penton base, are distinct from the 50 or to kDa receptor characterized in this study.

- The studies of Ad37-receptor interaction using VOPBAs are consistent with previous studies showing that subgroup D adenoviruses can bind to the
- 5 extracellular domain of CAR (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915). Biochemical and structural studies on knob-CAR interactions indicate that the CAR binding site is located on the AB-loop of the fiber knob. Alignment of the fiber sequences of Ad37 and other adenoviruses reveals that the AB-loop of Ad37 is similar to those of Ad12 and Ad5. Moreover, a phylogenetic tree of
- 10 adenovirus knobs (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915) shows that fiber proteins of subgroup D are similar to those of subgroup C and E, which use CAR as their primary receptor. Ad37 does not, however, appear to effectively use CAR as a primary receptor, as demonstrated by virus binding and infection studies on Chang C conjunctival cells and A549 lung epithelial cells.
- 15 It has been reported that Ad37 uses sialic acid as a receptor on chinese hamster ovary (CHO) cells and human lung carcinoma (A549) cells (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48). Human conjunctival cells were not studied. Human corneal epithelial (HCE) cells were the only ocular cell line studied and Ad37 binds relatively poorly to these cells, compared to binding on A549 cells
- 20 (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48). In addition, $8,4 \times 10^7$ wheat germ agglutinin molecules per cell were required to significantly inhibit Ad37 binding to sialic acid on sialic acid positive CHO cells (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), three orders of magnitude higher than the number of Ad37 receptors on Chang C conjunctival cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802).
- 25 Clearly, sialic acid is not the only factor responsible for Ad37 binding to the cell surface and its influence on Ad37 tropism is unclear.

The results herein show that Ad37 selects a 50 kDa cellular receptor for binding to conjunctival cells, but it is possible that sialic acid also plays a role in this interaction. The characterization and identification of the Ad37 receptor

30 have therapeutic implications and also explain the different tropism of Ad37. The 50 kDa receptor for Ad37 may also be the receptor for other subgroup D adenoviruses that cause severe cases of EKC, Ad19a and Ad8. Ad19p is a

-96-

nonpathogenic variant of Ad19 (Arnberg *et al.* (1998) *Virology* 227:239-244) while Ad19A, along with Ad8 and Ad37, are major causes of EKC. Ad19a and Ad37 have identical fiber proteins (Arnberg *et al.* (1998) *Virology* 227:239-244) and have similar tropism in vivo. Ad8, Ad19a, and Ad37 agglutinate dog and guinea pig erythrocytes more effectively than four other serotypes that are associated with less severe forms of conjunctivitis (Arnberg *et al.* (1998) *Virology* 227:239-244), implying that the receptors of Ad18, Ad19A, and Ad37 have similar characteristics. Hence, this 50 kDa receptor is an attractive drug target against EKC caused by adenoviruses to provide therapeutic intervention of ocular diseases associated with these viruses.

EXAMPLE 10

Targeting of the Ad5 vector to photoreceptor cells

The fiber-deleted adenovirus vector Ad5.GFP. Δ F was propagated in 705 cells, which express a modified Ad37 fiber protein. Viral particles (Ad5.GFP. Δ f/37F) were harvested, CsCl-purified and dialized into 0.9% NaCl, 10 mM Tris, pH 8.1, and 10% glycerol. Two to three μ l of the resulting solution, containing approximately 1×10^9 particles/ μ l was injected into the vitreous chamber of a mouse eye. Seven days post-injection, eyes were harvested, fixed with paraformaldehyde and cryo-sectioned. Sections were stained with an anti-rhodopsin antibody to identify photoreceptor cells and with DAPI to show all cell nuclei. The resulting sections showed red anti-rhodopsin staining in the photoreceptors, blue DAPI-stained nuclei, and green GFP staining in any transduced cells. The results revealed substantially exclusive transduction of photoreceptors. Co-localization of rhodopsin staining and GFP expression indicated selective transduction of photoreceptor cells.

As a control, contralateral eyes were injected with a stock of the fiber-deleted vector AD5. β gal. Δ F grown in the same Ad37 fiber-expressing cells. Since this virus (Ad5. β gal. Δ F/37F) produces β gal rather than GFP, the green staining is absent from the photoreceptors.

Additional experiments using the AD37 fiber for targeting to the photoreceptor cells have been performed. Subretinal and intravitreal injection have been used in mouse models and the results demonstrate targeting to the

-97-

photoreceptors. As with intravitreally injected eyes, the major cell type infected via subretinal administration was the photoreceptor.

As noted, Ad5.GFP. Δ F /37F infected Chang C cells efficiently, but A549 cells poorly. Ad37 fiber protein confers preferential infection on human
5 conjunctival cells, but not CAR-expressing human lung epithelial cells. Binding to conjunctival cells requires divalent cations.

Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims:

-98-

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule, comprising:
adenovirus inverted terminal repeat sequences; an adenovirus packaging
signal operatively linked thereto; and a photoreceptor-specific promoter.
- 5 2. The isolated nucleic acid molecule of claim 1, further comprising a
nucleic acid encoding a therapeutic product operatively linked to the promoter.
3. The isolated nucleic acid molecule of claim 1, wherein the
promoter is a rhodopsin promoter.
4. The nucleic acid molecule of claim 1, wherein the adenovirus
10 genome does not encode a functional fiber protein such that packaging the
nucleic acid requires complementation in a packaging cell.
5. A recombinant adenovirus vector, comprising the nucleic acid
molecule of any of claims 1-4 packaged therein.
6. A recombinant adenovirus vector of claim 5, wherein inverted
15 terminal repeat sequences (ITR) and a packaging signal are derived from
adenovirus type 2 or adenovirus type 5.
7. A recombinant adenovirus vector of claim 5, wherein the virus
comprises a fiber protein.
8. A recombinant adenovirus vector of claim 7, wherein the fiber
20 protein selectively binds to photoreceptors in the eye of a mammal.
9. A recombinant adenovirus vector of claim 7, wherein the fiber is a
chimera composed of N-terminal sequences from adenovirus type 2 or type 5,
and a sufficient portion of an adenovirus serotype D fiber for selective binding to
photoreceptors in the eye of a mammal.
- 25 10. A method for targeted delivery of a gene product to the eye of a
mammal, comprising:
administering a recombinant adenovirus virus that comprises heterologous
DNA encoding the gene product or resulting in expression of the gene product,
wherein the recombinant virus comprises a fiber protein that specifically or
30 selectively binds to receptors that are expressed on cells in the eye.

-99-

11. The method of claim 10, wherein the cells are photoreceptors.
12. The method of claim 10, wherein administration is effected by intraocular delivery.
13. The method of claim 10, wherein administration is effected by a
5 method selected from subretinal injection, intravenous administration, periorbital administration, and intravitreal administration.
14. The method of claim 10, wherein the recombinant virus comprises a fiber protein from an adenovirus type D serotype.
15. The method of any of claims 10-14, wherein the fiber protein is an
10 adenovirus type 37.
16. The method of any of claims 10-14, wherein the fiber is a chimeric protein containing a sufficient portion of the N-terminus of an adenovirus type 2 or type 5 fiber protein for interaction with an adenovirus type 2 or type 5 penton, and a sufficient portion of an adenovirus serotype D knob portion of the
15 fiber for selective binding to photoreceptors in the eye of a mammal.
17. The method of any of claims 10-16, wherein the recombinant virus is an adenovirus type D serotype.
18. The method of any of claims 10-17, wherein the encapsulated nucleic acid comprises a photoreceptor-specific promoter operatively linked to a
20 nucleic acid comprising the therapeutic product.
19. The method of claim 18, wherein the therapeutic product is selected from the group consisting of a trophic factor, an anti-apoptotic factor, a gene encoding a rhodopsin protein, a wild-type Stargardt disease gene (STDG1), an anti-cancer agent and a protein that regulates expression of a photoreceptor-
25 specific gene product.
20. The method of any of claims 10-19, wherein delivery is effected for treatment of an ocular disease.
21. The method of claim 20, wherein the disorder is a retinal degenerative disease.
- 30 22. The method of claim 20, wherein the disease is retinitis pigmentosa, Stargardt's disease, diabetic retinopathies, retinal vascularization, or retinoblastoma.

-100-

23. The method of any of claims 10-22, wherein the mammal is a human.
24. The method of any of claims 10-22, wherein the viral nucleic acid comprises:
- 5 an adenovirus inverted terminal repeat (ITR) sequences; and
an adenovirus packaging signal operatively linked thereto.
25. The method of claim 24, wherein the ITRs and packaging signal are derived from an adenovirus serotype B or C.
26. The method of claim 24, wherein the ITRs and packaging signal
10 are derived from an adenovirus type 2 or 5.
27. The method of claim 24, wherein the viral nucleic acid further comprises a photoreceptor-specific promoter.
28. A method of targeted gene therapy, comprising:
administering a recombinant viral vector that comprises an adenovirus
15 type 37 fiber protein or portion thereof, whereby the vector selectively transduces photoreceptors and delivers a gene product encoded by the recombinant viral vector; wherein the portion is sufficient for selective binding to photoreceptors.
29. The method of claim 28, wherein the vector is administered into
20 the eye.
30. The method of claim 28, wherein the vector is administered to the vitreous cavity of the eye.
31. The method of claim 28, wherein administration is effected by subretinal injection, intravenous administration, periorbital administration or
25 intravitreal administration.
32. The method of any of claims 10-31, wherein at least about 10^7 plaque forming units of virus are administered.
33. The method of any of claims 10-31, wherein about 1 plaque forming unit to about 10^{14} plaque forming units of virus are administered.

SEQUENCE LISTING

<110> VON SEGGERN, DANIEL
NEMEROW, GLEN R.
FRIEDLANDER, MARTIN

<120> VECTORS FOR OCULAR TRANSDUCTION AND USE THEREFOR FOR GENETIC THERAPY

<130> 756.1PCT/NOV0205P

<140>
<141> 2001-05-01

<150> 09/562,934
<151> 2000-05-01

<160> 51

<170> PatentIn Ver. 2.1

<210> 1
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 1
cggtacacag aattcaggag acacaactcc 30

<210> 2
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 2
gcctggatcc gggaagttac gtaacgtggg aaaac 35

<210> 3
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: linker

<400> 3
cgcggtatccg cg 12

<210> 4
<211> 8710
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 4

```

cacctaaatt gtaagcggtta atattttgtt aaaatttcggt ttaaattttt gttaaatacag 60
ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa aagaatagac 120
cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa agaacgtgga 180
ctccaacgtc aaaggcgaa aaaccgtcta tcaggggcgat ggcccactac gtgaaccatc 240
accctaatac agttttttgg ggtcgaggtg ccgtaaaagca ctaaatcgga accctaagg 300
gagccccga tttagagctt gacggggaaa gccggcgaa gtggcgagaa aggaagggaa 360
gaaagcga aaaggcggtg ctaggggcgct ggcaagtgtg gcggtcacgc tgcgcgtaac 420
caccacaccc gccgcgctta atgcgcgct acaggggcgct tcccattcgc cattcaggct 480
gcgcaactgt tgggaaggcg gatcggtgct ggccctcttcg ctattacgcc agctggcgaa 540
agggggatgt gctgcaaggc gattaagtgt ggtaacgcca gggttttccc agtcacgacg 600
ttgtaaaacg acggccagt gattgttaata cgactcacta tagggcgaa tgggtaccgg 660
gccccccctc gaggtcgacg gtatcgataa gcttgatata gaattcagga gacacaactc 720
caagtgcata ctctatgtca ttttcattgg acttggtctg ccacaactac attaatagg 780
tatttgccac atcctcttac actttttcat acattgcccc agaataaaga atcggttgtg 840
ttatgtttca acgtgtttat ttttcaattg cagaaaattt caagtcattt ttcattcagt 900
agtatagccc caccaccaca tagcttatac agatcacctg accttaatac aactcacaga 960
accctagtat tcaacctgcc acctccctcc caacacacag agtacacagt ctttctccc 1020
cggctggcct taaaaagcat catatcatgg gtaacagaca tattcttagg tgttatattc 1080
cacacggttt cctgtcgagc caaacgctca tcagtgtat taataaactc cccgggcagc 1140
tcacttaagt tcatgtcgct gtccagctgc tgagccacag gctgctgtcc aacttgccgt 1200
tgcttaacgg gcggcgaaagg agaagtcac gctacatgg gggtagagtc ataactcgtg 1260
atcagatag gcggtgtgtg ctgcagcagc gcgcaataaa actgctgccg ccgcccgtcc 1320
gtcctgcagg aatacaacat ggcagtggtc tctcagcga tgattcgac cgcccgcagc 1380
ataaggcgcc ttgtcctccg ggcacagcag cgcacctga tctcacttaa atcagcacag 1440
taactgcagc acagcaccac aatattgttc aaaatccac agtgcaaggc gctgtatcca 1500
aagtcacagt ggggaccac agaaccacg cgccatcat accacaagcg caggtagatt 1560
aagtggcgac cctcataaaa cagctggac ataaacatta cctcttttgg catgttgtta 1620
ttcaccacct cccggtacca tataaacctc tgattaaaca tggcgccatc caccaccatc 1680
ctaaaccagc tggccaaaac ctgcccgcg gctatacact gcagggaacc gggactggaa 1740
caatgcacgt ggagagccca ggactcgtaa ccattggatca tcatgctcgt catgatatta 1800
atgttggcac aacacaggca cagtgatata cacttctca ggattacaag ctccctccgc 1860
gttagaacca tatccaggg aacaacccat tctgaatca gcgtaaatcc cacactgcag 1920
ggaagacctc gcacgtaact caggttgtgc attgtcaaag tggtacattc gggcagcagc 1980
ggatgatcct ccagatggt agcgcggtt tctgtctcaa aaggaggtag acgatcccta 2040
ctgtacggag tgcgcccaga caaccgagat cgtgttggtc gtagtgctat gccaaatgga 2100
acgcccggag tagtcatatt tctgaagca aaaccaggtg cggcggtgac aaacagatct 2160
gcgtctccgg tctcgccgct tagatcgctc tgtgtagtag ttgtagtata tccactctct 2220
caaagcatcc aggcgcccc ttgcttcggg tctatgtaa actccttcac gcgcccgtgc 2280
cctgataaca tccaccacg cagaataagc cacaccacg caacctacac attcgttctg 2340
cgagtcacac acgggaggag cgggaagagc tggagaacc atgtttttt ttttattcca 2400
aaagattatc caaaacctca aaatgaagat ctattaagtg aacgcgctcc cctccggtg 2460
cgtggtcaaa ctctacagcc aaagaacaga taatggcatt tgtaagatgt tgcacatagg 2520
cttccaaaag cttacaggtc ctacagtcga agtgacgta aaggctaaac ccttcagggt 2580
gaatctctc tataaacatt ccagcacctt caacctgccc caaataatc tcatctcgcc 2640
accttctcaa tatatctcta agcaaatccc gaatattaag tccggccatt gtaaaaatct 2700
gtccagagc gccctccacc ttcagctca agcagcgaat catgattgca aaaattcagg 2760
ttcctcacag acctgtataa gattcaaaag cggaacatta acaaaaatc cgcatccc 2820
taggtccctt cgcagggcca gctgaacata atcgtgcagg tctgcacgga ccagcgcgcc 2880
cacttccccg ccaggaaact tgacaaaaga acccacactg attatgacac gcatactcgg 2940
agctatgcta accagcgtag ccccgatgta agctttgttg catgggccc gatataaaat 3000
gcaaggtgct gctcaaaaaa tcaggcaaa cctcgcgaa aaaagaaaag acatcgtagt 3060
catgctcatg cagataaagg caggttaagt ccggaaccac cacagaaaaa gacaccattt 3120
ttctctcaaa catgtctgct ggtttctgca taaacacaaa ataaaaaac aaaaaaacat 3180
ttaaacatta gaagcctgtc ttacaacagg aaaaacaacc cttataagca taagacggac 3240
tacggccatg ccggcgtagc cgtaaaaaaa ctggtcaccg tgattaaaaa gcaccacga 3300
cagctcctcg gtcattgtcc gagtcataat gtaagactcg gtaaacacat caggttgatt 3360
catcggtcag tgctaaaaag cgaccgaaat agcccgggg aatacatacc cgcaggcgta 3420
gagacaacat tacagcccc ataggaggta taacaaaatt aataggagag aaaaacacat 3480
aaacacctga aaacacctcc tgcctaggca aaatagcacc ctcccgtcc agaacaacat 3540

```

acagcgcttc	acagcggcag	cctaacagtc	agccttacca	gtaaaaaaga	aaacctatta	3600
aaaaaacacc	actcgacacg	gcaccagctc	aatcagtcac	agtgtaaaaa	agggccaagt	3650
gcagagcgag	tatatatagg	actaaaaaat	gacgtaacgg	ttaaagtcca	caaaaaacac	3720
ccagaaaacc	gcacgcgaac	ctacgcccag	aaacgaaagc	caaaaaaccc	acaacttcct	3780
caaatcgtea	cttcggtttt	cccacgttac	gtaacttccc	ggatccgcgg	cattcacagt	3840
tctccgcaag	aattgattgg	ctccaattct	tggagtggtg	aatccggttag	cgaggtgccg	3900
ccggcttcca	ttcaggtcga	ggtggcccg	ctccatgcac	cgcgacgcaa	cgcggggagg	3960
cagacaaggt	atagggcggc	gcctacaatc	catgccaaac	cgttccatgt	gctcgccgag	4020
gcggcataaaa	tcgcccgtgac	gatcagcggg	ccagtgatcg	aagtttaggct	ggtaagagcc	4080
gcgagcgatc	cttgaagctg	tccctgatgg	tcgtcatcta	cctgcctgga	cagcatggcc	4140
tgcaacgcgg	gcaccccgat	gcgcgcggaa	gcgagaagaa	tcataatggg	gaaggccatc	4200
cagcctcgcg	tcgcgaacgc	cagcaagacg	tagcccagcg	cgtcggccgc	catgccctgc	4260
ttcatccccg	tggcccggtg	ctcgcggttg	ctggcggtgt	ccccgggaaga	aatatatttg	4320
catgtcttta	gttctatgat	gacacaaaacc	ccgcccagcg	tcttgctatt	ggcgaattcg	4380
aacacgcaga	tcagtcggg	gcggcgcggt	cccaggtcca	cttcgcataat	taaggtgacg	4440
cgtgtggcct	cgaacaccga	gcgaccctgc	agcgaccgcg	ttaacagcgt	caacagcgtg	4500
ccgcagatcc	cgggcaatga	gatatgaaaa	agcctgaact	caccgcgacg	tctgtcgaga	4560
agtttctgat	cgaaaagtct	gacagcgtct	ccgacctgat	gcagctctcg	gagggcggaag	4620
aatctcgtgc	tttcagcttc	gatgtaggag	ggcgtggata	tgtcctgcgg	gtaaatagct	4680
gcgcccgatg	tttctacaaa	gatcggttatg	tttatcgcca	ctttgcatcg	gcgcgctccc	4740
cgattccgga	agtgtctgac	attggggaat	tcagcgagag	cctgacctat	tgcattctcc	4800
gccgtgcaca	gggtgtcacg	ttgcaagacc	tgccatgaaac	cgaactgccc	gctgttctgc	4860
agcgggtcgc	ggaggccatg	gatgcgatcg	ctgcggccga	tcttagccag	acgagcgggt	4920
tcggcccatt	cggaccgcaa	ggaatcggtc	aatacactac	atggcgatg	ttcatatcgc	4980
cgattgctga	ttcccattgt	tatcactggc	aaactgtgat	ggacgacacc	gtcagtgctg	5040
ccgctcgcgca	ggctctcgat	gagctgatgc	tttgggcccga	ggactgcccc	gaagtccggc	5100
acctcgtgca	cgcggaatttc	ggctccaaca	atgtcctgac	ggacaatggc	cgcataacag	5160
cggtcattga	ctggagcgag	gcgatgttcg	gggattccca	atacgaggtc	gccaacctct	5220
tcttctggag	gccgtgggtg	gcttgtatgg	aggcagcagc	gcgctacttc	gagcggaggc	5280
atccggagct	tcgaggatcg	ccgcggctcc	ggcgctatat	gctccgcatt	ggtcttgacc	5340
aactctatca	gagcttgggt	gacggcaatt	tcgatgatgc	agcttggggc	cagggctcat	5400
gcgcggccgt	ctggaccgat	ggctgtgtag	atgtcggggc	tacacaaatc	gcccgcagaa	5460
ccagcactcg	tcggagggca	aagggaatagg	ggagatgggg	gaggctaact	aaccgacgcc	5520
aggagacaat	accggaagga	acccgcgcta	tgacggcaat	aaaaagacag	aataaaacgc	5580
acgggtgttg	ggtcgtttgt	tcataaacgc	gggggttcggt	cccagggtcg	gcactctgtc	5640
gataccccac	cgagaccoca	ttggggccaa	tacgcccgcg	tttcttccct	ttccccaccc	5700
caccccccaa	gttcgggtga	aggcccaggg	ctcgcagcca	acgtcggggc	ggcaggccct	5760
gccatagcca	ctggccccgt	gggttaggga	cggggtcccc	catggggaat	ggtttatggt	5820
tcgtgggggt	tattattttg	ggcgttgctg	gggggtcgtg	ccacgactgg	actgagcaga	5880
cagaccocat	gtttttggat	ggcctgggca	tggaccgatc	gtactggcgc	gacacgaaca	5940
ccgggctgtc	gtggctgcca	aacacccccg	acccccaaaa	accaccgcgc	ggattttctg	6000
cgcccagtg	cgtcgaccgg	tcattggctgc	gccccgacac	ccgccaacac	ccgctgacgc	6060
gccctgacgg	gcttgtctgc	ttccggcatc	cgcttacaga	caagctgtga	ccgtctccgg	6120
gagctgcatt	tgtcagaggt	tttaccgctc	atcaccgaaa	cgcgcgaggc	agccggatca	6180
taatcagcca	taccacattt	gtagagggtt	tacttgcttt	aaaaaacctc	cccacctccc	6240
cctgaacctg	aaacataaaa	tgaatgcaat	tgttgtgtgt	aacttgttta	ttgcagctta	6300
taatggttac	aaataaagca	atagcatcac	aaatttcaca	aataaagcat	ttttttcact	6360
gcattctagt	tgtggtttgt	ccaaactcat	caatgtatct	tatcatgtct	ggatccacta	6420
gttctagagc	ggccgcccac	gcgggtggagc	tccagctttt	gttcccttta	gtgagggtta	6480
atttcagagc	tggcgtaatc	atggtcatag	ctgtttcctg	tgtgaaattg	ttatccgctc	6540
acaattccac	acaacatacg	agccgggaagc	ataaagtgtg	aagcctgggg	tgccataatg	6600
gtgagctaac	tcacattaat	tgcgttgccg	tcactgcccg	ctttccagtc	gggaaacctg	6660
tcgtgccagc	tcatttaattg	aatcggccaa	cgcgcgggga	gaggcggttt	gcgtattggg	6720
cgctcttcgg	cttccctcgt	cactgactcg	ctgcgctcgg	tcgttcggct	gcggcgagcg	6780
gtatcagctc	actcaaaggc	ggtaatacgg	ttatccacag	aatcagggga	taacgcagga	6840
aagaacatgt	gagcaaaaag	ccagcaaaaag	gccaggaacc	gtaaaaaggg	cgcggttgctg	6900
gcgttttttc	ataggctccg	ccccctgac	gagcatcaca	aaaatcgacg	ctcaagttag	6960
aggtggcgaa	acccgacagg	actataaaga	taccaggcgt	ttccccctgg	aagctccctc	7020
gtgcgctctc	ctgttccgac	cctgccgctt	accggatacc	tgtccgcctt	tctcccttcg	7080
ggaagcgtgg	cgctttctca	tagctcacgc	tgtaggatc	tcagttcggg	gtaggtcgtt	7140
cgctccaagc	tgggctgtgt	gcacgaaccc	ccggttcagc	ccgaccgctg	cgcttatccc	7200
						7260

```

ggtaactatc gtcttgagtc caaccggtg agacacgact tatcgccact ggagcagcc 7320
actggtaaca ggattagcag agcgaggatg gtaggcgggtg ctacagagtt cttgaagtgg 7380
tggcctaact acggctacac tagaaggaca gtatttggtg tctgcgctct gctgaagcca 7440
gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc 7500
ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat 7560
cctttgatct tttctacggg gtctgacgct cagtggaaacg aaaactcacg ttaagggatt 7620
ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt 7680
tttaaatcaa tctaaagtat atatgagtaa acttggtctg acagttacca atgcttaatc 7740
agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc ctgactcccc 7800
gtcgtgtaga taactacgat acgggagggc ttaccatctg gcccagtgcc tgcaatgata 7860
ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg 7920
gccgagcgca gaagtgtcc tgcaacttta tccgcctcca tccagtctat taattgttgc 7980
cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt tgccattgct 8040
acaggcatcg tgggtgcacg ctcgctcgtt ggtatggctt cattcagctc cggttcccaa 8100
cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag ctcccttcggt 8160
cctccgatcg ttgtcagaag taagtgggcc ccagtgttat cactcatggt tatggcagca 8220
ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac tggtagtagc 8280
tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg cccggcgcca 8340
atacgggata ataccgccc acatagcaga actttaaaag tgctcatcat tggaaaacgt 8400
tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaacct 8460
actcgtgcac ccaactgatc ttcagcatct tttactttca ccagcgtttc tgggtgagca 8520
aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggc cgacacggaa atgttgtaata 8580
ctcatactct tcctttttca atattattga agcatttatc agggttattg tctcatgagc 8640
ggatacatat ttgaatgtat ttagaataat aaacaaatag gggttccgca cacatttccc 8700
cgaaaagtgc                                     8710

```

```

<210> 5
<211> 30
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: primer

```

```

<400> 5
atgggatcca agatgaagcg cgcaagaccg 30

```

```

<210> 6
<211> 30
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: primer

```

```

<400> 6
cataacgcgg ccgcttcttt attcttgggc 30

```

```

<210> 7
<211> 7148
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: plasmid

```

```

<400> 7
gacggatcgg gagatctccc gatccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180

```

ttagggtag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatagc	cgttgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacgggggc	attagttcat	agccccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggcccgcc	tggctgaccg	cccaacgacc	360
cccgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tattttacggt	aaactgccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacgccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgccagta	catgacctta	tgggactttc	ctacttggca	gtacatctac	gtattagtca	600
tcgctattac	catgggtgatg	cggttttggc	agtacatcaa	tgggcgtgga	tagcgggttg	660
actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	caaatggggc	780
gtaggcggtg	acgggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gcttgggtacc	900
gagctcggat	ccaagatgaa	gcgcgcaaga	ccgtctgaag	ataccttcaa	ccccgtgtat	960
ccatatgaca	cggaaaccgg	tcctccaact	gtgccttttc	ttactcctcc	ctttgtatcc	1020
cccaatgggt	ttcaagagag	tccccctggg	gtactctctt	tgcgcctatc	cgaacctcta	1080
ggcaacctta	cctcccaaaa	tgtaaccaact	gtgagccac	ctctcaaaaa	aaccaagtca	1140
aacataaacc	tggaaatc	tgcacccctc	acagttacct	cagaagccct	aactgtgggt	1200
gccgccgac	ctctaattgt	cgcgggcaac	acactcacca	tgcaatcaca	ggccccgcta	1320
acgtgacag	actccaaact	tagcattgcc	acccaaggac	ccctcacagt	gtcagaagga	1380
aagctagccc	tgcaaacatc	aggccccctc	accaccaccg	atagcagtag	ccttactatc	1440
actgcctcac	ccccctaac	tactgccact	ggtagcttgg	gcattgactt	gaaagagccc	1500
atttatacac	aaaatggaaa	actaggacta	aagtacgggg	ctcctttgca	tgtaacagac	1560
gacctaataa	ctttgaccgt	agcaactggg	ccaggtgtga	ctattaataa	tacttccctg	1620
caaaactaag	ctttgggagc	cttgggtttt	gattcacaa	gcaatatgca	acttaagtga	1680
gcaggaggac	taaggattga	ttctcaaaac	agacgcctta	tacttgatgt	tagttatccg	1740
tttgatgctc	aaaaccaact	aaatctaaga	ctaggacagg	gccctctttt	tataaactca	1800
gcccacaact	tggatattaa	ctacaacaaa	ggcctttact	tgtttacagc	ttcaaacact	1860
aatgataagc	taactttgtg	cctaagcact	gccaaggggg	tgatggttga	cgctaacgac	1920
atagccatta	atgcaggaga	tgggcttgaa	tttgggttcac	ctaatagcac	aaacacaaat	1980
cccctcaaaa	caaaaattgg	ccatggccta	gaatttgatt	caaacaaggc	tatgggtccct	2040
aaactaggaa	ctggccttag	ttttgacagc	acaggtgcca	ttacagtagg	aaacaaaaat	2100
aatgataagc	taactttgtg	gaccacacca	gtcccatctc	ctaactgtag	actaaatgca	2160
gagaaagatg	ctaaactcac	tttggcttta	acaaaatgtg	gcagtcaaat	acttgctaca	2220
gtttcagttt	tggctgttaa	aggcagtttg	gtcccaatat	ctggaacagt	tcaaagtgtc	2280
catcttatta	taagatttga	cgaaaatgga	gtgctactaa	acaattcctt	cctggaccca	2340
gaatattgga	ctattagaaa	tggagatctt	actgaaggca	cagcctatac	aaacgtgtgt	2400
ggattttatg	ctaaccctac	agcttatcca	aaatctcacg	gtaaaactgc	caaaagtaac	2460
attgtcagtc	aagtttactt	aaacggagac	aaaactaaac	ctgtaacact	aaccattaca	2520
ctaaacggta	cacaggaaac	aggagacaca	actccaagtg	catactctat	gtcatttttc	2580
tgggactggg	ctggccacaa	ctacattaat	gaaatatttg	ccacatcctc	ttacactttt	2640
tcatacattg	cccaagaata	aagaagcggc	cgctcgagca	tgcatctaga	gggcccattt	2700
ctatagtgtc	acctaaatgc	tagagctcgc	tgatcagcct	cgactgtgcc	ttctagtgtg	2760
cagccatctg	ttgtttgccc	ctcccccggt	ccttccttga	ccctggaagg	tgccactccc	2820
actgtccttt	cctaataaaa	tgaggaaatt	gcacgcatt	gtctgagtag	gtgtcattct	2880
attctggggg	gtggggtggg	gcaggacagc	aagggggagg	attgggaaga	caatagcagg	2940
catgctgggg	atgcggtggg	ctctatggct	tctgaggcgg	aaagaaccag	ctggggctct	3000
aggggggtatc	cccacgcgcc	ctgtagcggc	gcattaagcg	cggcgggtgt	ggtgggttac	3060
cgcagcgtga	ccgctacact	tgccagcgcc	ctagcgcccg	ctcctttcgc	tttcttccct	3120
tcctttctcg	ccacgttcgc	cggctttccc	cgtcaagctc	taaatcgggg	catcccttta	3180
gggttccgat	ttagtgtctt	acggcacctc	gaccccaaaa	aacttgatta	gggtgatggg	3240
tcacgtagtg	ggccatcgcc	ctgatagacg	gtttttcgcc	ctttgacgtt	ggagtccacg	3300
ttcttttaata	gtggactctt	gttccaaact	ggaacaacac	tcaaccctat	ctcgggtctat	3360
tccttttgatt	tataagggat	tttggggatt	tcggcctatt	gggttaaaaa	tgagctgatt	3420
taacaaaaat	ttaacgcgaa	ttaattctgt	ggaatgtgtg	tcagttaggg	tgtggaaagt	3480
cccagggtc	cccaggcagg	cagaagtatg	caaagcatgc	atctcaatta	gtcagcaacc	3540
aggtgtggaa	agtcccagg	ctccccagca	ggcagaagta	tgcaaagcat	gcattctcaat	3600
tagtcagcaa	ccatagtccc	gcccctaact	cgccccatcc	cgccccctaac	tcggcccggt	3660
tcggcccat	ctccgcccc	ggcctgacta	atttttttta	tttatgcaga	ggccgaggcc	3720
gcctctgct	ctgagctatt	ccagaagtag	tgaggaggct	tttttgagg	cctaggcttt	3780
tgcaaaaagc	tcccgggagc	ttgtatatcc	attttcggat	ctgatcaaga	gacaggatga	3840
ggatcgtttc	gcctgattga	acaagatgga	ttgtcgcgag	gttctccggc	cgcttgggtg	3900

gagaggctat	tccggtatga	ctgggcacaa	cagacaatcg	gctgctctga	tgccgccgtg	3960
ttccggctgt	cagcgcaggg	gcgcccgggt	ctttttgtca	agaccgacct	gtccgggtgcc	4020
ctgaatgaac	tgaggacga	ggcagcgcgg	ctatcgtggc	tggccacgac	gggcgttcct	4080
tgccgcagctg	tgctcgacgt	tgctactgaa	gcgggaaggg	actggctgct	attggggcgaa	4140
gtgccggggc	aggatctcct	gtcatctcac	cttgctcctg	ccgagaaagt	atccatcatg	4200
gctgatgcaa	tgccggcggt	gcatacgctt	gatccggcta	cctgcccatt	cgaccaccaa	4260
gcgaaacatc	gcatacgagc	agcacgtact	cggatggaag	ccggtcttgt	cgatcaggat	4320
gatctggacg	aagagcatca	ggggctcgcg	ctgcgcgaac	tgttcgccag	gctcaaggcg	4380
cgcatgcccg	acggcgagga	tctcgtcgtg	acccatggcg	atgcctgctt	gccgaatatc	4440
atgggtgaaa	atggccgctt	ttctggattc	atcgactgtg	gccggctggg	tgtggcggac	4500
cgctatcagg	acatagcggt	ggctaccggt	gatattgctg	aagagcttgg	cggcgaatgg	4560
gctgaccgct	tcctcgtgct	ttacgggtatc	gccgctcccg	attcgagcgc	catcgccctc	4620
tatcgccctt	ttgacgaggt	cttctgagcg	ggactctggg	gttcgaaatg	accgaccaag	4680
cgacgcccac	cctgccatca	cgagatttct	attccaccgc	cgccctctat	gaaagggttg	4740
gcttcggaat	cgttttcccg	gacgcgggct	ggatgatcct	ccagcgcggg	gatctcatgc	4800
tgagattctt	cgcccacccc	aacttggtta	ctgcagctta	taatggttac	aaataaggca	4860
atagcatcac	aaatttcaca	aataaagcat	ttttttcact	gcattctagt	tgtgggttgt	4920
ccaaactcat	caatgtatct	tatcatgtct	gtataccgtc	gacctctagc	tagagcttgg	4980
cgtaatcatg	gtcatagctg	tttctgtgtg	gaaattgtta	tccgctcaca	attccacaca	5040
acatacgagc	cggaagcata	aagtgtaaag	cctgggggtgc	ctaagcagtg	agctaactca	5100
cattaattgc	gttgcgctca	ctgcccgtt	tccagtcggg	aaacctgtcg	tgccagctgc	5160
attaatgaat	cgcccaacgc	gcggggagag	gcggtttgcg	tattgggcgc	tcttccgctt	5220
cctcgctcac	tgactcgctg	cgctcggctg	ttcggctgcg	gcgagcggta	tcagctcact	5280
caaaggcggt	aatacgggtta	tccacagaat	caggggataa	cgcaggaaag	aacatgtgag	5340
caaaaaggcc	gcaaaaaggcc	aggaaccgta	aaaaggccgc	gttgctggcg	ttttcccata	5400
ggctccgccc	ccctgacgag	catcacaaaa	atcgacgctc	aagtcagagg	tgccgaaacc	5460
cgacaggact	ataaagatac	caggcggttc	cccctggaag	ctccctcgctg	cgctctcctg	5520
ttccgacctt	gccgcttacc	ggatacctgt	ccgcctttct	cccttcggga	agcgtggcgc	5580
tttctcaatg	ctcagcgtgt	aggatatctc	gttcgggtga	ggctgctcgc	tccaagcttg	5640
gctgtgtgca	cgaaccccc	gttcagcccc	accgctgcgc	cttatccggt	aactatcgct	5700
ttgagtcaa	cccggttaaga	cacgacttat	cgccactggc	agcagccact	ggtaacagga	5760
ttagcagag	gaggtatgta	ggcgggtgta	cagagttctt	gaagtgggtg	cctaactacg	5820
gctacatag	gagcacagta	tttggatatc	gcgctctgct	gaagccagtt	accttcggaa	5880
aaagagtgg	tagctcttga	tccggcaaac	aaaccaccgc	tggttagcgg	ggtttttttg	5940
tttgcaagca	gcagattacg	cgcagaaaaa	aaggatctca	agaagatcct	ttgatctttt	6000
ctacgggggtc	tgacgctcag	tggaacgaaa	actcacgtta	agggattttg	gtcatgagat	6060
tatcaaaaag	gatcttcacc	tagatccttt	ttaaattaaaa	atgaagtttt	aaatcaatct	6120
aaagtatata	tgagtaaact	tggtctgaca	gttaccaatg	cttaatcagt	gaggcaccta	6180
tctcagcgat	ctgtctattt	cgttcatcca	tagttgcctg	actccccgtc	gtgtagataa	6240
ctacgatacg	ggagggctta	ccatctggcc	ccagtgtctg	aatgataccg	cgagaccac	6300
gctcaccggc	tccagattta	tcagcaataa	accagccagc	cggaaggggc	gagcgcagaa	6360
gtggctcctgc	aactttatcc	gcctccatcc	agtctattaa	ttgttgccgg	gaagctagag	6420
taagtagttc	gccagttaat	agtttgcgca	acgttggtgc	cattgctaca	ggcatcggtg	6480
tgtcacgctc	gtcgtttggt	atggcttcat	tcagctccgg	ttcccaacga	tcaaggcgag	6540
ttacatgata	ccccatggtg	tgcaaaaaag	cgggttagctc	cttcggctcct	ccgatcggtg	6600
tcagaagtaa	gttggccgca	gtgttatcac	tcattggttat	ggcagcactg	cataattctc	6660
ttactgtcat	gccatccgta	agatgctttt	ctgtgactgg	tgagtactca	accaagtcac	6720
tctgagaata	gtgtatgcgg	cgaccgagtt	gctcttgccc	ggcgtcaata	cgggataata	6780
ccgcgccaca	tagcagaact	ttaaaagtgc	tcattcattgg	aaaacgttct	tcggggcgaa	6840
aactctcaag	gatcttaccg	ctgttgagat	ccagttcgat	gtaaccact	cgtgcaccca	6900
actgatcttc	agcatctttt	actttcacca	gcgtttctgg	gtgagcaaaa	acaggaaggc	6960
aaaatgccgc	aaaaaaggga	ataagggcga	cacggaaatg	ttgaatactc	atactcttcc	7020
tttttcaata	tattgaagc	atztatcagg	gttatgtctc	catgagcgga	tacatatttg	7080
aatgtattta	gaaaaataaa	caaatagggg	ttccgcgcac	atttccccga	aaagtgccac	7140
ctgacgtc						7148

<210> 8

<211> 7469

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 8

```

gacggatcgg gagatctccc gatccccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttaggggttag gcgtttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgacgc cccaacgacc 360
cccgcccatc gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggtttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttgcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccttgacg caaatgggcg 780
gtaggcgtgt acgggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840
ctgcttactg gcttatcgaa attaatacga ctactatag ggagacccaa gcttgggtacc 900
gagctcgagt ctgaattcga gctcgctgtt gggctcgcgg ttgaggacaa actcttcgcg 960
tgctttccag tactcttggg tccgaaaccc gtccgctcc gaacgggtact ccgccaccga 1020
gggacctgag cgagtcgcga tcgaccggat cggaaaacct ctcgagaag gcgtctaacc 1080
agtcacagtc gcaaggtagg ctgagcaccg tggcggggcg cagcgggttg cggtcggggg 1140
tggttctggc ggaggtgctg ctgatgatgt aattaaagta ggcggtcttg agacggcgga 1200
tggctcgaggt gagggtgtgc aggccttgaga tccaaagtga agcgcgcaag accgtctgaa 1260
gataccttca accccgtgta tccatatgac acggaaaccg gtctccaac tgtgcctttt 1320
cttactcctc cctttgtatc cccaatggg tttcaagaga gtccccctgg ggtactctct 1380
ttgcgcctat ccgaacctct agttacctcc aatggcatgc ttgcgctcaa aatgggcaac 1440
ggcctctctc tccgagaggc cggcaacctt acctcccaaa atgtaaccac tgtgagccca 1500
cctctcaaaa aaaccaagtc aaacataaac ctggaaatat ctgcacccct cacagttacc 1560
tcagaagccc taactgtggc tgccgcgcga cctctaattg tcgcgggcaa cacactcacc 1620
atgcaatcac aggcgccgct aaccgtgcac gactccaac ttagcattgc cacccaagga 1680
ccctcacag tagtcagaagg aaagctagcc ctgcaaacat caggccccct caccaccacc 1740
gatagcagta cccttactat cactgcctca cccctctaa ctactgccac tggtagcttg 1800
ggcattgact tgaaagagcc catttataca caaatggaa aactaggact aaagtacggg 1860
gctcctttgc atgtaacaga cgacctaaac actttgaccg tagcaactgg tccaggtgtg 1920
actatttaata atacttcctt gcaaaactaa gttactggag ccttgggttt tgattcaca 1980
ggcaatatgc aacttaatgt agcaggagga ctaaggattg attctcaaaa cagacgcctt 2040
atacttgatg ttagttatcc gtttgatgct caaaaccaac taaatctaag actaggacag 2100
ggccctcttt ttataaactc agcccacaac ttggatatta actacaacaa aggcctttac 2160
ttgtttacag cttcaaacaa tccaagaaag cttgaggtta acctaagcac tgccaagggg 2220
ttgatgtttg acgctacagc catagccatt aatgcaggag atgggcttga atttggttca 2280
cctaattgcac caaacacaaa tccctcaaaa acaaaaattg gccatggcct agaatttgat 2340
tcaaacaaag ctaggtttcc taaactagga actggcctta gttttgacag cacaggtgcc 2400
attacagtag gaaacaaaaa taatgataag ctaactttgt ggaccacacc agtccatct 2460
cctaactgta gactaaatgc agagaaagat gctaaactca ctttgggtct aacaaaatgt 2520
ggcagtcaaa tacttgctac agtttcagtt ttggctgtta aaggcagttt ggctccaata 2580
tctggaacag ttcaaagtgc tcatcttatt ataagatttg acgaaaatgg agtgctacta 2640
aacaattcct tcctggaccc agaataattg aactttagaa atggagatct tactgaaggc 2700
acagcctata caaacgctgt tggatttatg cctaacctat cagcttatcc aaaatctcac 2760
ggtaaaactg ccaaaagtaa cattgtcagt caagtttact taaacggaga caaaactaaa 2820
cctgtaacac taaccattac actaaacggt acacaggaaa caggagacac aactccaagt 2880
gcatactcta tgtcattttc atgggactgg tctggccaca actacattaa tgaatatatt 2940
gccacatcct cttacacttt ttcatacatt tccaagaat aaagaagcgg ccgctcgagc 3000
atgcatctag agggccctat tctatagtgt cacctaaatg ctagagctcg ctgatcagcc 3060
tcgactgtgc cttctagttg ccagccatct gttgtttgcc cctccccgt gccttctctg 3120
accctggaag gtgccactcc cactgtcctt tcctaataaa atgaggaaaat tgcacgcac 3180
tgttgagta ggtgtcattc tattctgggg ggtgggggtg ggcaggacag caagggggag 3240
gattgggaag acaatagcag gcattcggg gatcgggtgg gctctatggc ttctgaggcg 3300
gaaagaacca gctggggctc taggggggtat cccacgcgc cctgtagcgg cgcattaaagc 3360
gcggcgggtg tgggtggttac gcgcagcgtg accgctacac ttgccagcgc cctagcgccc 3420
gctcctttcg ctttcttccc ttcctttctc gccacgttcg ccggttttcc ccgtcaagct 3480

```

ctaaatcggg	gcatacccttt	agggttcgga	tttagtgctt	tacggcacct	cgaccccaaa	3540
aaacttgatt	agggtgatgg	ttcacgtagt	gggccatcgc	cctgatagac	ggtttttcgc	3600
cctttgacgt	tgagtcacac	gttctttaat	agtggactct	tgttccaaac	tggaacaaca	3660
ctcaacccta	tctcgggtcta	ttcttttgat	ttataaggga	ttttggggat	ttcggccctat	3720
tggttaaaaa	atgagctgat	ttaacaaaaa	tttaacgcga	attaattctg	tggaatgtgt	3780
gtcagttagg	gtgtggaaaag	tccccaggct	ccccaggcag	gcagaagtat	gcaaagcatg	3840
catctcaatt	agtacgaac	cagggtgtgga	aagtccccag	gctccccagc	aggcagaagt	3900
atgcaaagca	agacatctcaa	ttagtcagca	accatagtc	cgccccctaac	tccgcccac	3960
ccgcccctaa	ctccgcccag	ttccgccc	tctccgcccc	atggctgact	aatttttttt	4020
atztatgcag	aggccgaggc	cgccctctgcc	tctgagctat	tccagaagta	gtgaggaggc	4080
ttttttggag	gcctaggctt	ttgcaaaaag	ctcccgggag	cttgatatatc	catttttcgga	4140
tctgatcaag	agacaggatg	aggatcgttt	cgcatgattg	aacaagatgg	attgcacgca	4200
ggttctccgg	ccgcttgggt	ggagaggcta	ttcggtctatg	actgggcaca	acagacaatc	4260
ggctgctctg	atgccgcctg	gttccggctg	tcagcgcagg	ggcgcccgg	tctttttgtc	4320
aagaccgacc	tgtccgggtg	cctgaatgaa	ctgcaggacg	aggcagcgcg	gctatcggtg	4380
ctggccacga	cgggcgcttc	ttgcccagct	gtgctcgacg	ttgtcactga	agcgggaagg	4440
gactggctgc	tattggggcga	agtgcggggg	caggatctcc	tgctatctca	ccttgctcct	4500
gccgagaaaag	tatccatcat	ggctgatgca	atgcggcgcg	tgcatacgct	tgatccggct	4560
acctgccc	tcgaccacca	agcgaaacat	cgcatcgagc	gagcacgtac	tccggtggaa	4620
gccggtcctg	tcgatcagga	tgatctggac	gaagagcatc	aggggctcgc	gccagccgaa	4680
ctgttcgcca	ggctcaaggc	gcgcatgcc	gacggcgagg	atctcgtcgt	gacccatggc	4740
gatgcctgct	tgccgaatat	catgggtgaa	aatggccgct	tttctggatt	catcgactgt	4800
ggccggctgg	gtgtggcgga	ccgctatcag	gacatagcgt	tggtaccctg	tgatattgct	4860
gaagagcttg	goggcgaaatg	ggctgaccgc	ttcctcgtgc	tttacgggtat	cgccgctccc	4920
gattcgagc	gactcgccct	ctatcgccct	cttcgtgagc	tttctgagc	gggactctgg	4980
ggttcgaaat	gaccgacc	gcgacgcccc	acctgccatc	acgagatttc	gattccaccg	5040
ccgcccctcta	tgaaaggttg	ggcttcggaa	tcgtttttccg	ggacgcggcg	tggtatgatcc	5100
tccagcgcg	ggatctcatg	ctggagttct	tcgcccaccc	caacttgttt	attgcagctt	5160
ataatggtta	caaataaagc	aatagcatca	caaatttcac	aaataaagca	tttttttcac	5220
tgcatcttag	ttgtgggttg	tccaaactca	tcaatgtatc	ttatcatgtc	tgtataaccg	5280
cgacctctag	ctagagcttg	gcgtaatcat	ggctcatagct	gtttcctgtg	tgaaattggt	5340
atccgctcac	aattccacac	aacatacgag	ccggaagcat	aaagtgtaaa	gcctgggggtg	5400
cctaatgagt	gagctaactc	acattaattg	cgttgccgct	actgcccgc	ttccagtcgg	5460
gaaacctgtc	gtgccagctg	cattaatgaa	tcggcccaacg	cgcggggaga	ggcggtttgc	5520
gtattggcg	ctcttcgct	tctcgcctca	ctgactcgct	gcgctcggtc	gttcggctgc	5580
ggcgagcggt	atcagctcac	tcaaaggcgg	taatacgggt	atccacagaa	tcaggggata	5640
acgcagga	gaacatgtga	gcaaaaagcc	agcaaaagcc	caggaaaccg	aaaaagccg	5700
cgttgtggc	gtttttccat	aggctccgcc	ccccgacga	gcatacaaaa	aatcgacgt	5760
caagtcagag	gtggcgaaac	ccgacaggac	tataaagata	ccaggcggtt	ccccctggaa	5820
gctccctcgt	gcgctctcct	gttccgaccc	tgccgcttac	cggtatccctg	tccgcctttc	5880
tcccttcggg	aagcgtggcg	ctttctcaat	gctcacgctg	taggtatctc	agttcgggtg	5940
aggctcgttcg	ctccaagctg	ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctgcg	6000
ccttatccgg	taactatcgt	cttgagtcca	acccggtaag	acacgactta	tcgccactgg	6060
cagcagccac	tggtaacagg	attagcagag	cgaggatgt	aggcgggtgct	acagagttct	6120
tgaagtgggt	gcctaactac	ggctacacta	gaaggacagt	atgttggtatc	tgcgctctgc	6180
tgaagccagt	taccttcgga	aaaagagttg	gtagctcttg	atccggcaaa	caaaccaccg	6240
ctggtagcgg	tggttttttt	gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	6300
aagaagatcc	tttgatcttt	tctacggggt	ctgacgctca	gtggaacgaa	aactcacgtt	6360
aagggtat	ggctcatgaga	ttatcaaaaa	ggatcttcac	ctagatcctt	ttaaattaaa	6420
aatgaagt	taaatacaatc	taaagtatat	atgagtaaac	ttggtctgac	agttaccaat	6480
gcttaatcag	tgaggcacct	atctcagcga	tctgtctatt	tcgttcaccc	atagttgcct	6540
gactccccgt	cgtgtagata	actacgatac	gggagggtt	accatctggc	cccagtgctg	6600
caatgatacc	gcgagacca	cgctcacccg	ctccagattt	atcagcaata	aaccagccag	6660
ccggaaggcc	cgagcgaga	agtggctcctg	caactttatc	cgccctccatc	cagctctatta	6720
attgttgccg	ggaagctaga	gtaagtagtt	cgccagttaa	tagtttgcgc	aacgttggtg	6780
ccatgtctac	aggcatcgtg	gtgtcacgct	cgtcgtttgg	tatggcttca	ttcagctccg	6840
gttcccaacg	atcaaggcga	gttacatgat	ccccatggt	gtgcaaaaaa	gcgggttagct	6900
cctccggctc	tccgatcgtt	gtcagaagta	agttggccgc	agtgttatca	ctcatgggtta	6960
tggcagcact	gcataattct	cttactgtca	tgccatccgt	aagatgcttt	tctgtgactg	7020
gtgagtactc	aaccaagtca	ttctgagaat	agtgtatgcg	gcgaccgagt	tgctcttgcc	7080
cggcgctcaat	acgggataat	accgcgccac	atagcagaac	tttaaaagtg	ctcatcattg	7140
gaaaacgttc	ttcggggcga	aaactgtcaa	ggatcttacc	gctgttgaga	tccagttcga	7200

```

tgtaaccac tcgtgcaccc aactgatctt cagcatcttt tactttcacc agcgtttctg 7260
ggtgagcaaa aacaggaagg caaaatgccg caaaaaaggg aataagggcg acacggaaat 7320
gttgaatact catactcttc ctttttcaat attattgaag catttatcag ggttattgtc 7380
tcatgagcgg atacatattt gaatgtattt agaaaaataa acaaataggg gttccgcgca 7440
catttccccg aaaagtgcc cctgacgtc 7469

```

<210> 9
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

```

<400> 9
tgcttaagcg gccgcgaagg agaagtc 28

```

<210> 10
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

```

<400> 10
ccgagctagc gactgaaaat gag 23

```

<210> 11
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

```

<400> 11
cctctcgaga gacagcaaga cac 23

```

<210> 12
 <211> 11152
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid

```

<400> 12
aagcttgggc agaaatgggt gaactcccgga gagtgtccta cacctagggg agaagcagcc 60
aagggggtgt ttcccaccaa ggacgacccg tctgcgcaca aacggatgag cccatcagac 120
aaagacatat tcattctctg ctgcaaactt ggcatagctc tgctttgcct ggggctattg 180
ggggaagttg cgggttcgtg tcgcagggct ctcacccttg actcttttaa tagctcttct 240
gtgcaagatt acaatctaaa caattcggag aactcgacct tcctcctgag gcaaggacca 300
cagccaactt cctcttacia gccgcacatg ttttgcctt cagaaataga aataagaatg 360
cttgctaaaa attatatttt taccaataag accaatccaa taggtagatt attagtact 420
atggttaagaa atgaatcatt atcttttagt actattttta ctcaaattca gaagttagaa 480
atgggaatag aaaatagaaa gagacgctca acctcaattg aagaacaggt gcaaggacta 540
ttgaccacag gcctagaagt aaaaaaggga aaaaagagtg tttttgtcaa aataggagac 600
aggtggtggc aaccagggac ttatagggga ccttacatct acagaccaac agatgcccc 660
ttaccatata caggaagata tgacttaaat tgggataggt gggttacagt caatggctat 720

```

aaagtgttat atagatccct ccccttttcgt gaaagactcg ccagagctag acctccttgg 780
tgtatgttgt ctcaagaaga aaaagacgac atgaaacaac aggtacatga ttatatattat 840
ctaggaacag gaatgcactt ttggggaaaag attttccata ccaaggaggg gacagtggct 900
ggactaatag aacattatct tgcaaaaact catggcatga gttattatga atagccttta 960
ttggcccaac cttgcggttc ccagggccta agtaagtttt tgggtacaaa ctgttcttaa 1020
aacgaggatg tgagacaagt ggtttcctga cttgggttgg tatcaaaggt tctgatctga 1080
gctctgagtg ttctattttc ctatgttctt ttggaattta tccaaatctt atgtaaatgc 1140
ttatgtaaac caagatataa aagagtgtcg attttttgag taaacttgca acagtcctaa 1200
cattcacctc ttgtgtgttt gtgtctgttc gccatcccgt ctccgctcgt cacttatcct 1260
tcactttcca gaggttcccc ccgcagaccc cggcgaccct caggtcggcc gactgcgga 1320
gctggcgccc gaacaggac cctcgataa gtgacccttg tctctatttc tactatttgg 1380
tgtttgtctt gtattgtctc tttcttgtct ggctatcatc acaagagcgg aacggactca 1440
ccatagggac caagctagcg actgaaaatg agacatatta tctgccacgg aggtgttatt 1500
accgaagaaa tggccgcccag tcttttgagc cagctgatcg aagaggtaact ggctgataat 1560
cttccacctc ctagecattt tgaaccacct acccttcaag aactgtatga tttagacgtg 1620
acggcccccg aagatcccaa cggaggaggc gtttcgcaga tttttcccgga ctctgtaatg 1680
ttggcgggtg aggaaggatg tgacttactc acttttccgc cggcgcccggt tcttccggag 1740
ccgcctcacc tttcccgcca gcccgagcag ccggagcaga gagccttggg tccggtttct 1800
atgccaacac ttgtaccgga ggtgatcgat cttacctgcc acgaggctgg ctttccaccc 1860
agtgtacgac aggtgaaga gggtaggag tttgtgttag attatgtgga gcaccccggt 1920
cacggttgca ggtcttgtca ttatcacccg aggaatacgg gggaccaga tattatgtgt 1980
tcgctttgct atatgaggac ctgtggcatg tttgtctaca gtaagtgaat attatgggca 2040
gtgggtgata gagtgggtgg tttgggtgtg taattttttt ttttaattttt acagttttgt 2100
ggtttaaaaga attttgtatt gtgatttttt taaaaggctc tgtgtctgaa cctgagcctg 2160
agcccgagcc agaaccggag cctgcaagac ctaccgccc tctaaaaatg gcgcctgcta 2220
tcctgagacg cccgacatca cctgtgtcta gagaatgcaa tagtagtacg gatagctgtg 2280
actccggtcc ttctaacaca cctcctgaga tacaccgggt ggtcccgtcg tgccccatta 2340
aaccagttgc cgtgagagtt ggtgggctgc gccaggctgt ggaatgtatc gaggacttgc 2400
ttaacgagcc tgggcaacct ttggacttga cgtgtaaacg cccaggcca taaggtgtaa 2460
acctgtgatt gcgtgtgtgg ttaacgcctt tggttgcgta atgagttgat gtaagtttaa 2520
taaaagggtga gataatgttt aacttgcatg gcgtgttaaa tggggcgggg cttaaagggt 2580
atataatgag ccgtgggcta atcttggtta catctgacct catggaggct tgggagtgtt 2640
tggaagattt ttctgctgtg cgttaacttc tgaacagag ctctaacagt acctgttgtt 2700
tttggagggt tctgtggggc tcatcccagg caaagttagt ctgcagaatt aaggaggatt 2760
acaagtggga atttgaagag cttttgaaat cctgtgttga gctgtttgat tctttgaatc 2820
tggttcacca ggccgttttc caagagaagg tcatcaagac tttggatttt tccacaccgg 2880
ggcgcgctgc gctgctgttt gcttttttga gttttataaa ggataaatgg agcgaagaaa 2940
cccatctgag cggggggtac ctgctggatt ttctggccat gcatctgtgg agagcgggtg 3000
tgagacacaa gaatcgctg ctactgttgt cttccgtccg ccggcgcata ataccgacgg 3060
aggagcagca gcagcagcag gaggaagcca gggcgggcg gcaggagcag agcccatgca 3120
accgcagagc cgcctggac cctcggaat gaatgttga cagggtggctg aactgtatcc 3180
agaactgaga cgcattttga caattacaga ggatgggcag gggctaaagg gggtaagag 3240
ggagcggggg gcttgtgagg ctacagagga ggctaggaat ctagctttta gcttaatgac 3300
cagacaccgt cctgagtgtg ttacttttca acagatcaag gataattgag ctaatgagct 3360
tgatctgtct gcgcagaagt attccataga tgcaagggtg gcacttaggc cagattgcaa 3420
ggatgatttt gaggaggtta ttagggataa gcaaaagggt gacatttagc ggaacggggc 3480
gtacaagatc agcaaaactg taaatatcag gaattgttgc tacatttctg ggaacggggc 3540
cgaggtggag atagatacgg aggatagggt ggcctttaga tgtagcatga taaatatgtg 3600
gccgggggtg cctggcatgg acgggggtgt tattatgaat gtaaggttta ctggcccaa 3660
ttttagcggg acggttttcc tggccaatac caaccttacc ctacacgggt taagcttcta 3720
tggttttaac aatacctgtg tgggaagcctg gaccgatga agggttcggg gctgtgcctt 3780
ttactgctgc tgggaaggggg tgggtgtgtc ccccaaaagc agggcttcaa ttaagaaatg 3840
cctctttgaa aggtgtacct tgggtatcct gtctgagggt aactccaggg tgcgcccaa 3900
tgtggcctcc gactgtggtt gcttcatgct agtgaaaagc gtggctgtga ttaagcataa 3960
catgggtatg ggcaactgcg aggacagggc ctctcagatg ctgacctgct cggacggcaa 4020
ctgtcacctg ctgaagacca ttcacgtagc cagccactct cgcaaggcct ggccagtgtt 4080
tgagcataac atactgaccc gctgttccct gcatttgggt aacaggaggg ggggtgttcc 4140
accttaccaa tcgaatttga gtcacactaa gatattgctt gagcccgaga gcatgtccaa 4200
ggtgaacctg aacgggggtg ttgacatgac catgaagatc tgggaagggtc tgaggtagca 4260
tgagacccgc accaggtgca gaccctgcga gtgtggcggg aaacatatta ggaaccagcc 4320
tgtgatgctg gatgtgaccg aggagctgag gcccgatcac ttgggtgctg cctgcacccg 4380
cgctgagttt ggctctagcg atgaagatac agattgaggt actgaaatgt gtggcgctgg 4440

cttaaggggtg	ggaaagaata	tataaggtgg	gggtcttatg	tagttttgta	tctgttttgc	4500
agcagccgcc	gccgccatga	gcaccaactc	gtttgatgga	agcattgtga	gctcatattt	4560
gacaacgcgc	atgcccccat	gggcccgggt	gcgtcagaat	gtgatgggct	ccagcattga	4620
tggtcgcccc	gtcctgcccc	caaactctac	taccttgacc	tacgagaccg	tgctcggaac	4680
gccgttgagg	actgcagcct	ccgcccgcgc	ttcagccgct	gcagccaccg	cccgcgggat	4740
tgtgactgac	tttgctttcc	tgagcccgcct	tgcaagcagt	gcagcttccc	gttcatccgc	4800
ccgcgatgac	aagttgacgg	ctcttttggc	acaattggat	tctttgaccc	gggaacttaa	4860
tgtcgtttct	cagcagctgt	tggaatctgc	ccagcagggt	tctgccctga	aggcttcctc	4920
ccctcccaat	gcgggtttaa	acataaataa	aaaaccagac	tctgtttgga	tttggatcaa	4980
gcaagtgtct	tgctgtctct	cgagggatct	ttgtgaagga	accttacttc	tgtggtgtga	5040
cataattgga	caaactacct	acagagattt	aaagctctaa	ggtaaatata	aaatttttaa	5100
gtgtataatg	tgttaaaact	ctgattctaa	ttgtttgtgt	attttagatt	ccaacctatg	5160
gaactgatga	atgggagcag	tggtggaatg	cctttaatga	ggaaaacctg	ttttgctcag	5220
aagaaatgcc	atctagtgat	gatgaggcta	ctgctgactc	tcaacattct	actcctccaa	5280
aaaagaagag	aaaggtagaa	gaccccaagg	actttccttc	agaattgcta	agttttttga	5340
aagctgcact	gtttagtatg	agaactctgt	cttgetttgc	tatttacacc	acaaggaaa	5400
ataacagtta	taatacatac	aaatttatgg	aaaatatatt	tgtaaccttt	ataagtaggc	5460
ctattaataa	ctatgctcaa	aaatttgtgt	ttcttactcc	acacaggcat	agagtgtctg	5520
ataaggaata	tttgatgtat	agtgccttga	ccttttagctt	tttaatttgt	aaaggggtta	5580
gtagaggttt	tacttgcttt	taacttggtt	ctagagatca	taatacagca	taccacattt	5640
atgaatgcaa	ttgttggtgt	taacttggtt	ccacacctcc	ccttgaacct	gaaacataaa	5700
aatagcatca	caaatttcac	aaataaagca	attgcagctt	ataatgggta	caaataaagc	5760
tccaaactca	tcaatgtatc	ttatcatgtc	tttttttcac	tgcattctag	ttgtgggttg	5820
gggtgtggaa	agtcctcagg	ctcccagca	tggaatcggc	tggtggaatgt	gtgtcagtaa	5880
tagtcagcaa	ccaggtgtgg	aaagtcccca	ggcagaagta	tgcaagcat	gcatctcagt	5940
atgcatctca	attagtcagc	aaccatagtc	ggctccccag	caggcagaag	tatgcaaagc	6000
actccgcccc	gttccgcccc	ttctccgccc	ccgcccctaa	ctccgcccct	cccgccccta	6060
gaggccgagg	ccgcctcggc	ctctgagcta	catggctgac	taattttttt	tattttatgca	6120
ggcctaggct	tttgcaaaaa	gcttgacac	ttccagaagt	agtgaggagg	cttttttgga	6180
accactttat	ccgcgctcag	ggagaggcag	aagacaggct	tgcgagatat	gtttgagaat	6240
actgggtttt	agtgcgccag	atctctataa	tgcgtaaaaa	gacgcggact	catgtgaaat	6300
tttttaagcc	gtagataaac	aggctgggac	tctcgcgcaa	cctattttcc	cctcgaacac	6360
ctgggacatg	ttgcagatcc	atgcacgtaa	actcgcaagc	agcgaaaaat	acatcgctac	6420
atggaaaagg	attattgccg	taagccgtgg	actcgcaagc	cgactgatgc	cttctgaaca	6480
tgaactgggt	attcgctcat	tcgataccgt	cggtctggta	ccgggtgcgt	tactggcgcg	6540
gcgcgaggtg	aaagtgtga	aacgcgcaga	ttgtattttc	agctacgatc	acgacaacca	6600
tgacctgggt	gataccgggt	gtactgcggt	aggcgtgggc	gaaggcttca	tcgttattga	6660
ctttgtcacc	atcttcgcaa	aaccggctgg	tgcgattcgt	gaaatgtatc	caaaaggcca	6720
tatcccgcaa	gatacctgga	ttgaacagcc	tcgtccgctg	gttgatgact	atgttggtga	6780
aatctccggt	cgctaactct	ttcaacgcct	gtgggatatg	ggcgctcgat	tcgtcccgcg	6840
caggcggggt	acataagttt	ccagtaagta	ggcactgccg	ggcgttggtc	tttttaactt	6900
acctgagcga	aaccctgttc	aaaccccgct	ttctggaggc	tgcatccatg	acacaggcaa	6960
gccgctttaa	tcacggcgca	caaccgcctg	ttaaacatcc	tgaaacctcg	acgctagtcc	7020
ctcactggta	tcgcatgatt	aaccgtctga	tgcaactcgc	ccttgatggt	aaaaccatcc	7080
aaatcctcga	cgtccaggca	cgtattgtga	tgagcgatgc	gcggggcatt	gacccacgcg	7140
tatacgatac	gggtgattgg	taccgtggcg	gcaactggat	cgaacgtacc	gacgatgatt	7200
tttgtaagg	aaccttactt	ctgtgggtgt	ttatgagtgg	ttatgagtgg	gccccggatc	7260
taaaagctcta	aggtaaatat	aaaattttta	acataattgg	acaaactacc	tacagagatt	7320
attgtttgtg	tatttttagat	tccaacctat	agtgtataat	gtgttaaact	actgattcta	7380
gcctttaatg	aggaaaacct	gttttgctca	ggaactgatg	aatgggagca	gtggtggaat	7440
actgctgact	ctcaacattc	tactcctcca	caagaaatgc	catctagtga	tgatgaggct	7500
gactttcctt	cagaattgct	aagttttttg	aaaagaaga	gaaaggtaga	agaccccaag	7560
gcttgctttg	ctatttacac	cacaaaggaa	agtcatgctg	tgtttagtaa	tagaactcct	7620
gaaaaaatat	ctgtaacctt	tataagtagg	aaagtgcac	tgctatacaa	gaaaattatg	7680
tttcttactc	cacacaggca	tagagtgtct	cataacagtt	ataatcataa	catactgttt	7740
accttttagct	ttttaatttg	ttaaaggggt	gctattaata	actatgctca	aaaatttgtt	7800
actagagatc	ataatcagcc	ataccacatt	aataaggaat	atttgatgta	tagtgccttg	7860
cccacacctc	cccctgaacc	tgaaacataa	tgtagagggt	ttacttgctt	taaaaaacct	7920
tattgcagct	tataatgggt	acaaataaag	aatgaatgca	attgttggtt	ttactgtgtt	7980
atttttttca	ctgcattcta	gttggtggtt	caatagcatc	acaaatttca	caaataaagc	8040
ctggatcccc	aggaagctcc	tctgtgtcct	gtccaaactc	atcaatgtat	cttatcatgt	8100
			cataaccctt	aacctcctct	acttgagagg	8160

```

acattccaat cataggctgc ccatccaccc tctgtgtcct cctgttaatt aggtcactta 8220
acaaaaagga aattgggtag ggggttttca cagaccgctt tctaagggtta attttaaaat 8280
atctgggaag tcccttccac tgctgtgttc cagaagtgtt ggtaaacagc ccacaaatgt 8340
caacagcaga aacatacaag ctgtcagctt tgcaaacagg cccaacaccc tgctcatcaa 8400
gaagcactgt ggttgctgtg ttagtaatgt gcaaaacagg aggcacattt tccccacctg 8460
tgtagggtcc aaaatatcta gtgttttcat ttttacttgg atcaggaacc cagcactcca 8520
ctggataaagc attatcctta tccaaaacag ccttgtggtc agtgttcac tgctgactgt 8580
caactgtagc attttttggg gttacagttt gagcaggata tttggctctg tagtttgcta 8640
acacaccctg cagctccaaa ggttccccac caacagcaaa aaaatgaaaa tttgaccctt 8700
gaatgggttt tccagcacca ttttcatgag ttttttgtgt ccctgaatgc aagtttaaca 8760
tagcagttac cccaataacc tcagttttaa cagtaacagc tccccacatc aaaatatttc 8820
cacagggtta gtcctcattt aaattaggca aaggaattct tgaagacgaa agggctcgt 8880
gatacgccta tttttatagg ttaatgtcat gataataatg gtttcttaga cgtcagggtg 8940
cacttttcgg ggaaatgtgc gcggaacccc tatttgttta ttttctaaa tacattcaaa 9000
tatgtatccg ctcatgagac aataaccctg ataaatgctt caataatatt gaaaaaggaa 9060
gagtatgagt attcaacatt tccgtgtcgc ccttattccc ttttttgcgg cattttgcta 9120
tctgtttttt gctcaccag aaacgctggt gaaagtaaaa gatgctgaag atcagttggg 9180
tgcacgagtg ggttacatcg aactggatct caacagcggg aagatccttg agagtttctg 9240
ccccgaagaa cgttttccaa tgatgagcac ttttaaagtt ctgctatgtg gcgcggtatt 9300
atcccgtgtt gacgccgggc aagagcaact cggtcgcccgc atacactatt ctcagaatga 9360
cttgggttag tactcaccag tcacagaaaa gcattcttac gatggcatga cagtaagaga 9420
attatgcagt gctgccataa ccatgagtga taacactgcg gccaaacttac ttctgacaac 9480
gatcggagga ccgaaggagc taaccgcttt tttgcacaac atggggggatc atgtaactcg 9540
ccttgatcgt tgggaacogg agctgaatga agccatacca aacgacgagc gtgacaccac 9600
gatgcctgca gcaatggcaa caacggttgcg caaactatta actggcgaaac tacttactct 9660
agcttcccgg caacaattaa tagactggat ggaggcggat aaagttgcag gaccacttct 9720
gcgctcggcc ctcccggtcg gctgggttat tgctgataaa tctggagccg gtgagcgtgg 9780
gtctcgcggt atcattgcag cactggggcc agatggtaag ccctcccgtat tcgtagttat 9840
ctacacgacg gggagtcagg caactatgga tgaacgaaat agacagatcg ctgagatagg 9900
tgccctcactg attaaacatt ggtaactgtc agaccaagtt tactcatata tacttttagat 9960
tgatttaaaa cttcattttt aatttaaaag gatctaggtg aagatccttt ttgataatct 10020
catgacaaa atcccttaac gtgagttttt gttccactga gcgtcagacc ccgtagaaaa 10080
gatcaaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct tgcaaaacaaa 10140
aaaaccaccg ctaccagcgg tgggtttgtt gccggatcaa gagctaccaa ctctttttcc 10200
gaaggttaact ggcttcagca gagcgcagat accaaatact gtcccttctag tgtagccgta 10260
gttaggccac cacttcaaga actctgtagc accgectaca tacctcgctc tgctaactct 10320
gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accgggttgg actcaagacg 10380
atagttaccg gataaggcgc agcggtcggg ctgaacgggg gggtcgtgca cacagcccag 10440
cttgagcga acgacctaca ccgaactgag atacctacag cgtgagctat gagaaagcgc 10500
cacgcttccc gaagggagaa aggcggacag gtatccggta agcggcaggg tcggaacagg 10560
agagcgacg agggagcttc cagggggaaa cgcctgggtat ctttatagtc ctgtcgggtt 10620
tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc ggagcctatg 10680
gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc cttttgctca 10740
catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg cctttgagtg 10800
agctgatacc gctcgccgca gccgaacgac cgagcgcagc gagtcaagtga gcgaggaagc 10860
ggaagagcgc ctgatgcggt attttctcct tacgcatctg tgcggtattt cacaccgcat 10920
atggtgcact ctcatgacaa tctgctctga tgccgcatag ttaagccagt atacactccg 10980
ctatcgctac gtgactgggt catggctgcg ccccgacacc cgccaacacc cgctgacgcg 11040
ccctgacggg cttgtctgct cccggcatcc gttacagac aagctgtgac cgtctccggg 11100
agctgcattg gtcagaggtt ttcaccgtca tcaccgaaac gcgcgaggca gc 11152

```

<210> 13

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 13

gacggatcgg gagatctcc

<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 14
ccgcctcaga agccatagag cc

22

<210> 15
<211> 14455
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 15
aagcttgggc agaaatggtt gaactcccg gagtgtccta cacctagggg agaagcagcc 60
aaggggttgt tcccaccaa ggacgacccg tctgcgcaca aacggatgag cccatcagac 120
aaagacatat tcttctcttg ctgcaaaactt ggcatagctc tgctttgcct ggggctattg 180
ggggaagtgt cgggttcgtgc tcgcagggct ctcacccttg actcttttaa tagctcttct 240
gtgcaagatt acaatctaaa caattcggag aactcgacct tcctcctgag gcaaggacca 300
cagccaactt cctcttataa gccgcacga ttttgcctt cagaaataga aataagaatg 360
cttgctaaaa attatatatt taccataaag accaatocaa taggtagatt attagtact 420
atgttaagaa atgaatcatt atcttttagt actattttta ctcaaattca gaagttagaa 480
atgggaatag aaaatagaaa gagacgctca acctcaattg aagaacagggt gcaaggacta 540
ttgaccacag gcctagaagt aaaaaaggga aaaaagagtg tttttgtcaa aataggagac 600
agggtgtggc aaccagggac ttatagggga ccttacatct acagaccaac agatgcccc 660
ttaccatata caggaagata tgacttaaat tgggataggt ggggtacagt caatggctat 720
aaagtgttat atagatccct ccttttctgt gaaagactcg ccagagctag acctccttg 780
tgtatgttgt ctcaagaaga aaaagacgac atgaaacaac aggtacatga ttatatatt 840
ctaggaacag gaatgcactt ttggggaaag attttccata ccaaggagggt gacagtggct 900
ggactaatag aacattatct tgcaaaaact catggcatga gttattatga atagccttta 960
ttggcccaac cttgcggttc ccagggtcta agtaagtttt tgggtacaaa ctgttcttaa 1020
aacgaggatg tgagacaagt ggtttcctga cttgggtttg tatcaaagggt tctgatctga 1080
gctctgagtg ttctattttc ctatgttctt ttggaaattta tccaaatctt atgtaaatgc 1140
ttatgtaaac caagatataa aagagtgtct attttttgag taaacttgca acagtcttaa 1200
cattcacctc ttgtgtgttt gtgtctgttc gccatccctg ctccgctcgt cacttatcct 1260
tcactttcca gaggtcccc ccgcagaccc cggcgaccct caggctcgcc gactgcggca 1320
gctggcgccc gaacagggac cctcggataa gtgacccttg tctctatttc tactatttgg 1380
tgtttgtctt gtattgtctc tttcttgtct ggctatcatc acaagagcgg aacggactca 1440
ccatagggac caagctagcg actgaaaatg agacatatta tctgccacgg aggtgttatt 1500
accgaagaaa tggccgccag tcttttggac cagctgatcg aagagggtact ggtgataat 1560
cttcacactc ctagccattt tgaaccacct acccttcacg aactgtatga tttagacgtg 1620
acggcccccg aagatcccaa cgaggaggcg gtttgcgaga tttttcccga ctctgtaatg 1680
ttggcggtgc aggaaggat tgacttactc acttttccgc cggcgcccg gttctccggag 1740
ccgcctcacc tttcccggca gcccgagcag ccggagcaga gagccttggg tccggtttct 1800
atgccaacc ttgtaccgga ggtgatcgat cttacctgcc acgaggctgg ctttccacc 1860
agtgaacgag aggatgaaga gggtagggag tttgtgttag attatgtgga gcacccggg 1920
cacggttgca ggtcttgtca ttatcaccgg aggaatacgg gggaccaga tattatgtgt 1980
tcgctttgct atatgaggac ctgtggcatg tttgtctaca gtaagtgaat attatgggca 2040
gtgggtgata gagtgtgtgg tttggtgtgg taattttttt ttaattttt acagttttgt 2100
ggtttaagaa attttgtatt gtgatttttt taaaaggctc tgtgtctgaa cctgagcctg 2160
agcccagacc agaaccggag cctgcaagac ctaccccgcc tcctaaaatg gcgcctgcta 2220
tcctgagacg cccgacatca cctgtgtcta gagaatgcaa tagtagtacg gatagctgtg 2280
actccggttc ttctaacaca cctcctgaga tacaccgggt ggtcccgctg tgccccatta 2340
aaccagtgc cgtgagagtt ggtggcgctc gccaggctgt ggaatgtatc gaggacttgc 2400
ttaacgagcc tgggcaacct ttggacttga gctgtaaacy ccccgagcca taaggtgtaa 2460

acctgtgatt	gcgtgtgtgg	ttaacgcctt	tgtttgctga	atgagttgat	gtaagtttaa	2520
taaaggtgga	gataatgttt	aacttgcatg	gcgtgttaaa	tggggcgggg	cttaaagggt	2580
atataatgcg	ccgtgggcta	atcttggtta	catctgacct	catggaggct	tgggagtggt	2640
tggaagattt	ttctgctgtg	cgtaacttgc	tggaacagag	ctctaacagt	acctcttggt	2700
tttggaggtt	tctgtggggc	tcatcccagg	caaagttagt	ctgcagaatt	aaggaggatt	2760
acaagtggga	atttgaagag	cttttgaaat	cctgtggtga	gctgtttgat	tctttgaatc	2820
tgggtcacca	ggcgcttttc	caagagaagg	tcatcaagac	tttggatttt	tccacaccgg	2880
ggcgcgctgc	ggctgctgtt	gcttttttga	gttttataaa	ggataaatgg	agcgaagaaa	2940
cccattctgag	cggggggtac	ctgctggatt	ttctggccat	gcattctgtg	agagcgggtg	3000
tgagacacaa	gaatcgcctg	ctactgttgt	cttcgcgtccg	cccgccgata	ataccgacgg	3060
aggagcagca	gcagcagcag	gaggaagcca	ggcgccggcg	gcaggagcag	agcccatgga	3120
acccgagagc	cgccctggac	cctcggaat	gaattgttga	cagggtggctg	aactgtatcc	3180
agaactgaga	cgcattttga	caattacaga	ggatgggcag	gggctaaagg	gggtaaagag	3240
ggagcggggg	gcttgtgagg	ctacagagga	ggctaggaat	ctagctttta	gcttaatgac	3300
cagacaccgt	cctgagtgtg	ttacttttca	acagatcaag	gataattgctg	ctaattgagct	3360
tgatctgctg	gcgcagaagt	attccataga	gcagctgacc	acttactggc	tgacagcagg	3420
ggatgatttt	gaggaggcta	ttagggtata	tgcaaagggtg	gcacttaggc	cagattgcaa	3480
gtacaagatc	agcaaacttg	taaatatcag	gaattgttgc	tacatttctg	ggaacggggc	3540
cgagggtggag	atagatacgg	aggatagggt	ggcctttaga	tgtagcatga	taaataatgt	3600
gcccgggggtg	cttggcatgg	acgggggtggt	tactatgaat	gtaagggtta	ctggcccaaa	3660
ttttagcggg	acgggtttcc	tgcccaatac	caaccttatc	ctacacgggtg	taagcttcta	3720
tgggttttaac	aatacctgtg	tggaagcctg	gaccgatgta	aggggttcggg	gctgtgcctt	3780
ttactgctgc	tggaaggggg	tggtgtgtcg	ccccaaaagc	agggcttcaa	ttaagaaatg	3840
cctctttgaa	aggtgtacct	tggtgtacct	gtctgagggt	aactccaggg	tgccgcaaaa	3900
tggtggctcc	gactgtggtt	gcttcatgct	agtgaagagc	gtggctgtga	ttaagcataa	3960
catggtatgt	ggcaactgcg	aggacagggc	ctctcagatg	ctgacctgct	cggacggcaa	4020
ctgtcacctg	ctgaagacca	ttcacgtagc	cagccactct	ccgcaaggct	ggccagtggt	4080
tgagcataac	atactgacct	gctgttccct	gcatttgggt	aacaggaggg	gggtgttccct	4140
accttataaa	tgcaatttga	gtcacactaa	gatattgctt	gagcccgaga	gcatgtccaa	4200
ggtgaacctg	aacgggggtg	ttgacatgac	catgaagatc	tggaagggtg	tgaggtagca	4260
tgagacccgc	accagggtgca	gaccctgcga	gtgtggcggt	aaacatatta	ggaaccagcc	4320
tgtgatgctg	gatgtgaccg	aggagctgag	gcccgatcac	ttggtgctgg	cctgcacccg	4380
cgctgaagtt	ggctctagcg	atggaagatac	agattgaggt	actgaaatgt	gtgggcgtgg	4440
cttaaggggtg	ggaaagaata	tataagggtg	gggtcttatg	tagttttgta	tctgttttgc	4500
agcagccgcc	gcccgccatga	gcaccaactc	gtttgatgga	agcattgtga	gctcatattt	4560
gacaacgcgc	atgcccccat	gggcccgggt	gcgtcagaat	gtgatgggct	ccagcatgga	4620
tggtcgcccc	gtcctgcccg	caaactctac	taccttgacc	tacgagaccg	tgtctggaac	4680
gcccgttgag	actgcagcct	ccgcccgcgc	ttcagccgct	gcagccaccg	cccgcgggat	4740
tgtagctgac	tttgctttcc	tgagcccgcg	tgcaagcagt	gcagcttccc	gttcatccgc	4800
ccgcgatgac	aagttgacgg	ctcttttggt	acaattggat	tctttgacct	gggaacttaa	4860
tgtgttttct	cagcagctgt	tggtctctgc	ccagcagggt	tctgcccctga	aggtctcttc	4920
ccctcccaat	gcggtttaaa	acataaataa	aaaaccagac	tctgttttga	tttggatcaa	4980
gcaagtgtct	tgtgtgtctc	cgagggatct	ttgtgaagga	accttacttc	tgtggtgtga	5040
cataatttga	caaactacct	acagagattt	aaagctctaa	ggtaaatata	aaatttttaa	5100
gtgtataaat	tggttaaaact	ctgattctaa	ttgtttgtgt	attttagatt	ccaacctatg	5160
gaactgatga	atgggagcag	tggtggaatg	cctttaatga	ggaaaacctg	ttttgtctag	5220
aagaaatgcc	atctagtgat	gatgaggcta	ctgctgactc	tcaacattct	actcctccaa	5280
aaaagaagag	aaaggtagaa	gaccccaagg	actttccttc	agaattgcta	agttttttga	5340
gtcatgctgt	gtttagtaat	agaactcttg	cttgctttgc	tatttacacc	acaaaggaaa	5400
aaagtgcact	gctatacaag	aaaattatgg	aaaaatatcc	tgtaaccttt	ataagtaggc	5460
ataacagtta	taatcataac	atactgtttt	ttcttactcc	acacaggcat	agagtgtctg	5520
ctatttaata	ctatgctcaa	aaattgtgtg	ccttttagctt	tttaatttgt	aaaggggtta	5580
ataaggaata	tttgatgtat	agtgccctga	ctagagatca	taatcagcca	taccacattt	5640
gtagagggtt	tacttgcttt	aaaaaacctc	ccacacctcc	ccctgaacct	gaaacataaa	5700
atgaatgcaa	ttgttgttgt	taacttgttt	attgcagctt	ataatgggtg	caaataaagc	5760
aatagcatca	caaatttcac	aaataaagca	tttttttcac	tgcatcttag	ttgtgggttg	5820
tccaaactca	tcaatgtatc	ttatcatgtc	tggtaccggc	tggtggaatg	gtgtcagtta	5880
gggtgtggaa	gtccccagc	ctccccagca	ggcagaagta	tgcaaaagcat	gcatctcaat	5940
tagtcagcaa	ccagggtgtg	aaagtcccca	ggctcccgag	caggcagaag	tatgcaaagc	6000
atgcatctca	attagtcagc	aaccatagtc	ccgcccctaa	ctccgcccct	cccgcgccct	6060
actccgcccc	gttccgcccc	ttctccgccc	catggtgtgac	taattttttt	tatttatgca	6120
gaggccgagg	ccgcctcggc	ctctgagcta	ttccagaagt	agtgaggagg	cttttttggg	6180

ggcctaggct	tttgcaaaaa	gcttggacac	aagacaggct	tgcgagatat	gtttgagaat	6240
accactttat	cccgcgtcag	ggagaggcag	tgcgtaaaaa	gacgcggact	catgtgaaat	6300
actggttttt	agtgcgccag	atctctataa	tctcgcgcaa	cctattttcc	cctcgaacac	6360
tttttaagcc	gtagataaac	aggctgggac	acttcacatg	agcgaaaaat	acatcgtcac	6420
ctgggacatg	ttgcagatcc	atgcacgtaa	actcgcaagc	cgactgatgc	cttctgaaca	6480
atggaaaggc	attattgccg	taagccgtgg	cggtctggta	ccgggtgcgt	tactggcgcg	6540
tgaactgggt	attcgtcatg	tcgataccgt	ttgtatttcc	agctacgata	acgacaacca	6600
gcgcgagctt	aaagtgtctg	aacgcgcaga	aggcgatggc	gaaggcttca	tcgttattga	6660
tgacctgggt	gataccgggt	gtactgcggt	tgcgattcgt	gaaatgtatc	caaaagcgca	6720
ctttgtcacc	atcttcgcaa	aaccggctgg	tctgtccgctg	gttgatgact	atgttggtga	6780
tatcccgcga	gatacctgga	ttgaacagcc	gtgggatgat	ggcgtcgtat	tcgtcccgcg	6840
aatctccggt	cgctaattctt	ttcaacgcct	ggcactgccg	ggcgttggtc	tttttaactt	6900
caggcggggt	acaatagttt	ccagtaagta	ttctggaggc	tgcattccatg	acacaggcaa	6960
acctgagcga	aacctgttcc	aaaccccgct	ttaaacatcc	tgaacacctg	acgctagtcc	7020
gccgctttaa	tcacggcgca	caaccgcctg	tgcagtcggc	ccttgatggt	aaaaccatcc	7080
ctcactggta	tcgcatgatt	aaccgctcga	tgtggatctg	gcgcggcatt	gaccacgctt	7140
aaatcctcga	cgtccaggca	cgtattgtga	tgagcgatgc	cgaacgtacc	gacgatgatt	7200
tatacgatac	gggtgattggc	taccgtggcg	gcaactggat	ttatgagtgg	gccccggatc	7260
tttgtgaagg	aaccttactt	ctgtgggtgtg	acataattgg	acaaactacc	tacagagatt	7320
taaagctcta	aggtaaaatat	aaaattttta	agtgtataat	gtgttaaact	actgattcta	7380
attgtttgtg	tatttttagat	tccaacctat	ggaactgatg	aatgggagca	gtggtggaat	7440
gcctttaatg	aggaaaaact	gttttgctca	gaagaaatgc	catctagtga	tgatgaggct	7500
actgctgact	ctcaacattc	tactcctcca	aaaaagaaga	gaaaggtaga	agaccccaag	7560
gactttcctt	cagaattgct	aagttttttg	agtcactgct	tgtttagtaa	tagaactctt	7620
gcttgctttg	ctattttacac	cacaaaggaa	aaagctgcac	tgctatacaa	gaaaattatg	7680
gaaaaatatt	ctgtaacctt	tataagtagg	cataacagtt	ataatcataa	catactgttt	7740
tttcttactc	cacacaggca	tagagtgtct	gctattaata	actatgctca	aaaatttgtt	7800
accttttagt	ttttaatttg	taaaggggtt	aataaggaat	atttgatgta	tagtgccttg	7860
actagagatc	ataatcagcc	ataccacatt	tgtagagggt	ttacttgctt	taaaaaacct	7920
cccacacctc	cccctgaacc	tgaacataaa	aatgaatgca	attgttgttg	ttacttgtt	7980
tattgcagct	tataatgggt	acaaataaag	caatagcatc	acaaatttca	caaataaagc	8040
atttttttca	ctgcatctta	gttgtgtgtt	gtocaaactc	atcaatgtat	cttatcatgt	8100
ctggatcccc	aggaaagctc	tctgtgtcct	tctgtgtcct	aacctcctct	acttgagagg	8160
acattccaat	cataggctgc	ccatccaccc	tctgtgtcct	cctgttaatt	aggtcactta	8220
acaaaaagga	aattgggtag	gggtttttca	cagaccgctt	tctaagggtta	atttttaaat	8280
atctgggaag	tcctttccac	tgctgtgttc	cagaagtgtt	ggtaaacagc	ccacaaatgt	8340
caacagcaga	aacatacaag	ctgtcagctt	tgcaacaagg	cccaacaccc	tgctcatcaa	8400
gaagcactgt	ggttgctgtg	ttagtaatgt	gcaaaacagg	aggcacattt	ccccacctg	8460
tgtaggttcc	aaaatatcta	gtgttttcat	ttttacttgg	atcaggaacc	cagcactcca	8520
ctggataagc	attatcctta	tccaaaacag	ccttgtgttc	agtgttcac	tgctgactgt	8580
caactgttagc	attttttggg	gttacagttt	gagcaggata	tttggtcctg	tagtttgtct	8640
acacaccctg	cagctccaaa	ggttccccac	caacagcaaa	aaaatgaaaa	tttgaccctt	8700
gaatgggttt	tccagcacca	ttttcatgag	ttttttgtgt	ccctgaatgc	aagttaaaca	8760
tagcagttac	cccaataacc	tcagttttta	cagtaacagc	ttccacatc	aaaatatttc	8820
cacaggttaa	gtcctcattt	aaattaggca	aaggaattct	tgaagacgaa	agggcctcgt	8880
gatacgcccta	tttttatagg	ttaatgtcat	gataataatg	gtttcttaga	cgtcaggtgg	8940
cacttttccg	ggaaatgtgc	gcggaacccc	tatttgttta	tttttctaaa	tacattcaaa	9000
tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	gaaaaaggaa	9060
gagtatgagt	attcaacatt	tcctgtctgc	ccttattccc	ttttttgcgg	cattttgcct	9120
tcctgttttt	gctcaccacg	aaacgctggt	gaaagtaaaa	gatgctgaag	atcagttggg	9180
tgacagagtg	ggttacatcg	aactggatct	caacagcggg	aagatccttg	agagttttcg	9240
ccccgaagaa	cgttttccaa	tgatgagcac	tttttaaagt	ctgctatgtg	gcgcgggtatt	9300
atcccggtgt	gacgcggggc	aagagcaact	cggtcgccgc	atacactatt	ctcagaatga	9360
cttggttgag	tactcaccag	tcacagaaaa	gactcttacg	gatggcatga	cagtaagaga	9420
attatgcagt	gctgccataa	ccatgagtga	taacactcgc	gccaacttac	ttctgacaac	9480
gatcggagga	ccgaaggagc	taaccgcttt	tttgcacaa	atgggggatc	atgtaactcg	9540
ccttgatcgt	tggaacccgg	agctgaatga	agccatacca	aacgacgagc	gtgacaccac	9600
gatgcctgca	gcaactggca	caacgttgcg	caactatta	actggcgaa	tacttactct	9660
agcttcccg	caacaattaa	tagactggat	ggaggcggat	aaagtgtcag	gaccacttct	9720
gcgtcggcc	cttcgggctg	gctggtttat	tgctgataaa	tctggagccg	gtgagcgtgg	9780
gtctcgggt	atcattgcag	cactggggcc	agatggtaag	ccctcccgtg	tcgtagttat	9840
ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	agacagatcg	ctgagatagg	9900

tgccctcactg attaagcatt ggtaactgtc agaccaagtt tactcatata tacttttagat 9960
tgatttataaa cttcattttt aatttataaag gatctaggtg aagatccttt ttgataatct 10020
catgacccaaa atcccttaac gtgagttttc gttccactga gcgtcagacc ccgtagaaaa 10080
gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct tgcaaacaaa 10140
aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa ctctttttcc 10200
gaaggttaact ggcttcagca gagegcagat accaaatact gtccttctag tgtagccgta 10260
gttaggccac cacttcaaga actctgtagc accgctaca tacctcgtc tgctaactct 10320
gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accgggttg actcaagacg 10380
atagttaccg gataaggcgc agcggctcgg ctgaacgggg gggttcgtgca cacagcccag 10440
cttggagcga acgacctaca ccgaactgag atacctacag cgtgagctat gagaagcgc 10500
cacgcttccc gaaggagaa aggcggacag gtatccggtg agcggcaggg tcggaacagg 10560
agagcgcacg agggagcttc cagggggaaa cgcctggtat ctttatagtc ctgtcgggtt 10620
tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc ggagcctatg 10680
gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc cttttgtctca 10740
catgttcttt cctgcgttat cccctgatc tgtggataac cgtattaccg cttttgagt 10800
agctgatacc gctgcgcga gccgaacgac cgaggcgagc gagtcagtga gcgaggaagc 10860
ggaagagcgc ctgatgcggg attttctcct tacgcatctg tcgggtattt cacaccgcat 10920
accgctcag aagccataga gccaccgca tccccagcat gcctgctatt gtcttcccaa 10980
tcctccccct tgctgtcctg cccacccca cccccagaa tagaatgaca cctactcaga 11040
caatgcgagt caatttctc attttattag gaaaggacag tgggagtggc acctccagg 11100
gtcaaggaag gcacggggga ggggcaaaac acagatggct ggcaactaga aggcacagtc 11160
gaggctgac agcagctct agcatttagg tgacactata gaatagggcc ctctagatgc 11220
atgctcgagc ggccgcttct ttattcttgg gcaatgtatg aaaaagtgtg agaggatgtg 11280
gcaaatattt cattaatgta gttgtggca gaccagtccc atgaaaatga catagatgat 11340
gcacttgag ttgtgtctcc tgttctctgt gtaccgttta gtgtaattgt tagtgttaca 11400
ggtttagttt tgtctccgtt taagtaact tgactgacaa tgttactttt ggcagtttta 11460
ccgtgagatt ttggataagc tgataggtta ggcataaatc caacagcgtt tgtataggct 11520
gtgccttcag taagatctcc atttctaag ttccaatt ctgggtccag gaaggaattg 11580
tttagtagca ctccattttc gtcaaatct ataataagat gagcactttg aactgttcca 11640
gatattggag ccaactgcc tttaacagcc aaaactgaaa ctgtagcaag tatttgactg 11700
ccacattttg ttaagaccaa agtgagttta gcactttct ctgcatttag tctacagtta 11760
ggagatggag ctggtgtggt ccacaaagt agcttatcat tatttttgtt tctactgta 11820
atggcacctg tgcgtcaaa actaaggcca gttcctagt taggaaccat agccttgtt 11880
gaatcaaatt ctaggccatg gccaatttt gttttgagg gatttgtgtt tgggtgcatta 11940
ggtgaaccaa attcaagccc atctcctgca ttaatggcta tggctgtagc gtcaaacatc 12000
aacccttggc cagtgcctag gttaacctca agctttttg aattgtttga agctgtaaac 12060
aagttaaagg ctttgttga gtttaatatc aggttgggg ctgagtttat aaaaagagg 12120
ccctgtccta gtcttagatt tagttgggtt tgagcatcaa acggataact aacatcaagt 12180
ataaggcgtc tgttttgaga atcaatcctt agtccctctg ctacatgaag ttgcatattg 12240
ccttgtgaat caaaacccaa ggctccagta actttagttt gcaaggaagt attattaata 12300
gtcacacctg caacagttgc tacggtcaaa gcttttaggt cgtctgttac atgcaaaatg 12360
gccccgtact ttagtcctag ttttccattt tgtgtataaa tgggctctt caagtcaatg 12420
cccaagctac cagtggcagt agttagagg ggtgaggcag tgatagtaag ggtactgcta 12480
tcggtgggtg tgagggggcc tgatgtttgc agggctagct tctctctga cactgtgagg 12540
ggtccttggg tggcaatgct aagtttgag tctgtcacgg ttagcggggc ctgtgattgc 12600
atggtgagtg tgttgcgcgc gaccattaga ggtgcggcg cagccacagt tagggcttct 12660
gaggtaaactg tgaggggtgc agatatttcc aggttatgt ttgacttgg ttttttgaga 12720
ggtgggctca cagtgggtac attttgggag gtaagggtgc cggcctcgtc cagagagagg 12780
ccgttgccta ttttggcga aagcatgcca ttggaggtta ctagaggttc ggataggcgc 12840
aaagtagagta cccaggggg actctcttga aacctattg gggatacaaa gggaggagta 12900
agaaaaggca cagttggagg accggtttcc gtgtcatatg gatacacggg gttgaaggt 12960
tcttcagacg gtcttgccgc cttcatcttg gatctcaagc ctgccacacc tcacctcgac 13020
catccgcgct ctaagaccg cctactttaa ttacatcatc agcagcacct ccgccagaaa 13080
caaccccgac cgcacccgc tgccgcccgc cacggtgctc agcctacctt gccacttga 13140
ctggttagac gcctttctcg agaggtttc cgatccggtc gatgcggact cgctcaggtc 13200
cctcgggtggc gtagtaccgt tcggaggccg acgggtttcc gatccaagag tactggaaag 13260
accgcgaaga gtttgcctc aaccgcgagc ccaacagcga gctcgaattc agatccgagc 13320
tcggtaccac gcttgggtct ccttatagtg agtctatta atttcgataa gccagtaagc 13380
agtgggttct ctagttagcc agagagctct gcttatatag acctccacc gtacacgcct 13440
accgcccatt tgcgtcaatg gggcggagtt gttacgacat tttggaaagt cccgttgatt 13500
ttggtgccaa aacaaactcc cattgatgta aatggggtgg agacttgga atccccgtga 13560
gtcaaaccgc tatccacgcc cattgatgta ctgcccacac cgcatcacca tggtaatagc 13620

```

gatgactaat acgtagatgt actgccaagt aggaaagtcc cataagggtca tgtactgggc 13680
ataatgccag gcggggccatt taccgtcatt gacgtcaata gggggcgtag ttggcatatg 13740
atacacttga tgtactgcca agtgggcagt ttaccgtaaa tagtccaccc attgacgtca 13800
atggaaagtc cctattggcg ttactatggg aacatacgtc attattgacg tcaatgggcg 13860
gggggtcggtt ggcggtcagc caggcgggcc atttaccgta agttatgtaa cgcggaactc 13920
catatatggg ctatgaacta atgaccccggt aattgattac tattaataac tagtcaataa 13980
tcaatgtcaa cgcgatatatc tggcccgtag atcgcgaaagc agcgcaaaac gcctaaccct 14040
aagcagattc ttcatgcaat tgtcgggtcaa gccttgccctt gttgtagctt aaattttgct 14100
cgcgccactac tcagcgacct ccaacacaca agcagggagc agatactggc ttaactatgc 14160
ggcatcagag cagattgtac tgagagtcga ccatagggga tcgggagatc tcccgatccg 14220
tctatgggtgc actctcagta caatctgctc tgatgccgca tagttaagcc agtatacact 14280
ccgctatcgc tacgtgactg ggctcatggc gcgccccgac acccgccaac acccgctgac 14340
gcgcccgtgac gggcttgtct gctcccggca tccgcttaca gacaagctgt gaccgtctcc 14400
gggagctgca tgtgtcagag gttttccacc tcataccgca aacgcgcgag gcagc 14455

```

<210> 16

<211> 10610

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 16

```

gacggatcgg gagatccgcg cggtacacag aattcaggag acacaactcc aagtgcatac 60
tctatgtcat tttcatggga ctgggtctggc cacaactaca ttaatgaaat atttgccaca 120
tctctttaca ctttttcata cattgcccac gaataaagaa tcgtttgtgt tatgtttcaa 180
cgtgtttatt tttcaattgc agaaaatttc aagtcatttt tcattcagta gtatagcccc 240
accaccacat agcttatata gatcacgta ccttaatcaa actcacagaa ccctagtatt 300
caacctgcca cctccctccc aacacacaga gtacacagtc ctttctcccc ggctggcctt 360
aaaaagcatc atatcatggg taacagacat attccttaggt gttatattcc acacggtttc 420
ctgtcagacc gcagtggtct cctcagcgat cagtgtatatt aataaactcc cggggcagct cacttaagtt 480
catgtcgtcg tccagctgct gagccacagg ctgctgtcca acttgcggtt gcttaacggg 540
cggcgaaagg gaagtcacag cctacatggg ggtagagtca taatcgtgca tcaggatagg 600
cggttggtgc tgcagcagcg cgcgaaataa ctgctgccgc cgccgctccg tcttcgagga 660
atacaacatg gcagtggtct cctcagcgat ctctcgcacc gcccgagca taaggcgctc 720
tgtctccggg gcacagcagc gcacctgat ctcacttaaa tcagcacagt aactgcagca 780
cagcaccaca atattgttca aaatcccaca gtgcaaggcg ctgtatccaa agctcatggc 840
ggggaccaca gaacccacgt ggccatcata ccacaagcgc aggtagatta agtggcgacc 900
cctcataaac acgttggaac taaacattac ctcttttggc atgttgtaat tcaccacctc 960
ccggtaccat ataaacctct gattaaacat ggcgccatcc accaccatcc taaaccagct 1020
ggccaaaacc tgcccgcggg ctatacactg cagggaaacc ggactggaac aatgacagtg 1080
gagagcccag gactcgtaac catggatcat catgctcgct atgatataa tgttggcaca 1140
acacaggcac acgtgcatac acttctcagc gattacaagc tcttcccgcg ttagaacctc 1200
atcccaggga acaaccatt cctgaatccc cgtaaattcc gttacattcg ggcagcagcg gatgatctc 1320
cacgtaactc acgttgtgca ttgtcaaagt gttacattcg ggcagcagcg gatgatctc 1380
cagtatggta gcgcggtttt ctgtctcaaa aggaggtaga cgatccctac tgtacggagt 1440
gcgccgagac aaccgagatc gtgttggtcg tagtgtcatg ccaaattgga cgccggagct 1500
agtcataatt cctgaagcaa aaccaggtgc gggcgtaga aacagatctg cgtctccggg 1560
ctcgccgctt agatcgctct gtgtagtagt tgtagtatat ccactctctc aaagcatcca 1620
ggcgccccct ggcttcgggt tctatgtaaa ctcttcatg cgccgctgcc ctgataacat 1680
ccaccaccgc agaataagcc acaccagcc aacctacaca ttcggtctgc gagtcacaca 1740
cgggaggagc ggaagagact ggaagaacca tgtttttttt tttattccaa aagattatcc 1800
aaaacctcaa aatgaagatc tattaagtga acgcgctccc ctccggtggc gtggtcaaac 1860
tctacagcca aagaacagat aatggcattt gtaagatggt gcacaatggc ttccaaaagg 1920
caaacggccc tcagtcctcaa gtggacgtaa aggctaaacc cttcagggtg aatctcctct 1980
ataaacatgc cagcaccttc aaataattct catctcgcca cctctcctca 2040
atatctctaa gcaaatcccg aatattaagt ccggccattg taaaaatctg ctccagagcg 2100
ccctccacct tcagcctcaa gcagcgaatc atgattgcaa aaattcaggt tcttcacaga 2160
cctgtataag attcaaaagc ggaacattaa caaaaatacc gcgatcccggt aggtcccttc 2220
gcagggccag ctgaacataa tcgtgcaggt ctgcacggac cagcgcgggc acttcccgcg

```

caggaacctt	gacaaaagaa	cccacactga	ttatgacacg	catactcgga	gctatgctaa	2280
ccagcgtagc	cccgatgtaa	gctttgttgc	atggcgcgcg	atataaaatg	caaggtgctg	2340
ctcaaaaaat	caggcaaaagc	ctcgcgcaaa	aaagaaagca	catcgtagtc	atgctcatgc	2400
agataaaggg	aggtaagctc	cggaaaccacc	acagaaaaag	acaccatttt	tctctcaaac	2460
atgtctgcgg	gtttctgcat	aaacacaaaa	taaaataaca	aaaaaacatt	taaacattag	2520
aagcctgtct	tacaacagga	aaaacaaccc	ttataagcat	aagacggact	acggccatgc	2580
cggcgtgacc	gtaaaaaac	tggtcacctg	gattaaaaag	caccaccgac	agctcctcgg	2640
tcctgtccgg	agtcataatg	taagactcgg	taaaacacatc	aggttgattc	atcggtcagt	2700
gctaaaaagc	gaccgaaata	gcccggggga	atacatacc	gcaggcgtag	agacaacatt	2760
acagccccc	taggaggtat	aacaaaatta	ataggagaga	aaaacacata	aacacctgaa	2820
aaaccctcct	gcctaggcaa	aatagcacc	tcccgtctca	gaacaacata	cagcgcttca	2880
cagcggcagc	ctaaccagtca	gccttaccag	taaaaaagaa	aacctattaa	aaaaacacca	2940
ctcgacacgg	caccagctca	atcagtcaca	gtgtaaaaaa	gggccaagtg	cagagcgagt	3000
atatatagga	ctaaaaaatg	acgtaacggt	taaagtccac	aaaaaacacc	cagaaaaccg	3060
cacgcgaacc	tacgcccaga	aacgaaagcc	aaaaaaccca	caacttcctc	aatcgtcac	3120
ttccgttttc	ccaggttacg	taacttcccg	gatcctctcc	cgatccccta	tggtcgactc	3180
tcagtacaat	ctgctctgat	gccgcatagt	taagccagta	tctgctccct	gcttggtgtg	3240
tggaggtcgc	tgagtagtgc	gcgagcaaaa	tttaagctac	aacaaggcaa	ggcttgaccg	3300
acaattgcat	gaagaatctg	cttaggggta	ggcggtttgc	gctgcttcgc	gatgtacggg	3360
ccagatatac	gcgttgacat	tgattattga	ctagttatta	atagtaatca	attacggggg	3420
cattagttca	tagcccatat	atggagttcc	gcgttacata	acttacggta	aatggcccg	3480
ctggctgacc	gcccacacgac	ccccgcccat	tgacgtcaat	aatgacgtat	gttcccatag	3540
taacgccaat	agggactttc	cattgaecgtc	aatgggtgga	ctatttacgg	taaaactgccc	3600
acttggcagt	acatcaagtg	tatcatatgc	caagtacgcc	ccctattgac	gtcaatgacg	3660
gtaaatggcc	gcctggcatg	tatgccaggt	acatgacctt	atgggacttt	cctacttggc	3720
agtacatcta	cgtattagtc	atcgctatta	ccatggtgat	gcgggttttg	cagtacatca	3780
atgggctggt	atagcggttt	gactcacggg	gatttccaag	tctccacccc	attgacgtca	3840
atgggagttt	gttttggcac	caaaatcaac	gggactttcc	aaaatgtcgt	aacaactccg	3900
ccccattgac	gcaaatgggc	ggtaggcgtg	tacggtggga	ggtctatata	agcagagctc	3960
tctggctaac	tagagaaccc	actgcttact	ggcttatcga	aattaatacg	actcactata	4020
gggagaccga	agcttggtac	cgagctcgga	tctgaattcg	agctcgctgt	tgggctcgcg	4080
gttgaggaca	aactcttcgc	ggtctttcca	gtactcttgg	atcggaaaac	cgtcggcctc	4140
cgaacggtac	tcgcgccacc	agggaaacct	cgagtcgcgc	atcgaccgga	tcggaaaacc	4200
tctcgagaaa	ggcgtctaac	cagtcacagt	cgaaggttag	gctgagcacc	gtggcgggcg	4260
gcagcgggtg	gcggctcggg	ttgtttctgg	cggaggtgct	gctgatgatg	taattaaagt	4320
aggcggctct	gagacggcgg	atggctcagg	tgaggtgtgg	caggcttgag	atccaagatg	4380
aagcgcgcaa	gacggtctga	agataccttc	aaccccggtg	atccatata	cacggaaacc	4440
ggctcctcaa	ctgtgccttt	tcttactcct	ccctttgtat	cccccaatgg	gtttcaagag	4500
agtccccctg	gggtactctc	tttgccctca	tccgaacctc	tagttacctc	caatggcatg	4560
cttgcgctca	aaatgggcaa	cggcctctct	ctggacgagg	ccggcaacct	tacctcccaa	4620
aatgttaacca	ctgtgagccc	acctctcaaa	aaaaccaagt	caaacataaa	cctggaaata	4680
tctgcacccc	tcacagttac	ctcagaagcc	ctcaactgtg	ctgcgcgcgc	acctctaatg	4740
gtcgcgggca	acacactcac	catgcaatca	caggccccgc	taaccgtgca	cgactccaaa	4800
cttagcattg	ccacccaagg	acccctcaca	gtgtcagaag	gaaagctagc	cctgcaaaaca	4860
tcaggccccc	tcaccaccac	cgatagcagt	acccttacta	tcaactgcctc	acccctctca	4920
actactgcc	ctggtagctt	gggcattgac	ttgaaagagc	ccattttatac	acaaaatgga	4980
aaactaggac	taaagtacgg	ggctcctttg	catgtaacag	acgacctaaa	cactttgacc	5040
gtagcaactg	gtccagggtg	gactattaat	aatacttcc	tgcaaaactaa	agttaactgga	5100
gccttgggtt	ttgattcaca	aggcaatatg	caacttaatg	tagcaggagg	actaaggatt	5160
gattctcaaa	acagacgcct	tatacttgat	gttagttatc	cgtttgatgc	tcaaaaccaa	5220
ctaaatctaa	gactaggaca	gggcctctct	tttataaaact	cagcccacaa	cttgatattt	5280
aactacaaca	aaggccttta	cttggtttaca	gcttcaaaaca	attccaaaaa	gcttgagggtt	5340
aacctaaagca	ctgccaaagg	gttgatgttt	gacgctacag	ccatagccat	taatgcagga	5400
gatgggcttg	aatttgggtc	acctaattgca	ccaaacacaa	atcccccaa	aacaaaaatt	5460
ggccatggcc	tagaatttga	ttcaaaacaag	gctatgggtc	ctaaactagg	aactggcctt	5520
agttttgaca	gcacaggtgc	cattacagta	ggaaacaaaa	ataatgataa	gctaactttg	5580
tggaccacac	cagctccatc	tcctaactgt	agactaaatg	cagagaaaaga	tgctaaactc	5640
actttggtct	taacaaaatg	tggcagtcga	atacttgcta	cagtttcagt	tttggctgtt	5700
aaaggcagtt	tggctccaat	atctggaaca	gttcaaaagt	ctcatcttat	tataagattt	5760
gacgaaaaatg	gagtgtact	aaacaattcc	ttcctggacc	cagaatattg	gaactttaga	5820
aatggagatc	ttactgaagg	cacagcctat	acaaacgctg	ttggatttat	gcctaacctc	5880
tcagcttatac	caaaatctca	cggtaaaact	gccaaaagta	acattgtcag	tcaagtttac	5940

ttaaaccggag	acaaaactaa	acctgtaaca	ctaaccatta	cactaaaacgg	tacacaggaa	6000
acaggagaca	caactccaag	tgcatactct	atgtcatttt	catgggactg	gtctggccac	6060
aactacatta	atgaaatatt	tgccacatcc	tcttacactt	tttcatacat	tgcccaagaa	6120
taaagaagcg	gccgctcgag	catgcatcta	gagggcccta	ttctatagt	tcacctaaat	6180
gctagagctc	gctgatcagc	ctcgactgtg	ccttctagt	gccagccatc	tggtgtttgc	6240
ccctcccccg	tgcttctcct	gaccctggaa	gggtgccactc	ccactgtcct	ttcctaataa	6300
aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	gggtgggggtg	6360
gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	ggatgcgggtg	6420
ggctctatgg	cttctgaggg	ggaaagaacc	agctggggct	ctagggggta	tccccacggc	6480
ccctgtagcg	gcgcattaa	cgcgccgggt	gtggtgggta	cgcgacggct	gaccgctaca	6540
cttgccagcg	ccctagcgcc	cgtccttttc	gctttcttcc	cttcttttct	cgccacgttc	6600
gcgggctttc	cccgctcaagc	tctaaatcgg	ggcatccctt	tagggttccg	atttagtgct	6660
ttacggcacc	tcgaccccaa	aaaacttgat	tagggtgatg	gttcacgtag	tggggccatcg	6720
ccctgataga	cgggtttttcg	cccttttgacg	ttggagtoca	cgttctttta	tagtggactc	6780
ttgtttccaaa	ctggaacaac	actcaaccct	atctcggtct	attcttttga	tttataaggg	6840
atatttgggga	tttoggccta	ttggttaaaa	aabgagctga	tttaacaaaa	atttaacggc	6900
aattaattct	gtggaatgtg	tgctcagttag	gggtgtggaa	gtccccaggc	tccccaggca	6960
ggcagaagta	tgcaaagcat	gcattctcaat	tagtcagcaa	ccaggtgtgg	aaagtcccca	7020
ggctccccag	caggcagaag	tatgcaaagc	atgcattctca	attagtcagc	aaccatagtc	7080
ccgccccctaa	ctccgcccat	cccgccccca	actccgccca	gttccgccca	ttctccggcc	7140
catggctgac	taattttttt	tattttatgca	gagggccagg	ccgctctgct	ctctgagcta	7200
ttccagaagt	agtgaggagg	cttttttggga	ggcctaggct	tttgcaaaaa	gctcccggga	7260
gcttgatat	ccatttttcg	atctgatcaa	gagacaggat	gaggatcggt	tcgcatgatt	7320
gaacaagatg	gattgcacgc	aggttctccg	gocgcttggg	tgagagggt	attcggtat	7380
gactgggcac	aacagacaat	cggctgctct	gatcccgccg	tggtccggct	gtcagcgag	7440
gggcgccccg	ttctttttgt	caagaccgac	ctgtccgggt	ccctgaatga	actgcaggac	7500
gaggcagcgc	ggctatcggt	gctggccacg	acgggcggtc	cttgccgcagc	tgtgctcgac	7560
gttgtcactg	aagcgggaag	ggactggctg	ctattgggcg	aagtgcgggg	gcaggatctc	7620
ctgtcatctc	accttgctcc	tgcccgaa	tggtccatca	tggtgatgc	aatgcggcg	7680
ctgcatacgc	ttgatccggc	tacctgcccc	ttcgaccacc	aagcgaaaca	tcgcatcgag	7740
cgagcacgta	ctcggatgga	agccgggtctt	gtcgatcagg	atgatctgga	cgaagagcat	7800
caggggctcg	cgccagccga	actgttcgcc	aggctcaagg	cgccgatgcc	cgacggcgag	7860
gatctcgctg	tgacccatgg	cgatgctctg	ttgcccgaata	tcattggtgga	aaatgcggcg	7920
ttttctggat	tcactgactg	tgccgggctg	gggtgtggcg	accgctatca	ggacatagcg	7980
ttggctaccc	gtgatattgc	tgaagagctt	ggcgccgaat	gggctgaccg	cttctcgtg	8040
ctttacggta	ctgccgctcc	cgattcgcag	cgcctgcctt	tctatcgctt	tcttgacgag	8100
ttcttctgag	cgggactctg	gggttcgaaa	tgaccgacca	agcgacgccc	aacctcgcat	8160
cacgagattt	cgattccacc	gccgccttct	atgaaagggt	gggcttcgga	atcgttttcc	8220
gggacgcggg	ctggatgatc	ctccagcgcg	gggatctcat	gctggagtcc	ttcgccacc	8280
caaacttggt	tattgcagct	tataatgggt	acaaataaag	caatagcatc	acaaatttca	8340
caaaataagc	atttttttca	ctgcatttcta	gttggtgttt	gtccaaactc	atcaatgat	8400
cttatcatgt	ctgtataccg	tcgacctcta	gctagagctt	ggcgtaatca	tggtcatagc	8460
tgtttctctgt	gtgaaattgt	tatccgctca	caattccaca	caacatacga	gccggaagca	8520
taaagtgtaa	agcctggggg	gcctaattgag	tgagctaact	cacattaatt	gcgttgcgct	8580
cactgcccgc	tttccagtcg	ggaaacctgt	cgtgccagct	gcattaatga	atcgcccaac	8640
gcgcggggag	aggcgggttg	cgtattgggc	gctcttccgc	ttctcgtctc	actgactcgc	8700
tgcgctcggt	cgttcggctg	cgccgagcgg	tatcagctca	ctcaaaggcg	gtaatacggg	8760
tatccacaga	atcaggggat	aacgcaggaa	agaacatgtg	agcaaaaggc	cagcaaaagg	8820
ccaggaaccg	taaaaaggcc	gcgttgctgg	cgttttttcca	taggctccgc	ccccctgacg	8880
agcatcacia	aaatcgacgc	tcaagtcaga	gggtggcgaaa	cccagacagga	ctataaagat	8940
accaggcggt	tccccctgga	agctccctcg	tgcgctctcc	tggtccgacc	ctgccgctta	9000
ccggatacct	gtccgccttt	ctcccttcgg	gaagcggtgg	gctttctcaa	tgctcacgct	9060
gtaggtatct	cagttcggtg	taggtcggtt	gctccaagct	gggctgtgtg	cacgaacccc	9120
ccggtcagcc	cgaccgctgc	gccttatccg	gttaactatcg	tcttgagtcc	aaaccggtaa	9180
gacacgactt	atcgccactg	gcagcagcca	ctggttaacag	gattagcaga	gcgagggtatg	9240
tagggcggtg	tacagagttc	ttgaagtgg	ggcctaacta	cggctacact	agaaggacag	9300
tatttggat	ctgcgctctg	ctgaagccag	ttaccttcgg	aaaaagaggt	ggtagctctt	9360
gatccggcaa	acaaaccacc	gctggtagcg	gtggtttttt	tggttgcaag	cagcagatta	9420
cgcgagaaaa	aaaaggatct	caagaagatc	ctttgatctt	ttctacgggg	tctgacgctc	9480
agtgaacga	aaactcacgt	taagggattt	tggtcatgag	attatcaaaa	aggatcttca	9540
cctagatcct	tttaaattaa	aaatgaagtt	ttaaatcaat	ctaaagtata	tatgagtaaa	9600
cttggctctga	cagttacca	tgcttaatca	gtgaggcacc	tatctcagcg	atctgtctat	9660

```

ttcgttcatc catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct 9720
taccatctgg cccagtgct gcaatgatac cgcgagaccc acgctcaccg gctccagatt 9780
tatcagcaat aaaccagcca gccggaaggc ccgagcgagc aagtggtcct gcaactttat 9840
ccgcctccat ccagctctatt aattgttgcc gggagactag agtaagtagt tcgccagtta 9900
atagtttgcg caacgttgtt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg 9960
gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt 10020
tgtgcaaaaa agcgggttagc tcttcggtc ctccgatcgt tgtcagaagt aagttggccg 10080
cagtggtatc actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg 10140
taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc 10200
ggcgaccgag ttgctcttgc ccggcgctcaa tacgggataa tacgcgcgca catagcagaa 10260
ctttaaaagt gctcatcatt ggaaaacggt cttcggggcg aaaactctca aggatcttac 10320
cgctgttgag atccagttcg atgtaaccca ctcggtgcacc caactgatct tcagcatctt 10380
ttactttcac cagcgtttct gggtagagcaa aaacaggaag gcaaaatgcc gcaaaaaagg 10440
gaataaggcg gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa 10500
gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata 10560
aacaatatag gggtccgcgc acatttcccc gaaaagtgc acctgacgtc 10610

```

<210> 17

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 17

tgtagacacgg atccggcgca cacc

24

<210> 18

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 18

cacaacgagc tcaattaatt aattgccaca tcctc

35

<210> 19

<211> 4

<212> PRT

<213> adenovirus

<400> 19

Thr Leu Trp Thr

1

<210> 20

<211> 12

<212> PRT

<213> adenovirus

<400> 20

Pro Ser Ala Ser Ala Ser Ala Ser Ala Pro Gly Ser

1

5

10

<210> 22

<211> 327

<212> DNA

<213> adenovirus

<400> 22

```

agatctgaat tgcagctcgc tgttgggctc gcggttgagg aaaaactctt cgcggtcttt 60
ccagtactct tggatcggaa acccgtcggc ctccgaacgg tactccgcca ccgagggacc 120
tgagcgagtc cgcacgcacc ggatcggaaa acctctcgag aaaggcgtct aaccagtcac 180
agtcgcaagg taggctgagc accgtggcgg gcggcagcgg gtggcggtcg gggttgtttc 240
tgccggaggt gctgctgatg atgtaattaa agtaggcggg cttgagacgg cggatggtcg 300
aggtgaggtg tggcaggctt gagatct 327

```

<210> 23

<211> 32480

<212> DNA

<213> adenovirus

<400> 23

```

catcatcaat aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt 60
ttgtgacgtg gcgcggggcg tgggaacggg gcggttgacg tagtagtgtg gcggaagtgt 120
gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg 180
gtgtgcgcgg gtgtacacag gaagtacaaa ttttcgcgcg gtttttaggcg gatgtttag 240
taaatattggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300
agtgaatctt gaataatttt gtgttactca tagcgcgtaa tctctagcat cgatgtcgac 360
aagcttgaat tgcattaatg tgagttagct cactcattag gcaccccagg ctttacactt 420
tatgcttcgg gctcgatgtg tgtgtggaat tgtgagcggg taacaatttc acacaggaaa 480
cagctatgac catgattacg aattcggcgc agcaccatgg cctgaaataa cctctgaaag 540
aggaaacttg ttaggtacct tctgagggcg aaagaaccag ctgtggaatg tgtgtcagtt 600
aggggtgtgga aagtccccag gctccccagc aggcagaagt atgcaaagca tgcattctca 660
ttagtacgca accaggtgtg gaaagtcccc aggtccccca gcaggcagaa gtatgcaaag 720
catgcatctc aatttagtcag caaccatagt cccgcccta actccgcca tcccgccct 780
aactccgccc agttccgccc attctccgcc ccattggctga ctaatttttt ttatttatgc 840
agaggccgag gccgcctcgg cctctgagct attccagaag tagtgaggag gctttttttg 900
aggctatagg ttttgcacaa agcttgggat ctctataatc tcgcgcaacc tattttcccc 960
tcgaacactt ttttagccgt agataaacag gtgtggacac ttcacatgag cgaaaaatca 1020
atcgtcacct gggacatgtt gcagatccat gcacgtaaac tcgcaagccg actgatgcct 1080
tctgaacaat ggaagggcat tattgcgcta agccgtggcg gtctggtacc ggtgggtgaa 1140
gaccagaaac agcacctcga actgagccgc gatattgccc agcgtttcaa cgcgctgtat 1200
ggcgagatcg atcccgctgt tttacaacgt cgtgactggg aaaaccctgg cgttacccaa 1260
cttaatcgcc ttgcagcaca tccccctttc gccagctggc gtaatagcga agaggcccg 1320
accgatcgcc cttcccaaca gttgcgcagc ctgaatggcg aatggcgctt tgcctggttt 1380
ccggcaccag aagcggtgcc ggaaagctgg ctggagtgcg atcttcttga ggccgatact 1440
gtcagatctc ctcacaactg gcagatgcac cgtgactggg cgcacatcta caccaccaa 1500
acctatccca ttacggtcaa tccgcggttt gttccacagg agaatccgac ggggttgttac 1560
tcgctcacat ttaattgtga tgaaagctgg ctacaggaag gccagacgag aattattttt 1620
gatggcggtt actcggcggt tcatctgtgg tgcaacgggc gctgggtcgg ttacggccag 1680
gacagtcggt tgcgctctga atttgacctg agcgcatttt tacgcgccgg agaaaaccgc 1740
ctcgcggtga tgggtgctgcg ttggagtgcg ggcagttatc tgggaagatca ggatatgtgg 1800
cggatgagcg gcattttccg tgacgtctcg ttgctgcata aaccgactac acaaatcagc 1860
gattttccatg ttgccactcg ctttaattgat gatttcagcc gcgctgtact ggaggctgaa 1920
gttcagatgt gcggcgagtt gcgtgactac ctacgggtaa cagttttctt atggcagggt 1980
gaaacgcagg tcgccagcgg caccgcgcct ttcggcggtg aaattatcga tgagcgtgtg 2040
ggttatgccg atcgcgtcac actacgtctg aacgtcgaaa acccgaaact gtggagcgcc 2100
gaaatcccga atctctatcg tgcggtgggt gaactgcaca ccgccgacgg cagcgtgatt 2160
gaagcagaag cctgcgatgt cggtttccgc gagggtcgga ttgaaaatgg tctgctgtcg 2220
ctgaacggca agccggttgc gattcgaggc gtttaaccgt acgagcatca tccctcagc 2280
ggtcagggtc tggatgagca gacgatgggt caggatatcc tgctgatgaa gcagaacaac 2340
tttaacggcg tgcgctgttc gcattatccg aaccatccgc tgtggtacac gctgtgagc 2400
cgctacggcc tgtatgtggt ggatgaagcc aatattgaaa cccacggcat ggtgccaatg 2460
aatcgtctga ccgatgatcc gcgctggcta ccggcgatga gcgaacgcgt aacgcgaatg 2520
gtgcagcgcg atcgtaatca cccaggtgtg atcatctggt cgctggggaa tgaatcaggc 2580
cacggcgcta atcacgacgc gctgtatcgc tggatcaaat ctgtcgatcc tcccgcgccg 2640
gtgcagtatg aaggcggcgg agccgacacc acggccaccg atattatttg cccgatgtac 2700
gcgcgcgtgg atgaagacca gcccttcccc gctgtgcccga aatggtccat caaaaaatgg 2760

```


ctttcgctac	ctggagagac	gcgcccgtg	atcctttgog	aatacgccca	cgcgatgggt	2820
aacagtcttg	gcggtttcgc	taaatactgg	caggcgtttc	gtcagtatcc	ccgtttacag	2880
ggcggcttcg	tctgggactg	ggtggatcag	togctgatta	aatatgatga	aaacggcaac	2940
ccgtggctcg	cttacggcgg	tgattttggc	gatacgccga	acgatcgcca	gttctgtatg	3000
aacggtctgg	tctttgccga	ccgcacgcgg	catccagcgc	tgacggaagc	aaaacaccag	3060
cagcagtttt	tccagttccg	tttatccggg	caaaccatcg	aagtgaccag	cgaatacctg	3120
ttccgtcata	gcgataacga	gctcctgcac	tggtatggtg	cgctggatgg	taagccgctg	3180
gcaagcgggtg	aagtgcctct	ggatgtcgct	ccacaaggta	aacagttgat	tgaactgcct	3240
gaactaccgc	agccggagag	cgccggggcaa	ctctgggtca	cagtacgcgt	agtgcaccgc	3300
aacgcgaccg	catggtcaga	agccggggcac	atcagcgctt	ggcagcagtg	gcgtctggcg	3360
gaaaacctca	gtgtgacgct	ccccgcccgc	tcccacgcca	tcccgcattt	gaccaccagc	3420
gaaatggatt	tttgcatcga	gctgggtaat	aagcgttggc	aattttaaccg	ccagtccaggc	3480
tttctttcac	agatgtggat	tgggcgataaa	aaacaactgc	tgacgcccgt	gcgcgatcag	3540
ttccaccgtg	caccgctgga	taacgacatt	ggcgtaagtg	aagcgaccgc	cattgacctt	3600
aacgcctggg	tccaacgctg	gaaggcggcg	ggccattacc	aggccgaagc	agcgttggtg	3660
cagtgcacgg	cagatacact	tgctgatcgc	gtgctgatta	cgaccgctca	cgcggtggcag	3720
catcagggga	aaaccttatt	tatcagccgg	aaaaactacc	ggattgatgg	tagtgggtcaa	3780
atggcgatta	ccgttgatgt	tgaagtggcg	agcgatacac	cgcatccggc	gcggatgggc	3840
ctgaactgcc	agctggcgca	ggtagcagag	cggttaactt	ggctcggatt	agggccgcaa	3900
gaaaactatc	ccgaccgcct	tactgccgcc	tgttttgacc	gctgggatct	gccattgtca	3960
gacatgtata	ccccgtacgt	cttcccagagc	gaaaacggtc	tgcgctgcgg	gacgcgcgaa	4020
ttgaattatg	gcccacacca	gtggcgcggc	gacttccagt	tcaacatcag	ccgctacagt	4080
caacagcaac	tgatggaaac	cagccatcgc	catctgctgc	acgcggaaga	aggcacatgg	4140
ctgaatatcg	acggtttcca	tatggggatt	ggtagcgacg	actcctggag	cccgctcagt	4200
tccgcggaat	tccagctgag	cgccgggtcgc	taccattacc	agttggctcg	gtgtcaaaaa	4260
taataataac	cgggcaggcc	atgtctgccc	gtatttcgcg	taaggaaatc	cattatgtac	4320
tatttaaaaa	acacaaactt	ttggatgttc	ggtttattct	ttttctttta	cttttttate	4380
atgggagcct	acttcccgtt	tttcccgtat	ttgctacatg	acatcaacca	tatcagcaaa	4440
agtatacgg	gtattatatt	tgccgctatt	tctctgttct	cgctattatt	ccaaccgctg	4500
tttggctctg	tttctgacaa	actcggaaact	tgtttattgc	agcttataat	ggttacaaat	4560
aaagcaaat	ctcacaaat	ttcacaaata	aagcattttt	ttcactgcat	tctagttgtg	4620
gtttgtccaa	actcatcaat	gtatcttata	cttatctggat	ccagatctgg	gcgtggctta	4680
aggttgggaa	agaatatata	aggtgggggt	cttatgtagt	tttgtatctg	ttttgcagca	4740
gccgcccgcg	ccatgagcac	caactcgttt	gatggaagca	ttgtgagctc	atatttgaca	4800
acgcgcctgc	ccccatgggc	cggggtgcgt	cagaatgtga	tgggctccag	cattgatggg	4860
cgcccgcctc	cgcccgcgaa	ctctactacc	ttgacctacg	agaccgtgtc	tggaaacggc	4920
ttggagactg	cagcctccgc	cgccgcttca	gccgctgcag	ccaccgcccg	cggttatgtg	4980
actgactttg	ctttcctgag	cccgccttga	agcagtgacg	cttcccgttc	atccgcccgc	5040
gatgacaagt	tgacggctct	tttggcacia	ttggattctt	tgaccgggga	acttaagtgc	5100
gtttctctat	gtctgttggg	tctgcgccag	caggtttctg	ccctgaaggc	ttctccctct	5160
cccaatgcgg	ttttaaaccat	aaataaaaaa	ccagactctg	tttggatttg	gatcaagcaa	5220
gtgtcttctg	gtctttatatt	aggggttttg	cgcgccgggt	aggcccggga	ccagcggctt	5280
cggtcgttga	gggtcctgtg	tattttttcc	aggacgtggg	aaaggtgact	ctggatgttc	5340
agatacatgg	gcataagccc	gtctctgggg	tgagagtgag	accactgcag	agcttcacgc	5400
tgccgggttg	tggtgtagat	gatccagctg	tagcaggagc	gctgggcgtg	gtgcctaaaa	5460
atgtctttca	gtagcaagct	gattgccagg	ggcaggccct	tggtgttaag	gtttacaaag	5520
cggttaagct	gggatgggtg	catacgtggg	gatatgagat	gcattcttga	ctgtattttt	5580
aggtttggcta	tgttcccagc	catatccctc	cggggattca	tggtgtgcag	aaccaccagc	5640
acagtgtatc	cggtgcactt	gggaaatttg	tcatgtagct	tagaaggaaa	tgctgtggaag	5700
aacttggaga	cgcccttgtg	acctccaaga	ttttccatgc	attcgtccat	aatgatggca	5760
atgggcccac	gggcggcggc	ctgggcgaag	atatttcttg	gatcactaac	gtcatagtgt	5820
tggtccagga	tgagatcgct	ataggccatt	tttacaagag	gcgggcggag	gggtgccagac	5880
tgccgtataa	tggttccatc	cggcccaggg	gcgtagttac	cctcacagat	ttgcattttc	5940
cacgctttga	gttcagatgg	ggggatcatg	tctacctgcg	gggcgatgaa	gaaaacgggt	6000
tccggggtag	gggagatcag	ctgggaagaa	agcaggttcc	tgagcagctg	cgacttacgc	6060
cagccgggtg	gcccgtaaat	cacacctatt	accgggtgca	actggtagtt	aagagagctg	6120
cagctccgct	catccctgag	cagggggccc	acttcgttaa	gcatgtccct	gactgcacag	6180
ttttccctga	ccaaatccgc	cagaaggcgc	tcgcccgcga	gcgatagcag	ttcttgcaag	6240
gaagcaaat	ttttcaacgg	tttgagaccg	tccgcgtag	gcatgctttt	gagcgtttga	6300
ccaagcagtt	ccaggcggtc	ccacagctcg	gtcacctgct	ctacggcatc	tcgatccagc	6360
atatctcctc	gttttcgctg	ttggggcgcc	tttcgctgta	cggcagtagt	cggtgctcgt	6420
ccagacgggc	cagggtcatg	tctttccacg	ggcgccagggt	cctcgtcagc	gtagtctggg	6480

tcaagggtgaa gggggtgagct ccggggtgag cgtgggagc ggtgagcgtt aggcgtggtcc 6540
tgctgggtgct gaagcgctgc cgggtcttcgc cctgagcgtc ggccaggtag catttgacca 6600
tggtgtcata gtccagcccc tccgagcgtt ggcccttggt gcgcagcttg cccttgagg 6660
aggcgccgca cgaggggagc tgcagacttt tgaggcgta gagcttggtc gcgagaaata 6720
ccgattccgg ggagtaggca tccgagcgcg agggcccgca gacgggtctc cattccacga 6780
gccaggtgag ctctggccgt tcgggggtcaa aaaccaggtt tcccccatgc tttttgatgc 6840
gtttctttacc tctgggttcc atgagccggt gtccacgctc ggtgacgaaa aggcgtgtccg 6900
tgtccccgta tacagacttg agaggcctgt cctcgagcgg tgttccgagg ggccagcacg aaggaggcta 7020
atagaaactc ggaccactct gtagcggctc ttgtccacta ggggggtccac tcgctccagg gtgtgaagac 7080
acatgtcgcc ctcttcggca tcaaggaagg tgattgggtt gtaggtgtag gccacgtgac 7140
cgggtgttcc tgaagggggg ctataaaagg ggggtggggc gcgttcgtcc tccactctctt 7200
ccgcatcgct gtctgagagg gccagctggt ggggtgagta ctccctctga aaagcgggca 7260
tgacttctgc gctaagattg tcagtttcca aaaacgagga ggatttgata ttcacctggc 7320
ccgcggtgat gcctttgagg gtggcgcgat ccactctggtc agaaaagaca atctttttgt 7380
tgtcaagctt ggtggcaaac gaccgtaga gggcggttga cagcaacttg gcgtagtagc 7440
gcaggggttg gttttgtcgc cgatcgccgc gctccttggt cgcgatgttt agctgcacgt 7500
attcgccgag aacgcaccgc cattcgggaa agacgggtgt gcgctcgtcg ggcaccaggt 7560
gcacgcgcca accgcgggtg tgcaggggtg caaggtcaac gctgggtggct acctctccgc 7620
gtaggcgctc ttgggtccag cagagggcgg cggccttgct cgagcagaat ggcggtaggg 7680
ggtctagctg cgtctcgtcc ggggggtctg cgtccacggt aaagaccccg ggccagcaggc 7740
gcgcgtcgaa gtagtctatc ttgcatcctt gcaagtctag cgctcgtcgc catgcgcggg 7800
cggcaagcgc gcgctcgtat ggggttagtg ggggacccca tggcatgggg tgggtgagcg 7860
cggaggcgta atgcccga atgctgtaaa ctctctgagt attccaagat 7920
atgtagggtg gcatcttcca ccgcggatgc tggcgcgcac gtaatcgtat agtctgtgag 7980
agggagcgag gaggtcggga ccgaggttgc tacgggaggc ctgctctgct cggaagacta 8040
tctgcctgaa gatggcatgt gagttggatg atattggttg acgctggaag acgttgaagc 8100
tggcgctcgt gagacctacc gcgtcacgca cgaaggaggc gtaggagtcg cgcagcttgt 8160
tgaccagctc gggcggtgacc tgcacgtcta ggcgcagta gtccaggggt tcccttgatga 8220
tgtcatactt atcctgtccc ttttttttcc acagctcgcg gttgaggaca aactcttcgc 8280
ggtctttcca gtactcttgg atcggaaacc cgtcggcctc cgaacggtaa gagcctagca 8340
tgtagaactc gttgacggcc tggtaggcgc agcatccctt ttctacgggt agcgcgtatg 8400
cctgcgcggc ctcccgagc gaggtgtggg gtagcgcaaa ggtgtccctg accatgactt 8460
tgaggtagtg gtatttgaag tcagtgtcgt cgcctccgag ctgctcccag agcaaaaagt 8520
ccgtgcgctt tttggaacgc ggatttggca gggcggaagg gacatcggtg aagagtatct 8580
ttccgcgcgc aggcataaag ttgctgttga tgcggaaggg tcccggcacc tcggaacggt 8640
tgttaattac ctgggcggcg agcacgatct agcacaagcc gttgatgttg tggcccacaa 8700
tgtaaagtcc caagaagcgc gggatgccct tgatggaagg caatttttta agttcctcgt 8760
aggtgagctc ttcaggggag ctgagcccggt gctctgaaag ggcccagctc gcaagatgag 8820
ggttggaaag gacgaatgag ctccacaggt caccgggcat tagcatttgc aggtgggtcgc 8880
gaagagctct aaactggcga cctatggcca ttttttctgg ggtgatgcag tagaaggtta 8940
gcgggtcttg tcccagcggc tcccatccaa ggttcgcggc taggtctcgc gcggcagta 9000
ctagaggctc atctccgccc aacttcatga ccagcatgaa gggcacgagc tgcttcccaa 9060
aggccccatc ccaagtatag gtctctacat cgtaggtgac aaagagacgc tcgggtgcgag 9120
gatgcgagcc gatcggaag aactggatct cccgcacca attggaggag tggctattga 9180
tgtggtgaaa gtagaagtcc ctgcgacggg ccgaacactc gtgctggctt ttgtaaaaac 9240
gtgcgcagta ctggcagcgg tgcacgggct gtacatcctg cagaggttg acctgacgac 9300
cgcgcaaaag gaagcagagt ggggaatttga gcccctcgcc tggcggggtt ggctgggtgt 9360
gttctacttc ggctgctgt ccttgaccgt ctgggtgctc gaggggagtt acggtggatc 9420
ggaccaccac gccgcgcgag agatgtccgc gcgcggcggt cggagcttga 9480
tgacaacatc gcgcagatgg gagctgtcca tgggtctggag ctcccgcggc gtcaggctag 9540
gcgggagctc ctgcaggttt acctcgcata gacgggtcag ggcgcgggct agatccaggt 9600
gatacctaata ttcagggggc tgggttggtg ggcgctcgat ggcttgcaag aggcgcgcat 9660
ccgcgcggcg gactacgcta ccgcggcgcg ggcgggtggc cgcgggggtg tcccttgatg 9720
atgcatctaa aagcgggtgac gggggcgagc ccccgagggt aggggggggt ccggacccgc 9780
cgggagaggg ggcaggggca cgtcggcgcc gcgcgcgggc aggagctggt gctgcgcgcg 9840
taggttgctg gcgaacgcga cgacgcggcg gttgatctcc tgaatctggc gcctctgcgt 9900
gaagacgacg ggcgggtg gacttgagct gaaagagagt tgcacagaat caatttcggt 9960
gtcgttgacg gcggcctggc gcaaaatctc cgtcacgtct cctgagttgt cttgataggc 10020
gatctcgccc atgaactgct cgatctcttc ctctggaga tctccgctc cggtctgcctc 10080
cacgggtggc gcgaggtcgt tggaaatcg ggcctagagc tgcgagaagg cggttagggc 10140
tccctcgttc cagacgcggc tgtagaccac gccccttcg gcacgcggg cgcgcagtag 10200

cacctgcgcg	agattgagct	ccacgtgccg	ggcgaagacg	gcgtagtttc	gcaggcgctg	10260
aaagaggtag	ttgaggggtg	tggcggtgtg	ttctgccacg	aagaagtaca	taaccacagc	10320
tcgcaacgtg	gattcggtga	tatcccccaa	ggcctcaagg	cgctccatgg	cctcgtagaa	10380
gtccacggcg	aagttgaaaa	actgggagtt	gcgcgcgcac	acggttaact	cctcctccag	10440
aagacggatg	agctcggcga	cagtgtcgcg	cacctcgcg	tcaaaggcta	caggggcctc	10500
ttcttcttct	tcaatctcct	cttcataaag	ggcctcccct	tcttcttctt	ctggcgcgcg	10560
tgggggaggg	gggacacggc	ggcgacgacg	gcgcacgggg	aggcggtcga	caaagcgctc	10620
gatcatctcc	ccgcggcgac	ggcgcatggt	ctcggtgacg	gcgcggccgt	tctcgcgggg	10680
gcgcagttgg	aagacgcgcg	ccgtcatgtc	ccggttatgg	gttggcgggg	ggctgccatg	10740
ggcgagggat	acggcgctaa	cgatgcatct	caacaattgt	tgtgtaggta	ctccgcgcgc	10800
cagggaacctg	agcgagtccg	catcgaccgg	atcggaaaaa	ctctcgagaa	aggcgtctaa	10860
ccagtcacag	tcgcaaggta	ggctgagcac	cgtggcgggc	ggcagcgggc	ggcggtcggg	10920
gttgtttctg	gcggaggtgc	tgtgatgat	gtaattaaag	taggcggtct	tgagacggcg	10980
gatggtcgac	agaagcacca	tgtccttggg	tccggcctgc	tgaatgcgca	ggcggtcggc	11040
catgccccag	gcttcggttt	gacatcggcg	caggtctttg	tagtagtctt	gcatagacct	11100
ttctacccgg	acttcttctt	ctccttcttc	ttgtcctgca	tctcttgcat	ctatcgcggtc	11160
ggcgggcgcg	gagtttgccc	gtaggtggcg	ccctcttctc	cccatgcgtg	tgaccctcgaa	11220
gccccctcat	ggctgaagca	gggctaggtc	ggcgacaacg	cgctcggcta	atatggcctg	11280
ctgcacctgc	gtgagggtag	actggaagtc	atccatgtcc	acaaagcggt	ggtagtcgccc	11340
cgtgttgatg	gtgtaagtgc	agttggccat	aacggaccag	ttaacggtct	ggtgaccggg	11400
ctgcgagagc	tcggtgtacc	tgagacgcga	gtaagccctc	gagtcaaaata	cgtagctcgtt	11460
gcaagtccgc	accaggtact	ggtatcccac	caaaaagtgc	ggcgggcggt	ggcggtagag	11520
ggggcagcgt	agggtggcgg	gggctccggg	ggcgagatct	tccaacataa	ggcgatgata	11580
tccgtagatg	tacctggaca	tcagggtgat	gccggcgggc	gtggtggagg	cgcgcgaaaa	11640
gtcgcgagac	cggttccaga	tgttgcgag	cgcgaaaaaag	tgctccatgg	tcgggctcgtt	11700
ctggccggtc	aggcgcgcg	aatcgttgac	gctctagacc	gtgcaaaaag	agagcctgta	11760
agcgggcact	cttccgtggt	ctggtggata	aattcgcaag	ggtatcatgg	cggacgaccg	11820
gggttccgag	cccgtatccg	gcgctccgcc	gtgatccatg	cggttaccgc	cccgctgtcg	11880
aaaccaggtg	tgcgacgtca	gacaacgggg	gagtgctcct	tttggtctcc	ttccagctcg	11940
ggcggtgctg	gcgctagctt	ttttggccac	tggccgcgcg	cagcgtaagc	ggttaggctg	12000
gaaagcgaaa	gcattaagtg	gctcgtctcc	tgtagccgga	gggttatttt	ccaaggggtg	12060
agtcgcggga	ccccgggttc	gagtcctcgga	ccggccggac	tgccggcgaa	gggggttttg	12120
ctccccgtca	tgcaagacct	cgcttgcaaa	ctcctccgga	aacagggaag	agcccccttt	12180
ttgcttttcc	cagatgcac	cggtgctgcg	gcagatgcgc	ccccctctc	agcagcgcca	12240
agagcaagag	cagcggcaga	catgcagggc	accctcccct	cctcctaccg	cgtcaggagg	12300
ggcgacatcc	gcggttgacg	cggcagcaga	tggtgattac	gaacccccgc	ggcgccgggc	12360
ccggcactac	ctggacttgg	aggagggcga	gggcttgccg	cggctaggag	cgccctctcc	12420
tgagcggtac	ccaaggtg	agctgaagcg	tgatacgctg	gaggcgtagc	tgcccgggca	12480
gaacctgttt	cgcgaccgcg	agggagagga	gcccagaggag	atgcgggatc	gaaagttcca	12540
cgcagggcgc	gagctgcggc	atggcctgaa	tcgcgagcgg	ttgctgcgcg	aggaggactt	12600
tgagcccgac	ggcggaaccg	ggattagtcc	cgcgcgcgca	cacgtggcgg	ccgcccacct	12660
ggtaaccgca	tacgagcaga	cggtgaacca	ggagattaac	tttcaaaaaa	gctttaacaa	12720
ccacgtgcgt	acgcttgtgg	cgcgcgagga	ggtggctata	ggactgatgc	atctgtggga	12780
ctttgtaagc	gcgctggagc	aaaacccaaa	tagcaagccg	ctcatggcgc	agctgttctc	12840
tatagtgcag	cacagcaggg	acaacgaggg	attcagggat	gcgctgctaa	acatagtaga	12900
gcccaggggc	cgctggctgc	tcgatttgat	aaacatcctg	cagagcatag	tgggtgcagg	12960
gcgcagcttg	agcctggctg	acaaggtggc	cgccatcaac	tattccatgc	ttagcctggg	13020
caagttttac	gcccgcgaag	tataccatac	cccttacgtt	cccatagaca	aggaggtaaa	13080
gatcgagggg	ttctacatgc	gcatggcgct	gaaggtgctt	accttgagcg	acgacctggg	13140
cgtttatcgc	aacgagcgca	tcacaaagcg	cgtgagcgtg	agccggcgcg	gcgagctcag	13200
cgaccgcgag	ctgatgcaca	gcctgcaaa	ggccttggtc	ggcacgggca	gcggcgatag	13260
agagggccgag	tcctactttg	acgcggcgcg	tgacctgcgc	tgggccccaa	gccgacgcgc	13320
cctggaggca	gctggggccg	gacctgggct	ggcggtggca	cccgcgcgcg	ctggcaacct	13380
cggcggcgtg	gaggaatatg	acgaggacga	tgagtacgag	ccagaggacg	gcgagtagta	13440
agcggtgatg	tttctgatca	gatgatgcaa	gacgcaacgg	acccggcggt	gcggggcgcg	13500
ctgcagagcc	agccgtccgg	ccttaactcc	acggacgact	ggcgccaggt	catggaccgc	13560
atcatgtcgc	tgactgcgcg	caatcctgac	gcgttccggc	agcagccgca	ggccaaccgg	13620
ctctccgcaa	ttctggaagc	ggtggtccc	gcgcgcgcaa	accccacgca	cgagaaggtg	13680
ctggcgatcg	taaacgcgct	ggccgaaaac	agggccatcc	ggcccgacga	ggccggcctg	13740
gtctacgacg	cgctgcttca	gcgcgtggct	cgttacaaca	gcggcaacgt	gcagaccaac	13800
ctggaccggc	tgggtggggg	tgtgcgcgag	gcccgtggcg	agcgtgagcg	cgcgacgacg	13860
cagggaacc	tgggctccat	ggttgacta	aacgccttcc	tgagtacaca	gcccgcgaac	13920

gtgcccgcggg	gacaggagga	ctacaccaac	tttgtgagcg	caactgcccgt	aatgggtgact	13980
gagacacccg	aaagtgaggt	gtaccagtct	gggcccagact	atctttttcca	gaccagtaga	14040
caaggcctgc	agaccgtaaa	cctgagccag	gcttttcaaaa	acttgccagg	gctgtggggg	14100
gtgcccgcctc	ccacaggcga	cgcgcgcgacc	gtgtctagct	tgctgacgcc	caactcgcgc	14160
ctgttgctgc	tgctaatagc	gcccttcacg	gacagtggca	gcgtgtccc	ggacacatac	14220
ctaggtcact	gtctgacact	gtaccgcgag	gccataggtc	aggcgcagtg	ggacgagcat	14280
actttccagg	agattacaag	tgctagccgc	gcgctggggc	aggaggacac	gggcagcccg	14340
gaggcaaccc	taaaactacct	gctgaccaac	cggcggcgaga	agatcccctc	gttgccacagt	14400
ttaaacagcg	aggaggagcg	cattttgcgc	tacgtgcagc	agagcgtgag	ccttaacctg	14460
atgcgcgacg	gggtaacgcg	cagcgtggcg	ctggacatga	ccgcgcgcgaa	catggaaccg	14520
ggcatgtatg	cctcaaaccg	gccgtttatc	aaccgcctaa	tggaactactt	gcactcgcgcg	14580
gccgcgctga	accccgagta	tttcaccaat	gccatcttga	acccgcactg	gctaccgccc	14640
cctggtttct	acaccggggg	attcgcaggtg	cccagagggtg	acgatggatt	cctctggggac	14700
gacatagacg	acagcgtgtt	ttccccgcaa	ccgcagaccc	tgctagagtt	gcaacagcgc	14760
gagcaggcag	aggcggcgct	gcgaaaaggaa	agcttccgca	ggccaagcag	cttgtccgat	14820
ctaggcgctg	cggccccgcg	gtcagatgct	agtagcccat	ttccaagcct	gatagggctc	14880
cttaccagca	ctcgcaccac	ccgcgccgcg	ctgctggggc	aggaggagta	cctaaacaac	14940
tcgctgctgc	agccgcagcg	cgaaaaaaac	ctgcctccgg	catttcccaa	caacgggata	15000
gagagcctag	tgacaagat	gagtagatgg	aagacgtacg	cgcaggagca	cagggacgtg	15060
ccaggcccg	gcccgcccac	ccgtcgtcaa	aggcacgacc	gtcagcgggg	tctgggtgtg	15120
gaggacgatg	actcggcaga	cgacagcagc	gtcctggatt	tgaggaggag	tggaaccccg	15180
tttgccgacc	ttcgccccag	gctggggaga	atgtttttaa	aaaaaaaaaag	catgatgcaa	15240
aataaaaaaac	tcaccaaggc	catggcaccg	agcgttgggt	ttctgttatt	ccccttagta	15300
tgccgcgcgc	ggcgatgtat	gaggaagggtc	ctcctccctc	ctacgagagt	gtggtgagtg	15360
cggcgccaggt	ggcgccggcg	ctgggttctc	ccttcgatgc	tcccctggac	ccgccgtttg	15420
tgccctccgcg	gtacctgcgg	cctaccgggg	ggagaaacag	catccgttac	tctgagttgg	15480
caccctctatt	cgacaccacc	cgtgtgtacc	tggtggacaa	caagtcaacg	gatgtggcat	15540
ccctgaacta	ccagaacgac	acacagacca	ttctgaccac	ggtcattcaa	aacaatgact	15600
acagcccggg	ggaggcaagc	cataccaaca	tcaatcttga	cgaccggtcg	cactggggcg	15660
gcgacctgaa	aaccatcctg	atggtgtcgc	tgccaaatgt	gaacgagttc	atgtttacca	15720
ataagttaa	ggcgccgggtg	gcttgccctac	taaggacaat	taaggacaat	caggtggagc	15780
tgaaatacga	gtgggtggag	ccgagggcaa	ctactccgag	accatgacca	accatgacca	15840
tagaccttat	gaacaacgcg	actacttgaa	agtgggcaga	cagaacgggg	cagaacgggg	15900
ttctggaaag	cgacatcggg	gtaaaagttg	acaccgcgaa	cttcagactg	gggtttgacc	15960
ccgtcactgg	tcttgtcatg	cctgggggat	atacaaacga	agccttccat	ccagacatca	16020
ttttgtctgc	gtggacttca	ccacagccg	cctgagcaac	ctgagcagac	ttgttgggca	16080
tccgcaagcg	gcaacccttc	caggagggtc	ttaggatcac	ctacgatgat	ctggagggtg	16140
gtaacattcc	cgcactgttg	gatgtggacg	cctaccaggc	gagcttgaaa	gatgacaccg	16200
aacaggggcg	gggtggcgca	ggcggcgagca	acagcagttg	cagcggcgcg	gaagagaact	16260
ccaacgcggc	agccgcggca	atgcagccg	tgaggagcat	gaacgatcat	gccattccgc	16320
gcgacacctt	tgccacacgg	gctgaggaga	agcgcgctga	ggccgaagca	gcggccgaag	16380
ctgccgcccc	cgctgcgcaa	cccagggtcg	agaagcctca	gaagaaaccg	gtgatcaaac	16440
ccctgacaga	ggacagcaag	aaacgcagtt	acaacctaat	aagcaatgac	agcaccttca	16500
cccagatccg	cagctggtag	cttgcataca	actacggcga	ccctcagacc	ggaatccgct	16560
catggaccct	gctttgcact	cctgacgtaa	cctcgggctc	ggagcagggtc	tactggtcgt	16620
tgccagacat	gatgcaagac	cccgtgacct	tccgctccac	gcgccagatc	agcaactttc	16680
cgggtgggtgg	cgccgagctg	ttgcccgctg	actccaagag	cttctacaac	gaccaggccg	16740
tctactccca	actcatccgc	cagtttacct	ctctgaccca	cgtgttcaat	cgctttcccg	16800
agaaccagat	tttgccgcgc	ccgccagccc	ccaccatcac	caccgtcagt	gaaaacgttc	16860
ctgctctcac	agatcacggg	acgctaccgc	tgccgaacag	catcggaggga	gtccagcgag	16920
tgaccattac	tgacgccaga	cgccgcacct	gcccctacgt	ttacaaggcc	ctgggcatag	16980
tctcgcccg	cgctcctatcg	agccgcactt	tttgagcaag	catgtccatc	cttatatcgc	17040
ccagcaataa	cacaggctgg	ggcctgcgct	tcccaagcaa	gatgtttggc	ggggccaaga	17100
agcgtccga	ccaacaccca	gtgcgcgtgc	gcgggcacta	ccgcgcgcgc	tgggggcgcg	17160
acaaacgcgg	ccgcactggg	cgcaccaccg	tcgatgacgc	catcgacgcg	gtggtggagg	17220
aggcgcgcaa	ctacacgccc	acgcgcgccac	cagtggtccac	agtggacgcg	gccattcaga	17280
ccgtgggtgc	cggagcccg	cgctatgcta	aaatgaagag	acggcggagg	cgcgtagcac	17340
gtcgccaccg	ccgcgcaccc	ggcactgcgc	cccaacgcgc	ggcggcgccc	ctgcttaacc	17400
gcgcacgtcg	caccggccga	cggggcgcca	tgccggccgc	tcgaaggctg	gccgcgggta	17460
ttgtcactgt	gccccccagg	tccaggcgac	gagcggccgc	cgcagcagcc	gcggccatta	17520
gtgctatgac	tcagggtcgc	aggggcaacg	tgtattgggt	gcgcgactcg	gttagcggcc	17580
tgccgcgtg	cgtgcgcacc	cgcccccg	gcaactagat	tgcaagaaaa	aactacttag	17640

actcgtactg	ttgtatgtat	ccagcggcgg	cggcgcgcaa	cgaagctatg	tccaagcgca	17700
aaatcaaaga	agagatgctc	caggtcatcg	cgccggagat	ctatggcccc	cgaagaagg	17760
aagagcagga	ttacaagccc	cgaaagctaa	agcgggtcaa	aaagaaaaag	aaagatgatg	17820
atgatgaact	tgacgacgag	gtggaactgc	tgcacgctac	cgcgcccagg	cgacgggtac	17880
agtggaaaag	tcgacgcgta	aaacgtgttt	tgcgaccggy	caccaccgta	gtctttacgc	17940
ccggtgagcg	ctccaccgcg	acctacaagc	gcgtgtatga	tgaggtgtac	ggcgacgagg	18000
acctgcttga	gcaggccaac	gagcgctctg	gggagtttgc	ctacggaaaag	cggcataagg	18060
acatgctggc	gttgccgctg	gacgagggca	acccaacacc	tagcctaaag	cccgtaacac	18120
tgcagcaggt	gctgcccgcg	cttgacaccgt	ccgaagaaaa	gcgcggccta	aagcgcgagt	18180
ctgggtgactt	ggcaccacc	gtgcagctga	tggtagccaa	gcgcagcgca	ctggaagatg	18240
tcttggaaaa	aatgaccgtg	gaacctgggc	tggagcccga	ggtccgctg	cggccaatca	18300
agcaggtggc	gcccgggactg	ggcgtgcaga	ccgtggacgt	tcagataccc	actaccagta	18360
gcaccagtat	tgccaccgcc	acagagggca	tggagacaca	aacgtccccg	gttgccctcag	18420
cggtggcgga	tgccgcggtg	caggcggtcg	ctgcggccgc	gtccaagacc	tctacggagg	18480
tgcaaacgga	ccctgggatg	tttcgcgttt	cagcccccg	gcgcgcgcgc	ggttcgagga	18540
agtacggcgc	cgccagcgcg	ctactgcccc	aatahgccct	acatccttcc	attgcgccta	18600
ccccgggcta	tcgtggctac	acctaccgcc	ccagaagacg	agcaactacc	cgacgcccga	18660
ccaccactgg	aaccgcggcg	cgccgtcgcc	gtcgccagcc	cgtgctggcc	ccgatttccg	18720
tcgcaggggt	ggctcgcaaa	ggagggcagga	ccctgggtgt	gccaacagcg	cgctaccacc	18780
ccagcatcgt	ttaaaaagccg	gtctttgtgg	ttcttgca	tatggccctc	acctgcgcgc	18840
tccgtttccc	ggtgccggga	ttccgaggaa	gaatgcaccg	taggaggggc	atggccggcc	18900
acggcctgac	gggcggcatg	cgctcgcgcg	accaccggcg	gcggcgcgcg	tcgcaccgtc	18960
gcctgcgcgg	cggtatcctg	ccccctctta	ttccactgat	cgccgcggcg	attggcgccg	19020
tgcccggaat	tgcatccgtg	gccttgccag	cgagagaca	ctgattaaaa	acaagttgca	19080
tgtgaaaaaa	tcaaaataaa	aagtctggac	tctcacgctc	gcttggtcct	gtaactattt	19140
tgtagaatgg	aagacatcaa	ctttgcgtct	ctggccccgc	gacacggctc	gcgcccgttc	19200
atgggaaact	ggcaagatat	cggcaccagc	aatatgagcg	gtggcgccct	cagctggggc	19260
tcgctgtgga	gcggcattaa	aaatttcggt	tcaccgctta	agaactatgg	cagcaaggcc	19320
tggaaacagca	gcacaggcca	gatgctgagg	gataagttga	aagagcaaaa	tttcccaaaa	19380
aaggtggtag	atggcctggc	ctctggcatt	agcggggtgg	tggacctggc	caaccaggca	19440
gtgcaaaaata	agattaaacag	taagcttgat	ccccgccttc	ccgtagagga	gcctccaccg	19500
gocgttgaga	cagtgtctcc	agagggcggt	ggcgaaaaag	gtccgcgcgc	cgacagggga	19560
gaaactctgg	tgacgcaaat	agacgagcct	ccctcgtagc	aggaggcact	aaagcaaggc	19620
ctgcccacca	cccgtcccat	cgcgcccag	gctaccggag	tgctgggcca	gcacacacc	19680
gtaacgctgg	acctgcctcc	ccccgcggac	accagcaga	aacctgtgct	gccaggcccg	19740
accgcggttg	ttgtaaccgc	tcctagccgc	gcgtccctgc	gcccgcgcgc	cagcggtccg	19800
cgatcggtgc	ggcccgtagc	cagtggcaac	tggcaaacga	cactgaacag	catcggggt	19860
ctgggggtgc	aatccctgaa	gcgcccagca	tgcttctgaa	tagctaacgt	gtcgtatgtg	19920
tgtcatgtat	gcgtccatgt	cgcgcccaga	ggagctgtg	agccgcgcgc	cgcccgttt	19980
ccaagatggc	tacccttctg	atgatgcgcg	agtggtctta	catgcacatc	tcggggcagg	20040
acgcctcgga	gtactgtgag	cccgggctgg	tgagtttgc	cgcgcccacc	gagacgtact	20100
tcagcctgaa	taacaagttt	agaaacccca	cgggtggcgcc	tacgcacgac	gtgaccacag	20160
accgggtccca	gcgtttgacg	ctgcggttca	tcctgtgga	ccgtgaggat	actgcgtact	20220
cgtacaaggc	gcggttcacc	ctagctgtgg	gtgataaccg	tgtgctggac	atggcttcca	20280
cgtactttga	catccgcggc	gtgctggaca	ggggccctac	ttttaagccc	tactctggca	20340
ctgcctacaa	cgccctggct	cccaagggtg	ccccaaatcc	ttgcgaatgg	gatgaagctg	20400
ctactgctct	tgaataaaac	ctagaagaag	aggacgatga	caacgaagac	gaagtagacg	20460
agcaagctga	gcagcaaaaa	actcacgtat	ttgggcaggc	gccttattct	ggtataaata	20520
ttacaaaagga	gggtattcaa	ataggtgtcg	aaggtcaaac	acctaaatat	gccgataaaa	20580
catttcaacc	tgaacctcaa	ataggagaat	ctcagtggta	cgaaactgaa	attaatcatg	20640
cagctgggag	agtccttaaa	aagactacc	caatgaaacc	atgttacggt	tcatatgcaa	20700
aaccacaaaa	tgaaaatgga	gggcaaggca	ttcttgtaaa	gcaacaaaat	ggaaagctag	20760
aaagtcaagt	ggaaatgcaa	tttttctcaa	ctactgaggc	gaccgcaggc	aatggtgata	20820
acttgactcc	taaaagtggta	ttgtacagtg	aagatgtaga	tatagaaacc	ccagacactc	20880
atatttctta	catgcccact	attaaggaag	gtaactcacg	agaactaatg	ggccaacaat	20940
ctatgcccac	caggccta	tacattgctt	ttagggaaca	ttttattggt	ctaattgtatt	21000
acaacagcac	gggtaatatg	ggtgttctgg	cgggccaaagc	atcgagttg	aatgctgttg	21060
tagatttgca	agacagaaac	acagagcttt	ctaccagct	tttgcttgat	tccattggtg	21120
atagaaccag	gtacttttct	atgtggaatc	aggctgttga	cagctatgat	ccagatgtta	21180
gaattattga	aaatcatgga	actgaagatg	aacttccaaa	ttactgcttt	ccactgggag	21240
gtgtgattaa	tacagagact	cttaccagg	taaaacctaa	aacaggtcag	gaaaatggat	21300
gggaaaaaga	tgctacagaa	ttttcagata	aaaatgaaat	aagagttgga	aataattttg	21360

ccatggaaat caatctaaat gccaacctgt ggagaaatct cctgtactcc aacatagcgc 21420
tgtattttgcc cgacaagcta aagtacagtc cttccaacgt aaaaatttct gataacccaa 21480
acacctacga ctacatgaac aagcgagtg tggctcccgg gttagtggac tgctacatta 21540
accttggagc acgctggtcc cttgactata tggacaacgt caaccattt aaccaccacc 21600
gcaatgctgg cctgcgctac cgtcfaatgt tggctgggcaa tggctgctat gtgcccctcc 21660
acatccaggt gcctcagaag ttcttttgcca ttaaaaacct ccttctcctg ccggggtcat 21720
acacctacga gtggaacttc aggaaggatg ttaacatggt tctgcagagc tccttaggaa 21780
atgacctagc ggttgacgga gccagcatta agtttgatag cattedgctt tacgccacct 21840
tcttccccat ggcccacaac accgcctcca cgcttgaggc catgcttaga aacgacacca 21900
acgaccagtc ctttaacgac tatctctccg ccgccaacat gctctaccct ataccgcga 21960
acgtaccaca cgtgcccata tccatcccc cccgcaactg ggcggtttt ccggtgtggg 22020
ccttcacgag ccttaagact aaggaaacct catcactggg ctggggtac gaccttatt 22080
acacctactc tggctctata ccctacctag atggaacctt ttacctcaac cacaccttta 22140
agaaggtggc cattaccttt gactcttctg tcagctggcc tggcaatgac cgctgtctta 22200
cccccaacga gtttgaatt aagcgctcag ttgacgggga ggggttacaac gttgccagc 22260
gtaacatgac caaagactgg ttctggtac aactgttagc taactacaac attggctacc 22320
agggcttcta tatcccagag agctacaagg accgcatgta ctcttcttt agaaacttcc 22380
agcccatgag ccgtcaggtg gtggatgata ctaaatataa ggactacca caggtgggca 22440
tcctacacca acacaacaac tctggatttg ttggctacct tgccccacc atgcgcgaag 22500
gacaggccta cctgtctaac ttccctatc cgcttatagg caagaccgca gttgacagca 22560
ttaccagaa aaagtcttct tgcgatcgca cctttggcg catccattc tccagtaact 22620
ttatgtccat gggcgactc acagacctgg gccaaaacct tctctacgc aactccgcc 22680
acgctctaga catgactttt gaggtggatc ccatggacga gccaccctt ctttatgtt 22740
tgtttgaagt ctttgacgtg gtcctgtgac accggcgca ccggggcgtc atcgaaaccg 22800
tgttctctgc cagcccttc tggcgcgga acgcccaca ataaagaagc aagcaaatc 22860
aacaacagct gccgccatgg gctccagtga gcaggaactg aaagccattg tcaaagatct 22920
tggttgtggg ccatattttt tgggcaccta tgacaagcgc tttccaggct ttgtttctcc 22980
acacaagctc gcctgcgca tagtcaatac ggccggtcgc gagactggg gcgtacactg 23040
gatctgcctt actccgaacc cgcactcaaa acatgctac ctctttgagc cctttgctt 23100
ttctgaccag cgactcaagc aggtttacca gtttgagtag gagtactcc tgcgcgtag 23160
cgccattgct tcttcccccg accgctgtat aacgctggaa aagtccacc aaagcgtaca 23220
ggggcccaac tggcgccct gtggactatt ctgctgcatg tttctccacg cctttgccaa 23280
ctggcccaaa actcccatgg atcacaacc cccatgaac ctattaccg ggtaccctt 23340
ctcatgctc aacagtccc aggtacagcc caccctgcgt cgcaaccagc aacagctcta 23400
cagcttctctg gagcgccact cgcctactt ccgcagccac agtgcgaga ttaggagcgc 23460
cacttctttt tgtcacttga aaaacatgta aaaataatgt actagagaca ctttcaataa 23520
aggcaaatgt ttttattgt acactctcg gtgattattt acccccacc ttgctgtctg 23580
cgccgtttta aaatcaaagg ggttctgccc cgcactgcta tgcgccactg gcagggacac 23640
gttgcgatac tgggttttag tgcctcactt aaactcagc acaaccatcc gcggcagctc 23700
ggtgaagttt tactccaca ggctgcgcac catcaccac gcgttttaga ggtcgggccc 23760
cgatatcttg aagtgcagc tggggcctcc gccctgcgc cgcgagttgc gatacacagg 23820
gttgcagcac tgggaacata gtagcgccg ctgggtgacg ctggccagca cgctctgtc 23880
ggagatcaga tccgcgtcca ggtcctccgc gttgctcagg gcgaacggag tcaactttgg 23940
tagctgcctt cccaaaaagg gcgcgtgccc aggttttag ttgcaactgc accgtagtgg 24000
catcaaaagg tgaccgtgccc cggctctgggc gttaggatac agcgccctgca taaaagcctt 24060
gatctgctta aaagccacct gagcctttgc gccttcagag aagaacatgc cgcaagactt 24120
gccggaaaaac tgattggccg gacaggccgc gtcgtgacg cagcaccttg cgtcggtgtt 24180
ggagatctgc accacatttc ggccccaccg gttcttcacg atcttggcct tgctagactg 24240
ctccttcagc gcgcgtgccc cgttttctgct cgtcacatcc atttcaatca cgtgctcctt 24300
atttatcata atgcttccgt gtagacactt aagctcgct tcgatctcag cgcagcggtg 24360
cagccacaac gcgcagcccg tgggctcgtg atgctttag gtcacctctg caaacgactg 24420
caggtacgcc tgcaggaatc gcccacatcat cgtcacaag gtcttgttgc tgggtgaagg 24480
cagctgcaac ccgcggtgct cctcgttcag ccaggtcttg catacggcgc ccagagcttc 24540
cacttgggtca ggcagtagtt tgaagtctgc ctttagatcg ttatccacgt ggtacttgtc 24600
catcagcgcg cgcgcagcct ccatgccctt cttccacgca gacacgatc gcacactcag 24660
cgggttcac accgtaattt cactttccgc ttctgtgggc tcttctctt cctcttgcgt 24720
ccgcatacca cgcgccactg ggtcgtcttc attcagccgc cgcactgtgc gcttacctcc 24780
tttgccatgc ttgattagca ccggtgggtt gctgaaaccc accatttcta gcgccacac 24840
ttctctttct tctcgtgtt ccacgattac cctctgtgat ggcggcgct cgggcttggg 24900
agaagggcgc ttctttttct tcttgggcgc aatggccaaa tccgcgcgc aggtcgatgg 24960
ccgcgggctg ggtgtgcgcg gcaccagcgc gtcttgtgat gagtcttct cgtcctcgga 25020
ctcgatacgc cgctcatcc gcttttttgg gggcgcccg ggaggcgcg gcgacgggga 25080

cggggacgac	acgtcctcca	tggttggggg	acgtcgcgcc	gcaccgcgtc	cgcgctcggg	25140
gggtggtttcg	cgctgctcct	cttcccgaact	ggccattttcc	ttctcctata	ggcagaaaaa	25200
gatcatggag	tcagtcgaga	agaaggacag	cctaaccgcc	ccctctgagt	tcgccaccac	25260
cgcctccacc	gatgccgcca	acgcgcctac	caccttcccc	gtcgaggcac	ccccgcttga	25320
ggaggaggaa	gtgattatcg	agcaggaccc	aggttttgta	agcgaagacg	acgaggaccg	25380
ctcagtagca	acagaggata	aaaagcaaga	ccaggacaac	gcagaggcaa	acgaggaaaca	25440
agtcggggcgg	ggggacgaaa	ggcatggcga	ctacctagat	gtgggagacg	acgtgctggt	25500
gaagcatctg	cagcgccagt	gcgccattat	ctgcgacgcg	ttgcaagagc	gcagcgatgt	25560
gccccctgcc	atagcggatg	tcagccttgc	ctacgaacgc	cacctattct	caccgcgcgt	25620
accccccaaa	cgccaagaaa	acggcacatg	cgagcccaac	ccgcgcctca	acttctaccc	25680
cgtatttgcc	gtgccagagg	tgcttgccac	ctatcacatc	tttttccaaa	actgcaagat	25740
acccctatcc	tgccgtgcc	accgcagccg	agcggacaag	cagctggcct	tgccgcaggg	25800
cgctgtcata	cctgatatcg	cctcgctcaa	cgaagtgcc	aaaatctttg	agggtcttgg	25860
acgcgacgag	aagcgcgcgg	caaacgctct	gcaacaggaa	aacagcgaaa	atgaaagtca	25920
ctctggagtg	ttggtggaac	tcgagggtga	caacgcgcgc	ctagccgtac	taaaacgcag	25980
catcgaggtc	acccactttg	cctacccggc	acttaacct	ccccccaagg	tcctgagcac	26040
agtcagtgtg	gagctgatcg	tgccgcgtgc	gcagcccttg	gagaggggatg	caaatttgca	26100
agaacaaaca	gaggagggcc	tacccgcagt	tgccgacgag	cagctagcgc	gctggcttca	26160
aacgcgcgag	cctgccgact	tgaggagcgc	caacgaacta	atgatggcgc	cagtgtcgt	26220
taccgtggag	cttgagtgtca	tgacgcggtt	ctttgctgac	ccggagatgc	agcgaagct	26280
agaggaaaca	ttgcactaca	cctttcgaca	gggctacgta	cgccaggcct	gcaagatctc	26340
caacgtggag	ctctgcaacc	tggtctccta	ccttggaatt	ttgcacgaaa	accgccttgg	26400
gcaaaaacgtg	cttcattcca	cgctcaaggc	cgagcgcgc	cgcgactacg	tccgcgcgt	26460
cgtttactta	tttctatgct	acacctggca	gacggccatg	ggcgtttggc	agcagtgtct	26520
ggaggagtgc	aacctcaagg	agctgcagaa	actgctaaag	caaaacttga	aggacctatg	26580
gacggccttc	aacgagcgtc	ccgtggcgcg	gcacctggcg	gacatcattt	tccccgaacg	26640
cctgcttaaa	accctgcaac	agggctcgcc	agacttcacc	agtcaaaagca	tgttgcaaaa	26700
ctttaggaac	tttatcctag	agcgctcagg	aatcttgccc	gccacctgct	gtgacttccc	26760
tagcgacttt	gtgcccatta	agtaccgcga	atgccctccg	ccgctttggg	gccactgcta	26820
ccttctgcag	ctagccaact	accttgcccta	ccactctgac	ataatggaag	acgtgagcgg	26880
tgacgaattc	ctggagtgtc	actgtcgctg	caacctatgc	accccgaccc	gctccctggt	26940
ctcgctgac	gaaaagtccg	cggtccggg	gttgaaactc	actccggggc	tgaggggtcc	27000
ggcttacctt	cgcaaatttg	tacctgagga	ctaaccgcgc	cacgagatta	ggttctacga	27060
agacaaatcc	cgcccccaaa	atgcggagct	taccgcctgc	gtcattaccc	agggccacat	27120
tcttgcccaa	ttgcaagcca	tcaacaaagc	ccgccaagag	tttctgctac	gaaagggacg	27180
gggggtttac	ttggaccccc	agtccggcga	ggagctcaac	ccaatcccc	cgccgcgcga	27240
gcccctatcag	cagcagccgc	gggcccctgc	ttcccaggat	ggcaccocaaa	aagaagctgc	27300
agctgccgcc	gccaccacag	gacgaggagg	aatactggga	cagtcaggca	gaggagggtt	27360
tggaagagga	ggaggaggac	atgatggaag	actgggagag	cctagacgag	gaagcttccg	27420
aggtcgaaga	ggtgtcagac	gaaacaccgt	cacctctggt	cgcattcccc	tcgcccggcg	27480
cccagaaatc	ggcaaccggt	tccagcatgg	ctacaacctc	cgctcctcag	gcgcgcgcgg	27540
cactgccccg	tcgccgaccc	aaccgtagat	gggacaccac	tggaaccagg	gccggtaagt	27600
ccaagcagcc	gccgcccgtta	gcccagagc	aacaacagcg	ccaaggctac	cgctcatggc	27660
gcgggcacaa	gaacgccata	gttgcttgct	tgcaagactg	tgggggcaac	atctccttcg	27720
cccgcgcgtt	tcttctctac	catcacggcg	tgcccttccc	ccgtaacatc	ctgcattact	27780
accgtcatct	ctacagccca	tactgcaccg	gcggcagcgg	cagcggcagc	aacagcagcg	27840
gccacacaga	agcaaaaggc	accgatagc	aagactctga	caaagcccaa	gaaatccaca	27900
gcggcgccag	cagcaggagg	aggagcgtg	cgtctggcgc	ccaacgaacc	cgtatcgacc	27960
cgcgagctta	gaaacaggat	ttttccact	ctgtatgcta	tattttcaaca	gagcaggggc	28020
caagaacaa	agctgaaaat	aaaaaacagg	tctctgcat	ccctcacccg	cagctgcctg	28080
tatcacaaaa	gcgaagatca	gcttcggcgc	acgttggaag	acgcggaggc	tctcttcagt	28140
aaatactgcg	cgctgactct	taaggactag	tttcgcgcgc	tttctcaaat	ttaagcgcga	28200
aaactacgtc	atctccaggg	accagacccc	ggccagacac	ctctcgtcac	ccccattata	28260

ttcacgcctc	gtcaggcaat	cctaactctg	cagacctcgt	cctctgagcc	gcgctctgga	28860
ggcattggaa	ctctgcaatt	tattgaggag	tttgtgccat	cggctctactt	taacccttc	28920
tcgggacctc	cgggccacta	tccggatcaa	tttattccta	actttgacgc	ggtaaaggac	28980
tcggcggacg	gctacgactg	aatgttaagt	ggagaggcag	agcaactgcg	cctgaaacac	29040
ctgggtccact	gtcgccgccca	caagtgcctt	gcccgcgact	ccggtgagtt	ttgctacttt	29100
gaattgcccc	aggatcatat	cgagggcccg	gcgcacggcg	tccggcttac	cgcccaggga	29160
gagcttgccc	gtagcctgat	tcgggagttt	accacagccc	ccctgctagt	tgagcgggac	29220
aggggacctt	gtgttctcac	tgtgatttgc	aactgtccta	accttggatt	acatcaagat	29280
ttaattaatt	gccacatcct	cttacacttt	ttcatacatt	gcccagaagt	aaagaatcgt	29340
ttgtgttatg	tttcaacgtg	tttatttttc	aattgcagaa	aatttcaagt	catttttcat	29400
tcagtagtat	agccccacca	ccacatagct	tatacagatc	accgtacctt	aatcaaaactc	29460
acagaacctt	agtattcaac	ctgccacctc	cctcccaaca	cacagagtac	acagtccttt	29520
ctccccggct	ggccttaaaa	agcatcatat	catgggtaac	agacatattc	ttaggtgtta	29580
tattccacac	ggtttctctg	cgagccaaac	gctcatcagt	gatattaata	aactccccgg	29640
gcagctcact	taagttcatg	tcgctgtcca	gctgtgagc	cacaggctgc	tgtccaaact	29700
gcggttgctt	aacggggcgc	gaaggagaag	tccacgccta	catgggggta	gagtcataat	29760
cgtgcatcag	gatagggcgg	tgggtctgca	gcagcgcgcg	aataaactgc	tgccgcgcgc	29820
gctccgtcct	gcaggaatac	aacatggcag	tggctctcct	agcgtatgatt	cgcaccgccc	29880
gcagcataag	gcgccttgct	ctccgggcac	agcagcgcac	cctgatctca	cttaaatcag	29940
cacagtaact	gcagcacagc	accacaatat	tgctcaaaat	cccacagtgc	aaggcgtctgt	30000
atccaaagct	catggcgggg	accacagAAC	ccagctggcc	atcataccac	aagcgcaggt	30060
agattaagtg	gcgacccctc	ataaacacgc	tggacataaa	cattacctct	tttggcatgt	30120
tgttaattcac	cacctccccg	taccatataa	acctctgatt	aaacatggcg	ccatccacca	30180
ccatcctaaa	ccagctggcc	aaaacctgcc	cgccggctat	acactgcagg	gaaccgggac	30240
tggaacaatg	acagtgagga	gcccaggact	cgtaaccatg	gatcatcatg	ctcgtcatga	30300
tatcaatggt	ggcacaacac	aggcacacgt	gcatacactt	cctcaggatt	acaagctcct	30360
cccgcgttag	aacctatccc	cagggaacaa	cccatctctg	aatcagcgta	aatcccacac	30420
tcgctgcctc	aatctgcacg	taactcacgt	tgtgcattgt	caaagtgtta	cattcgggca	30480
gcagcggatg	atcctccagt	atggtagcgc	gggtttctgt	ctcaaaagga	ggtagacgat	30540
ccctactgta	cggagtgccg	cgagacaacc	gagatcgtgt	tggctgtagt	gtcatgccaa	30600
atggaacgcc	ggagctagtc	atatttccctg	aagcaaaacc	aggctcgggc	gtgacaaaca	30660
ctcggagcta	tgctgctcgt	ccgcttagat	cgctctgtgt	agtagttgta	gtatatccac	30720
tctctcaaag	catccaggcg	ccccctggct	tcgggttcta	tgtaaactcc	ttcatgcgcc	30780
gctgccctga	taacatccac	caccgcagaa	taagccacac	ccagccaacc	tacacattcg	30840
ttctgcgagt	cacacacggg	aggagcggga	agagctggaa	gaaccatgtt	ttttttttta	30900
ttccaaaaga	ttatccaaa	cctcaaaatg	aagatctatt	aagtgaacgc	gctccctccc	30960
gggtggcgtyg	tcaaaactcta	cagccaaaga	gcataataatg	gcatttgtta	gatgttgac	31020
aatggcttcc	aaaaggcaaa	cggccctcac	gtccaagtgg	acgtaaaggc	taaacccttc	31080
aggggtgaatc	tcctctataa	acattccagc	accttcaacc	atgcccaaat	aattctcatc	31140
tgccacacct	ctcaatatat	ctctaagcaa	atccogaata	ttaagtccgg	ccattgttaa	31200
aatctgctcc	agagcgccct	ccaccttcag	cctcaagcag	cgaatcatga	ttgcaaaaat	31260
tcagggttct	cacagacctg	tataagattc	aaaagcggaa	cattaacaaa	aataccgcga	31320
tcccgtaggt	cccttcgcag	ggccagctga	acataatcgt	gcaggctctgc	acggaccagc	31380
gcggccactt	ccccgccagg	aaccttgaca	aaagaaccca	cactgattat	gacacgcata	31440
ctcggagcta	tgctaaccag	cgtagccccg	atgtaagctt	tgttgcatgg	gcggcgatat	31500
aaaatgcaag	gtgctgctca	aaaaatcagg	caaagcctcg	cgcaaaaaag	aaagcacatc	31560
gtagtcatgc	tcatgcagat	aaaggcaggt	aagctccgga	accaccacag	aaaaagacac	31620
cattttttctc	tcaaacatgt	ctgcgggttt	ctgcataaac	acaaaataaa	ataacaaaaa	31680
aacattttaa	cattagaagc	ctgtcttaca	acaggaaaaa	caacccttat	aagcataaga	31740
cggactacgg	ccatgccggc	gtgaccgtaa	aaaaactggt	caccgtgatt	aaaaagcacc	31800
accgacagct	cctcggtcat	gtccggagtc	ataatgtaag	actcggtaaa	cacatcaggt	31860
tgattcatcg	gtcagtgcta	aaaagcgacc	gaaatagccc	gggggaatac	ataccgcgag	31920
gcgtagagag	aacattacag	ccccatagg	aggtataaca	aaattaatag	gagagaaaaa	31980
cacataaaca	cctgaaaaac	cctcctgcct	aggcaaaata	gcaccctccc	gctccagAAC	32040
aacatacagc	gcttcacagc	ggcagcctaa	cagtcagcct	taccagtaaa	aaagaaaacc	32100
tattaaaaaa	acaccactcg	acacggcacc	agctcaatca	gtcacagtgt	aaaaaagggc	32160
caagtgcaga	gcgagtatat	ataggactaa	aaaatgacgt	aacggttaaa	gtccacaaaa	32220
aacaccagga	aaaccgcacg	cgaacctacg	cccagaaacg	aaagccaaaa	aaccaccaac	32280
ttcctcaaat	cgtcacttcc	gttttccac	gttacgtaac	ttcccatttt	aagaaaacta	32340
caattcccaa	cacatacaag	ttactccgcc	ctaaaaccta	cgtcaccgcg	cccgttccca	32400
cgccccgcgc	cacgtcacaa	actccacccc	ctcattatca	tattggcttc	aatccaaaat	32460
aaggtatat	attgatgatg					32480

<210> 24
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 24
 ctcaacaatt gtggatccgt actcc 25

<210> 25
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 25
 gtgctcagca gatcttgcca ctgtg 25

<210> 26
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 26
 ggcgcgttcg gatccactct cttcc 25

<210> 27
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 27
 ctacatgcta ggcagatctc gttcggag 28

<210> 28
 <211> 1240
 <212> DNA
 <213> adenovirus

<400> 28
 ggatccactc tcttccgcat cgctgtctgc gagggccagc tggtggggtg agtactccct 60
 ctgaaaagcg ggcataactt ctgcgctaag attgtcagtt tccaaaaacg aggaggattt 120
 gatattcacc tggcccgcgg tgatgccttt gaggggtggc gcatccatct ggtcagaaaa 180
 gacaatcttt ttgttgtaa gcttggtggc aaacgaccg tagaggcgct tggacagcaa 240
 cttggcgatg gagcgaggg tttggttttt gtgcgcatcg gcgcgtcct tggccgcgat 300
 gtttagctgc acgtattcgc gcgcaacgca ccgccattcg ggaaagacgg tggcgcgctc 360
 gtcgggcacc aggtgcacgc gccaacgcgc gttgtgcagg gtgacaaggt caacgctggt 420
 ggctacctct ccgcgtaggc gtcggttggt ccagcagagg cggccgccct tgcgcgagca 480
 gaatggcggt agggggtcta gctgcgtctc gtccgggggg tctgcgtcca cggtaaagac 540
 cccgggcagc aggcgcgcgt cgaagtagtc tatcttgcac cttgcaagt ctacgcgctg 600


```

ctgccatgcg cgggcgggcaa ggcgcgcgtc gtatgggttg agtggggggac cccatggcat 660
gggggtgggtg agcgcgagg cgtacatgcc gcaaatgtcg taaacgtaga ggggctctct 720
gagtattcca agatatgtag ggtagcatct tccacgcggg atgctggcgc gcacgtaatc 780
gtatagttcg tgccgaggag cgaaggaggtc gggaccgagg ttgctacggg cgggctgctc 840
tgctcggaag actatctgcc tgaagatggc atgtgagttg gatgatatgg ttggacgctg 900
gaagacgttg aagctggcgt ctgtgagacc taccgcgtca cgcacgaagg aggcgtagga 960
gtcgcgcagc ttgttgacca gctcggcggg gacctgcacg tctagggcgc agtagtccag 1020
ggtttccctg atgatgtcat acttatcctg tccctttttt ttccacagct cgcggttgag 1080
gacaaactct tcgcggctct tccagtactc ttggatcgga aaccgcgcgg cctccgaacg 1140
agatccgtac tccgcgcgcg agggacctga atcgaccgga tcggaaaacc 1200
tctcgagaaa ggcgtctaac cagtcacagt cgcaagatct 1240

```

<210> 29

<211> 8383

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid pDV60

<400> 29

```

gacggatcgg gagatctccc gatcccttat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gaggtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttaggggttag gcgtttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacgggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcg tggctgaccg cccaacgacc 360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgcccgtag catgacctta tgggactttc ctacttgcca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780
gtatttgata acggtgggag gtctatataa cgagagctct ctggctaact agagaacgca 840
ctgcttactg gcttatcgaa attaatacga ctactatag ggagacccaa gcttggtagc 900
gagctcggat ccactctctt ccgcatcgct gtctgcgagg gccagctgtt ggggtgagta 960
ctccctctga aaagcgggca tgacttctgc gctaagattg tcagtttcca aaaacgagga 1020
ggatttgata ttcacctggc ccgcttgatg gcctttgagg gtggccgcat ccactctggtc 1080
agaaaagaca atctttttgt tgtcaagctt ggtggcaaac gaccgtaga gggcggtgga 1140
cagcaacttg gcgatggagc gcagggtttg gtttttgcg cgatcggcgc gctccttggc 1200
cgcgatgttt agctgcacgt attcgcgcgc aacgcaccgc cattcgggaa agacgggtgt 1260
gcgctcgctg ggcaccaggt gcacgcgcca accgcggttg tgcagggtga caaggtcaac 1320
gctggtggct acctctccgc gtaggcgtc gttgggtccag cagaggcggc cgcccttgcg 1380
cgagcagaat ggcggtaggg ggtctagctg cgtctcgtcc ggggggtctg cgtccacggt 1440
aaagaccccg ggcagcaggc gcgcgtcgaa gtagtctatc ttgcatcctt gcaagtctag 1500
cgcctgctgc catgcgcggg cggcaagcgc gcgctcgtat ggggtgagtg ggggacccca 1560
tggcatgggg tgggtgagcg cggaggcgta catgccgcaa atgtcgtaaa cgtagagggg 1620
ctctctgagt attccaagat atgtagggta gcatcttcca ccgcgatgc tggcgcgcac 1680
gtaatcgtat agttcgtgcg agggagcgag gaggtcggga ccgaggttgc tacgggctgg 1740
ctgctctgct cggaagacta tctgcctgaa gatggcatgt gaggttgatg atatggttgg 1800
acgctggaag acgttgaagc tggcgtctgt gagacctacc gcgtcacgca cgaaggaggg 1860
gtaggagtcg cgcagcttgt tgaccagctc ggcggtgacc tgcacgtcta gggcgagta 1920
gtccagggtt tccctgatga tgtcatactt atcctgtccc ttttttttcc acagctcgcg 1980
gttgaggaca aactcttcgc ggtctttcca gtactcttg atcgaaaacc cgtcggcctc 2040
cgaacgagat ccgtactccg ccgcccaggg acctgagcga gtccgcatcg accggtacgg 2100
aaaacctctc gagaaaggcg tctaaccagt cacagtcgca agatccaaga tgaagcgcg 2160
aagaccgtct gaagatacct tcaaccccg gtatccatat gacacggaaa ccggtcctcc 2220
aactgtgcct tttcttactc ctccctttgt atccccaat ggggttcaag agagtcctcc 2280
tgggttactc tctttgcgcc tatccgaacc tctagtacc tccaatggca tgcttgcgct 2340
caaatgggc aacggcctct ctctgacga ggcggcaac cttacctccc aaaatgtaac 2400
cactgtgagc ccacctctca aaaaaaccaa gtcaaacata aacctggaaa tatctgcacc 2460

```

```

cctcacagtt acctcagaag ccctaactgt ggctgccgcc gcacctctaa tggctcgccgg 2520
caacacactc accatgcaat cacaggcccc gctaaccgtg cactgactcca aacttagcat 2580
tgccacccaa ggacccctca cagtgtcaga aggaagacta gccctgcaaa catcaggccc 2640
cctcaccacc accgtagca gtacccttac tatcactgcc tcacccctc taactactgc 2700
cactggtagc ttgggcattg acttgaaaga gccatttat acacaaaatg gaaaactagg 2760
actaaagtac ggggctcctt tgcatgtaac agacgacctt aacactttga ccgtagcaac 2820
tgggtccaggt gtgactatta ataatacttc cttgcaaaact aaagttactg gagccttggg 2880
ttttgattca caaggcaata tgcaacttaa tgtagcagga ggactaagga ttgattctca 2940
aaacagacgc cttatacttg atgttagtta tccgtttgat gctcaaaacc aactaaatct 3000
aagactagga cagggccctc tttttataaa ctcagccac aacttgata ttaactacaa 3060
caaaggcctt tacttgttta cagcttcaaa caattccaaa aagcttgagg ttaacctaa 3120
cactgccaa ggggtgatgt ttgacgtac agccatagcc attaatgcag gagatgggct 3180
tgaatttggg tcacctaatg caccaaacac aaatccctc aaaacaaaaa ttggccattg 3240
cctagaatgt gattcaaaac aggtatggg tcctaaacta ggaactggcc ttagttttga 3300
cagcacaggt gccattacag taggaacaaa aaataatgat aagctaactt tgtggaccac 3360
accagctoca tctcctaact gttagactaa gatgctaaac tcactttggg 3420
cttaacaaaa tgtggcagtc aaatacttgc tacatttca gttttggctg ttaaaggcag 3480
tttggctcca atatctggaa cagttcaaag tgctcatctt attataagat ttgacgaaaa 3540
tggagtgtca ctaaacattt ccttctgga cccagaatat tggaaacttta gaaatggaga 3600
tcttactgaa ggcacagcct atacaaacgc tggtggattt atgcctaacc tatcagctta 3660
tccaaaatct cagcgtaaaa ctgccaaaag taacattgtc agtcaagttt acttaaacgg 3720
agacaaaact aaacctgtaa cactaaccat tactaaac ggtaacaggg aaacaggaga 3780
cacaactcca agtgcatact ctatgtcatt ttcattgggac tggctctggcc acaactacat 3840
taatgaaata tttggccacat cctcttacac tttttcatac attgcccag aataaaagaa 3900
gcggccgctc gagcatgcat cttaggggcc ctattctata gtgtcaccta aatgctagag 3960
ctcgtctgat agcctcgact gtgccttcta gttgccagcc atctgttgtt tgccctccc 4020
ccgtgccttc cttgacctg gaaggtgcca ctccactgt cctttcctaa taaaatgagg 4080
aaattgcac gcatgtctg agtaggtgtc attctattct ggggggtggg gtggggcagg 4140
acagcaaggg ggaggattgg gaagacaata gcaggcatgc tggggatgag gtgggctcta 4200
tggcttctga ggcgaaaga accagctggg gctctaggg gtatccccac gcgccctgta 4260
ggcgcgcat aaagcgggcg ggtgtgggtg ttacgcgcag cgtgaccgct acacttgcca 4320
gcgcctagc gccgcctcct ttcgctttct tcccttctct tctcgccacg ttcgcggct 4380
ttccccgta ccaaaaaactt cggggcctcc cgtattaggt ccgatttagt gctttacggc 4440
acctcgaccc caaaaaactt gattaggggt atggttcacg tagtgggcca tcgccctgat 4500
agacggtttt tcgccctttg acgttggagt ccactgtctt taatagtggg ctctgttcc 4560
aaactggaac aactcaac cctatctcgg tctattcttt tgatttataa gggattttgg 4620
ggatttccgc ctattgggta aaaaatgagc gattttaaca aaaatttaac gcgaattcta 4680
tctgtggaat gtgtgtcagt taggggtgtg aaagtccca ggctccccag gcaggcagaa 4740
gtatgcaaag catgcatctc aattagtcag caaccaggtg tggaaagtcc ccaggctccc 4800
cagcaggcag aagtatgcaa agcatgcac tcaattagtc agcaaccata gtcccgccc 4860
taactccgc ctaactccgc cgaattccgc ccattctccg cccatgccc 4920
gactaatatt ttttatttat gcagaggccg aggcgcctc tgctctgag ctattccaga 4980
agtagtgagg aggttttttt ggaggcctag gcttttgcaa aaagctcccg ggagcttgta 5040
tatccatttt cggatctgat caagagacag gatgaggatc gtttcgcatg attgaacaag 5100
atggattgca cgcaggttct cggccgctt ggggtggagag gctattcggc tatgactggg 5160
cacaacagac aatcggctgc tctgatgccg ccgtgttccg gctgtcagcg caggggcgcc 5220
cggttctttt tgtcaagacc gacctgtccg gtgcctgaa tgaactgcag gacgaggcag 5280
cgcggtatc gtggctggcc acgacgggag ttccttgccg agctgtgctc gacgttgtca 5340
ctgaagcggg aagggaactg ctgctattgg gcgaagtgc ggggcaggat ctctgtcat 5400
ctcaccttgc tctgcccag aaagtatcca tcatggctga tgcaatgcgg cggctgcata 5460
cgcttgatcc ggctacctgc ccattcgacc accaagcgaa acatcgcatc gagcgagcac 5520
gtactcggat ggaagccggg cttgtcgatc aggatgatct ggacgaagag catcaggggc 5580
tcgcgccagc gccaggtctc aggcgcgcac ccccgacggc gaggatctcg 5640
tcgtgacca ctggtggccg ctggttgcga atatcatggt ggaaaatggc cgcttttctg 5700
gattcatcga ctgtggccgg ctgggtgtgg cggaccgcta tcaggacata gcgttggtca 5760
cccgtgatat tgcgaagag cttggcggcg aatgggctga ccgcttctc gtgctttacg 5820
gtatccgcgc tcccgattcg cagcgcactg ccttctatcg ccttcttgac gatttctct 5880
gagcgggact ctgggttctg aaatgaccga ccaagcgag ccaacctgc catcacaga 5940
tttcgattcc accgcgcct tctatgaaag gttgggcttc ggaatcggtt tccgggacgc 6000
cggttgatg atcctccagc gcggggatct catgctggag ttcttcgccc accccaactt 6060
gtttattgca gttataatg gttacaaata aagcaatagc atcacaatt tcacaaataa 6120
agcatttttt tcaatgcatt ctagtgtgg tttgtccaaa ctcataatg tatcttatca 6180

```

tgtctgtata	ccgtcgacct	ctagctagag	cttggcgtaa	tcatggatcat	agctgtttcc	6240
tgtgtgaaat	tggtatccgc	tcacaattcc	acacaacata	cgagccggaa	gcataaagtg	6300
taaagcctgg	gggtgccta	gagtgagcta	actcacatta	attgcgttgc	gctccactgcc	6360
cgctttccag	tcgggaaacc	tgctgtgcca	gctgcattaa	tgaatcgccc	aacgcgcggg	6420
gagaggcgg	ttgcgtattg	ggcgtctctc	cgcttctctc	ctcactgact	cgctgcgctc	6480
ggctgctcgg	ctgcggcgag	cggtatcagc	tactcaaaag	gcggtaatac	ggttatccac	6540
agaatcaggg	gataacgcag	gaaagaacat	gtgagcaaaa	ggccagcaaa	aggccaggaa	6600
ccgtaaaaag	gcgcgcttgc	tggtgttttt	ccataggctc	cgccccctg	acgagcatca	6660
caaaaatcga	cgctcaagtc	agaggtggcg	aaacccgaca	ggactataaa	gataccaggc	6720
gtttccccct	ggaagctccc	tcgtgcgctc	tcctgttccg	accctgccc	ttaccggata	6780
cctgtccggc	tttctccctt	cggtgaagct	ggcgctttct	caatgctcac	gctgtaggta	6840
tctcagttcg	gtgtaggctg	ttcgctccaa	gctgggctgt	gtgcacgaac	ccccggttca	6900
gcccagaccg	tgccgcttat	ccggtaaact	tcgtcttgag	tccaaccccg	taagacacga	6960
cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	agagcgaggt	atgtaggcgg	7020
tgctacagag	ttcttgaagt	gggtggccta	ctacggctac	actagaagga	cagtattttg	7080
tatctgcgct	ctgtgaagc	cagttacctt	cggaaaaaag	gttggttagct	cttgatcccg	7140
caaaacaaac	accgctggta	gcggtgggtt	ttttgtttgc	aagcagcaga	ttacgcgcag	7200
aaaaaaagga	tctcaagaag	atcctttgat	cttttctacg	gggtctgacg	ctcagtgga	7260
cgaaaaactca	cgtaaaggga	ttttgggtcat	gagattatca	aaaaggatct	tcacctagat	7320
ccttttaaat	taaaaatgaa	gtttttaaact	aatctaaagt	atatatgagt	aaacttgggtc	7380
tgacagttac	caatgcttaa	tcagtggagg	acctatctca	gcgatctgtc	tatttcgttc	7440
atccatagtt	gcctgactcc	ccgtcgtgta	gataactacg	atacgggagg	gcttaccatc	7500
tggccccagt	gctgcaatga	taccgcgaga	cccacgctca	ccggctccag	atttatcagc	7560
aataaaccag	ccagccggaa	gggcccagcg	cagaagtgg	cctgcaactt	tatccgcctc	7620
catccagttc	attaattgtt	gccgggaagc	tagagtaagt	agttcgccag	ttaatagttt	7680
gcgcaacgtt	gttgccattg	ctacaggeat	cgtgggtgta	cgctcgtcgt	ttgggtatggc	7740
ttcattcagc	tcgggttccc	aacgatcaag	gcgagttaca	tgatccccc	tggtgtgcaa	7800
aaaagcgggt	agctccttcg	gtcctccgat	cgttgtcaga	agtaagttgg	ccgcagtgtt	7860
atcactcatg	gttatggcag	cactgcataa	ttctcttact	gtcatgccat	ccgtaagatg	7920
cttttctgtg	actggtgagt	actcaaccaa	gtcattctga	gaatagtgt	tgccggcgacc	7980
gagttgctct	tgcccggcgt	caataccgga	taataccgcg	ccacatagca	gaactttaaa	8040
agtgtctcat	attgaaaaac	gttcttccgg	gcgaaaaact	tcaaggatct	taccgctgtt	8100
gagatccagt	tcgagtgaac	ccactcgtgc	acccaactga	tcttcagcat	cttttacttt	8160
caccagcgtt	tctgggtgag	caaaaacagg	aaggcaaaat	gccgcaaaaa	aggggaataag	8220
ggcgacacgg	aaatgttgaa	tactcatact	cttccttttt	caatattatt	gaagcattta	8280
tcagggttat	tgtctcatga	gcggatacat	atttgaatgt	atttagaaaa	ataaacaat	8340
aggggttccg	cgcacatttc	cccgaaaagt	gccacctgac	gtc		8383

<210> 30

<211> 7960

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid pDV67

<400> 30

gacggatcgg	gagatctccc	gatccccctat	ggctcgactct	cagtacaatc	tgctctgatg	60
ccgcatagtt	aagccagtat	ctgctccctg	cttgtgtgtt	ggaggtcgct	gagtagtgcg	120
cgagcaaaat	taaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
ttagggttag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agcccatata	300
tgtagttccg	cgttacataa	cttacggtaa	atggcccggc	tggttgaccg	cccaacgacc	360
ccgcccatt	gagctcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttacggt	aaactgccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacggcc	cctattgacg	tcaatgacgg	taaattggcc	gcctggcatt	540
atgcccagta	catgacctta	tggtgacttt	ctacttgcca	gtacatctac	gtattagtca	600
tcgtatttac	catggtgatg	cggttttggc	agtacatcaa	tggtcggtgga	tagcgggttg	660
actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tggtgagttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgt	acaactccgc	ccattgacg	caaatggcg	780
gtaggcgtgt	acggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaacca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gctggctagc	900

gtttaaactt	aagcttggta	ccgagctcgg	atccactctc	ttccgcacgc	ctgtctgcga	960
gggccagctg	ttgggggtgag	tactccctct	gaaaagcggg	catgacttct	gcgctaagat	1020
tgtcagtttc	caaaaacgag	gaggatttga	tattcacctg	gcccgcgggtg	atgcctttga	1080
gggtggccgc	atccatctgg	tcagaaaaga	caatcttttt	gttgtcaagc	ttgggtggcaa	1140
acgaccgcta	gagggcgctg	gacagcaact	tggcgatgga	gcgcaggggtt	tggtttttgt	1200
cgcatcgccg	gcgctccttg	gccgcgatgt	ttagctgcac	gtattcgcgc	gcaacgcacc	1260
gccattcggg	aaagacgggtg	gtgcgctcgt	gcggcaccag	gtgcacgcgc	caaccgcggt	1320
tgtgcagggt	gacaagggtca	acgctgggtg	ctacctctcc	gcgtaggcgc	tcgttgggtcc	1380
agcagaggcg	gccgcctctg	cgcgagcaga	atggcggttag	gggggtctagc	tgcgctctcgt	1440
ccgggggggtc	tgcgctccacg	gtaaaagacc	cgggcagcag	gcgcgcgctg	aagtagtcta	1500
tcttgcatcc	ttgcaagtct	agcgctcgtc	gccatgcgcg	ggcggaagc	gcgcgctcgt	1560
atgggttgag	tggggggaccc	catggcatgg	ggtgggtgag	cgcgaggcgc	tacatgccgc	1620
aaatgtcgta	aacgtagagg	ggctctctga	gtattccaag	atatgtaggg	tagcatcttc	1680
caccgcggat	gctggcgcg	acgtaatcgt	atagttcgtg	cgagggagcg	aggaggtcgg	1740
gaccgaggtt	gctacgggcg	ggctgctctg	gggaagac	tatctgcctg	aagatggcat	1800
gtgagttgga	tgatatgggt	ggacgctgga	agacgttgaa	gctggcgctc	gtgagacctt	1860
ccgcgtcacg	cacgaaggag	gcgtaggagt	cgcgacgctt	gttgaccagc	tcggcggtga	1920
cctgcacgtc	tagggcgag	tagtccaggg	tttctctgat	gatgtcatac	ttatcctgtc	1980
cccttttttt	ccacagctcg	cgggttagga	caaacctctc	gcggtctttc	cagtagtcta	2040
ggatcgga	cccgctcgcc	tccgaacgag	atccgtactc	cgccgcgag	ggacctgagc	2100
gagtcgcat	cgaccggatc	ggaaaacctc	tcgagaaagg	cgtctaacca	gtcacagtcg	2160
caagatccaa	gatgaagcgc	gcaagaccgt	ctgaagatac	cttcaacccc	gtgtatccat	2220
atgacacgga	aaccggtcct	ccaactgtgc	cttttcttac	tcttcccttt	gtatccccc	2280
atgggtttca	agagagtccc	cctggggtac	tctctttgcy	cctatccgaa	cctctagtta	2340
ctcctcaatgg	catgcttgcg	ctcaaaatgg	gcaacggcct	ctctctggac	gagggcggga	2400
accttaacctc	ccaaaatgta	accactgtga	gcccacctct	caaaaaaac	aagtcaaac	2460
taaacctgga	aatatctgca	ccccctacag	ttacctcaga	agccctaact	gtggctgccc	2520
cgcacactct	aattggtcgcg	cgcaacacac	tcacctatga	atcacaggcc	ccgctaaccg	2580
tgacgactc	caaacttagc	attgccaccc	aaggaccctc	cacagtgtca	gaaggaaagc	2640
tagccctgca	aacatcaggc	ccccctacca	ccaccgatag	cagtaccctt	actatcactg	2700
cctcaccccc	tctaactact	gccactggta	gcttgggcat	tgacttgaaa	gagcccat	2760
atacacaaaa	tgaaaaacta	ggactaaaag	acggggctcc	tttgcattga	acagacgacc	2820
taaacacttt	gaccgtagca	actggtccag	gtgtgactat	taataatact	tccttgcaaa	2880
ctaaagttac	tggagccttg	ggtttttgatt	cacaaggcaa	tatgcaactt	aatgtagcag	2940
gaggactaa	gattgattct	caaaacagac	gccttatact	tgatgttagt	tatccgtttg	3000
atgtcaaaa	ccaactaaat	ctaagactag	gacagggcc	tctttttata	aactcacacc	3060
acaacttgg	tattaactac	aacaaaaggcc	tttacttggt	tacagcttca	aacaattcca	3120
aaaagcttga	ggttaacctt	agcactgcc	aggggttgat	gtttgacgct	acagccatag	3180
ccattaatgc	aggagatggg	cttgaatttg	gttcacctaa	tgacacaaac	acaaatcccc	3240
tcaaaacaaa	aattggccat	ggcctagaat	ttgattcaaa	caaggctatg	gttcctaaac	3300
taggaactgg	ccttagtttt	gacagcacag	gtgccattac	agtaggaaac	aaaaataatg	3360
ataagctaac	tttgtggacc	acaccagctc	catctcctaa	ctgtagacta	aatgcagaga	3420
aagatgctaa	actcactttg	gtcttaacaa	aatgtggcag	tcaaatactt	gctacagttt	3480
cagttttggc	tgtaaaaggc	agtttggctc	caatatctgg	aacagttcaa	agtgtctatc	3540
ttattataag	atttgacgaa	aatggagtgc	tactaaacaa	ttccttcctg	gaccagaat	3600
attggaactt	tagaaatgga	gatcttactg	aaggcacagc	ctatacaaac	gctgttggat	3660
ttatgcctaa	cctatcagct	tatccaaaat	ctcacggtaa	aactgcacaa	agtaacattg	3720
tcagtcaagt	ttacttaaac	ggagacaaaa	ctaaacctgt	aacactaacc	attacactaa	3780
acggtacaca	ggaaaacagga	gacacaactc	caagtgcata	ctctatgtca	ttttcatggg	3840
actggtctgg	ccacaactac	attaatgaaa	tatttgccac	atcctcttac	actttttcat	3900
acattgccca	agaataaaa	aagcgccgc	tcgagctctag	agggcccgtt	taaacccgct	3960
gatcagcctc	gactgtgcct	tctagtggcc	agccatctgt	tgtttgcccc	cccccgctgc	4020
cttccttgac	cctggaagg	gccactcca	ctgtcctttc	ctaataaaa	gaggaaattg	4080
catcgattg	tctgagtagg	tgctattcta	ttctgggggg	tggggtgggg	caggacagca	4140
agggggagga	ttgggaagac	aatagcaggc	atgctgggga	tgcggtgggc	tctatggctt	4200
ctgaggcgga	aagaaccagc	tggggtctta	gggggtatcc	ccacgcgcgc	tgtagcgcg	4260
cattaagcgc	ggcgggtgtg	gtggttacgc	gcagcgtgac	cgctacactt	gccagcgccc	4320
tagcgccgcg	tcctttcgct	ttcttccctt	cctttctcgc	cagtttcgct	ggctttcccc	4380
gtcaagctct	aaatcggggc	atccctttag	ggttcgatt	tagtgcctta	cggcacctcg	4440
acccccaaaa	acttgattag	ggtgatggtt	cacgtagtgg	gccatcgccc	tgatagacgg	4500
tttttcgccc	tttgacgttg	gagtcacagt	tctttaatag	tggactcttg	ttccaaactg	4560
gaacaacact	caaccctatc	tcggtctatt	cttttgattt	ataagggatt	ttggggattt	4620

```

cggcctattg gttaaaaaat gagctgattt aacaaaaatt taacgcgaat taattctgtg 4680
gaatgtgtgt cagtttaggt gtggaaaagtc cccaggctcc ccaggcagggc agaagtatgc 4740
aaagcatgca tctcaattag tcagcaacca ggtgtggaaa gtccccaggc tccccagcag 4800
gcagaagtat gcaaagcatg catctcaatt agtcagcaac catagtcccg cccctaactc 4860
cgcccatccc gccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa 4920
ttttttttat ttatgcagag gccgaggccg cctctgcctc tgagctattc cagaagtagt 4980
gaggaggctt ttttggaggc ctaggctttt gcaaaaaagct ccggggagct tgtatatcca 5040
ttttcggatc tgatcagcac gtgttgacaa ttaatcatcg gcatagtata tcggcatagt 5100
ataatacgac aaggtgagga actaaacccat ggccaagtgt accagtgcgc ttccgggtgct 5160
caccgcgcgc gacgtcgccg gagcgggtcga gttctggacc gaccggctcg gggtctcccg 5220
ggacttctgt gaggacgact tcgcccgtgt ttccgggac gacgtgaccc tgttcacag 5280
cgcggtccag gaccagggtg tgccggacaa caccctggcc tgggtgtggg tcgcgggcct 5340
ggacgagctg tacgcccagt ggtcggaggt cgtgtccacg aacttccggg acgcctccgg 5400
gccggccatg accgagatcg gcgagcagcc gtggggggcg gagttcgccc tcgcgcgaccc 5460
ggccggcaac tgcgtgcaac tcgtggccga ggagcaggga tgacacgtgc tacgagattt 5520
cgattccacc gccgccttct atgaaaggtt gggcgtcgga atcgttttcc gggagccggg 5580
ctggatgac ctccagcgcg gggatctcat gctggagttc ttcccccacc ccaacttggt 5640
tattgcagct tataatggtt acaataaag caatagcatc acaaatttca caaataaagc 5700
atttttttca ctgcattcta gttgtggtt gtccaaact atcaatgtat cttatcatgt 5760
ctgtataccg tcgacctcta gctagagctt ggcgtaatca tgggtcatagc tgtttcctgt 5820
gtgaaattgt tatccgctca caattccaca caacatacga gccggaagca taaagtgtaa 5880
agcctggggt gcctaagtga tgagctaact cacattaatt cgcgttgcgt cactgcccgc 5940
tttccagtcg ggaaacctgt cgtgccagct gcattaatga atcggccaac gcgcggggag 6000
aggcgtttg cgtattgggc gctcttcgc ttctcgcctc actgactcgc tcgcctcggg 6060
cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacggg tatccacaga 6120
atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg ccaggaaccg 6180
taaaaaggcc gcgttgctgg cgtttttcca taggctccgc cccctgacg agcatcaca 6240
aaatcacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat accaggcgtt 6300
tccccctgga agctccctcg tgcgtctccc tgttccgacc ctgcccgtta ccggatacct 6360
gtccgccttt ctcccttcgg gaagcgtggc gctttctcaa tgctcacgct gtaggtatct 6420
cagttcgggt taggtcgttc gctccaagct gggctgtgtg cacgaacccc ccgttcagcc 6480
cgactccgct gccttatccg gtaactatcg tcttgagtc aaccgggtaa gacacgact 6540
atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggatg taggcgggtg 6600
tacagagttc ttgaagtgtt ggcctaacta cggctacact agaaggacag tatttggtat 6660
ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa 6720
acaaaccacc gctggtagcg gtggtttttt ttttgcaag cagcagatta cgcgcagaaa 6780
aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc agtggaacga 6840
aaactcacgt taagggtatt tgggtcatgag attatcaaaa aggatcttca cctagatcct 6900
tttaaattaa aaatgaagtt ttaaataaat ctaaagtata tatgagtaaa cttggtctga 6960
cagttaccac tgcttaacta gtgaggcacc tatctcagcg atctgtctat ttctgtctatc 7020
catagttgcc tgactccctg tcgtgtagat aactacgata cgggagggct taccatctgg 7080
ccccagtgct gcaatgatac ccgagagacc acgctcaccg gctccagatt tatcagcaat 7140
aaaccagcca gccggaaggg ccgagcgcag aagtggctct gcaactttat ccgcctccat 7200
ccagtcattt aattgttgcc gggaaagtag agtaagtag tcgccagtta atagtttgcg 7260
caacgttggt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg gtatggcttc 7320
attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt tgtgcaaaaa 7380
agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg cagtgttatc 7440
actcatgggt atggcagcac tgcataatc ttctactgtc atgccatccg taagatgctt 7500
ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc ggcgaccgag 7560
ttgctcttgc ccggcgtaaa tacgggataa taccgcgcca catagcagaa ctttaaaagt 7620
gctcatcatt ggaaaacggt cttcggggcg aaaactctca aggatcttac cgctgttgag 7680
atccagttcg atgtaaccca ctctgcacc caactgatct tcagcatctt ttactttcac 7740
cagcgtttct ggggtagcaa aaacaggag gccaaaaagg gaataaggcg 7800
gacacggaaa tgttgaatac tcatactctt cttttttcaa tattattgaa gcatttatca 7860
gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaatagg 7920
ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc 7960

```

<210> 31

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 31

atgggatcca agatgaagcg cgcaagaccg

30

<210> 32

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 32

cactatagcg gccgcattct cagtcattct

30

<210> 33

<211> 7989

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid pDV69

<400> 33

gacggatcgg	gagatctccc	gatccctat	ggtcgactct	cagtacaatc	tgctctgatg	60
ccgcatagtt	aagccagtat	ctgctccctg	cttgtgtgtt	ggaggctcgt	gagtagtgcg	120
cgagcaaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
ttagggttag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacgggggc	attagttcat	agcccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggcccgcg	tggctgaccg	cccaacgacc	360
cccgcgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttacggt	aaactgcccc	cttggcagta	catcaagtgt	480
atcatacgcc	aagtacgccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgcccgagta	catgacctta	tgggactttc	ctacttggca	gtacatctac	gtattagtca	600
tcgctattac	catggtgatg	cggttttggc	agtacatcaa	tgggcgtgga	tagcggtttg	660
actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	caaatgggcg	780
gtaggcgtgt	acgggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gctggctagc	900
gtttaaactt	aagcttggta	ccgagctcgg	atccactctc	ttccgcatcg	ctgtctcgca	960
gggcccagctg	ttggggtgag	tactccctct	gaaaagcggg	catgacttct	gcgctaagat	1020
tgtcagtttc	caaaaacgag	gaggatttga	tattcacctg	gcccgcgggtg	atgcctttga	1080
gggtggccgc	atccatctgg	tcagaaaaga	caatcttttt	gttgtcaagc	ttgggtggcaa	1140
acgacccgta	gagggcgctg	gacagcaact	tggcgatgga	gcgcaggggt	tggtttttgt	1200
cgcatcggc	gcgtcccttg	gccgcgatgt	ttagctgcac	gtattcgcg	gcaacgcacc	1260
gccattcggg	aaagacgggtg	gtgcgctcgt	cgggcaccag	gtgcacgcgc	caaccgcggg	1320
tgtgcagggt	gacaagggtca	acgctggtgg	ctacctctcc	gcgtaggcgc	tcgttgggtcc	1380
agcagaggcg	gccgcccttg	cgcgagcaga	atggcggtag	ggggtctagc	tgcgtctcgt	1440
ccgggggggtc	tgctccacg	gtaaaagacc	cgggcagcag	gcgcgcgtcg	aagtagtcta	1500
tcttgcaccc	ttgcaagtct	agcgctctgt	gccatgcgcg	ggcggcaagc	gcgcgctcgt	1560
atgggttgag	tgggggaccc	catggcatgg	ggtgggtgag	cgcgaggcgc	tacatgcgcg	1620
aaatgtcgta	aacgtagagg	ggctctctga	gtattccaag	atatgtaggg	tagcatcttc	1680
caccgcggat	gctggcgcgc	acgtaatcgt	atagttcgtg	cgagggagcg	aggaggtcgg	1740
gaccgagggt	gctacggggt	ggctgctctg	ctcggaagac	tatctgcctg	aagatggcat	1800
gtgagttgga	tgatatgggt	ggacgctgga	agacgttgaa	gctggcgctc	gtgagacctt	1860
ccgcgtcacg	cacgaaggag	gcgtaggagt	cgcgacgctt	gttgaccagc	tcggcgggtga	1920
cctgcacgtc	tagggcgag	tagtccaggg	tttccttgat	gatgtcatac	ttatcctgtc	1980
cctttttttt	ccacagctcg	cggttgagga	caaactcttc	gcggctcttc	cagtactctt	2040
ggatcggaaa	cccgtcggcc	tccgaacgag	atccgtactc	cgccgcggag	ggacctgagc	2100
gagtcgcgat	cgaccggatc	ggaaaacctc	tcgagaaagg	cgtctaacca	gtcacagtcg	2160

caagatccaa	gatgaagcgc	gcaagaccgt	ctgaagatac	cttcaacccc	gtgtatccat	2220
atgacacgga	aaccggctcc	ccaactgtgc	cttttcttac	tcctcccttt	gtatccccc	2280
atgggtttca	agagagtcct	cctggggtag	tctctttgcg	cctatccgaa	cctctagtta	2340
cctccaatgg	catgcttgcg	ctcaaatgga	gcaacggcct	ctctctggac	gaggccggca	2400
accttacctc	ccaaaatgta	accactgtga	gccacacctc	caaaaaaac	aagtcaaaac	2460
taaacctgga	aatatctgca	cccctcacag	ttacctcaga	agccctaact	gtggctgcg	2520
ccgcacctct	aatggctcgc	ggcaacacac	tcaccatgca	atcacaggcc	ccgctaaccg	2580
tgcacgactc	caaacttagc	attgccaccc	aaggaccctc	cacagtgtca	gaaggaaagc	2640
tagccctgca	aacatcaggc	cccctcacca	ccaccgatag	cagtaccctt	actatcactg	2700
cctcaccccc	tctaactact	gccactggta	gcttgggcat	tgacttgaac	gagcccatat	2760
atacaaaaaa	tggaaaaacta	ggactaaagt	acggggctcc	tttgcatgta	acagcagacc	2820
taaacacttt	gaccgtagca	actggtccag	gtgtgactat	taataatact	tccttgcaaa	2880
ctaaagttac	tggagccttg	ggttttgatt	cacaaggcaa	tatgcaactt	aatgtagcag	2940
gaggactaag	gattgattct	caaaacagac	gccttatact	tgatgttagt	tatccgtttg	3000
atgctcaaaa	ccaactaaat	ctaagactag	gacaggcccc	tctttttata	aactcagccc	3060
acaacttgga	tattaactac	aacaaaggcc	tttacttggt	tacagcttca	aacaattcca	3120
aaaagcttga	ggttaacctc	agcactgcc	aggggttgat	gtttgacgct	acagccatag	3180
ccattaatgc	aggagatggg	cttgaatttg	gttcacctaa	tgacacaaac	acaaatcccc	3240
tcaaaaacaaa	aattggccat	ggcctagaat	ttgattcaaa	caaggctatg	gttcctcaac	3300
taggaactgg	ccttagtttt	gacagcacag	gtgccattac	agtaggaaac	aaaaataatg	3360
ataagctaac	tttgtggacc	gggtccaaaac	cagaagccaa	ctgcataatt	gaatacggga	3420
aacaaaaccc	agatagcaaa	ctaactttaa	tccttgtaaa	aaatggaggga	attgttaatg	3480
gatagttaac	gctaattgga	gcctcagact	acgttaacac	cttatttaaa	aacaaaaatg	3540
tctccattaa	tgtagaacta	tactttgatg	ccactgggtc	tataattacca	gactcatctt	3600
ctcttaaaac	agatctagaa	ctaaaatata	agcaaaccgc	tgactttagt	gcaagaggtt	3660
ttatgccaa	tactacagcg	tatocatttg	tccttcctaa	tgccgggaaca	cataatgaaa	3720
attatatttt	tgggtcaatgc	tactacaaag	caagcgatgg	tgcccttttt	ccgttggaag	3780
tactgtttat	cttaataaaa	cgcttgccag	attagtgcac	atcctatggt	atgacttttt	3840
tatggtcctt	gaatgctggt	ctagctccag	aaactactca	ggcaaccctc	ataacctccc	3900
catttacctt	ttccttatatt	agagaagatg	actgattttt	aagaagcggc	cgctcgagtc	3960
tagaggggcc	gtttaaaccc	gctgatcagc	ctcgactgtg	ccttctagtt	gccagccact	4020
tggtgtttgc	ccctccccc	tccttccctt	gacccctgga	ggtgccactc	ccactgtctc	4080
ttcctaataa	aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	4140
gggtgggggtg	gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	4200
ggatgcggtg	ggctctatgg	cttctgaggc	ggaaagaacc	snccntagct	ggggctctag	4260
gggtgtatccc	cacgcgcctc	gtagcggcgc	attaaagcgc	gcgggtgtgg	tggttacgcg	4320
cagcgtgacc	gctacacttg	ccagcgcctc	agcgcgcgct	cctttctgctt	tcctcccttc	4380
ctttctcgcc	acgttcgcgc	gctttccccc	tcaagctcta	aatcggggca	tccttttagg	4440
gttccgattt	agtgtctttc	ggcacctcga	ccccaaaaaa	cttgattagg	gtgatgggtt	4500
acgttagtggg	catgcgcctc	gatagacggt	ttttgccttc	ttgacgttgg	agtccagctt	4560
ctttaatagt	ggactcttgt	tccaaactgg	aacaacactc	aaccttatct	cggtctattc	4620
ttttgattta	taagggtatt	tggggatttc	ggcctattgg	ttaaaaaatg	agctgattta	4680
acaaaaattt	aacgcgaatt	aattctgtgg	aatgtgtgtc	agttagggtg	tggaaagtcc	4740
ccaggctccc	caggcaggca	gaagtatgca	aagcatgcat	ctcaattagt	cagcaaccag	4800
gtgtggaaag	tcccagggct	cccagcagg	cagaagtatg	caaagcatgc	atctcaatta	4860
gtcagcaacc	atagtcgccg	ccctaactcc	gcccatcccc	ccctaactc	cgccaggttc	4920
gcgccattct	ccgccccatg	gctgactaat	tttttttatt	tatgcagagg	ccgaggccgc	4980
ctctgcctct	gagctattcc	agaagtagtg	aggaggcttt	tttggaggcc	taggcttttg	5040
caaaaagctc	ccgggagctt	gtatatccat	tttcggatct	gatcagcacg	tggtgacaat	5100
taatcatcgg	catagtatat	cggcatagta	taatacgaca	aggtgaggaa	ctaaaccatg	5160
gccaaagtga	ccagtgcctg	tccggtgctc	accgcgcgcg	acgtcgccgg	agcggctcag	5220
ttctgctctc	accggctcgg	gttctcccg	gacttctgtg	aggacgactt	cgccgggtgtg	5280
gtccgggacg	acgtgacctc	gttcacagc	gcgggtccagg	accagggtgt	gccgggcaac	5340
accctggcct	gggtgtgggt	gcgcggcctg	gacgagctgt	acgccgagtg	gtcggagggtc	5400
gtgtccacga	acttccggga	cgctccgggg	ccggccatga	ccgagatcgg	cgagcagccg	5460
tggggggcggg	agttcgccct	gcgcgacccg	gccggcaact	gcgtgcactt	cgtggccgag	5520
gagcaggact	gacacgtgct	acgagatttc	gattccaccg	cgccttctta	tgaaagggtt	5580
ggcttcggaa	tcgttttccg	ggacgcgcgc	tggtatgatc	tccagcgcgg	ggatctcatg	5640
ctggagttct	tcgcccaccc	caacttggtt	attgcagctt	ataatgggtta	caaataaagc	5700
aatagcatca	caaatttcac	aaataaagca	tttttttcac	tgcatcttag	ttgtgggttg	5760
tccaaactca	tcaatgtatc	ttatcatgtc	tgtataccgt	cgacctctag	ctagaggttg	5820
gcgtaatcat	gggtcatagct	gtttcctgtg	tgaattgttt	atccgctcac	aattccacac	5880


```

aacatacgag ccggaagcat aaagtgtaaa gcctgggggt cctaattgagt gagctaactc 5940
acattaattg cgttgcgctc actgcccgtt ttccagtcgg gaaacctgtc gtgccagctg 6000
cattaatgaa tcggccaacg cgcggggaga ggcggtttgc gtattgggag ctcttccgct 6060
tcctcgctca ctgactcgct gcgctcggtc gttcggtgc ggagagcggg atcagctcac 6120
tcaaaggcgg taatacgggt atccacagaa tcaggggata acgcaggaaa gaacatgtga 6180
gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat 6240
aggctccgcc cccctgacga gcatacacia aatcgacgt caagtcagag gtggcgaaac 6300
ccgacaggac tataaagata ccaggcggtt cccctggaa gctccctcgt gcgctctcct 6360
gttccgaccc tgccgcttac cggatacctg tcgcctttc tcccttcggg aagcgtggcg 6420
ctttctcaat gctcacgtg taggtatctc agttcggtgt aggtcggtcg ctccaagctg 6480
ggctgtgtgc accaaccgcc cggtcagccc gaccgctgcg ccttatccgg taactatcgt 6540
cttagtcca acccggtta acacgactta tcgccactgg cagcagccac tggtaacagg 6600
attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggg gcctaactac 6660
ggctacacta gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga 6720
aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt 6780
gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgactctt 6840
tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga 6900
ttatcaaaaa ggatcttcac ctatgctctt ttaaattaaa aatgaagttt taaatcaatc 6960
taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct 7020
atctacgca tctgtctatt tcgttctacc atagttgct gactccccgt cgtgtagata 7080
actacgatac gggagggtt accatctggc ccagtgctg caatgatacc gcgagaccca 7140
cgctcaccgg ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgcgaga 7200
agtggctctg caactttatc cgcctccatc cagtctatta attgttgcg ggaagctaga 7260
gtaagttagt ccgcagttaa tagtttgcc aacgttggt ccattgctac aggcactgtg 7320
gtgtacgct cgctggttg tatggcttca ttcagctccg gttcccaacg atcaaggcga 7380
gttacatgat ccccatgtt gtgcaaaaaa gcggttagct ccttcggtcc tccgatcggt 7440
gtcagaagta agttggccgc agtggtatca ctcatggtta tggcagcact gcataattct 7500
cttactgtca tggcatcgt aagatgcttt ttgtgactg gtgagtactc aaccaagtca 7560
ttctgagaat agtgtagcg gcgaccgagt tgctcttgc cggcgtcaat acgggataat 7620
accgcgccac atagcagaac tttaaaagt ctcatcattg gaaaacgttc ttcggggcga 7680
aaactctcaa ggatcttaac gctgttgaga tccagttcga tgtaaccac tcgtgcaccc 7740
aactgatctt cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacaggaagg 7800
caaatgccc caaaaaagg aataaggcg acacggaaat gttgaatact catactcttc 7860
ctttttcaat attattgaag catttatcag ggttattgtc tcatgagcgg atacatattt 7920
gaatgtattt agaaaaataa acaaataggg gttccgcgca catttccccg aaaagtgcc 7980
cctgacgtc

```

<210> 34

<211> 7607

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid GRE5-E1-SV40-Hygro

<400> 34

```

tctagaagat ccgctgtaca ggatgttcta gctactttat tagatccgct gtacaggatg 60
ttctagctac tttattagat ccgctgtaca ggatgttcta gctactttat tagatccgct 120
gtacaggatg ttctagctac tttattagat ccgctgtacg gatgttctag ctactttatt 180
agatcgatct cctggccggt cgggggtcaaa aaccagggtt ggctataaaa ggggggtggg 240
gcgcttctgt cctcactctc ttccgcatcg ctgtctgcga gggccaggat cgatcctgag 300
aacttcaggg tgagtttggg gacccttgat tgttctttct ttttcgctat tgtaaaattc 360
atgttatatg gagggggcaa agttttcagg gtgttgttta gaatgggaag atgtcccttg 420
tatcaccatg gacctcatg ataattttgt ttcttcaact ttctactctg ttgacaacca 480
ttgtctctc ttattttctt ttcatcttct gtaacttttt cgttaaactt tagcttgcat 540
ttgtaacgaa tttttaaatt cacttttggt tatttgtcag attgtaagta ctttctctaa 600
tcaacttttt ttcaaggcaa tcagggtata ttatattgta cttcagcaca gtttttagaga 660
acaattgtta taattaaatg ataaggtaga atatttctgc atataaattc tggctggcgt 720
ggaaatattc ttattggtag aaacaactac atcctggta tcatcctgcc tttctcttta 780
tggttacaat gatatacact gtttgagatg aggataaaat actctgagtc caaaccgggc 840
ccctctgcta accatgttca tgccttcttc ttttctctac agctcctggg caacgtgctg 900
gttattgtgc tgtctcatca ttttggtcaa gaattagatc taagcttctg cagctcgagg 960

```


actcggtcga	ctgaaaatga	gacatattat	ctgccacgga	ggtgttatta	ccgaagaaat	1020
ggccgccagt	cttttgacc	agctgatcga	agaggtactg	gctgataatc	ttccacctcc	1080
tagccatttt	gaaccaccta	cccttcacga	actgtatgat	ttagacgtga	cggcccccga	1140
agatcccaac	gaggaggcgg	tttcgcagat	ttttcccgac	tctgtaatgt	tggcgggtgca	1200
ggaagggatt	gacttactca	cttttccgcc	ggcgcccggt	tctccggagc	cgccctcacct	1260
ttcccggcag	cccagcagc	cggagcagag	agccttgggt	ccggtttcta	tgccaaacct	1320
tgtaccggag	gtgatcgatc	ttacctgcc	cgaggctggc	tttccacca	gtgacgacga	1380
ggatgaagag	ggtgaggagt	ttgtgttaga	ttatgtggag	caccccgggc	acggttgcag	1440
gtcttgtcat	tatcaccgga	ggaatacggg	ggaccagat	attatgtgtt	cgctttgcta	1500
tatgaggacc	tgtggcatgt	ttgtctacag	taagtgaata	ttatgggcag	tgggtgatag	1560
agtgggtggg	tgggtgtggt	aatttttttt	ttaattttta	cagttttgtg	gtttaaagaa	1620
ttttgtattg	tgattttttt	aaaaggctct	gtgtctgaac	ctgagcctga	gcccagagcca	1680
gaaccggagc	ctgcaagacc	taccgcgcgt	cctaaaatgg	cgctgtctat	cctgagacgc	1740
ccgacatcac	ctgtgtctag	agaatgcaat	agtagtacgg	atagctgtga	ctccggctcct	1800
tctaaccacac	ctcctgagat	acaccgggtg	gtcccgctgt	gccccattaa	accagttgccc	1860
gtgagagtgt	gtgggcgtcg	ccaggctgtg	gaatgtatcg	aggacttgct	taacgagcct	1920
gggcaacctt	tggacttgag	ctgtaaacgc	cccaggccat	aaggtgtaaa	cctgtgattg	1980
cgtgtgtggt	taacgccttt	gtttgctgaa	tgagttgatg	taagtttaat	aaaggggtgag	2040
ataatgttta	acttgcattg	cgtgttaaat	ggggcggggc	ttaaagggtg	tataatgcgc	2100
cgtgggctaa	tcttgggtac	atctgacctc	atggaggcct	gggagtgttt	ggaagatctt	2160
tctgctgtgc	gtaacttgct	ggaacagagc	tctaacagta	cctcttggtt	ttggagggtt	2220
ctgtggggct	catcccaggc	aaagtttagt	tgcagaatta	aggaggatta	caagtgaggaa	2280
tttaagagagc	ttttgaaatc	ctgtggtgag	ctgtttgatt	ctttgaatct	gggtcaccag	2340
gcgcttttcc	aagagaaggt	catcaagact	ttggattttt	ccacaccggg	gcgcgtctgc	2400
gctgctgttg	cttttttgag	ttttataaag	gataaatgga	gcgaagaaac	ccatctgagc	2460
gggggggtacc	tgctggattt	tctggccatg	catctgtgga	gagcgggtgt	gagacacaag	2520
aatcgccctgc	tactgttgct	ttccgtccgc	ccggcgataa	taccgacgga	ggagcagcag	2580
cagcagcagg	aggaagccag	gcggcgccgg	caggagcaga	gccccatgaa	cccagagacc	2640
ggcctggacc	ctcggaatg	aatgttgtac	aggtggctga	actgtatcca	gaactgagac	2700
gcattttgac	aattacagag	gatgggcagg	ggctaaaggg	ggtaaagagg	gagcgggggg	2760
cttgtgaggc	tacagaggag	gctaggaatc	tagcttttag	cttaatgacc	agacaccgtc	2820
ctgagtgtat	tacttttcaa	cagatcaagg	ataattgcgc	taatgagctt	gatctgctgg	2880
cgcagaagta	ttccatagag	cagctgacca	cttactggct	gcagccaggg	gatgattttg	2940
aggaggctat	tagggatat	gcaaagggtg	cacttaggcc	agattgcaag	tacaagatca	3000
gcaaacttgt	aaatatcagg	aattgttgct	acatttctgg	gaacggggcc	gaggtggaga	3060
tagatgacga	ggatagggtg	gccttttagat	tgatcatgat	aaatatgtgg	ccgggggtgc	3120
ttggcatgga	cgggggtggt	attatgaatg	taaggtttac	tggccccaat	tttagaggta	3180
cgggttttct	ggccaatacc	aaccttatcc	tacacggtgt	aagcttctat	gggtttaaca	3240
atacctgtgt	ggaagcctgg	accgatgtaa	gggttcgggg	ctgtgccttt	tactgtctgt	3300
ggaagggggg	ggtgtgtcgc	cccaaaagca	gggcttcaat	taagaaatgc	ctctttgaaa	3360
ggtgtacctt	gggtatcctg	tctgagggtg	actccagggt	gcgccacaat	gtggcctccg	3420
actgtggttg	cttcatgcta	gtgaaaagcg	tggctgtgat	taagcataac	atggtatgtg	3480
gcaactgcga	ggacagggcc	tctcagatgc	tgacctgtc	ggacggcaac	tgtcacctgc	3540
tgaagaccat	tcacgtagcc	agccactctc	gcaaggcctg	gccagtgttt	gagcataaca	3600
tactgacccg	ctgttctctg	catttgggta	acaggagggg	ggtgttccta	ccttaccat	3660
gcaatttgag	tcacactaag	atattgcttg	agcccagag	catgtccaag	gtgaacctga	3720
acgggggtgt	tgacatgacc	atgaagatct	ggaagggtgt	gaggtacgat	gagacccgca	3780
ccaggtgcag	accctgcgag	tgtggcggtg	aacatattag	gaaccagcct	gtgatgctgg	3840
atgtgaccga	ggagctgagg	cccgatcact	tgggtctggc	ctgcacccgc	gctgagtttg	3900
gctctagcga	tgaagataca	gattgaggtg	ctgaaatgtg	tgggcgtggc	tttaagggtg	3960
gaaagaatat	ataagggtgg	ggtcttatgt	agttttgtat	ctgttttgca	gcagccgccc	4020
cgcccatgag	caccaactcg	tttgatggaa	gcattgtgag	ctcatatttg	acaacgcgca	4080
tgcccccattg	ggccgggggtg	cgtcagaatg	tgatgggctc	cagcattgat	ggctgcccgc	4140
tcctgcccgc	aaactctact	accttgacct	acgagaccgt	gtctggaaag	ccgttgaggag	4200
ctgcagcctc	cgccgcgcgt	tcagccgctg	cagccaccgc	ccgcgggatt	gtgactgact	4260
ttgcttttct	gagcccgcgt	gcaagcagtg	cagcttcccg	ttcatccgcc	cgcgatgaca	4320
agttgacggc	tcttttgga	caattggatt	cttgaccgc	ggaacttaac	gtcgtttctc	4380
agcagctgtt	ggatctgcgc	cagcagggtt	ctgccctgaa	ggcttctctc	cctcccaatg	4440
cggtttaaaa	cataaataaa	aaaccagact	ctgtttggat	ttggatcaag	caagtgtctt	4500
gctgtctcag	ctgactgctt	aagtcgcaag	ccgaattgga	tccaattcgg	atcgatctta	4560
ttaaagcaga	actgttttat	tgcagcttat	aatggttaca	aataaagcaa	tagcatcaca	4620
aatttcacaa	ataaagcatt	tttttcaact	cattctagtt	gtgggttgct	caaactcatc	4680

```

aatgtatctt atcatgtctg gtcgactcta gactcttccg cttcctcgt cactgactcg 4740
ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg 4800
ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag 4860
gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctcgg ccccccctgac 4920
gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga 4980
taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac cctgcccgtt 5040
accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca tagctcacgc 5100
tgtaggtatc tcagttcggg gtaggtcggt cgctccaagc tgggctgtgt gcacgaaccc 5160
cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caaccgggta 5220
agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag agcgagggtat 5280
gtaggcgggtg ctacagagtt cttgaagtgg tggcctaact acggctacac tagaaggaca 5340
gtatttggtg tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct 5400
tgatccggca aacaaaccac cgtcggtagc ggtgggtttt ttgtttgcaa gcagcagatt 5460
acgcgcagaa aaaaaggatg tcaagaagat cctttgatct tttctacggg gtctgacgct 5520
cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa aaggatcttc 5580
acctagatcc ttttaaatga aaaatgaagt tttaaatcaa tctaagtat atagagtaa 5640
acttgggtctg acagttacca atgcttaate agtgaggcac ctatctcagc gatctgtcta 5700
tttcgcttcac ccattagttgc ctgactcccc gtcgtgtaga taactacgat acgggaggggc 5760
ttaccatctg gcccagtgcc tgcaatgata ccgcgagacc cagcctcacc ggctccagat 5820
ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtgggtc tgcaacttta 5880
tccgcctcca tccagtcctat taattgttgc cgggaagcta gagtaagtag ttcccgagtt 5940
aatagtttgc gcaacgttgt tgccattgct acaggcatcg ttggtgcacg ctgcgtcttt 6000
ggtatggctt cattcagctc cgtttcccaa cgatcaaggc gagttacatg atcccccatg 6060
ttgtgcaaaa aagcggttag ctccctcggg cctccgatcg ttgtcagaag taagttggcc 6120
gcagtggttat cactcatggt tatggcagca ctgcataatt ctcttactgt catgccatcc 6180
gtaagatgct tttctgtgac ttgtgagtac tcaaccaagt cattctgaga atagtgtatg 6240
cggcgaccga ttgtctcttg cccggcgcca ataccgggata ataccgcgcc acatagcaga 6300
actttaaaag tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta 6360
ccgctgttga gatccagttc gatgtaaccc actcgtgcac ccaactgac ctagcatct 6420
tttactttca ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag 6480
ggataaagg cgacacggaa atgttgaata ctcatactct tcttttttca atattattga 6540
agcatttatc agggttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat 6600
aaacaaatag gggttccgcg cacatttccc cgaaaagtgc cactgacgt ctaagaaacc 6660
attattatca tgacattaac ctataaaaaat aggcgtatca cgaggccctc ttcgtctcgc 6720
cgttttcggg gatgacgggt aaaacctctg acacatgcag ctcccggaga cggtcacagc 6780
ttgtctgtaa gcggatgccg ggagcagaca agcccgtcag ggcgcgtcag cgggtgttg 6840
cgggtgtcgg ggctggctta actatgcggc atcagagcag attgtactga gagtgacca 6900
tatgcgggtg gaaataccgc acagatgcgt aaggagaaaa taccgcatca ggaaattgta 6960
agcgttaata ttttgttaaa attcgcgtta aatttttgtt aaatcagctc attttttaac 7020
caataggccg aatccggcaa aatcccttat aaatcaaaaag aatagaccga gatagggttg 7080
agtgttgttc cagtttgtaa caagagtcca ctattaaaga acgtggactc caacgtcaaa 7140
gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc ctaatcaagt 7200
tttttggggg cgaggtgccg taaagcacta aatcggaacc ctaaaggagg ccccgattt 7260
agagcttgac ggggaaaagc ggcgaaacgt gcgagaaaag aagggaagaa agcgaaaagga 7320
gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacaccgcc 7380
gcgcttaatg gcgcgctaca gggcgcgctc cattcgccat tcaggctgcy caactgttg 7440
gaagggcgat cgggtgcggc ctcttcgcta ttacgccagc tggcgaaaag gggatgtgct 7500
gcaaggcgat taagttgggt aacgccaggg ttttcccagt cagcaggttg taaaacgacg 7560
gccagtgaat tgtaatacga ctactatag ggcgaattaa ttcgggg 7607

```

<210> 35

<211> 11600

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid MMTV-E2a-SV40-Neo

<400> 35

```

gaattccgca ttgcagagat attgtattta agtgcctagc tcgatacaat aaacgccatt 60
tgaccattca ccacattggg gtgcacctcc aagcttgggc agaaatgggt gaactccgca 120

```

gagtgtccta	cacctagggg	agaagcagcc	aaggggttgt	ttcccaccaa	ggacgacccg	180
tctgcgacac	aacggatgag	cccacagac	aaagacatat	tcattctctg	ctgcaaaactt	240
ggcatagctc	tgctttgcct	ggggctattg	ggggaagtgt	cggttcgtgc	tgcaggggt	300
ctcacccttg	actcttttaa	tagctcttct	gtgcaagatt	acaatctaaa	caattcggag	360
aactcgacct	tctcctgag	gcaaggacca	cagccaactt	cctcttataa	gccgcatcga	420
ttttgtcctt	cagaaataga	aataagaatg	cttgctaaaa	attatatattt	taccaataag	480
accaatccaa	taggtagatt	attagttact	atgttaagaa	atgaatcatt	atcttttagt	540
actattttta	ctcaaattca	gaagttagaa	atgggaatag	aaaatagaaa	gagacgctca	600
acctcaattg	aagaacaggt	gcaaggacta	ttgaccacag	gcctagaagt	aaaaaaggga	660
aaaaagagtg	tttttgtcaa	aataggagac	aggtgggtggc	aaccagggac	ttatagggga	720
cctttacatct	acagaccaac	agatgcccc	ttaccatata	caggaagata	tgacttaaat	780
tggttagagt	gggttacagt	caatggctat	aaagtgttat	atagatccct	cccttttcgt	840
gaaagactcg	ccagagctag	acctccttgg	tgtatgttgt	ctcaagaaga	aaaagacgac	900
atgaaacaac	aggtacatga	ttatatattat	ctaggaacag	gaatgcactt	ttgggggaaag	960
attttccata	ccaaggaggg	gacagtggct	ggactaatag	aacattatct	tgcaaaaaact	1020
catggcatga	gttattatga	atagccttta	ttggcccaac	cttgcggttc	ccaggggtta	1080
agtaagtttt	tggttacaaa	ctgttcttaa	aacgaggatg	tgagacaagt	ggtttctctga	1140
cttgggtttg	tatcaaaggt	tctgatctga	gctctgagtg	ttctattttc	ctatgttctt	1200
ttggaattta	tccaaatctt	atgtaaatgc	ttatgtaaac	caagatataa	aagagtgtctg	1260
attttttag	taaacttgca	acagtctctaa	cattcacctc	ttgtgtgttt	gtgtctgttc	1320
gccatcccg	ctccgctcgt	cacttatect	tcactttcca	gaggggtccc	ccgcagaccc	1380
cggcgaccct	caggtcggcc	gactgcggca	gctggcgccc	gaacagggac	cctcgggataa	1440
gtgacccttg	tctctatttc	tactatttgc	tgtttgtctt	gtattgtctc	tttcttctgt	1500
ggctatcatc	acaagagcgg	aacggactca	ccatagggac	caagctagcg	cttctcgtcg	1560
cgtccaagac	cctcaaagat	ttttggcact	tcgttgagcg	aggcgatata	aggtatgaca	1620
gcgcccctgc	gcaaggccag	ctgcttgtcc	gctcggctgc	ggttggcacg	gcaggatagg	1680
ggtatcttgc	agttttggaa	aaagatgtga	taggtggcaa	gcacctctgg	cacggcacaat	1740
acggggtaga	agttgaggcg	cgggttgggc	tcgcatgtgc	cgttttcttg	gcgtttgggg	1800
ggtagcgcg	gtgagaatag	gtggcgctcg	tgagcaaggc	tgacatccgc	tatggcgagg	1860
ggcacatcgc	tgcgctcttg	caacgcgtcg	cagataatgg	cgactggcg	ctgcagatgc	1920
ttcaacagca	cgctcgtctc	cacatctagg	tagtcgccat	gcctttcgtc	ccccgcggcg	1980
acttgttctc	cgtttgcctc	tgcgttgcct	tggtcttgc	ttttatctc	tgttgggtact	2040
gagcggctc	cgctgctctc	gcttacaata	cctgggtcct	gctcgataat	cacttctctc	2100
tcctcaagcg	ggggtgcctc	gacggggaag	gtggtaggcg	cgttggcggc	atcgttggag	2160
gcgggtggtg	cgaactcaga	ggggcggtt	aggctgtcct	tcttctcgac	tgactccatg	2220
atctttttct	gcctatagga	gaaggaaatg	ccagtcggg	aagaggagca	gcgcgaaacc	2280
accocccagc	gcgagcgcg	tgccgcgcga	cgtccccaa	ccatggagga	cgtgtcgtcc	2340
ccgtccccgt	cgccgcgcgc	tccccgggcg	cccccaaaaa	agcggatgag	gcggcgatatc	2400
gagtccgagg	acgaggaaga	ctcatcacia	gacgcgctgg	tgccgcgcac	accagacccg	2460
cggcctatga	cctcggcgcc	ggatttggcc	attgcgccc	agaagaaaaa	gaagcgccct	2520
tctoccaagc	ccgagcgccc	gccatcacca	gagtaaatcg	tggaacagca	ggaagaaaga	2580
gaagatgtgg	cgctacaaat	ggtgggttct	agcaaccac	cgtgtctaata	caagcatggc	2640
aaaggaggta	agcgcacagt	gcggcggtg	aatgaagacg	accagtggtg	gcgtggtatg	2700
cggacgcaag	aggaagagga	agagcccagc	gaagcggaaa	gtgaaattac	ggtgatgaac	2760
ccgctgagtg	tgccgatcgt	gtctgcgtgg	gagaaggcca	tggaaggctgc	gcgcgcgctg	2820
atggacaagt	accacgtgga	taacgatcta	aaggcgaaact	tcaaactact	gcctgaccaa	2880
gtggaagctc	tggcgcccg	atgcaagacc	tggctgaacg	aggagcacccg	cgggttgacg	2940
ctgaccttca	ccagcaacaa	gacctttgtg	acgatgatgg	ggcgattcct	gcaggcgtag	3000
ctgcagtcgt	ttgcagaggt	gacctacaag	catcacgagc	ccacgggctg	cgcgttgtgg	3060
ctgcaccgct	gcgctgagat	cgaaggcgag	cttaagtgtc	tacacggaag	cattatgata	3120
aataaggagc	acgtgattga	aatggatgtg	acgagcgaaa	acgggcagcg	cgcgctgaag	3180
gagcagctca	gcaaggccaa	gatcgtgaag	aacgggtggg	gccgaaatgt	ggtgcagatc	3240
tccaacaccg	acgcaagggt	ctcgtgcac	gacgcggcct	gtccggccaa	tcagttttcc	3300
ggcaagtctt	gcggcatggt	cttctctgaa	ggcgcaaaag	ctcaggtggc	ttttaagcag	3360
atcaaggctt	ttatgcaggc	gctgtatcct	aacgcccaga	ccgggcacgg	tcaccttttg	3420
atgccactac	ggtgcgagtg	caactcaaa	cctgggcacg	cgcccttttt	gggaaggcag	3480
ctaccaaagt	tgactccggt	cgccttgagc	aacgcggagg	acctggacgc	ggatctgac	3540
tccgacaaga	gcgtgctggc	cagcgtgcac	caccggcgcc	tgatagtgtt	ccagtgtctg	3600
aaccctgtgt	atcgcaactc	gcgcgcgcag	ggcggaggcc	ccaactgcga	cttcaagata	3660
tccggcggcg	acctgctaaa	cgcgttggtg	atggtgcgca	gcctgtggag	tgaaaacttc	3720
accgagctgc	gcgggatggg	tgtgcctgag	tttaagtggg	gactaaaca	ccagtatcgc	3780
aacgtgtccc	tgccagtggtg	gcatagcgat	gcgcggcgag	acccctttga	tttttaaacg	3840

gcgcagacgg caagggtggg ggtaaataat cccccgagag tgtacaaata aaagcatttg 3900
cctttattga aagtgtctct agtacattat ttttcatgt ttttcaagtg acaaaaagaa 3960
gtggcgctcc taatctgcgc actgtggctg cggaagtagg gcgagtggcg ctccaggaag 4020
ctgtagagct gttcctgggt gcgacgcagg gtgggctgta cctggggact gttgagcatg 4080
gagttgggta ccccggtaat aagggtcatg gtgggggtgt gatccatggg agtttggggc 4140
cagttggcaa aggcgtggag aaacatgcag cagaatagtc cacaggcgcc cgagttgggc 4200
ccctgtacgc tttgggtgga cttttccagc gttatacagc ggtcggggga agaagcaatg 4260
gcgctacggc gcaggagtga ctcgactca aactggtaaa cctgcttgag tcgctggtca 4320
gaaaagccaa agggctcaaa gaggtagcat gttttttagt gcgggttcca ggcaaaggcc 4380
atccagtga cgcccccagt ctgcgaccg gccgtattga ctatggcgca ggcgagcttg 4440
tgtggagaaa caaagcctgg aaagcgcttg tcataggtgc ccaaaaaata tggcccacaa 4500
ccaagatctt tgacaatggc tttcagttcc tgctcactgg agcccatggc ggcagctggt 4560
gttgatgttg cttgcttctt tatgttggcg cgttgccggc cgagaaggcg gtgcgcaggt 4620
acacgggttc gatagcgccg cgggtcggcc ggtgcacag gaccacgtca aagacttcaa 4680
acaaaacata aagaagggtg ggctcgtcca tgggatccat atataggggc cgggttataa 4740
ttacctcagg tcgacctcga gggatccttg tgaaggaaac ttacttctgt ggtgtgacat 4800
aattggacaa actacctaca gagattttaa gctctaaggt aaatataaaa tttttaagt 4860
tataatgtgt taaactactg attctaattg tttgtgtatt ttagattcca acctatggaa 4920
ctgatgaatg ggagcagtg tggaatgcct ttaatgagga aaacctgttt tgctcagaag 4980
aaatgccatc tagtgatgat gaggctactg ctgactctca acattctact cctccaaaaa 5040
agaagagaaa ggtagaagac cccaaggact ttcttccaga attgctaagt tttttgagtc 5100
atgctgtgtt tagtaataga actcttgctt gctttgctat ttacaccaca aaggaaaaag 5160
ctgcaactgt atacaagaaa attatggaaa aatatctctg aacctttata agtaggcata 5220
acagttataa tcataacata ctgttttttc ttactccaca caggcataga gtgtctgcta 5280
ttaataacta tgctcaaaaa ttgtgtacct ttagcttttt aatttgtaaa ggggttaata 5340
aggaatattt gatgtatagt gccttgacta gagatcataa tcagccatac cacatttcta 5400
gaggttttac ttgctttaa aaacctcca caccctccc tgaacctgaa acataaaatg 5460
aatgcaattg ttgtgttaa cttgtttatt gcagcttata atggttaca ataaagcaat 5520
agcatcacia atttcacaaa taaagcattt ttttactgc attctagtgt tggttgtcc 5580
aaactcatca atgtatctta tcatgtctgg atccggctgt ggaatgtgtg tcagttagg 5640
tgtggaaagt ctgcagcggc agaagtagc aaagcatgca tctcaattag 5700
tcagcaacca ggtgtggaaa gtccccaggc tccccagcag gcagaagtat gcaaagcatg 5760
catctcaatt agtcagcaac catagtccc cccctaactc cgcccatccc gccctaact 5820
ccgcccagtt ccgcccattc tccgcccatt ggctgactaa tttttttat ttatgcagag 5880
gccgaggccg cctggcctc tgagctatc cagaagtagt gaggaggctt ttttggaggc 5940
ctaggctttt gcaaaaagct tcacgtgcc gcaagcactc agggcgcaag ggctgctaa 6000
ggaagcggaa cagtagaaa gccagtcgc agaaacggtg ctgaccccg atgaatgtca 6060
gctactgggc tatctggaca agggaaaacg caagcgcaa gagaaagcag gtagcttgca 6120
gtgggtttac atggcgatg ctgactggg cggttttatg gacagcaagc gaaccggaat 6180
tgccagctgg ggccgctct ggaagcctg tgaagcctc caaagttaac tggatgctt 6240
tcttgccgcc aaggatctga tggcgaggg gatcaagatc tgatcaagag acaggatgag 6300
gatcgtttcg catgattgaa caagatggat tgcacgcagg ttctccggcc gcttgggtg 6360
agaggctatt cggctatgac tgggcacaa agacaatcgg ctgctctgat gccgctgt 6420
tccgctgtc agcgagggg cggcgggtt ttttgtcaa gaccgacctg tccgtgccc 6480
tgaatgaact gcaggacgag gcagcgccg tategtggct ggccacgagc ggcgttctt 6540
gcgcagctgt gctcgacgtt gtactgaag cgggaaggga ctggctgcta ttgggcgaag 6600
tgccggggca ggtctcctg tcatctcacc ttgtcctgc cgagaaagta tccatcatg 6660
ctgatgcaat cgccggctg catacgttg atccggctac ctgcccattc gaccaccaag 6720
cgaaacatcg catcgagcga gcacgtactc ggatggaagc cggctctgtc gatcaggatg 6780
atctggacga agagcatcag gggctcgcgc cagccgaact gttcgccagg ctcaaggcgc 6840
gcatgcccga cggcgaggat ctgctcgtga cccatggcga tgctgcttg ccgaatata 6900
tggtggaaaaa tggccgcttt tctggattca tgaactgtg cggctgggt gtggcgacc 6960
gctatcagga catagcgttg gctaccgtg atattgctga agagctggc ggcgaatggg 7020
ctgaccgctt cctcgtgctt tacggtatcg ccgctcccga ttcgacgcgc atcgcttct 7080
atcgcttct tgacgagttc ttctgagcgg gactctgggg ttcgaaatga ccgaccaagc 7140
gacggccaac ctgctcatc gagatttoga ttccaccgc gccttctatg aaaggttggg 7200
cttcggaatc gttttccggg acgcccgtg gatgatctc cagcgcggg atctcatgct 7260
ggagttcttc gccaccccc ggctcgatcc cctcgcgagt tggttcagct gctgctgag 7320
gctggacgac ctgcggaggt tctaccggca gtgcaaatcc gtcggcatcc aggaaccag 7380
cagcgctat ccgcgcctcc atgccccga actctgtgg tggggaggca cgatggccgc 7440
tttggctccg gatctttgtg aaggaaacct tgtgacataa ttggacaaac 7500
tacctacaga gatttaaagc tctaaggtaa atataaaatt ttttaagtga taatgtgtta 7560

aactactgat	tctaattggt	tgtgtatttt	agattccaac	ctatggaact	gatgaatggg	7620
agcagtgggtg	gaatgccttt	aatgagga	acctgttttg	ctcagaagaa	atgccatcta	7680
gtgatgatga	ggctactgct	gactctcaac	attctactcc	tccaaaaaag	aagagaaagg	7740
tagaagaccc	caaggacttt	ccttcagaat	tgctaagttt	tttgagtcat	gctgtgttta	7800
gtaatagaac	tcttgcttgc	tttgctatatt	acaccacaaa	ggaaaaagct	gcactgctat	7860
acaagaaaaat	tatggaaaaa	tattctgtaa	cctttataag	taggcataac	agttataatc	7920
ataacatact	gttttttctt	actccacaca	gctcatagagt	gtctgctatt	aataactatg	7980
ctcaaaaatt	gtgtaccttt	agctttttta	tttgtaaagg	ggttaataag	gaatatttga	8040
tgtatagtgc	cttgactaga	gatcataatc	agccataacca	catttgtaga	ggttttactt	8100
gctttaaaaa	acctcccaca	cctccccctg	aacctgaaac	ataaaatgaa	tgcaattggt	8160
gttggttaact	ctgtttattgc	agcttataat	ggttacaaat	aaagcaatag	catcacaaat	8220
ttcacaaaata	aagcattttt	ttcactgcat	tctagtgtgtg	gtttgtccaa	actcatcaat	8280
gtatcttatc	atgtctggat	ccccaggaag	ctcctctgtg	tcctcataaa	ccctaacctc	8340
ctctacttga	gaggacattc	caatcatagg	ctgcccattc	accctctgtg	tcctcctggt	8400
aaaatttgca	cttaacaaaa	aggaaattgg	gtaggggttt	ttcacagacc	gctttctaag	8460
ggtaattttaa	aaatatctgg	gaagtccctt	ccactgctgt	gttccagaag	tgttggttaa	8520
cagcccacaa	atgtcaacag	cagaaacata	caagctgtca	gctttgcaca	agggcccaac	8580
accctgctca	tcaagaagca	ctgtgggtgc	tgtgttagta	atgtgcaaaa	caggaggcac	8640
attttcccca	ctgtgttagg	ttccaaaata	tctagtgttt	tcatttttac	ttggatcagg	8700
aaccagcac	tcactggat	aagcattatc	cttatccaaa	acagccttgt	ggtcagtgtt	8760
catctgctga	ctgtcaactg	tagcattttt	tggggttaca	gtttgagcag	gatatttggt	8820
cctgtagtgt	gctaacacac	cctgcagctc	caaagggttc	ccaccaacag	caaaaaatg	8880
aaaatttgca	ccttgaattg	gtttccagc	accattttca	tgagtttttt	gtgtcctga	8940
atgcaagtgt	aacatagcag	ttaccccaat	aacctcagtt	ttaacagtaa	cagcttccca	9000
catcaaaaata	tttccacagg	ttaagtcttc	atttaaatta	ggcaaaggaa	ttcttgaaga	9060
cgaaggggcc	tcgtgatacg	cctattttta	taggttaatg	tcatagataat	aatgggttct	9120
tagacgtcag	gtggcacttt	tcggggaaat	gtgcgcggaa	cccctatttg	tttatttttc	9180
taaatacat	caaatagtta	tcogctcatg	agacaataac	cctgataaat	gcttcaataa	9240
tattgaaaaa	ggaagagtat	gagtattcaa	catttccgtg	tcgcccctat	tccttttttt	9300
gcggcatttt	gccttccctgt	ttttgctcac	ccagaaacgc	tggtgaaagt	aaaagatgct	9360
gaagagagt	tgggtgcacg	agtgggttac	atcgaactgg	atctcaacag	cggtaagata	9420
cttgagagtt	ttcgcccgga	agaacgtttt	ccaatgatga	gcacttttaa	agttctgcta	9480
tgtggcgcg	tattatcccg	tgttgacgcc	gggcaagagc	aactcggtcg	ccgcatacac	9540
tattctcaga	atgacttggt	tgagtactca	ccagtcacag	aaaagcatct	tacggatggc	9600
atgacagtga	gagaattatg	cagtgtctgc	ataaccatga	gtgataaac	tgccggccaac	9660
ttacttctga	caacgatcgg	aggaccgaag	agcctaaccg	cttttttgca	caactcgggg	9720
gatcatgtaa	ctcgccctga	tcgttgggaa	ccggagctga	atgaagccat	accaaaccgac	9780
gagcgtgaca	ccacgatgcc	tgcagcaatg	gcaacaacgt	tgcgcaaaact	attaactggc	9840
gaactactta	ctctagcttc	ccggcaacaa	ttaatagact	ggatggaggc	ggataaagtt	9900
gcaggaccac	ttctgcgctc	ggcccttccg	gtctggctgt	ttattgctga	taaatctgga	9960
gccggtgagc	gtgggtctcg	cggtatcatt	gcagcactgg	ggccagatgg	taagccctcc	10020
cgtatcgtag	ttatctacac	gacggggagt	caggcaacta	tggatgaacg	aaatagacag	10080
atcgctgaga	taggtgcttc	actgattaag	catttggtaac	tgtcagacca	agtttactca	10140
tatatacttt	agattgattt	aaaacttcat	ttttaattta	aaaggatcta	ggtgaagata	10200
ctttttgata	atctcatgac	caaaatccct	taacgtgagt	tttcgttcca	ctgagcgtca	10260
gaccccgtag	aaaagatcaa	aggatcttct	tgagatcctt	tttttctgcg	cgtaactctgc	10320
tgcttgcaaaa	caaaaaaacc	accgctacca	gcggtgggtt	gtttgccgga	tcaagagcta	10380
ccaactcttt	ttccgaagg	aactggcttc	agcagagcgc	agataccaaa	tactgtcctt	10440
ctagtgtagc	cgtagttagg	ccaccacttc	aagaactctg	tagcaccgoc	tacatacctc	10500
gctctgttaa	tcctgttacc	agtggctgct	gccagtggcg	ataagtcgtg	tcttaccggg	10560
ttggactcaa	gacgatagtt	accggataag	gcgcagcgg	cgggtgaaac	gggggggttcg	10620
tgcacacagc	ccagcttga	gcgaacgacc	tacacgaac	tgagatacct	acagcgtgag	10680
ctatgagaaa	gcgccacgct	tcocgaagg	agaaaggcgg	acaggtatcc	ggtaagcggc	10740
agggctcgaa	caggagagcg	cacgagggag	cttccagggg	gaaacgcctg	gtatctttat	10800
agtcctgtcg	ggtttcgcca	cctctgactt	gagcgtcgat	ttttgtgatg	ctcgctcagg	10860
ggcgaggagc	tatggaaaaa	cgccagcaac	cgcccttttt	tacggttcct	ggccttttgc	10920
tggccttttg	ctcacatggt	cttctctgcg	attctgtgga	taacctgtat	taacctgtat	10980
accgcctttg	agtgtgctga	taccgctcgc	cgcagccgaa	cgaccgagcg	cagcgagtca	11040
gtgagcgagg	aagcggaaga	gcgcctgatg	cggtattttc	tccttacgca	tctgtgcggt	11100
atttcacacc	gcataatggg	cactctcagt	acaactctgt	ctgatgccgc	atagttaagc	11160
cagtatctgc	tcctgtcttg	tgtgttgagg	gtcgtgtgag	agtgccgcgag	caaaatttaa	11220
gctacaacaa	ggcaaggctt	gaccgacaat	tgcatgaaga	atctgcttag	ggttaggcgt	11280

tttgcgctgc ttcgcgatgt acgggccaga tatacgcgta tctgagggga ctagggtgtg 11340
tttaggcgaa aagcggggct tcggttgtag gcggttagga gtcccctcag gatatagtag 11400
tttcgctttt gcatagggag ggggaaatgt agtcctatgc aatacacttg tagtcttgca 11460
acatggtaac gatgagttag caacatgcct tacaaggaga gaaaaagcac cgtgcatgcc 11520
gattgggtgga agtaagggtg tacgatcgtg ccttattagg aaggcaacag acgggtctga 11580
catggattgg acgaaccact 11600

<210> 36
<211> 53
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 36
gtcactcgag gactcggctg actgaaaatg agacátatta tctgccacgg acc 53

<210> 37
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 37
cgagatcgat cacctccggt acaaggtttg gcatag 36

<210> 38
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 38
catgaagatc tggaaggtgc tgaggtacga tgagacc 37

<210> 39
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 39
gcgacttaag cagtcagctg agacagcaag acacttgctt gatccaaatc c 51

<210> 40
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 40
cacgaattcg tcagcgcttc tcgtcgcgtc caagaccc 38

<210> 41
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 41
caccgccggg aggcggcggc gacggggacg gg

32

<210> 42
<211> 7231
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid pDV80

<400> 42
ctgctccctg cttgtgtgtt ggaggtcgt gagtagtgcg cgagcaaaat ttaagctaca 60
acaaggcaag gcttgaccga caattgcatg aagaatctgc ttagggtag gcgttttgcg 120
ctgcttcgag atgtacgggc cagatatacg cgttgacatt gattattgac tagttattaa 180
tagtaataca ttacgggggc attagttcat agcccatata tggagttccg cgttacataa 240
cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgccatt gacgtcaata 300
atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca atgggtggac 360
tatttacggg aaactgcccc cttggcagta catcaagtgt atcatatgcc aagtacgccc 420
cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta catgacctta 480
tgggactttc ctacttgcca gtacatctac gtattagtca tcgctattac catgggtgatg 540
cggttttggc agtacatcaa tgggcgtgga tagcggttg actcacgggg atttccaagt 600
ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg ggactttcca 660
aaatgtcgta acaactcgc cccattgacg caaatggcg gtaggcgtgt acgggtggag 720
gtctatataa gcagagctct ctggctaact agagaaccca ctgcttactg gcttatcgaa 780
attaatacga ctactatag ggagacccaa gctggctagc gtttaaactt aagcttgga 840
ccgagctcgg atccactctc ttccgcatcg ctgtctcgca gggccagctg ttgggtgag 900
tactccctct gaaaagcggg catgacttct gcgctaagat tgtcagtttc caaaaacgag 960
gaggatttga tattcaactg gcccgcggtg atgccttga ggggtggcgc atccatctgg 1020
tcagaaaaga caactttttt gttgtcaagc ttgggtggca acgaccgta gagggcgttg 1080
gacgaacat tggcgatgga gcgcagggtt tgggtttgt cgcgatcggc gcgctccttg 1140
gccgcgatgt ttagctgcac gtattcgcgc gcaacgcacc gccattcggg aaagacgggtg 1200
gtgcgctcgt cgggcaccag gtgcacgcgc caaccgcggg tgtgcagggt gacaaggta 1260
acgctgggtg ctacctctcc gcgtaggcgc tcgttggtcc agcagaggcg gccgcccttg 1320
cgcgagcaga atggcggtag ggggtctagc tgcgtctcgt ccgggggggc tgctccacg 1380
gtaaagaccc cgggcagcag gcgcgcgtcg aagtagtcta tcttgcatcc ttgcaagtct 1440
agcgctcgt gccatgcgcg gcgcgcaagc gcgcgctcgt atgggttagg tgggggaccc 1500
catggcatgg ggtgggtgag cgcggaggcg tacatgcgcg aaatgtcgta aacgtagagg 1560
ggctctctga gtattccaag atatgtagg tagcatcttc caccgcggat gctggcgcg 1620
acgtaatcgt atagtctgt cgagggagcg aggaggtcgg gaccgaggtt gctacggcg 1680
ggctgctctg ctcggaagac tatctgcctg aagatggcat gtgagttgga tgatatggtt 1740
ggacgctgga agacgttgaa gctggcgtct gtgagacctt ccgctcacg cacgaaggag 1800
gcgtaggagt cgcgcagctt gttgaccagc tcggcggtga cctgcacgtc tagggcgcg 1860
tagtccaggg tttccttgat gatgtcatac ttatcctgtc cctttttttt ccacagctcg 1920
cggttgagga caaactcttc gcggtcttcc cagtactctt ggatcggaac cccgtcggcc 1980
tccgaacgag atccgtactc cgcgcggcgg ggacctgagc gagtccgat ccgaccggtc 2040
ggaaaacctc tcgagaaagg cgtctaacca gtcacagtcg caagatccaa gatgaagcgc 2100
gcccccccca gcgaagatga cttcaacccc gtctaccct atggctacgc gcggaatcag 2160
aatatccctc tctcactctc cccctttgtc tctccgatg gattcaaaaa cttccccctc 2220
gggtactgt cactcaaaact ggctgatcca atcaccatta ccaatgggga tgtatccctc 2280
aagtggggag gtggtctcac tttgcaagat ggaagcctaa ctgtaaaccc taaggctcca 2340
ctgcaagtta atactgataa aaaacttgag cttgcatatg ataactcatt tgaaagttag 2400
gctaataaac ttagtttaaa agtaggacat ggattaaaag tattagatga aaaaagtgc 2460

gcgggggttaa	aagatttaaat	tggcaaaactt	gtgggttttaa	caggaaaagg	aataggcact	2520
gaaaatttag	aaaatacaga	tggtagcagc	agaggaattg	gtataaatgt	aagagcaaga	2580
gaagggttga	catttgacaa	tgatggatac	ttggtagcat	ggaacccaaa	gtatgacacg	2640
cgcacacttt	ggacaacacc	agacacatct	ccaaactgca	caattgctca	agataaggac	2700
tctaaactca	ctttggtact	tacaaagtgt	ggaagtcaaa	tattagctaa	tgtgtctttg	2760
attgtggtcg	caggaaagta	ccacatcata	aataataaga	caaatccaaa	aataaaaagt	2820
tttactatta	aactgctatt	taataagaac	ggagtgcctt	tagacaactc	aaatcttggg	2880
aaagcttatt	ggaacttttag	aagtggaaat	tccaatgttt	cgacagctta	tgaaaaagca	2940
attggtttta	tgcctaattt	ggtagcgtat	ccaaaaccca	gtaattctaa	aaaatatgca	3000
agagacatag	tttatggaac	tatatatctt	ggtggaaaac	ctgatcagcc	agcagtcatt	3060
aaaactacct	ttaaccaaga	aactggatgt	gaataactcta	tcacatttaa	ctttagttag	3120
tccaaaacct	atgaaaatgt	tgaatttgaa	accacctctt	ttaccttctc	ctatatgtgc	3180
caagaatgaa	agagcggccg	ctcgagtcta	gagggcccg	ttaaacccgc	tgatcagcct	3240
cgactgtgcc	ttctagtgc	cagccatctg	ttgtttgccc	ctcccccggt	ccttccctga	3300
ccctggaagg	tgccactccc	actgtccttt	cctaataaaa	tgaggaaatt	gcacgcatt	3360
gtctgagtag	gtgtcattct	attctggggg	gtgggtggg	gcaggacagc	aagggggagg	3420
attgggaaga	caatagcagg	catgctgggg	atgcggtggg	ctctatggct	tctgaggcgg	3480
aaagaaccag	ctggggctct	agggggtatc	cccacgcgcc	ctgtagcggc	gcattaaagg	3540
cggcggtgt	ggtggttacg	cgcagcgtga	cgcctacact	tgccagcgcc	ctagcgcccg	3600
ctcctttcgc	tttcttccct	tcttttctcg	ccacgttcgc	cggctttccc	cgtcaagctc	3660
taaatcgggg	catcccttta	gggttccgat	ttagtgcctt	acggcacctc	gaccccaaaa	3720
aacttgatta	gggtgatggt	tcacgtatgt	ggccatcgcc	ctgataagacg	gtttttcgcc	3780
ctttgacgtt	ggagtccacg	ttctttaata	gtggactctt	gttccaaact	ggaacaacac	3840
tcaacctat	ctcgtctat	tcttttgatt	tataagggat	tttggggatt	tcggcctatt	3900
ggttaaaaa	tgagctgatt	taacaaaaat	ttaacgcgaa	ttaattctgt	ggaatgtgtg	3960
tcagttaggg	tgtgaaagt	ccccaggctc	ccagcgagg	cagaagtatg	caaagcatgt	4020
atctcaatta	gtcagcaacc	aggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	4080
tgcaaagcat	gcattctaat	tagtcagcaa	ccatagtcgc	gccccctaact	ccgcccattc	4140
cgccccctaac	tccgcccagt	tccgcccatt	ctccgcccc	tggtgacta	atttttttta	4200
tttatgcaga	ggcgaggcc	gcctctgctt	ccagaagtatg	tgaggaggct	tgaggaggct	4260
tttttgagg	cctaggcttt	tgcaaaaagc	tcccgggagc	ttgtatatcc	attttcggat	4320
ctgatcagca	cgtgttgaca	attaatcatc	ggcatagtat	atcggcatag	tataatacga	4380
caagggtagg	aactaaacca	tggccaagt	gaccagtgc	gttccgggtg	tcaccgcg	4440
cgagctcgcc	ggagcggctg	agttctggac	gaccggctc	gggttctccc	gggactctg	4500
ggaggacgac	ttcgccggtg	tggctccggg	cgacgtgacc	ctgttcatca	gcgcggtcca	4560
ggaccaggtg	gtgccggaca	acaccctggc	ctgggtgtgg	gtgcgcggcc	tggaagagct	4620
gtacgcccag	tggctggagg	tcgtgtccac	gaacttccgg	gacgctccg	ggccggccat	4680
gaccagatc	ggcgagcagc	cgtggggggc	ggagttcgcc	ctgcgcgacc	cggccggcaa	4740
ctgcgtgcac	ttcgtggccg	aggagcagga	ctgacacgtg	ctacgagatt	tcgattccac	4800
cgcgccttc	tatgaaagg	tgggtctcgg	aatcgtttcc	cgggacgccc	gctggatgat	4860
cctccagcgc	ggggatctca	tgctggagtt	cttcgcccac	cccaacttgt	ttattgcagc	4920
ttataatggt	tacaaataaa	gcaatagcat	cacaaatttc	acaaataaag	catttttttc	4980
actgcattct	agttgtggtt	tgtccaaact	catcaatgta	tcttatcatg	tctgtatacc	5040
gtcgacctct	agctagagct	tggcgtaatc	atggctcatg	ctgtttctctg	tgtgaaattg	5100
ttatccgctc	acaattccac	acaacatacg	agccggaagc	ataaagtgtg	aagcctgggg	5160
tgcctaata	gtgagctaac	tcacattaat	tgcgttgcgc	tcactgccc	ctttccagtc	5220
gggaaacctg	tcgtgccagc	tgcattaatg	aatcggccaa	cgcgcgggga	gaggcggttt	5280
gcgtattggg	cgtcttccg	cttctctcgt	caactgactg	ctgcgctcgg	tcgttcggct	5340
gcggcgagcg	gtatcagctc	actcaaaagg	ggtaatacgg	ttatccacag	aatcaggggg	5400
taacgcagga	aagaacatgt	gagcaaaaag	ccagcaaaaag	gccaggaacc	gtaaaaaggc	5460
cgcgttgctg	cgttttttcc	ataggctccg	ccccctgac	gagcatcaca	aaaatcgacg	5520
ctcaagtcag	aggtggcgaa	acccgacagg	actataaaga	taccaggcgt	ttccccctgg	5580
aagctccctc	gtgcgctctc	ctgttccgac	cctgcccgtt	accggatacc	tgtccgcctt	5640
tctcccttcg	ggaagcgtgg	cgttttctca	atgctcacgc	tgtaggtatc	tcagttcggt	5700
gtaggtcggt	cgctccaagc	tgggctgtgt	gcacgaaccc	cccgttcagc	ccgacccagc	5760
cgccttatcc	ggtaactatc	gtcttgagtc	caacccggta	agacacgact	tatcgccact	5820
ggcagcagcc	actggttaaca	ggattagcag	agcgaggtat	gtaggcggtg	ctacagagtt	5880
cttgaagtgg	tggcctaact	acggctacac	tagaaggaca	gtatttggtg	tctgcgctct	5940
gctgaagcca	gttaccttcg	gaaaaagagt	tggtagctct	tgatccggca	aacaaaccac	6000
cgtggttagc	ggtggttttt	ttgtttgcaa	gcagcagatt	acgcgcagaa	aaaaaggatc	6060
tcaagaagat	cctttgatct	tttctacggg	gtctgacgct	cagtggaaag	aaaactcacg	6120
ttaagggtatt	ttggtcatga	gattatcaaa	aaggatcttc	acctagatcc	ttttaaatta	6180


```

aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggtctg acagttacca 6240
atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc 6300
ctgactcccc gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtcg 6360
tgcaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc 6420
agccggaagg gccgagcgca gaagtgggcc tgcaacttta tccgcctcca tccagtctat 6480
taattgttgc cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt 6540
tgccattgct acaggcatcg tgggtgcacg ctcgctggtt ggtatggctt cattcagctc 6600
cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcgggttag 6660
ctccttcggt cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt 6720
tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac 6780
tgggtgagtac tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg 6840
cccggcgctca atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat 6900
tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc 6960
gatgtaaccc actcgtgcac ccaactgato ttcagcatct tttactttca ccagcgtttc 7020
tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa 7080
atgttgaata ctcatactct tcctttttca atattattga agcatttatc agggttattg 7140
tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg 7200
cacatttccc cgaaaagtgc cacctgacgt c 7231

```

<210> 43

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 43

tgtcttggat ccaagatgaa gcgcgcccgc cccagcgaag atgacttc

48

<210> 44

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 44

aaacacggcg gccgctcttt cattcttg

28

<210> 45

<211> 17

<212> PRT

<213> Ad 37 N-terminus

<400> 45

```

Met Ser Lys Arg Leu Arb Val Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr
  1           5           10           15

```

<210> 46

<211> 6

<212> PRT

<213> artificial sequence

<400> 46

```

Lys Arg Ala Arg Pro Ser
  1           5

```

<210> 47

<211> 17

<212> PRT

<213> Ad5 modified N-terminus

<400> 47

Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr
1 5 10 15

<210> 48

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 48

ggatccatgg gatacttggt agca

24

<210> 49

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 49

gcaactcgag tcattcttgg gcaatatagg

30

<210> 50

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 50

gcgctgact ctttaaggact agtttc

26

<210> 51

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 51

gcgcttaatt aacatcatca ataataacc ttatttt

37

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/083729 A3

- (51) International Patent Classification⁷: C12N 15/861, A61K 48/00, A61P 27/02
- (21) International Application Number: PCT/EP01/04863
- (22) International Filing Date: 30 April 2001 (30.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/562,934 1 May 2000 (01.05.2000) US
- (71) Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US).
- (71) Applicants and
(72) Inventors: NEMEROW, Glen, R. [US/US]; 462 Cerro Street, Encinitas, CA 92024 (US). VON SEGGERN, Daniel, J. [US/US]; Apartment 30, 5175 Luigi Terrace, San Diego, CA 92122 (US). FRIEDLANDER, Marty [US/US]; 1720 Zapo Street, Del Mar, CA 92014 (US).
- (74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
19 September 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/083729 A3

(54) Title: VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY

(57) Abstract: Adenovirus vector-based gene therapy methods for treating ocular disorders are provided. Adenovirus vectors for therapy of ocular diseases and methods of treatment using the vectors are provided. Compositions, kits, and methods of preparation and use of the vectors for gene therapy are provided.

Internal Application No

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/861 A61K48/00 A61P27/02

B. FIELDS SEARCHED

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, BIOSIS, MEDLINE, EMBASE, SCISEARCH, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

☒ Further documents are listed in the continuation of box C.

Y Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- *T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *& document member of the same patent family

Date of the actual completion of the international search

11 April 2002

Date of mailing of the international search report

15/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Sitch, W

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 01/04863

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	<p>page 1161, right-hand column, paragraph 3 -page 1162, left-hand column, paragraph 1 page 1162, left-hand column, paragraph 4 -page 1162, right-hand column, paragraph 2 ---</p>	
X	<p>WO 95 26409 A (ABITBOL MARC ;MALLET JACQUES (FR); REVAH FREDERIC (FR); ROUSTAN PA) 5 October 1995 (1995-10-05) page 1, line 3 - line 7 page 4, line 26 -page 5, line 26 page 6, line 1 - line 23 page 10, line 10 - line 19 claims 1,11-24 ---</p>	1-7
Y	<p>HUANG SHUANG ET AL: "A single amino acid in the adenovirus type 37 fiber confers binding to human conjunctival cells" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 4, April 1999 (1999-04), pages 2798-2802, XP002139782 ISSN: 0022-538X the whole document ---</p>	8-33
A	<p>ARNBERG NIKLAS ET AL: "Fiber genes of adenoviruses with tropism for the eye and the genital tract" VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 227, no. 1, 1997, pages 239-244, XP002139781 ISSN: 0042-6822 page 239 abstract page 242; figure 2 page 244, left-hand column ---</p>	
A	<p>WO 98 22609 A (ARMENTANO DONNA E ;GREGORY RICHARD J (US); GENZYME CORP (US); SMIT) 28 May 1998 (1998-05-28) page 6, line 16 -page 7, line 28 ---</p>	
A	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994 GOURAS PETER ET AL: "Reporter gene expression in cones in transgenic mice carrying bovine rhodopsin promoter/lacZ transgenes." Database accession no. PREV199598013526 XP002195797 abstract & VISUAL NEUROSCIENCE, vol. 11, no. 6, 1994, pages 1227-1231, ISSN: 0952-5238 ---</p>	1
	<p>--- -/--</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/04863

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 48027 A (UNIV FLORIDA) 29 October 1998 (1998-10-29) page 2, line 22 -page 3, line 5 page 3, line 33 -page 4, line 33 ---	1
A	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TSUBOTA, KAZUO ET AL: "Adenovirus-mediated gene transfer to the ocular surface epithelium" retrieved from STN Database accession no. 130:177282 HCA XP002195798 abstract & EXP. EYE RES. (1998), 67(5), 531-538 , ---	8
A	ABRAHAM N G ET AL: "Adenovirus-mediated heme oxygebase-1 gene transfer into rabbit ocular tissues" INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 36, no. 11, 1 October 1995 (1995-10-01), pages 2202-2210, XP002086227 ISSN: 0146-0404 page 2203, right-hand column, paragraph 3 -page 2204, left-hand column, paragraph 2 page 2204, left-hand column, paragraph 4 -right-hand column, paragraph 1 page 2206, right-hand column, paragraph 2 -page 2207, right-hand column, paragraph 2 ---	8
A	WO 96 13276 A (GENENTECH INC) 9 May 1996 (1996-05-09) page 6, line 2 -page 18, line 6 -----	8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 01/04863

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 10-33 (all partially, insofar as they concern in vivo methods) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
information on patent family members

International Application No

PCT/EP 01/04863

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9526409	A	05-10-1995	FR 2718150 A1	06-10-1995
			AU 2142595 A	17-10-1995
			CA 2184755 A1	05-10-1995
			EP 0753067 A1	15-01-1997
			WO 9526409 A1	05-10-1995
			JP 9510621 T	28-10-1997
			ZA 9502563 A	21-12-1995
WO 9822609	A	28-05-1998	US 5877011 A	02-03-1999
			AU 732220 B2	12-04-2001
			AU 5455298 A	10-06-1998
			EP 0946742 A1	06-10-1999
			JP 2001505054 T	17-04-2001
			WO 9822609 A1	28-05-1998
WO 9848027	A	29-10-1998	AU 735788 B2	12-07-2001
			AU 7140698 A	13-11-1998
			AU 7467598 A	13-11-1998
			BR 9808606 A	23-05-2000
			EP 0977841 A2	09-02-2000
			EP 0977880 A2	09-02-2000
			JP 2001523959 T	27-11-2001
			JP 2001527399 T	25-12-2001
			US 6225291 B1	01-05-2001
			WO 9848009 A2	29-10-1998
			WO 9848027 A2	29-10-1998
WO 9613276	A	09-05-1996	US 5827702 A	27-10-1998
			CA 2203374 A1	09-05-1996
			EP 0789592 A1	20-08-1997
			JP 10508025 T	04-08-1998
			US 6204251 B1	20-03-2001
			WO 9613276 A1	09-05-1996